{"820e6f7e64f138df4e2686cfc5b58c0ac6a3dd35": [["In the absence of standardized diagnosis and the presence of unique clinical syndromes, it is not surprising that considerable differences exist in the number of reported incidences of disease and the outcomes of various infections in cardiothoracic transplant (CTTX) recipients.", [["infections", "DISEASE", 221, 231], ["unique clinical syndromes", "PROBLEM", 61, 86], ["disease", "PROBLEM", 185, 192], ["various infections", "PROBLEM", 213, 231], ["cardiothoracic transplant (CTTX) recipients", "TREATMENT", 235, 278], ["disease", "OBSERVATION", 185, 192], ["various", "OBSERVATION_MODIFIER", 213, 220], ["infections", "OBSERVATION", 221, 231], ["cardiothoracic transplant", "ANATOMY", 235, 260]]], ["Publications to date have employed variable and heterogeneous definitions of CTTX-related infections, thereby limiting the comparison between the types and incidence of infections and the generalizability of these data across transplant centers.", [["CTTX", "CHEMICAL", 77, 81], ["infections", "DISEASE", 90, 100], ["infections", "DISEASE", 169, 179], ["CTTX", "PROBLEM", 77, 81], ["related infections", "PROBLEM", 82, 100], ["infections", "PROBLEM", 169, 179], ["heterogeneous", "OBSERVATION_MODIFIER", 48, 61], ["infections", "OBSERVATION", 90, 100], ["infections", "OBSERVATION", 169, 179]]], ["Currently, there are no standard international definitions for infections uniquely related to CTTX, with the exception of Chagas disease and toxoplasmosis.", [["infections", "DISEASE", 63, 73], ["CTTX", "DISEASE", 94, 98], ["Chagas disease", "DISEASE", 122, 136], ["toxoplasmosis", "DISEASE", 141, 154], ["infections", "PROBLEM", 63, 73], ["CTTX", "TEST", 94, 98], ["Chagas disease", "PROBLEM", 122, 136], ["toxoplasmosis", "PROBLEM", 141, 154], ["no", "UNCERTAINTY", 21, 23], ["infections", "OBSERVATION", 63, 73], ["Chagas disease", "OBSERVATION", 122, 136], ["toxoplasmosis", "OBSERVATION", 141, 154]]], ["1 The purpose of the present working formulation is to provide consensus-derived expert opinion of definitions for infections in CTTX for epidemiologic, research and registry data use.ScopeStandard definitions of infections specifically related to CTTX will allow for meaningful comparison of the type and incidence of these infections between different types of CTTXs, different regimens of immunosuppression and between different transplant centers, thereby improving the reporting of infection-related morbidity and mortality after cardiothoracic transplantation.", [["infections", "DISEASE", 115, 125], ["infections", "DISEASE", 213, 223], ["infections", "DISEASE", 325, 335], ["infection", "DISEASE", 487, 496], ["infections", "PROBLEM", 115, 125], ["infections", "PROBLEM", 213, 223], ["CTTX", "TREATMENT", 248, 252], ["these infections", "PROBLEM", 319, 335], ["CTTXs", "TREATMENT", 363, 368], ["different regimens", "TREATMENT", 370, 388], ["immunosuppression", "TREATMENT", 392, 409], ["different transplant centers", "TREATMENT", 422, 450], ["infection", "PROBLEM", 487, 496], ["cardiothoracic transplantation", "TREATMENT", 535, 565], ["infections", "OBSERVATION", 213, 223], ["infections", "OBSERVATION", 325, 335], ["infection", "OBSERVATION", 487, 496]]], ["The definitions proposed herein are suitable for epidemiologic investigations and are intended to facilitate clinical decision-making.ScopeThe definitions described in what follows have been reviewed and approved by a multidisciplinary working group of The International Society for Heart and Lung Transplantation (ISHLT).SourceThese definitions were adapted from surveillance definitions of healthcare-associated sinusitis, tracheobronchitis and pneumonia, used in reporting to the National Healthcare Safety Network (NHSN) and the Centers for Disease Control and Prevention's (CDC) surveillance system for patient and healthcare personnel safety.", [["Heart", "ANATOMY", 283, 288], ["Lung", "ANATOMY", 293, 297], ["sinusitis", "DISEASE", 414, 423], ["tracheobronchitis", "DISEASE", 425, 442], ["pneumonia", "DISEASE", 447, 456], ["Lung", "ORGAN", 293, 297], ["patient", "ORGANISM", 608, 615], ["patient", "SPECIES", 608, 615], ["epidemiologic investigations", "TEST", 49, 77], ["Heart and Lung Transplantation", "TREATMENT", 283, 313], ["healthcare-associated sinusitis", "PROBLEM", 392, 423], ["tracheobronchitis", "PROBLEM", 425, 442], ["pneumonia", "PROBLEM", 447, 456], ["Disease Control", "TREATMENT", 545, 560], ["surveillance system", "TEST", 584, 603], ["Heart", "ANATOMY", 283, 288], ["Lung", "ANATOMY", 293, 297], ["Transplantation", "OBSERVATION", 298, 313], ["sinusitis", "OBSERVATION", 414, 423], ["tracheobronchitis", "OBSERVATION", 425, 442], ["pneumonia", "OBSERVATION", 447, 456]]], ["2 Definitions of invasive fungal infection (IFI) were based on those proposed by the European Organization for Research and Treatment of Cancer and the Mycoses Study Group of the National Institutes of Health (EORTC/MSG), 3 whereas definitions from the American Society of Transplantation and other source documents represented the foundation for defining viral infections.", [["invasive fungal infection", "DISEASE", 17, 42], ["IFI", "DISEASE", 44, 47], ["Cancer", "DISEASE", 137, 143], ["viral infections", "DISEASE", 356, 372], ["invasive fungal infection", "PROBLEM", 17, 42], ["Cancer", "PROBLEM", 137, 143], ["the Mycoses Study", "TEST", 148, 165], ["Transplantation", "TREATMENT", 273, 288], ["viral infections", "PROBLEM", 356, 372], ["invasive", "OBSERVATION_MODIFIER", 17, 25], ["fungal", "OBSERVATION_MODIFIER", 26, 32], ["infection", "OBSERVATION", 33, 42], ["Cancer", "OBSERVATION", 137, 143], ["infections", "OBSERVATION", 362, 372]]], ["1, 4 Bacterial infection overviewAll bacterial infectionsBacterial infections are a major contributor of complications in the early post-transplant period in heart-and lung-transplanted patients.", [["heart", "ANATOMY", 158, 163], ["lung", "ANATOMY", 168, 172], ["infection", "DISEASE", 15, 24], ["bacterial infections", "DISEASE", 37, 57], ["Bacterial infections", "DISEASE", 57, 77], ["heart", "ORGAN", 158, 163], ["lung", "ORGAN", 168, 172], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 186, 194], ["Bacterial infection", "PROBLEM", 5, 24], ["All bacterial infectionsBacterial infections", "PROBLEM", 33, 77], ["complications", "PROBLEM", 105, 118], ["Bacterial", "OBSERVATION_MODIFIER", 5, 14], ["infection", "OBSERVATION", 15, 24], ["bacterial", "OBSERVATION_MODIFIER", 37, 46], ["infections", "OBSERVATION", 47, 57], ["infections", "OBSERVATION", 67, 77], ["complications", "OBSERVATION", 105, 118], ["heart", "ANATOMY", 158, 163], ["lung", "ANATOMY", 168, 172], ["transplanted", "OBSERVATION", 173, 185]]], ["5, 6 Some bacterial infections (e.g., pre-transplant colonization or donor-derived infections) have unique issues and implications in CTTX recipients 5, [7] [8] [9] [10] [11] [12] ; therefore, the definitions for these infections for epidemiologic, research or ISHLT registry purposes are specifically addressed herein.", [["bacterial infections", "DISEASE", 10, 30], ["infections", "DISEASE", 83, 93], ["infections", "DISEASE", 219, 229], ["[7] [8] [9] [10", "SIMPLE_CHEMICAL", 153, 168], ["Some bacterial infections", "PROBLEM", 5, 30], ["pre-transplant colonization", "PROBLEM", 38, 65], ["donor-derived infections", "PROBLEM", 69, 93], ["unique issues", "PROBLEM", 100, 113], ["implications in CTTX recipients", "TREATMENT", 118, 149], ["these infections", "PROBLEM", 213, 229], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["infections", "OBSERVATION", 20, 30], ["infections", "OBSERVATION", 219, 229]]], ["Many other bacterial infections (e.g., methicillin-resistant Staphylococcus aureus or vancomysin-resistant enterococcus) are present similarly across hospitalized patients and solid-organ transplant (SOT) recipients and are therefore not directly addressed in what follows.All bacterial infectionsThe existing literature in CTTX has largely classified bacterial infections as \"early\" (e.g., post-operative) or \"late\" onset after transplantation, allowing transplant clinicians to determine the source of these infections and focus prevention strategy and early empirical antibiotic treatment regimens on the temporal onset of these infections.", [["organ", "ANATOMY", 182, 187], ["bacterial infections", "DISEASE", 11, 31], ["methicillin", "CHEMICAL", 39, 50], ["Staphylococcus aureus", "DISEASE", 61, 82], ["vancomysin", "CHEMICAL", 86, 96], ["bacterial infections", "DISEASE", 277, 297], ["CTTX", "CHEMICAL", 324, 328], ["infections", "DISEASE", 362, 372], ["infections", "DISEASE", 510, 520], ["infections", "DISEASE", 632, 642], ["methicillin", "CHEMICAL", 39, 50], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 39, 82], ["vancomysin-resistant enterococcus", "ORGANISM", 86, 119], ["patients", "ORGANISM", 163, 171], ["solid-", "CANCER", 176, 182], ["organ", "ORGAN", 182, 187], ["CTTX", "CANCER", 324, 328], ["Staphylococcus aureus", "SPECIES", 61, 82], ["patients", "SPECIES", 163, 171], ["Staphylococcus aureus", "SPECIES", 61, 82], ["Many other bacterial infections", "PROBLEM", 0, 31], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 39, 82], ["vancomysin", "PROBLEM", 86, 96], ["resistant enterococcus", "PROBLEM", 97, 119], ["solid-organ transplant", "TREATMENT", 176, 198], ["All bacterial infections", "PROBLEM", 273, 297], ["bacterial infections", "PROBLEM", 352, 372], ["transplantation", "TREATMENT", 429, 444], ["these infections", "PROBLEM", 504, 520], ["focus prevention strategy", "TREATMENT", 525, 550], ["early empirical antibiotic treatment regimens", "TREATMENT", 555, 600], ["these infections", "PROBLEM", 626, 642], ["bacterial", "OBSERVATION_MODIFIER", 11, 20], ["infections", "OBSERVATION", 21, 31], ["Staphylococcus aureus", "OBSERVATION", 61, 82], ["resistant enterococcus", "OBSERVATION", 97, 119], ["organ", "ANATOMY", 182, 187], ["transplant", "OBSERVATION", 188, 198], ["bacterial", "OBSERVATION_MODIFIER", 277, 286], ["infections", "OBSERVATION", 287, 297], ["bacterial", "OBSERVATION_MODIFIER", 352, 361], ["infections", "OBSERVATION", 362, 372], ["infections", "OBSERVATION", 510, 520], ["infections", "OBSERVATION", 632, 642]]], ["A further timeline is used to classify all infections diagnosed in the hospital setting as nosocomial, with onset 48 hours after the patient is admitted to the hospital, and communityacquired infection, with onset at the time of admission or within 48 hours of admission.", [["infections", "DISEASE", 43, 53], ["infection", "DISEASE", 192, 201], ["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["all infections", "PROBLEM", 39, 53], ["nosocomial", "PROBLEM", 91, 101], ["communityacquired infection", "PROBLEM", 174, 201], ["infections", "OBSERVATION", 43, 53], ["infection", "OBSERVATION", 192, 201]]], ["The latter definitions of infection may be artificial in the setting of CTTX as some infections, although related to healthcare and immunosuppression, may not occur within the established time-line of nosocomial infections.", [["infection", "DISEASE", 26, 35], ["CTTX", "CHEMICAL", 72, 76], ["infections", "DISEASE", 85, 95], ["nosocomial infections", "DISEASE", 201, 222], ["infection", "PROBLEM", 26, 35], ["CTTX", "PROBLEM", 72, 76], ["some infections", "PROBLEM", 80, 95], ["immunosuppression", "TREATMENT", 132, 149], ["nosocomial infections", "PROBLEM", 201, 222], ["infection", "OBSERVATION", 26, 35], ["infections", "OBSERVATION", 85, 95], ["nosocomial", "OBSERVATION_MODIFIER", 201, 211], ["infections", "OBSERVATION", 212, 222]]], ["To fully appreciate the impact of the potential source of infection, we propose using the categories of nosocomial (after 48 hours of hospitalization) and community-acquired (prior to 48 hours of hospitalization) with the added category of community-acquired \"transplant-related\" infections.", [["infection", "DISEASE", 58, 67], ["nosocomial", "DISEASE", 104, 114], ["infections", "DISEASE", 280, 290], ["infection", "PROBLEM", 58, 67], ["nosocomial", "PROBLEM", 104, 114], ["community-acquired \"transplant", "TREATMENT", 240, 270], ["\" infections", "PROBLEM", 278, 290], ["infection", "OBSERVATION", 58, 67], ["infections", "OBSERVATION", 280, 290]]], ["This category would include infections by pathogens acquired by the CTTX patient prior to time of transplantation and that are clearly related to the immunocompromised state of the CTTX patient after transplantation that may increase the risk for specific bacterial pathogens that are not common in the community.", [["infections", "DISEASE", 28, 38], ["patient", "ORGANISM", 73, 80], ["patient", "ORGANISM", 186, 193], ["patient", "SPECIES", 73, 80], ["patient", "SPECIES", 186, 193], ["infections", "PROBLEM", 28, 38], ["pathogens", "PROBLEM", 42, 51], ["transplantation", "TREATMENT", 98, 113], ["transplantation", "TREATMENT", 200, 215], ["specific bacterial pathogens", "PROBLEM", 247, 275], ["infections", "OBSERVATION", 28, 38], ["immunocompromised", "OBSERVATION", 150, 167]]], ["These pathogens may be related to the donor or the recipient via pre-transplant colonization of the respiratory or gastrointestinal (GI) tract and can be therefore regarded as \"transplant-related\" in this setting.", [["respiratory", "ANATOMY", 100, 111], ["gastrointestinal (GI) tract", "ANATOMY", 115, 142], ["respiratory or gastrointestinal (GI) tract", "DISEASE", 100, 142], ["gastrointestinal", "ORGAN", 115, 131], ["These pathogens", "PROBLEM", 0, 15], ["the donor", "PROBLEM", 34, 43], ["the respiratory or gastrointestinal (GI) tract", "PROBLEM", 96, 142], ["transplant", "TREATMENT", 177, 187], ["pathogens", "OBSERVATION", 6, 15], ["respiratory", "ANATOMY", 100, 111], ["gastrointestinal", "ANATOMY", 115, 131]]], ["12, 13 It is also to be noted that community-acquired pneumonia may be transplant-related if caused by organisms that are typically associated with transplants (e.g., fungal, multidrug-resistant or atypical bacteria).Respiratory bacterial infectionsRespiratory bacterial infections occur frequently in lung transplant recipients.", [["lung", "ANATOMY", 302, 306], ["pneumonia", "DISEASE", 54, 63], ["Respiratory bacterial infections", "DISEASE", 217, 249], ["bacterial infections", "DISEASE", 261, 281], ["lung", "ORGAN", 302, 306], ["community-acquired pneumonia", "PROBLEM", 35, 63], ["transplant", "TREATMENT", 71, 81], ["organisms", "PROBLEM", 103, 112], ["transplants (e.g., fungal, multidrug-resistant or atypical bacteria", "PROBLEM", 148, 215], ["Respiratory bacterial infections", "PROBLEM", 217, 249], ["Respiratory bacterial infections", "PROBLEM", 249, 281], ["lung transplant recipients", "TREATMENT", 302, 328], ["pneumonia", "OBSERVATION", 54, 63], ["atypical", "OBSERVATION_MODIFIER", 198, 206], ["bacteria", "OBSERVATION", 207, 215], ["bacterial", "OBSERVATION_MODIFIER", 229, 238], ["infections", "OBSERVATION", 239, 249], ["bacterial infections", "OBSERVATION", 261, 281], ["lung", "ANATOMY", 302, 306], ["transplant", "OBSERVATION", 307, 317]]], ["In one study, 72 episodes per 100 lung transplants per year were reported.", [["lung", "ANATOMY", 34, 38], ["lung", "ORGAN", 34, 38], ["one study", "TEST", 3, 12], ["lung", "ANATOMY", 34, 38], ["transplants", "OBSERVATION", 39, 50]]], ["14 The definitions of bacterial pneumonia present significant challenges in CTTX.", [["pneumonia", "DISEASE", 32, 41], ["bacterial pneumonia", "PROBLEM", 22, 41], ["bacterial", "OBSERVATION_MODIFIER", 22, 31], ["pneumonia", "OBSERVATION", 32, 41], ["significant", "OBSERVATION_MODIFIER", 50, 61]]], ["Frequent use of empirical anti-bacterial agents prior to specimen collection and the possibility of concurrent allograft rejection make the use of standard guidelines, as presented by the Centers for Disease Control and Prevention (CDC) for healthcareassociated infections (HCAIs), difficult to apply.", [["specimen", "ANATOMY", 57, 65], ["allograft", "ANATOMY", 111, 120], ["healthcareassociated infections", "DISEASE", 241, 272], ["HCAIs", "DISEASE", 274, 279], ["allograft", "ORGAN", 111, 120], ["empirical anti-bacterial agents", "TREATMENT", 16, 47], ["specimen collection", "TEST", 57, 76], ["concurrent allograft rejection", "PROBLEM", 100, 130], ["Disease Control", "TREATMENT", 200, 215], ["healthcareassociated infections (HCAIs)", "PROBLEM", 241, 280], ["allograft rejection", "OBSERVATION", 111, 130], ["infections", "OBSERVATION", 262, 272]]], ["2 In addition, some microbiologic diagnostic procedures may not be routinely practiced at many transplant centers and this may limit the employment of diagnostic criteria for infections that require quantification of bacterial colonyforming units per milliliter in the bronchoalveolar lavage (BAL) samples.", [["bronchoalveolar lavage (BAL) samples", "ANATOMY", 269, 305], ["infections", "DISEASE", 175, 185], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 269, 291], ["some microbiologic diagnostic procedures", "TEST", 15, 55], ["infections", "PROBLEM", 175, 185], ["bacterial colonyforming units", "TREATMENT", 217, 246], ["the bronchoalveolar lavage", "TEST", 265, 291], ["bronchoalveolar lavage", "OBSERVATION", 269, 291]]], ["Further, the thresholds proposed may underestimate the episodes of bacterial pneumonia in the CTTX population, 20 where early empirical intervention with anti-microbial agents prior to obtaining the samples with suspected pneumonia is common practice.", [["samples", "ANATOMY", 199, 206], ["pneumonia", "DISEASE", 77, 86], ["pneumonia", "DISEASE", 222, 231], ["bacterial pneumonia", "PROBLEM", 67, 86], ["early empirical intervention", "TREATMENT", 120, 148], ["anti-microbial agents", "TREATMENT", 154, 175], ["the samples", "TEST", 195, 206], ["pneumonia", "PROBLEM", 222, 231], ["bacterial", "OBSERVATION_MODIFIER", 67, 76], ["pneumonia", "OBSERVATION", 77, 86], ["pneumonia", "OBSERVATION", 222, 231]]], ["Presence of endobronchial stents in lung transplant recipients further complicates the picture in defining various clinical syndromes.Respiratory bacterial infectionsFor these reasons, a specific classification of bacterial pneumoniae in CTTX recipients is proposed based on radiographic findings, clinical symptoms, microbiology and histopathology (including consideration of acute rejection in lung transplant patients).Respiratory bacterial infectionsIn lung transplant recipients, the use of differential cytology in BAL may be helpful.", [["endobronchial", "ANATOMY", 12, 25], ["lung", "ANATOMY", 36, 40], ["lung", "ANATOMY", 396, 400], ["lung transplant", "ANATOMY", 457, 472], ["BAL", "ANATOMY", 521, 524], ["Respiratory bacterial infections", "DISEASE", 134, 166], ["bacterial pneumoniae", "DISEASE", 214, 234], ["Respiratory bacterial infections", "DISEASE", 422, 454], ["endobronchial stents", "PATHOLOGICAL_FORMATION", 12, 32], ["lung", "ORGAN", 36, 40], ["bacterial pneumoniae", "ORGANISM", 214, 234], ["lung", "ORGAN", 396, 400], ["patients", "ORGANISM", 412, 420], ["lung", "ORGAN", 457, 461], ["BAL", "ORGANISM_SUBSTANCE", 521, 524], ["patients", "SPECIES", 412, 420], ["endobronchial stents", "TREATMENT", 12, 32], ["lung transplant recipients", "TREATMENT", 36, 62], ["various clinical syndromes", "PROBLEM", 107, 133], ["Respiratory bacterial infections", "PROBLEM", 134, 166], ["bacterial pneumoniae", "PROBLEM", 214, 234], ["CTTX recipients", "TREATMENT", 238, 253], ["radiographic findings", "TEST", 275, 296], ["clinical symptoms", "PROBLEM", 298, 315], ["microbiology", "TEST", 317, 329], ["histopathology", "TEST", 334, 348], ["acute rejection", "PROBLEM", 377, 392], ["lung transplant", "TREATMENT", 396, 411], ["Respiratory bacterial infections", "PROBLEM", 422, 454], ["lung transplant recipients", "TREATMENT", 457, 483], ["differential cytology in BAL", "TEST", 496, 524], ["endobronchial", "ANATOMY", 12, 25], ["stents", "OBSERVATION", 26, 32], ["lung", "ANATOMY", 36, 40], ["transplant", "OBSERVATION", 41, 51], ["bacterial", "OBSERVATION_MODIFIER", 146, 155], ["infections", "OBSERVATION", 156, 166], ["bacterial", "OBSERVATION_MODIFIER", 214, 223], ["pneumoniae", "OBSERVATION", 224, 234], ["acute", "OBSERVATION_MODIFIER", 377, 382], ["rejection", "OBSERVATION", 383, 392], ["lung", "ANATOMY", 396, 400], ["transplant", "OBSERVATION", 401, 411], ["bacterial", "OBSERVATION_MODIFIER", 434, 443], ["infections", "OBSERVATION", 444, 454], ["lung", "ANATOMY", 457, 461], ["transplant recipients", "OBSERVATION", 462, 483]]], ["[21] [22] [23] The predominance of neutrophils with intracellular bacteria (hematoxylin-eosin and gram stain) is more suggestive of the presence of a bacterial pneumonia than a high proportion of lymphocytes or eosinophils in BAL.", [["neutrophils", "ANATOMY", 35, 46], ["intracellular", "ANATOMY", 52, 65], ["lymphocytes", "ANATOMY", 196, 207], ["eosinophils", "ANATOMY", 211, 222], ["BAL", "ANATOMY", 226, 229], ["pneumonia", "DISEASE", 160, 169], ["hematoxylin", "CHEMICAL", 76, 87], ["eosin", "CHEMICAL", 88, 93], ["[21] [22] [23]", "SIMPLE_CHEMICAL", 0, 14], ["neutrophils", "CELL", 35, 46], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 52, 65], ["hematoxylin-eosin", "SIMPLE_CHEMICAL", 76, 93], ["lymphocytes", "CELL", 196, 207], ["eosinophils", "CELL", 211, 222], ["BAL", "CELL", 226, 229], ["neutrophils", "CELL_TYPE", 35, 46], ["lymphocytes", "CELL_TYPE", 196, 207], ["eosinophils", "CELL_TYPE", 211, 222], ["neutrophils", "TEST", 35, 46], ["intracellular bacteria", "PROBLEM", 52, 74], ["hematoxylin", "TEST", 76, 87], ["gram stain", "TEST", 98, 108], ["a bacterial pneumonia", "PROBLEM", 148, 169], ["lymphocytes", "PROBLEM", 196, 207], ["eosinophils in BAL", "PROBLEM", 211, 229], ["intracellular bacteria", "OBSERVATION", 52, 74], ["more suggestive of", "UNCERTAINTY", 113, 131], ["bacterial", "OBSERVATION_MODIFIER", 150, 159], ["pneumonia", "OBSERVATION", 160, 169], ["lymphocytes", "OBSERVATION", 196, 207]]], ["On the other hand, a lymphocytic or eosinophilic BAL could indicate an acute graft reaction, although cytomegalovirus (CMV), other viruses and atypical pathogens would need to be ruled out.Respiratory bacterial infectionsAcute rejection (AR) of the graft in lung transplant recipients presents a significant consideration in the diagnosis of all pneumonias, including those due to bacteria.", [["lymphocytic", "ANATOMY", 21, 32], ["eosinophilic BAL", "ANATOMY", 36, 52], ["graft", "ANATOMY", 77, 82], ["graft", "ANATOMY", 249, 254], ["lung", "ANATOMY", 258, 262], ["cytomegalovirus (CMV), other viruses", "DISEASE", 102, 138], ["Respiratory bacterial infections", "DISEASE", 189, 221], ["pneumonias", "DISEASE", 346, 356], ["lymphocytic", "CANCER", 21, 32], ["graft", "TISSUE", 77, 82], ["cytomegalovirus", "ORGANISM", 102, 117], ["CMV", "ORGANISM", 119, 122], ["graft", "TISSUE", 249, 254], ["lung", "ORGAN", 258, 262], ["CMV", "SPECIES", 119, 122], ["a lymphocytic or eosinophilic BAL", "PROBLEM", 19, 52], ["an acute graft reaction", "PROBLEM", 68, 91], ["cytomegalovirus (CMV)", "PROBLEM", 102, 123], ["other viruses", "PROBLEM", 125, 138], ["atypical pathogens", "PROBLEM", 143, 161], ["Respiratory bacterial infections", "PROBLEM", 189, 221], ["Acute rejection (AR", "PROBLEM", 221, 240], ["the graft", "TREATMENT", 245, 254], ["lung transplant recipients", "TREATMENT", 258, 284], ["all pneumonias", "PROBLEM", 342, 356], ["bacteria", "PROBLEM", 381, 389], ["lymphocytic", "OBSERVATION", 21, 32], ["eosinophilic BAL", "OBSERVATION", 36, 52], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["graft reaction", "OBSERVATION", 77, 91], ["cytomegalovirus", "OBSERVATION", 102, 117], ["atypical", "OBSERVATION_MODIFIER", 143, 151], ["pathogens", "OBSERVATION", 152, 161], ["bacterial", "OBSERVATION_MODIFIER", 201, 210], ["infections", "OBSERVATION", 211, 221], ["rejection", "OBSERVATION", 227, 236], ["graft", "OBSERVATION", 249, 254], ["lung", "ANATOMY", 258, 262], ["transplant", "OBSERVATION", 263, 273], ["significant", "OBSERVATION_MODIFIER", 296, 307], ["all", "OBSERVATION_MODIFIER", 342, 345], ["pneumonias", "OBSERVATION", 346, 356]]], ["There are frequent clinical scenarios where distinction between rejection and infection is critically dependent upon histopathologic findings.", [["infection", "DISEASE", 78, 87], ["frequent clinical scenarios", "PROBLEM", 10, 37], ["rejection", "PROBLEM", 64, 73], ["infection", "PROBLEM", 78, 87], ["critically dependent upon histopathologic findings", "PROBLEM", 91, 141], ["frequent", "OBSERVATION_MODIFIER", 10, 18], ["rejection", "OBSERVATION", 64, 73], ["infection", "OBSERVATION", 78, 87]]], ["In many cases, evidence for infection and rejection coexist.", [["infection", "DISEASE", 28, 37], ["infection", "PROBLEM", 28, 37], ["rejection coexist", "PROBLEM", 42, 59], ["evidence for", "UNCERTAINTY", 15, 27], ["infection", "OBSERVATION", 28, 37], ["rejection", "OBSERVATION", 42, 51]]], ["Therefore, in the setting of lung transplantation, the diagnosis of bacterial (or any) pneumonia is more precisely defined by the confirmation or exclusion of AR when microbiologic criteria are not met.", [["lung", "ANATOMY", 29, 33], ["pneumonia", "DISEASE", 87, 96], ["lung", "ORGAN", 29, 33], ["AR", "GENE_OR_GENE_PRODUCT", 159, 161], ["AR", "PROTEIN", 159, 161], ["lung transplantation", "TREATMENT", 29, 49], ["bacterial (or any) pneumonia", "PROBLEM", 68, 96], ["the confirmation", "TEST", 126, 142], ["AR", "PROBLEM", 159, 161], ["microbiologic criteria", "TEST", 167, 189], ["lung", "ANATOMY", 29, 33], ["transplantation", "OBSERVATION", 34, 49], ["bacterial", "OBSERVATION_MODIFIER", 68, 77], ["pneumonia", "OBSERVATION", 87, 96]]], ["24 The determination of AR requires histologic examination.", [["AR", "GENE_OR_GENE_PRODUCT", 24, 26], ["AR", "PROTEIN", 24, 26], ["histologic examination", "TEST", 36, 58]]], ["If an AR is documented and clinical and laboratory criteria for bacterial pneumonia are also fulfilled, the diagnosis of AR and concomitant pneumonia is possible.", [["pneumonia", "DISEASE", 74, 83], ["pneumonia", "DISEASE", 140, 149], ["AR", "GENE_OR_GENE_PRODUCT", 6, 8], ["AR", "GENE_OR_GENE_PRODUCT", 121, 123], ["AR", "PROTEIN", 6, 8], ["an AR", "PROBLEM", 3, 8], ["bacterial pneumonia", "PROBLEM", 64, 83], ["AR", "PROBLEM", 121, 123], ["concomitant pneumonia", "PROBLEM", 128, 149], ["bacterial", "OBSERVATION_MODIFIER", 64, 73], ["pneumonia", "OBSERVATION", 74, 83], ["concomitant", "OBSERVATION_MODIFIER", 128, 139], ["pneumonia", "OBSERVATION", 140, 149]]], ["24 Accordingly, pneumonia should be indicated as pneumonia combined with an AR.Respiratory bacterial infection diagnostic tools\u2022 Direct examination by light microscopy [gram stain, modified acid-fast bacilli (AFB) stain for Nocardia spp, AFB stains for Mycobacteria].Respiratory bacterial infection diagnostic tools\u2022 Culture (including rapid culture methods for Legionella spp, Mycobacteria spp and prolonged culture periods for detection of bacteria-causing infective endocarditis). \u2022 BAL cell analysis: rule-out contamination with \u03fd1% epithelial cells, 20 Definitions of bacterial pneumonia and colonization in CTTX are given in Table 1a , whereas the definitions of tracheobronchitis are given in Table 1b .General comments regarding bacterial pneumonia/tracheobronchitis1.", [["BAL cell", "ANATOMY", 486, 494], ["epithelial cells", "ANATOMY", 537, 553], ["pneumonia", "DISEASE", 16, 25], ["pneumonia", "DISEASE", 49, 58], ["Respiratory bacterial infection", "DISEASE", 79, 110], ["Respiratory bacterial infection", "DISEASE", 267, 298], ["infective endocarditis", "DISEASE", 459, 481], ["pneumonia", "DISEASE", 583, 592], ["tracheobronchitis", "DISEASE", 669, 686], ["pneumonia", "DISEASE", 747, 756], ["tracheobronchitis1", "DISEASE", 757, 775], ["Legionella spp", "ORGANISM", 362, 376], ["Mycobacteria spp", "ORGANISM", 378, 394], ["BAL cell", "CELL", 486, 494], ["epithelial cells", "CELL", 537, 553], ["AR", "PROTEIN", 76, 78], ["epithelial cells", "CELL_TYPE", 537, 553], ["pneumonia", "PROBLEM", 16, 25], ["pneumonia", "PROBLEM", 49, 58], ["an AR", "PROBLEM", 73, 78], ["Respiratory bacterial infection", "PROBLEM", 79, 110], ["Direct examination", "TEST", 129, 147], ["light microscopy", "TEST", 151, 167], ["gram stain", "TEST", 169, 179], ["modified acid-fast bacilli", "TEST", 181, 207], ["Nocardia spp", "TEST", 224, 236], ["AFB stains", "TEST", 238, 248], ["Mycobacteria", "PROBLEM", 253, 265], ["Respiratory bacterial infection", "PROBLEM", 267, 298], ["Culture", "TEST", 317, 324], ["rapid culture methods", "TEST", 336, 357], ["Legionella spp", "TEST", 362, 376], ["Mycobacteria spp", "PROBLEM", 378, 394], ["prolonged culture periods", "TEST", 399, 424], ["bacteria", "PROBLEM", 442, 450], ["infective endocarditis", "PROBLEM", 459, 481], ["BAL cell analysis", "TEST", 486, 503], ["contamination", "PROBLEM", 514, 527], ["\u03fd1% epithelial cells", "PROBLEM", 533, 553], ["bacterial pneumonia", "PROBLEM", 573, 592], ["colonization in CTTX", "PROBLEM", 597, 617], ["tracheobronchitis", "PROBLEM", 669, 686], ["bacterial pneumonia", "PROBLEM", 737, 756], ["tracheobronchitis1", "PROBLEM", 757, 775], ["pneumonia", "OBSERVATION", 16, 25], ["pneumonia", "OBSERVATION", 49, 58], ["bacterial", "OBSERVATION_MODIFIER", 91, 100], ["infection", "OBSERVATION", 101, 110], ["bacterial", "OBSERVATION_MODIFIER", 279, 288], ["infection", "OBSERVATION", 289, 298], ["infective", "OBSERVATION_MODIFIER", 459, 468], ["endocarditis", "OBSERVATION", 469, 481], ["BAL cell", "OBSERVATION", 486, 494], ["epithelial cells", "OBSERVATION", 537, 553], ["bacterial", "OBSERVATION_MODIFIER", 573, 582], ["pneumonia", "OBSERVATION", 583, 592], ["colonization", "OBSERVATION_MODIFIER", 597, 609], ["tracheobronchitis", "OBSERVATION", 669, 686], ["bacterial", "OBSERVATION_MODIFIER", 737, 746], ["pneumonia", "OBSERVATION", 747, 756]]], ["Ventilator-associated pneumonia should be designated when reporting data.", [["pneumonia", "DISEASE", 22, 31], ["Ventilator-associated pneumonia", "PROBLEM", 0, 31], ["pneumonia", "OBSERVATION", 22, 31]]], ["A distinction should be made between non-invasive and invasive ventilation.", [["non-invasive and invasive ventilation", "TREATMENT", 37, 74], ["invasive ventilation", "OBSERVATION", 54, 74]]], ["Aspiration pneumonia should be considered if the criteria are fulfilled for pneumonia (Table 1a ).", [["Aspiration pneumonia", "DISEASE", 0, 20], ["pneumonia", "DISEASE", 76, 85], ["Aspiration pneumonia", "PROBLEM", 0, 20], ["pneumonia", "PROBLEM", 76, 85], ["pneumonia", "OBSERVATION", 11, 20], ["pneumonia", "OBSERVATION", 76, 85]]], ["The cause of this type of pneumonia should be noted.", [["pneumonia", "DISEASE", 26, 35], ["pneumonia", "PROBLEM", 26, 35], ["pneumonia", "OBSERVATION", 26, 35]]], ["Multiple or concurrent episodes of post-transplant pneumonia may occur.", [["pneumonia", "DISEASE", 51, 60], ["post-transplant pneumonia", "PROBLEM", 35, 60], ["post-transplant", "OBSERVATION_MODIFIER", 35, 50], ["pneumonia", "OBSERVATION", 51, 60]]], ["To determine a new episode in a single patient, resolution of the initial infection must be determined by clinical, laboratory or histologic evidence.", [["infection", "DISEASE", 74, 83], ["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["a new episode", "PROBLEM", 13, 26], ["the initial infection", "PROBLEM", 62, 83], ["new", "OBSERVATION_MODIFIER", 15, 18], ["infection", "OBSERVATION", 74, 83]]], ["The isolation of a new pathogen alone is not indicative of a new episode of pneumonia.", [["pneumonia", "DISEASE", 76, 85], ["a new pathogen", "PROBLEM", 17, 31], ["pneumonia", "PROBLEM", 76, 85], ["new", "OBSERVATION_MODIFIER", 19, 22], ["pathogen", "OBSERVATION", 23, 31], ["not indicative of", "UNCERTAINTY", 41, 58], ["new", "OBSERVATION_MODIFIER", 61, 64], ["pneumonia", "OBSERVATION", 76, 85]]], ["In contrast, a second pneumonia may develop in a patient after single lung transplantation.", [["lung", "ANATOMY", 70, 74], ["pneumonia", "DISEASE", 22, 31], ["patient", "ORGANISM", 49, 56], ["lung", "ORGAN", 70, 74], ["patient", "SPECIES", 49, 56], ["a second pneumonia", "PROBLEM", 13, 31], ["single lung transplantation", "TREATMENT", 63, 90], ["pneumonia", "OBSERVATION", 22, 31], ["lung", "ANATOMY", 70, 74], ["transplantation", "OBSERVATION", 75, 90]]], ["Here, the contralateral lung may develop an \"independent\" pneumonia by another organism.", [["lung", "ANATOMY", 24, 28], ["pneumonia", "DISEASE", 58, 67], ["lung", "ORGAN", 24, 28], ["an \"independent\" pneumonia", "PROBLEM", 41, 67], ["another organism", "PROBLEM", 71, 87], ["contralateral", "ANATOMY_MODIFIER", 10, 23], ["lung", "ANATOMY", 24, 28], ["pneumonia", "OBSERVATION", 58, 67]]], ["Sputum samples are frequently contaminated with airway colonizers (e.g., coagulase-negative Staphylococcus and Enterococcus spp), and therefore must be interpreted cautiously.", [["Sputum samples", "ANATOMY", 0, 14], ["airway", "ANATOMY", 48, 54], ["Sputum samples", "ORGANISM_SUBSTANCE", 0, 14], ["airway colonizers", "PATHOLOGICAL_FORMATION", 48, 65], ["coagulase-negative Staphylococcus", "GENE_OR_GENE_PRODUCT", 73, 106], ["Enterococcus spp", "ORGANISM", 111, 127], ["Sputum samples", "TEST", 0, 14], ["airway colonizers", "PROBLEM", 48, 65], ["coagulase", "TEST", 73, 82], ["Staphylococcus", "PROBLEM", 92, 106], ["Enterococcus spp", "PROBLEM", 111, 127], ["airway", "ANATOMY", 48, 54]]], ["The interferon-gamma release assay (IGRA) serum test is not recommended for diagnosis of acute tracheobronchitis disease, although a positive result is an indication of latent disease or recent infection and a useful screening test if baseline IGRA testing is performed prior to transplantation.", [["serum", "ANATOMY", 42, 47], ["tracheobronchitis disease", "DISEASE", 95, 120], ["infection", "DISEASE", 194, 203], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 4, 20], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["interferon", "PROTEIN", 4, 14], ["IGRA", "PROTEIN", 244, 248], ["The interferon-gamma release assay", "TREATMENT", 0, 34], ["IGRA) serum test", "TEST", 36, 52], ["acute tracheobronchitis disease", "PROBLEM", 89, 120], ["latent disease", "PROBLEM", 169, 183], ["recent infection", "PROBLEM", 187, 203], ["a useful screening test", "TEST", 208, 231], ["baseline IGRA testing", "TEST", 235, 256], ["transplantation", "TREATMENT", 279, 294], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["tracheobronchitis", "OBSERVATION", 95, 112], ["latent", "OBSERVATION_MODIFIER", 169, 175], ["disease", "OBSERVATION", 176, 183], ["infection", "OBSERVATION", 194, 203]]], ["Episodes of airway colonization are not recorded as infections.General comments regarding bacterial pneumonia/tracheobronchitis7.", [["airway", "ANATOMY", 12, 18], ["infections", "DISEASE", 52, 62], ["pneumonia", "DISEASE", 100, 109], ["tracheobronchitis7", "DISEASE", 110, 128], ["airway", "MULTI-TISSUE_STRUCTURE", 12, 18], ["airway colonization", "PROBLEM", 12, 31], ["infections", "PROBLEM", 52, 62], ["bacterial pneumonia", "PROBLEM", 90, 109], ["tracheobronchitis7", "PROBLEM", 110, 128], ["airway", "ANATOMY", 12, 18], ["colonization", "OBSERVATION", 19, 31], ["infections", "OBSERVATION", 52, 62], ["bacterial", "OBSERVATION_MODIFIER", 90, 99], ["pneumonia", "OBSERVATION", 100, 109]]], ["Histologic representation of chronic graft rejection may not impact the diagnosis of bacterial pneumonia.", [["graft", "ANATOMY", 37, 42], ["pneumonia", "DISEASE", 95, 104], ["graft", "TISSUE", 37, 42], ["chronic graft rejection", "PROBLEM", 29, 52], ["bacterial pneumonia", "PROBLEM", 85, 104], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["graft rejection", "OBSERVATION", 37, 52], ["bacterial", "OBSERVATION_MODIFIER", 85, 94], ["pneumonia", "OBSERVATION", 95, 104]]], ["Therefore, it is not included as criteria for pneumonia definition.", [["pneumonia", "DISEASE", 46, 55], ["pneumonia definition", "PROBLEM", 46, 66], ["pneumonia", "OBSERVATION", 46, 55]]], ["The definition of \"possible pneumonia\" category allows recording of pneumonia after lung transplantation even if required diagnostic procedures were missed, which may occur with prior anti-microbial treatment or delay in diagnostic testing, etc. 9.", [["lung", "ANATOMY", 84, 88], ["pneumonia", "DISEASE", 28, 37], ["pneumonia", "DISEASE", 68, 77], ["lung", "ORGAN", 84, 88], ["pneumonia", "PROBLEM", 28, 37], ["pneumonia", "PROBLEM", 68, 77], ["lung transplantation", "TREATMENT", 84, 104], ["diagnostic procedures", "TEST", 122, 143], ["prior anti-microbial treatment", "TREATMENT", 178, 208], ["diagnostic testing", "TEST", 221, 239], ["possible", "UNCERTAINTY", 19, 27], ["pneumonia", "OBSERVATION", 28, 37], ["pneumonia", "OBSERVATION", 68, 77], ["lung", "ANATOMY", 84, 88], ["transplantation", "OBSERVATION", 89, 104]]], ["In lung transplant recipients, it is desirable to always give additional information if evidence of acute graft rejection exists either by clinical or by histopathologic diagnosis.", [["lung transplant", "ANATOMY", 3, 18], ["graft", "ANATOMY", 106, 111], ["lung", "ORGAN", 3, 7], ["graft", "TISSUE", 106, 111], ["lung transplant recipients", "TREATMENT", 3, 29], ["acute graft rejection", "PROBLEM", 100, 121], ["lung", "ANATOMY", 3, 7], ["transplant", "OBSERVATION", 8, 18], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["graft", "OBSERVATION", 106, 111], ["rejection", "OBSERVATION", 112, 121]]], ["It is possible to have concurrent infections-pneumonia with sinusitis or anastomotic tracheobronchitis.", [["infections", "DISEASE", 34, 44], ["pneumonia", "DISEASE", 45, 54], ["sinusitis", "DISEASE", 60, 69], ["anastomotic tracheobronchitis", "DISEASE", 73, 102], ["concurrent infections", "PROBLEM", 23, 44], ["pneumonia", "PROBLEM", 45, 54], ["sinusitis", "PROBLEM", 60, 69], ["anastomotic tracheobronchitis", "PROBLEM", 73, 102], ["possible to have", "UNCERTAINTY", 6, 22], ["infections", "OBSERVATION", 34, 44], ["pneumonia", "OBSERVATION", 45, 54], ["sinusitis", "OBSERVATION", 60, 69], ["anastomotic tracheobronchitis", "OBSERVATION", 73, 102]]], ["Quantification of organisms in BAL is not considered essential for the diagnosis of ventilator-associated pneumonia (VAP).", [["BAL", "ANATOMY", 31, 34], ["ventilator-associated pneumonia", "DISEASE", 84, 115], ["VAP", "DISEASE", 117, 120], ["BAL", "CELL", 31, 34], ["organisms in BAL", "PROBLEM", 18, 34], ["ventilator-associated pneumonia", "PROBLEM", 84, 115], ["VAP", "PROBLEM", 117, 120], ["organisms", "OBSERVATION", 18, 27], ["pneumonia", "OBSERVATION", 106, 115]]], ["27 However, invasive diagnostics may help withdraw anti-bacterial therapy, which may prevent further emergence of multi-resistant organisms in future.", [["invasive diagnostics", "TEST", 12, 32], ["anti-bacterial therapy", "TREATMENT", 51, 73], ["multi-resistant organisms", "PROBLEM", 114, 139]]], ["The category of bacterial tracheobronchitis is classified into probable and proven categories.", [["tracheobronchitis", "DISEASE", 26, 43], ["bacterial tracheobronchitis", "PROBLEM", 16, 43], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["tracheobronchitis", "OBSERVATION", 26, 43]]], ["They can only be diagnosed in the presence of bronchoscopic findings.", [["bronchoscopic findings", "TEST", 46, 68], ["bronchoscopic", "OBSERVATION", 46, 59]]], ["We have refrained from using the term microbiogically negative tracheobrochitis as it requires more evidence.General comments regarding bacterial pneumonia/tracheobronchitis13.", [["tracheobrochitis", "DISEASE", 63, 79], ["bacterial pneumonia", "DISEASE", 136, 155], ["bacterial pneumonia", "PROBLEM", 136, 155], ["tracheobronchitis13", "PROBLEM", 156, 175], ["bacterial", "OBSERVATION_MODIFIER", 136, 145], ["pneumonia", "OBSERVATION", 146, 155]]], ["Endobronchial stent-associated tracheobronchitis or bronchial anastomotic infections, both fungal and bacterial, are categorized as probable (Table 2 ).", [["Endobronchial", "ANATOMY", 0, 13], ["tracheobronchitis", "ANATOMY", 31, 48], ["bronchial", "ANATOMY", 52, 61], ["tracheobronchitis", "DISEASE", 31, 48], ["bronchial anastomotic infections", "DISEASE", 52, 84], ["Endobronchial stent", "TREATMENT", 0, 19], ["tracheobronchitis", "PROBLEM", 31, 48], ["bronchial anastomotic infections", "PROBLEM", 52, 84], ["bacterial", "PROBLEM", 102, 111], ["stent", "OBSERVATION", 14, 19], ["tracheobronchitis", "OBSERVATION", 31, 48], ["bronchial", "ANATOMY", 52, 61], ["anastomotic infections", "OBSERVATION", 62, 84], ["fungal", "OBSERVATION_MODIFIER", 91, 97], ["bacterial", "OBSERVATION_MODIFIER", 102, 111]]], ["No attempt is made to redefine atypical mycobacterial infections or pulmonary tracheobronchitis in lung transplant recipients and the use of existing definitions from European and North American societies are encouraged until further data emerge.", [["pulmonary", "ANATOMY", 68, 77], ["lung", "ANATOMY", 99, 103], ["mycobacterial infections", "DISEASE", 40, 64], ["pulmonary tracheobronchitis", "DISEASE", 68, 95], ["pulmonary", "ORGAN", 68, 77], ["lung", "ORGAN", 99, 103], ["atypical mycobacterial infections", "PROBLEM", 31, 64], ["pulmonary tracheobronchitis", "PROBLEM", 68, 95], ["lung transplant recipients", "TREATMENT", 99, 125], ["atypical", "OBSERVATION_MODIFIER", 31, 39], ["mycobacterial", "OBSERVATION_MODIFIER", 40, 53], ["infections", "OBSERVATION", 54, 64], ["pulmonary", "ANATOMY", 68, 77], ["tracheobronchitis", "OBSERVATION", 78, 95], ["lung", "ANATOMY", 99, 103], ["transplant", "OBSERVATION", 104, 114]]], ["It is preferable to document the use of antibiotics in patients with pneumonia at the time of culture data collection.Viral infection overview All viral infectionsCardiothoracic transplant recipients are at an increased risk for viral infections with severe clinical sequelae.", [["pneumonia", "DISEASE", 69, 78], ["Viral infection", "DISEASE", 118, 133], ["viral infections", "DISEASE", 147, 163], ["viral infections", "DISEASE", 229, 245], ["patients", "ORGANISM", 55, 63], ["recipients", "ORGANISM", 189, 199], ["patients", "SPECIES", 55, 63], ["antibiotics", "TREATMENT", 40, 51], ["pneumonia", "PROBLEM", 69, 78], ["culture data collection", "TEST", 94, 117], ["Viral infection", "PROBLEM", 118, 133], ["All viral infections", "PROBLEM", 143, 163], ["Cardiothoracic transplant recipients", "TREATMENT", 163, 199], ["viral infections", "PROBLEM", 229, 245], ["severe clinical sequelae", "PROBLEM", 251, 275], ["pneumonia", "OBSERVATION", 69, 78], ["infection", "OBSERVATION", 124, 133], ["viral", "OBSERVATION_MODIFIER", 147, 152], ["infections", "OBSERVATION", 153, 163], ["transplant recipients", "OBSERVATION", 178, 199], ["viral", "OBSERVATION_MODIFIER", 229, 234], ["infections", "OBSERVATION", 235, 245], ["severe", "OBSERVATION_MODIFIER", 251, 257]]], ["Some viral infections have unique considerations and implications in CTTX recipients.", [["viral infections", "DISEASE", 5, 21], ["CTTX recipients", "ORGANISM", 69, 84], ["Some viral infections", "PROBLEM", 0, 21], ["CTTX recipients", "TREATMENT", 69, 84], ["viral", "OBSERVATION_MODIFIER", 5, 10], ["infections", "OBSERVATION", 11, 21]]], ["The definitions for these viral infections are specifically addressed herein and may be used for epidemiologic, research or registry purposes in CTTX recipients.", [["viral infections", "DISEASE", 26, 42], ["recipients", "ORGANISM", 150, 160], ["these viral infections", "PROBLEM", 20, 42], ["CTTX recipients", "TREATMENT", 145, 160], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["infections", "OBSERVATION", 32, 42]]], ["Many other non-respiratory viral infections present similarly across SOT recipients.", [["viral infections", "DISEASE", 27, 43], ["Many other non-respiratory viral infections", "PROBLEM", 0, 43], ["non-respiratory", "OBSERVATION", 11, 26], ["viral infections", "OBSERVATION", 27, 43]]], ["Diagnosis and management of these viral infections have been addressed ade- quately in other guidelines 1 and therefore will not be addressed herein.Respiratory viral infectionsRespiratory viral infections, including newly emerging viruses, occur frequently in lung transplant recipients.", [["lung", "ANATOMY", 261, 265], ["viral infections", "DISEASE", 34, 50], ["Respiratory viral infections", "DISEASE", 149, 177], ["Respiratory viral infections", "DISEASE", 177, 205], ["lung", "ORGAN", 261, 265], ["management", "TREATMENT", 14, 24], ["these viral infections", "PROBLEM", 28, 50], ["Respiratory viral infections", "PROBLEM", 149, 177], ["Respiratory viral infections", "PROBLEM", 177, 205], ["newly emerging viruses", "PROBLEM", 217, 239], ["lung transplant recipients", "TREATMENT", 261, 287], ["viral", "OBSERVATION_MODIFIER", 34, 39], ["infections", "OBSERVATION", 40, 50], ["viral infections", "OBSERVATION", 161, 177], ["viral infections", "OBSERVATION", 189, 205], ["viruses", "OBSERVATION", 232, 239], ["lung", "ANATOMY", 261, 265], ["transplant", "OBSERVATION", 266, 276]]], ["34 Some epidemiologic studies have suggested an association between respiratory viral infection and the development of bronchiolitis obliterans syndrome (BOS).", [["respiratory viral infection", "DISEASE", 68, 95], ["bronchiolitis obliterans syndrome", "DISEASE", 119, 152], ["BOS", "DISEASE", 154, 157], ["Some epidemiologic studies", "TEST", 3, 29], ["respiratory viral infection", "PROBLEM", 68, 95], ["bronchiolitis obliterans syndrome", "PROBLEM", 119, 152], ["respiratory", "ANATOMY", 68, 79], ["viral infection", "OBSERVATION", 80, 95], ["bronchiolitis obliterans syndrome", "OBSERVATION", 119, 152]]], ["[35] [36] [37] [38] [39] [40] These studies yielded mixed results and the association between respiratory virus infection and BOS remains unclear.", [["respiratory virus infection", "DISEASE", 94, 121], ["BOS", "DISEASE", 126, 129], ["[35] [36] [37] [38] [39] [40]", "SIMPLE_CHEMICAL", 0, 29], ["respiratory virus", "ORGANISM", 94, 111], ["These studies", "TEST", 30, 43], ["respiratory virus infection", "PROBLEM", 94, 121], ["BOS", "PROBLEM", 126, 129], ["respiratory virus infection", "OBSERVATION", 94, 121]]], ["41, 42 The recent availability of molecular diagnostics, including PCR and multiplex gene techniques for the recovery of many viruses simultaneously from a single specimen, increased the recovery of pathogens in respiratory infections that previously were considered to be of undetermined etiology.", [["specimen", "ANATOMY", 163, 171], ["respiratory", "ANATOMY", 212, 223], ["respiratory infections", "DISEASE", 212, 234], ["molecular diagnostics", "TEST", 34, 55], ["PCR", "TEST", 67, 70], ["multiplex gene techniques", "TREATMENT", 75, 100], ["many viruses", "PROBLEM", 121, 133], ["pathogens", "PROBLEM", 199, 208], ["respiratory infections", "PROBLEM", 212, 234], ["viruses", "OBSERVATION", 126, 133], ["pathogens", "OBSERVATION_MODIFIER", 199, 208], ["respiratory infections", "OBSERVATION", 212, 234]]], ["42 Other viruses have been identified and are of uncer-CMV in the lungDefinitions for CMV infection and disease, especially for use in research, have been reported in the literature and used in other studies.", [["lung", "ANATOMY", 66, 70], ["CMV infection", "DISEASE", 86, 99], ["lung", "ORGAN", 66, 70], ["CMV", "ORGANISM", 86, 89], ["CMV", "SPECIES", 86, 89], ["Other viruses", "PROBLEM", 3, 16], ["CMV infection", "PROBLEM", 86, 99], ["disease", "PROBLEM", 104, 111], ["other studies", "TEST", 194, 207], ["viruses", "OBSERVATION", 9, 16], ["lung", "ANATOMY", 66, 70], ["CMV infection", "OBSERVATION", 86, 99]]], ["1, 4 The methodology for CMV recovery has shifted at many centers over the past decade from conventional viral culture methods and antigenemia toward quantitative molecular diagnostics, including PCR and hybrid capture assays.", [["CMV", "ORGANISM", 25, 28], ["CMV", "SPECIES", 25, 28], ["CMV recovery", "PROBLEM", 25, 37], ["conventional viral culture methods", "TEST", 92, 126], ["antigenemia", "PROBLEM", 131, 142], ["quantitative molecular diagnostics", "TEST", 150, 184], ["PCR", "TEST", 196, 199], ["hybrid capture assays", "TEST", 204, 225], ["CMV", "OBSERVATION", 25, 28]]], ["[45] [46] [47] However, the issues related to the recovery of CMV in BAL fluid in the absence of histopathologic evidence of CMV remain unresolved, 48 and investigations are ongoing to resolve this issue.", [["BAL fluid", "ANATOMY", 69, 78], ["CMV", "ORGANISM", 62, 65], ["BAL fluid", "MULTI-TISSUE_STRUCTURE", 69, 78], ["CMV", "ORGANISM", 125, 128], ["CMV", "SPECIES", 125, 128], ["CMV in BAL fluid", "PROBLEM", 62, 78], ["CMV", "PROBLEM", 125, 128], ["CMV", "OBSERVATION", 62, 65], ["BAL fluid", "OBSERVATION", 69, 78], ["evidence of", "UNCERTAINTY", 113, 124], ["CMV", "OBSERVATION", 125, 128]]], ["Asymptomatic viral shedding in the upper oropharynx by CMV is distinguished from active CMV disease in these definitions and will assist in further assessing the role of CMV in CTTX.", [["upper oropharynx", "ANATOMY", 35, 51], ["CMV disease", "DISEASE", 88, 99], ["upper oropharynx", "ORGAN", 35, 51], ["CMV", "ORGANISM", 55, 58], ["CMV", "ORGANISM", 88, 91], ["CMV", "ORGANISM", 170, 173], ["CMV", "SPECIES", 55, 58], ["CMV", "SPECIES", 88, 91], ["CMV", "SPECIES", 170, 173], ["Asymptomatic viral shedding in the upper oropharynx", "PROBLEM", 0, 51], ["CMV", "PROBLEM", 55, 58], ["active CMV disease", "PROBLEM", 81, 99], ["CMV in CTTX", "TREATMENT", 170, 181], ["viral", "OBSERVATION", 13, 18], ["upper", "ANATOMY_MODIFIER", 35, 40], ["oropharynx", "ANATOMY", 41, 51], ["CMV", "OBSERVATION", 55, 58], ["active", "OBSERVATION_MODIFIER", 81, 87], ["CMV disease", "OBSERVATION", 88, 99], ["CMV", "OBSERVATION", 170, 173]]], ["In early studies, the recovery of CMV by viral culture in the absence of tissue diagnosis was considered diagnostic of CMV pneumonitis.", [["tissue", "ANATOMY", 73, 79], ["pneumonitis", "DISEASE", 123, 134], ["CMV", "ORGANISM", 34, 37], ["tissue", "TISSUE", 73, 79], ["CMV", "ORGANISM", 119, 122], ["CMV", "SPECIES", 34, 37], ["CMV", "SPECIES", 119, 122], ["CMV", "PROBLEM", 34, 37], ["viral culture", "TEST", 41, 54], ["CMV pneumonitis", "PROBLEM", 119, 134], ["CMV", "OBSERVATION", 34, 37], ["CMV pneumonitis", "OBSERVATION", 119, 134]]], ["49, 50 However, further studies did not suggest that CMV recovery from BAL was predictive of subsequent CMV pneumonitis.", [["BAL", "ANATOMY", 71, 74], ["pneumonitis", "DISEASE", 108, 119], ["CMV", "ORGANISM", 53, 56], ["BAL", "ORGANISM_SUBSTANCE", 71, 74], ["CMV", "ORGANISM", 104, 107], ["CMV", "SPECIES", 53, 56], ["CMV", "SPECIES", 104, 107], ["further studies", "TEST", 16, 31], ["CMV recovery", "PROBLEM", 53, 65], ["BAL", "TEST", 71, 74], ["subsequent CMV pneumonitis", "PROBLEM", 93, 119], ["CMV pneumonitis", "OBSERVATION", 104, 119]]], ["[51] [52] [53] [54] [55] With the advent of sophisticated molecular diagnostics, the recovery of CMV from BAL became more specific and reproducible compared with conventional or shell-vial culture, 53 and additional studies suggested that CMV viral load in BAL fluid may be correlated with invasive CMV pneumonia.", [["BAL", "ANATOMY", 106, 109], ["BAL fluid", "ANATOMY", 257, 266], ["pneumonia", "DISEASE", 303, 312], ["[51] [52] [53] [54] [55]", "SIMPLE_CHEMICAL", 0, 24], ["CMV", "ORGANISM", 97, 100], ["BAL", "ORGANISM_SUBSTANCE", 106, 109], ["CMV", "ORGANISM", 239, 242], ["BAL fluid", "ORGANISM_SUBSTANCE", 257, 266], ["CMV", "ORGANISM", 299, 302], ["CMV", "SPECIES", 97, 100], ["CMV", "SPECIES", 239, 242], ["CMV", "SPECIES", 299, 302], ["CMV from BAL", "TEST", 97, 109], ["conventional or shell-vial culture", "TEST", 162, 196], ["additional studies", "TEST", 205, 223], ["CMV viral load in BAL fluid", "TEST", 239, 266], ["invasive CMV pneumonia", "PROBLEM", 290, 312], ["CMV", "OBSERVATION", 97, 100], ["CMV", "OBSERVATION", 239, 242], ["viral load", "OBSERVATION", 243, 253], ["BAL fluid", "OBSERVATION", 257, 266], ["pneumonia", "OBSERVATION", 303, 312]]], ["2, 56, 57 However, the utility of CMV viral load in BAL in predicting CMV pneumonitis remains uncertain in studies to date.CMV diagnostic tools\u2022 Molecular diagnostics (from whole blood, plasma, BAL or tissue).CMV diagnostic tools-Quantitative DNA PCR or hybrid capture assays.CMV diagnostic tools-Qualitative PCR.CMV diagnostic tools-Genotypic resistance testing.CMV diagnostic tools\u2022 Antigen pp65.CMV diagnostic tools\u2022 Viral culture (conventional or shell-vial centrifugation).CMV diagnostic tools\u2022 In situ immunohistochemistry.CMV diagnostic tools\u2022 Serology: not recommended for diagnosis.CMV diagnostic toolsDefinitions for respiratory viral infections are given in Table 3a and 3b.Fungal infection overview All fungal infectionsCTTX recipients in general and lung transplant recipients in particular have the highest risk of mold infection.", [["BAL", "ANATOMY", 52, 55], ["whole blood", "ANATOMY", 173, 184], ["plasma", "ANATOMY", 186, 192], ["BAL", "ANATOMY", 194, 197], ["tissue", "ANATOMY", 201, 207], ["lung", "ANATOMY", 763, 767], ["pneumonitis", "DISEASE", 74, 85], ["respiratory viral infections", "DISEASE", 627, 655], ["Fungal infection", "DISEASE", 685, 701], ["mold infection", "DISEASE", 829, 843], ["CMV", "ORGANISM", 34, 37], ["BAL", "MULTI-TISSUE_STRUCTURE", 52, 55], ["CMV", "ORGANISM", 70, 73], ["CMV", "ORGANISM", 123, 126], ["blood", "ORGANISM_SUBSTANCE", 179, 184], ["plasma", "ORGANISM_SUBSTANCE", 186, 192], ["BAL", "ORGANISM_SUBSTANCE", 194, 197], ["tissue", "TISSUE", 201, 207], ["CMV", "ORGANISM", 209, 212], ["DNA", "CELLULAR_COMPONENT", 243, 246], ["CMV", "ORGANISM", 276, 279], ["CMV", "ORGANISM", 363, 366], ["pp65", "GENE_OR_GENE_PRODUCT", 393, 397], ["CMV", "ORGANISM", 398, 401], ["CMV", "ORGANISM", 478, 481], ["CMV", "ORGANISM", 529, 532], ["CMV", "ORGANISM", 591, 594], ["lung", "ORGAN", 763, 767], ["Antigen pp65", "PROTEIN", 385, 397], ["CMV", "SPECIES", 34, 37], ["CMV", "SPECIES", 70, 73], ["CMV", "SPECIES", 123, 126], ["CMV", "SPECIES", 209, 212], ["CMV", "SPECIES", 276, 279], ["CMV", "SPECIES", 363, 366], ["CMV", "SPECIES", 398, 401], ["CMV", "SPECIES", 478, 481], ["CMV", "SPECIES", 529, 532], ["CMV", "SPECIES", 591, 594], ["CMV viral load", "TEST", 34, 48], ["BAL", "TEST", 52, 55], ["CMV pneumonitis", "PROBLEM", 70, 85], ["CMV diagnostic tools", "TEST", 123, 143], ["Molecular diagnostics", "TEST", 145, 166], ["whole blood", "TEST", 173, 184], ["CMV diagnostic tools", "TEST", 209, 229], ["Quantitative DNA PCR", "PROBLEM", 230, 250], ["hybrid capture assays", "TEST", 254, 275], ["CMV diagnostic tools", "TEST", 276, 296], ["Genotypic resistance testing", "TEST", 334, 362], ["CMV diagnostic tools", "TEST", 363, 383], ["Antigen pp65", "TEST", 385, 397], ["CMV diagnostic tools", "TEST", 398, 418], ["Viral culture", "TEST", 420, 433], ["conventional or shell-vial centrifugation", "TREATMENT", 435, 476], ["CMV diagnostic tools", "TEST", 478, 498], ["CMV diagnostic tools", "TEST", 529, 549], ["Serology", "TEST", 551, 559], ["CMV diagnostic tools", "TEST", 591, 611], ["respiratory viral infections", "PROBLEM", 627, 655], ["Fungal infection", "PROBLEM", 685, 701], ["All fungal infectionsCTTX recipients", "PROBLEM", 711, 747], ["lung transplant recipients", "TREATMENT", 763, 789], ["mold infection", "PROBLEM", 829, 843], ["CMV", "OBSERVATION", 34, 37], ["viral load", "OBSERVATION", 38, 48], ["CMV pneumonitis", "OBSERVATION", 70, 85], ["situ", "OBSERVATION_MODIFIER", 503, 507], ["immunohistochemistry", "OBSERVATION", 508, 528], ["viral infections", "OBSERVATION", 639, 655], ["infection", "OBSERVATION", 692, 701], ["fungal", "OBSERVATION_MODIFIER", 715, 721], ["infectionsCTTX recipients", "OBSERVATION", 722, 747], ["lung", "ANATOMY", 763, 767], ["transplant", "OBSERVATION", 768, 778], ["mold infection", "OBSERVATION", 829, 843]]], ["58, 59 Among mold infections, the overwhelming majority of infections are due to Aspergillus spp, followed by Scedopsorium spp and zygomycetes.", [["zygomycetes", "ANATOMY", 131, 142], ["mold infections", "DISEASE", 13, 28], ["infections", "DISEASE", 59, 69], ["Aspergillus spp", "DISEASE", 81, 96], ["Aspergillus spp", "ORGANISM", 81, 96], ["Scedopsorium spp", "ORGANISM", 110, 126], ["zygomycetes", "CANCER", 131, 142], ["Scedopsorium spp", "SPECIES", 110, 126], ["Aspergillus spp", "SPECIES", 81, 96], ["Scedopsorium spp", "SPECIES", 110, 126], ["mold infections", "PROBLEM", 13, 28], ["infections", "PROBLEM", 59, 69], ["Aspergillus spp", "PROBLEM", 81, 96], ["zygomycetes", "PROBLEM", 131, 142], ["Among mold", "OBSERVATION_MODIFIER", 7, 17], ["infections", "OBSERVATION", 18, 28], ["infections", "OBSERVATION", 59, 69]]], ["60 Despite the advancement in anti-fungal therapy, mortality remains at approximately 29% in Aspergillus infections.", [["Aspergillus infections", "DISEASE", 93, 115], ["anti-fungal therapy", "TREATMENT", 30, 49], ["Aspergillus infections", "PROBLEM", 93, 115], ["anti-fungal therapy", "OBSERVATION", 30, 49], ["Aspergillus infections", "OBSERVATION", 93, 115]]], ["60 Candida species was noted to be a major pathogen during the early CTTX period, although it is rarely seen in lung transplant recipients in the current era.", [["lung", "ANATOMY", 112, 116], ["Candida species", "ORGANISM", 3, 18], ["lung", "ORGAN", 112, 116], ["Candida species", "TEST", 3, 18], ["a major pathogen", "PROBLEM", 35, 51], ["lung transplant recipients", "TREATMENT", 112, 138], ["lung", "ANATOMY", 112, 116], ["transplant", "OBSERVATION", 117, 127]]], ["61 Although the incidence of invasive candidiasis has remained low in lung transplant recipients, this was the most common fungal infection noted in heart transplant recipients.", [["invasive candidiasis", "ANATOMY", 29, 49], ["lung transplant", "ANATOMY", 70, 85], ["heart", "ANATOMY", 149, 154], ["candidiasis", "DISEASE", 38, 49], ["fungal infection", "DISEASE", 123, 139], ["candidiasis", "CANCER", 38, 49], ["lung", "ORGAN", 70, 74], ["heart", "ORGAN", 149, 154], ["invasive candidiasis", "PROBLEM", 29, 49], ["lung transplant recipients", "TREATMENT", 70, 96], ["the most common fungal infection", "PROBLEM", 107, 139], ["heart transplant recipients", "TREATMENT", 149, 176], ["invasive", "OBSERVATION_MODIFIER", 29, 37], ["candidiasis", "OBSERVATION", 38, 49], ["low", "OBSERVATION_MODIFIER", 63, 66], ["lung", "ANATOMY", 70, 74], ["transplant", "OBSERVATION", 75, 85], ["most common", "OBSERVATION_MODIFIER", 111, 122], ["fungal", "OBSERVATION_MODIFIER", 123, 129], ["infection", "OBSERVATION", 130, 139], ["heart", "ANATOMY", 149, 154], ["transplant recipients", "OBSERVATION", 155, 176]]], ["60Respiratory fungal infectionsFungal infections in lung transplant recipients have certain characteristics that make them unique compared with other SOT recipients as well as other immunocompromised hosts.", [["lung transplant", "ANATOMY", 52, 67], ["fungal infections", "DISEASE", 14, 31], ["Fungal infections", "DISEASE", 31, 48], ["60Respiratory fungal", "ORGANISM", 0, 20], ["lung", "ORGAN", 52, 56], ["SOT recipients", "ORGANISM", 150, 164], ["60Respiratory fungal infections", "PROBLEM", 0, 31], ["Fungal infections", "PROBLEM", 31, 48], ["lung transplant recipients", "TREATMENT", 52, 78], ["fungal", "OBSERVATION_MODIFIER", 14, 20], ["infections", "OBSERVATION", 21, 31], ["Fungal", "OBSERVATION_MODIFIER", 31, 37], ["infections", "OBSERVATION", 38, 48], ["lung", "ANATOMY", 52, 56], ["transplant", "OBSERVATION", 57, 67]]], ["This includes the presence of certain risk factors, such as airway ischemia and native lung or unique clinical syndromes, including tracheobronchitis, bronchial anastomotic infection and colonization-syndromes observed only in lung transplant recipients ( Figure 2 ).", [["airway", "ANATOMY", 60, 66], ["lung", "ANATOMY", 87, 91], ["bronchial", "ANATOMY", 151, 160], ["lung", "ANATOMY", 227, 231], ["airway ischemia", "DISEASE", 60, 75], ["tracheobronchitis", "DISEASE", 132, 149], ["bronchial anastomotic infection", "DISEASE", 151, 182], ["airway", "MULTI-TISSUE_STRUCTURE", 60, 66], ["lung", "ORGAN", 87, 91], ["lung", "ORGAN", 227, 231], ["certain risk factors", "PROBLEM", 30, 50], ["airway ischemia", "PROBLEM", 60, 75], ["native lung or unique clinical syndromes", "PROBLEM", 80, 120], ["tracheobronchitis", "PROBLEM", 132, 149], ["bronchial anastomotic infection", "PROBLEM", 151, 182], ["colonization", "PROBLEM", 187, 199], ["syndromes", "PROBLEM", 200, 209], ["lung transplant recipients", "TREATMENT", 227, 253], ["airway", "ANATOMY", 60, 66], ["ischemia", "OBSERVATION", 67, 75], ["lung", "ANATOMY", 87, 91], ["tracheobronchitis", "OBSERVATION", 132, 149], ["bronchial", "ANATOMY", 151, 160], ["anastomotic infection", "OBSERVATION", 161, 182], ["lung", "ANATOMY", 227, 231], ["transplant", "OBSERVATION", 232, 242]]], ["62 Rejection syndromes in lung transplant recipients further complicate the clinical presentation.", [["lung", "ANATOMY", 26, 30], ["lung", "ORGAN", 26, 30], ["Rejection syndromes", "PROBLEM", 3, 22], ["lung transplant recipients", "TREATMENT", 26, 52], ["Rejection", "OBSERVATION", 3, 12], ["lung", "ANATOMY", 26, 30], ["transplant", "OBSERVATION", 31, 41]]], ["Diagnosis of fungal infection based on histology alone may not be as accurate due to the concomitant presence of acute or chronic rejection in these individuals.", [["fungal infection", "DISEASE", 13, 29], ["fungal infection", "PROBLEM", 13, 29], ["histology", "TEST", 39, 48], ["acute or chronic rejection in these individuals", "PROBLEM", 113, 160], ["fungal", "OBSERVATION_MODIFIER", 13, 19], ["infection", "OBSERVATION", 20, 29], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["chronic", "OBSERVATION_MODIFIER", 122, 129], ["rejection", "OBSERVATION", 130, 139]]], ["24 Similarly, it is not only the unique clinical syndromes of fungal infection that set them apart from the other immunocompromised hosts, but the diagnostic utility of non-invasive testing also is different.", [["fungal infection", "DISEASE", 62, 78], ["fungal infection", "PROBLEM", 62, 78], ["non-invasive testing", "TEST", 169, 189], ["fungal", "OBSERVATION_MODIFIER", 62, 68], ["infection", "OBSERVATION", 69, 78]]], ["Serum galactomannan has markedly lower sensitivity (30%) in lung transplant recipients as compared with other immunocompromised hosts.", [["Serum", "ANATOMY", 0, 5], ["lung transplant", "ANATOMY", 60, 75], ["galactomannan", "CHEMICAL", 6, 19], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["galactomannan", "GENE_OR_GENE_PRODUCT", 6, 19], ["lung", "ORGAN", 60, 64], ["Serum galactomannan", "TEST", 0, 19], ["markedly lower sensitivity", "PROBLEM", 24, 50], ["lung transplant recipients", "TREATMENT", 60, 86], ["other immunocompromised hosts", "PROBLEM", 104, 133], ["markedly", "OBSERVATION_MODIFIER", 24, 32], ["lower sensitivity", "OBSERVATION_MODIFIER", 33, 50], ["lung", "ANATOMY", 60, 64], ["transplant", "OBSERVATION", 65, 75]]], ["63, 64 Similarly, the sensitivity of other serologic markers such as serum cryptococcal or coccidiodal antigen, histoplasma urine antigen may be variable.", [["serum", "ANATOMY", 69, 74], ["urine", "ANATOMY", 124, 129], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["cryptococcal", "ORGANISM_SUBSTANCE", 75, 87], ["coccidiodal antigen", "GENE_OR_GENE_PRODUCT", 91, 110], ["histoplasma urine antigen", "GENE_OR_GENE_PRODUCT", 112, 137], ["serologic markers", "PROTEIN", 43, 60], ["serum cryptococcal or coccidiodal antigen", "PROTEIN", 69, 110], ["histoplasma urine antigen", "PROTEIN", 112, 137], ["other serologic markers", "TEST", 37, 60], ["serum cryptococcal", "TEST", 69, 87], ["coccidiodal antigen", "TEST", 91, 110], ["histoplasma urine antigen", "TEST", 112, 137]]], ["[65] [66] [67] [68] The use of BAL for GM has resulted in sensitivities of \u03fe66% when a 0.58 or 0.66 optical density (OD) index was used as a cutoff.", [["GM", "CHEMICAL", 39, 41], ["[65] [66] [67] [68]", "SIMPLE_CHEMICAL", 0, 19], ["BAL for GM", "TEST", 31, 41], ["sensitivities", "TEST", 58, 71]]], ["69,70 A higher cutoff (1.5 OD) yielded better results in one study.", [["A higher cutoff", "PROBLEM", 6, 21], ["one study", "TEST", 57, 66]]], ["71 We suggest the use of BAL GM in the diagnosis of invasive aspergillosis (IA) in lung transplant recipi-ents.", [["invasive aspergillosis", "ANATOMY", 52, 74], ["lung", "ANATOMY", 83, 87], ["GM", "CHEMICAL", 29, 31], ["aspergillosis", "DISEASE", 61, 74], ["IA", "DISEASE", 76, 78], ["aspergillosis", "CANCER", 61, 74], ["lung", "ORGAN", 83, 87], ["BAL GM", "TREATMENT", 25, 31], ["invasive aspergillosis", "PROBLEM", 52, 74], ["lung transplant recipi-ents", "TREATMENT", 83, 110], ["invasive", "OBSERVATION_MODIFIER", 52, 60], ["aspergillosis", "OBSERVATION", 61, 74], ["lung", "ANATOMY", 83, 87], ["transplant", "OBSERVATION", 88, 98]]], ["Similarly, fungal PCRs, especially from BAL specimens, are more likely to be less sensitive for the diagnosis of disease than BAL specimens from other immunocompromised hosts owing to colonization of the airways.", [["BAL specimens", "ANATOMY", 40, 53], ["BAL specimens", "ANATOMY", 126, 139], ["airways", "ANATOMY", 204, 211], ["BAL specimens", "CANCER", 40, 53], ["BAL specimens", "CANCER", 126, 139], ["airways", "MULTI-TISSUE_STRUCTURE", 204, 211], ["fungal PCRs", "TEST", 11, 22], ["BAL specimens", "TEST", 40, 53], ["disease", "PROBLEM", 113, 120], ["BAL specimens", "TEST", 126, 139], ["other immunocompromised hosts", "PROBLEM", 145, 174], ["colonization of the airways", "PROBLEM", 184, 211], ["fungal PCRs", "OBSERVATION", 11, 22], ["more likely", "UNCERTAINTY", 59, 70], ["disease", "OBSERVATION", 113, 120], ["airways", "ANATOMY", 204, 211]]], ["Cell wall components of fungi have also been used in the diagnosis of fungal infections.", [["Cell wall", "ANATOMY", 0, 9], ["fungal infections", "DISEASE", 70, 87], ["Cell", "CELL", 0, 4], ["Cell wall components of fungi", "PROBLEM", 0, 29], ["fungal infections", "PROBLEM", 70, 87], ["wall", "ANATOMY_MODIFIER", 5, 9], ["fungi", "OBSERVATION", 24, 29], ["fungal", "OBSERVATION_MODIFIER", 70, 76], ["infections", "OBSERVATION", 77, 87]]], ["Currently available \u2424-glucan is non-specific and is negative in cases of cryptococcosis and zygomycosis.", [["\u2424-glucan", "CHEMICAL", 20, 28], ["cryptococcosis", "DISEASE", 73, 87], ["zygomycosis", "DISEASE", 92, 103], ["\u2424-glucan", "CHEMICAL", 20, 28], ["\u2424-glucan", "SIMPLE_CHEMICAL", 20, 28], ["cryptococcosis", "CANCER", 73, 87], ["cryptococcosis", "PROBLEM", 73, 87], ["zygomycosis", "PROBLEM", 92, 103], ["cryptococcosis", "OBSERVATION", 73, 87], ["zygomycosis", "OBSERVATION", 92, 103]]], ["72 In a recent study of lung transplant recipients, serum \u2424-D-glucan sensitivity was reported to be 93%, whereas specificity was merely 71%.", [["lung transplant", "ANATOMY", 24, 39], ["serum", "ANATOMY", 52, 57], ["\u2424-D-glucan", "CHEMICAL", 58, 68], ["lung", "ORGAN", 24, 28], ["recipients", "ORGANISM", 40, 50], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["\u2424-D-glucan", "SIMPLE_CHEMICAL", 58, 68], ["a recent study", "TEST", 6, 20], ["lung transplant recipients", "TREATMENT", 24, 50], ["serum \u2424-D-glucan sensitivity", "TEST", 52, 80], ["lung", "ANATOMY", 24, 28], ["transplant", "OBSERVATION", 29, 39]]], ["73 The Mycoses Study Group (MSG) and the European Organization for Research and Treatment (EORTC) recently updated the definitions of fungal infections in immunocompromised hosts.", [["fungal infections", "DISEASE", 134, 151], ["Research and Treatment (EORTC)", "TREATMENT", 67, 97], ["fungal infections in immunocompromised hosts", "PROBLEM", 134, 178], ["Mycoses", "OBSERVATION", 7, 14], ["fungal", "OBSERVATION_MODIFIER", 134, 140], ["infections", "OBSERVATION", 141, 151], ["immunocompromised hosts", "OBSERVATION", 155, 178]]], ["3 These definitions represent an excellent attempt to standardize the reporting of fungal infections in studies.", [["fungal infections", "DISEASE", 83, 100], ["fungal infections", "PROBLEM", 83, 100], ["excellent", "OBSERVATION_MODIFIER", 33, 42], ["fungal", "OBSERVATION_MODIFIER", 83, 89], ["infections", "OBSERVATION", 90, 100]]], ["However, they fail to address the unique nature of clinical syndromes in lung transplant recipients, particularly colonization, tracheobronchitis and bronchial anastomotic infections.", [["lung transplant", "ANATOMY", 73, 88], ["bronchial", "ANATOMY", 150, 159], ["tracheobronchitis", "DISEASE", 128, 145], ["bronchial anastomotic infections", "DISEASE", 150, 182], ["lung", "ORGAN", 73, 77], ["clinical syndromes", "PROBLEM", 51, 69], ["lung transplant recipients", "TREATMENT", 73, 99], ["colonization", "PROBLEM", 114, 126], ["tracheobronchitis", "PROBLEM", 128, 145], ["bronchial anastomotic infections", "PROBLEM", 150, 182], ["lung", "ANATOMY", 73, 77], ["transplant", "OBSERVATION", 78, 88], ["tracheobronchitis", "OBSERVATION", 128, 145], ["bronchial", "ANATOMY", 150, 159], ["anastomotic infections", "OBSERVATION", 160, 182]]], ["8, 74, 75 Also, the radiologic presentation of invasive mycoses in cardiothoracic organ transplant recipients may not conform to the classical \"halo sign\" presentation in neutropenic or stem a In the absence of biopsy categorize as probable: In the presence of histologic findings of both acute rejection and fungal invasion it should be classified as acute rejection with proven fungal infection. b The presence of mosaic appearance and ground-glass opacity may represent development of bronchiolitis obliterans syndrome or obliterative bronchiolitis. c Isolation of non-pathogenic molds in culture (e.g., Cladosporium spp, Phialemonium, Chaetomium, Cunninghamella, Syncephalastrum, Curvularia, Dactylaria, Graphium or Phialophora) or other non-pathogenic fungi [e.g., Penicillium (non-Marnefii), Paecilomyces or basidiomyctes] do not qualify for the \"probable\" category.", [["mycoses", "ANATOMY", 56, 63], ["organ", "ANATOMY", 82, 87], ["mycoses", "DISEASE", 56, 63], ["neutropenic", "DISEASE", 171, 182], ["fungal invasion", "DISEASE", 309, 324], ["fungal infection", "DISEASE", 380, 396], ["bronchiolitis obliterans syndrome", "DISEASE", 488, 521], ["bronchiolitis", "DISEASE", 538, 551], ["organ", "ORGAN", 82, 87], ["Cladosporium spp", "ORGANISM", 607, 623], ["Cunninghamella, Syncephalastrum", "ORGANISM", 651, 682], ["Curvularia, Dactylaria", "ORGANISM", 684, 706], ["Phialophora", "GENE_OR_GENE_PRODUCT", 720, 731], ["non-Marnefii", "ORGANISM", 783, 795], ["Cladosporium spp", "SPECIES", 607, 623], ["Cladosporium spp", "SPECIES", 607, 623], ["invasive mycoses", "PROBLEM", 47, 63], ["cardiothoracic organ transplant recipients", "TREATMENT", 67, 109], ["biopsy categorize", "TEST", 211, 228], ["both acute rejection", "PROBLEM", 284, 304], ["fungal invasion", "PROBLEM", 309, 324], ["acute rejection", "PROBLEM", 352, 367], ["fungal infection", "PROBLEM", 380, 396], ["mosaic appearance", "PROBLEM", 416, 433], ["ground-glass opacity", "PROBLEM", 438, 458], ["bronchiolitis obliterans syndrome", "PROBLEM", 488, 521], ["obliterative bronchiolitis", "PROBLEM", 525, 551], ["non-pathogenic molds in culture", "PROBLEM", 568, 599], ["Cladosporium spp", "TEST", 607, 623], ["Phialemonium", "PROBLEM", 625, 637], ["Chaetomium", "PROBLEM", 639, 649], ["Cunninghamella", "PROBLEM", 651, 665], ["Syncephalastrum", "PROBLEM", 667, 682], ["Curvularia", "PROBLEM", 684, 694], ["Dactylaria", "PROBLEM", 696, 706], ["Graphium", "PROBLEM", 708, 716], ["Phialophora", "PROBLEM", 720, 731], ["other non-pathogenic fungi", "PROBLEM", 736, 762], ["Penicillium (non-Marnefii)", "TREATMENT", 770, 796], ["Paecilomyces", "TREATMENT", 798, 810], ["basidiomyctes", "TREATMENT", 814, 827], ["invasive", "OBSERVATION_MODIFIER", 47, 55], ["mycoses", "OBSERVATION", 56, 63], ["cardiothoracic organ", "ANATOMY", 67, 87], ["neutropenic", "OBSERVATION", 171, 182], ["biopsy", "OBSERVATION", 211, 217], ["histologic", "OBSERVATION", 261, 271], ["both", "OBSERVATION_MODIFIER", 284, 288], ["acute", "OBSERVATION_MODIFIER", 289, 294], ["rejection", "OBSERVATION", 295, 304], ["fungal", "OBSERVATION_MODIFIER", 309, 315], ["invasion", "OBSERVATION", 316, 324], ["acute", "OBSERVATION_MODIFIER", 352, 357], ["rejection", "OBSERVATION", 358, 367], ["fungal", "OBSERVATION_MODIFIER", 380, 386], ["infection", "OBSERVATION", 387, 396], ["mosaic", "OBSERVATION_MODIFIER", 416, 422], ["ground-glass opacity", "OBSERVATION", 438, 458], ["may represent", "UNCERTAINTY", 459, 472], ["bronchiolitis obliterans syndrome", "OBSERVATION", 488, 521], ["obliterative", "OBSERVATION_MODIFIER", 525, 537], ["bronchiolitis", "OBSERVATION", 538, 551], ["non-pathogenic molds", "OBSERVATION", 568, 588]]], ["They should only be considered in the \"proven\" category.Respiratory fungal infectionscell transplant recipients ( Figure 2 ).", [["Respiratory fungal infectionscell transplant recipients", "TREATMENT", 56, 111], ["fungal", "OBSERVATION_MODIFIER", 68, 74]]], ["76 Moreover, the definitions do not account for the differences in the sensitivity of serologic tests, particularly galactomannan in lung transplant recipients.", [["lung", "ANATOMY", 133, 137], ["galactomannan", "CHEMICAL", 116, 129], ["galactomannan", "SIMPLE_CHEMICAL", 116, 129], ["lung", "ORGAN", 133, 137], ["serologic tests", "TEST", 86, 101], ["galactomannan", "TEST", 116, 129], ["lung transplant recipients", "TREATMENT", 133, 159], ["lung", "ANATOMY", 133, 137], ["transplant", "OBSERVATION", 138, 148]]], ["69, 70, 77, 78 In addition, the category of possible fungal infection might not be applicable in lung transplant recipients owing to a multitude of possible diagnoses in these patients.", [["lung transplant", "ANATOMY", 97, 112], ["fungal infection", "DISEASE", 53, 69], ["lung", "ORGAN", 97, 101], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["fungal infection", "PROBLEM", 53, 69], ["lung transplant recipients", "TREATMENT", 97, 123], ["possible", "UNCERTAINTY", 44, 52], ["fungal", "OBSERVATION_MODIFIER", 53, 59], ["infection", "OBSERVATION", 60, 69], ["lung", "ANATOMY", 97, 101], ["transplant", "OBSERVATION", 102, 112]]], ["The American Society of Transplantation (AST) also put forward a set of definitions to be used in the study of these infections in SOT recipients.", [["infections", "DISEASE", 117, 127], ["SOT recipients", "ORGANISM", 131, 145], ["Transplantation (AST)", "TREATMENT", 24, 45], ["these infections", "PROBLEM", 111, 127], ["infections", "OBSERVATION", 117, 127]]], ["1 The AST definitions do take into account some unique clinical syndromes in lung transplant recipients but lack the detailed description of clinical syndromes.", [["lung transplant", "ANATOMY", 77, 92], ["lung", "ORGAN", 77, 81], ["The AST definitions", "TEST", 2, 21], ["some unique clinical syndromes", "PROBLEM", 43, 73], ["lung transplant recipients", "TREATMENT", 77, 103], ["clinical syndromes", "PROBLEM", 141, 159], ["lung", "ANATOMY", 77, 81], ["transplant", "OBSERVATION", 82, 92]]], ["Reported studies of fungal infections in lung transplant recipients used diverse definitions.", [["lung", "ANATOMY", 41, 45], ["fungal infections", "DISEASE", 20, 37], ["lung", "ORGAN", 41, 45], ["fungal infections", "PROBLEM", 20, 37], ["lung transplant recipients", "TREATMENT", 41, 67], ["fungal", "OBSERVATION_MODIFIER", 20, 26], ["infections", "OBSERVATION", 27, 37], ["lung", "ANATOMY", 41, 45], ["transplant", "OBSERVATION", 46, 56]]], ["14,79 -83 The following sets of definitions are proposed to standardize the reporting of fungal infections, particularly mold and yeast (endemic mycoses, Candida spp and Cryptococcus spp) infections in CTTX recipients, especially among general and lung transplant recipients.", [["lung", "ANATOMY", 248, 252], ["14,79 -83", "CHEMICAL", 0, 9], ["fungal infections", "DISEASE", 89, 106], ["mycoses", "DISEASE", 145, 152], ["Candida spp", "DISEASE", 154, 165], ["Cryptococcus spp) infections", "DISEASE", 170, 198], ["Candida spp", "ORGANISM", 154, 165], ["Cryptococcus spp", "ORGANISM", 170, 186], ["lung", "ORGAN", 248, 252], ["yeast", "SPECIES", 130, 135], ["Cryptococcus spp", "SPECIES", 170, 186], ["yeast", "SPECIES", 130, 135], ["fungal infections", "PROBLEM", 89, 106], ["mold", "PROBLEM", 121, 125], ["yeast (endemic mycoses", "PROBLEM", 130, 152], ["Candida spp", "PROBLEM", 154, 165], ["Cryptococcus spp) infections in CTTX recipients", "PROBLEM", 170, 217], ["lung transplant recipients", "TREATMENT", 248, 274], ["fungal infections", "OBSERVATION", 89, 106], ["lung", "ANATOMY", 248, 252], ["transplant", "OBSERVATION", 253, 263]]], ["The isolation of non-pathogenic molds or other non-pathogenic fungi in BAL or sputum is not believed to satisfy the microbiologic criteria for the diagnosis of probable invasive fungal infections in these patients without histologic confirma-tion (Tables 4a and 4b) .", [["BAL", "ANATOMY", 71, 74], ["sputum", "ANATOMY", 78, 84], ["fungal infections", "DISEASE", 178, 195], ["BAL", "ORGANISM_SUBSTANCE", 71, 74], ["sputum", "ORGANISM_SUBSTANCE", 78, 84], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["non-pathogenic molds", "PROBLEM", 17, 37], ["other non-pathogenic fungi in BAL", "PROBLEM", 41, 74], ["sputum", "PROBLEM", 78, 84], ["invasive fungal infections", "PROBLEM", 169, 195], ["non-pathogenic molds", "OBSERVATION", 17, 37], ["non-pathogenic", "OBSERVATION_MODIFIER", 47, 61], ["fungi", "OBSERVATION", 62, 67], ["BAL", "OBSERVATION", 71, 74], ["sputum", "OBSERVATION", 78, 84], ["probable", "UNCERTAINTY", 160, 168], ["invasive", "OBSERVATION_MODIFIER", 169, 177], ["fungal", "OBSERVATION_MODIFIER", 178, 184], ["infections", "OBSERVATION", 185, 195]]], ["However, these definitions of fungal infections do not address Pneumocystis jiroveci infection, which has previously been adequately defined for use in CTTX.", [["fungal infections", "DISEASE", 30, 47], ["Pneumocystis jiroveci infection", "DISEASE", 63, 94], ["Pneumocystis jiroveci", "ORGANISM", 63, 84], ["Pneumocystis jiroveci", "SPECIES", 63, 84], ["Pneumocystis jiroveci", "SPECIES", 63, 84], ["fungal infections", "PROBLEM", 30, 47], ["Pneumocystis jiroveci infection", "PROBLEM", 63, 94], ["fungal", "OBSERVATION_MODIFIER", 30, 36], ["infections", "OBSERVATION", 37, 47], ["Pneumocystis", "OBSERVATION_MODIFIER", 63, 75], ["jiroveci", "OBSERVATION", 76, 84]]], ["1Fungal infection diagnostic tools\u2022 Direct examination by light microscopy (gram, Giemsa and calcofluor stains). \u2022 Culture. \u2022 Histopathology: routine stains (hemotoxylin-eosin), special (Gomori methenamine silver, mucicarmine, periodic acid-Schiff), direct immunofluorescence and in situ hybridization).Fungal infection diagnostic toolsHistopathologic diagnosis is useful in establishing the diagnosis of endemic fungi because of their distinctive morphology.", [["infection", "DISEASE", 8, 17], ["hemotoxylin-eosin", "CHEMICAL", 158, 175], ["methenamine silver", "CHEMICAL", 194, 212], ["mucicarmine", "CHEMICAL", 214, 225], ["Fungal infection", "DISEASE", 303, 319], ["eosin", "CHEMICAL", 170, 175], ["Gomori methenamine silver", "CHEMICAL", 187, 212], ["mucicarmine", "CHEMICAL", 214, 225], ["acid-Schiff", "CHEMICAL", 236, 247], ["hemotoxylin-eosin", "SIMPLE_CHEMICAL", 158, 175], ["Gomori methenamine silver", "SIMPLE_CHEMICAL", 187, 212], ["mucicarmine", "SIMPLE_CHEMICAL", 214, 225], ["1Fungal infection", "PROBLEM", 0, 17], ["Direct examination", "TEST", 36, 54], ["light microscopy", "TEST", 58, 74], ["Giemsa", "TEST", 82, 88], ["calcofluor stains", "TEST", 93, 110], ["Culture", "TEST", 115, 122], ["routine stains", "TEST", 142, 156], ["hemotoxylin", "TEST", 158, 169], ["eosin", "TREATMENT", 170, 175], ["special (Gomori methenamine silver", "TREATMENT", 178, 212], ["mucicarmine", "TREATMENT", 214, 225], ["periodic acid-Schiff", "TREATMENT", 227, 247], ["direct immunofluorescence", "TEST", 250, 275], ["Fungal infection", "PROBLEM", 303, 319], ["endemic fungi", "PROBLEM", 405, 418], ["infection", "OBSERVATION", 8, 17], ["infection", "OBSERVATION", 310, 319], ["endemic fungi", "OBSERVATION", 405, 418]]], ["3 However, confusion may occur when attempting to differentiate the hyaline molds that commonly cause invasive disease.", [["hyaline molds", "ANATOMY", 68, 81], ["confusion", "DISEASE", 11, 20], ["confusion", "PROBLEM", 11, 20], ["the hyaline molds", "PROBLEM", 64, 81], ["invasive disease", "PROBLEM", 102, 118], ["hyaline molds", "OBSERVATION", 68, 81], ["invasive disease", "OBSERVATION", 102, 118]]], ["84 Fusarium spp and Scedosporium spp cannot be distinguished from Aspergillus spp in tissue sections and even the zygomycetes, which are morphologically quite distinct from Fusarium spp, The presence of mosaic appearance and ground-glass opacity may represent development of bronchiolitis obliterans syndrome or obliterative bronchiolitis. a In the absence of biopsy categorized as probable: In the presence of histologic findings of both acute rejection and fungal invasion it should be classified as acute rejection with proven fungal infection. b Isolation of non-pathogenic molds in culture (e.g., Cladosporium spp, Phialemonium, Chaetomium, Cunninghamella, Syncephalastrum, Curvularia, Dactylaria, Graphium or Phialophora) or other non-pathogenic fungi [e.g., Penicillium (non-Marnefii), Paecilomyces or basidiomyctes] do not qualify for the \"probable\" category.", [["tissue sections", "ANATOMY", 85, 100], ["zygomycetes", "ANATOMY", 114, 125], ["Fusarium spp", "DISEASE", 173, 185], ["bronchiolitis obliterans syndrome", "DISEASE", 275, 308], ["bronchiolitis", "DISEASE", 325, 338], ["fungal invasion", "DISEASE", 459, 474], ["fungal infection", "DISEASE", 530, 546], ["Fusarium spp", "ORGANISM", 3, 15], ["Scedosporium spp", "ORGANISM", 20, 36], ["Aspergillus spp", "ORGANISM", 66, 81], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 85, 100], ["zygomycetes", "CANCER", 114, 125], ["Fusarium spp", "ORGANISM", 173, 185], ["Cladosporium spp", "ORGANISM", 602, 618], ["Cunninghamella, Syncephalastrum", "ORGANISM", 646, 677], ["Phialophora", "GENE_OR_GENE_PRODUCT", 715, 726], ["non-Marnefii", "ORGANISM", 778, 790], ["Scedosporium spp", "SPECIES", 20, 36], ["Cladosporium spp", "SPECIES", 602, 618], ["Cladosporium spp", "SPECIES", 602, 618], ["Fusarium spp", "TEST", 3, 15], ["Scedosporium spp", "PROBLEM", 20, 36], ["Aspergillus spp in tissue sections", "PROBLEM", 66, 100], ["the zygomycetes", "PROBLEM", 110, 125], ["mosaic appearance", "PROBLEM", 203, 220], ["ground-glass opacity", "PROBLEM", 225, 245], ["bronchiolitis obliterans syndrome", "PROBLEM", 275, 308], ["obliterative bronchiolitis", "PROBLEM", 312, 338], ["biopsy", "TEST", 360, 366], ["both acute rejection", "PROBLEM", 434, 454], ["fungal invasion", "PROBLEM", 459, 474], ["acute rejection", "PROBLEM", 502, 517], ["fungal infection", "PROBLEM", 530, 546], ["non-pathogenic molds in culture", "PROBLEM", 563, 594], ["Cladosporium spp", "TEST", 602, 618], ["Phialemonium", "PROBLEM", 620, 632], ["Chaetomium", "PROBLEM", 634, 644], ["Cunninghamella", "PROBLEM", 646, 660], ["Syncephalastrum", "PROBLEM", 662, 677], ["Curvularia", "PROBLEM", 679, 689], ["Dactylaria", "PROBLEM", 691, 701], ["Graphium", "PROBLEM", 703, 711], ["Phialophora", "PROBLEM", 715, 726], ["other non-pathogenic fungi", "PROBLEM", 731, 757], ["Penicillium (non-Marnefii)", "TREATMENT", 765, 791], ["Paecilomyces", "TREATMENT", 793, 805], ["basidiomyctes", "TREATMENT", 809, 822], ["Scedosporium", "OBSERVATION", 20, 32], ["zygomycetes", "OBSERVATION", 114, 125], ["mosaic", "OBSERVATION_MODIFIER", 203, 209], ["ground-glass opacity", "OBSERVATION", 225, 245], ["may represent", "UNCERTAINTY", 246, 259], ["bronchiolitis obliterans syndrome", "OBSERVATION", 275, 308], ["obliterative", "OBSERVATION_MODIFIER", 312, 324], ["bronchiolitis", "OBSERVATION", 325, 338], ["histologic", "OBSERVATION", 411, 421], ["both", "OBSERVATION_MODIFIER", 434, 438], ["acute", "OBSERVATION_MODIFIER", 439, 444], ["rejection", "OBSERVATION", 445, 454], ["fungal", "OBSERVATION_MODIFIER", 459, 465], ["invasion", "OBSERVATION", 466, 474], ["acute", "OBSERVATION_MODIFIER", 502, 507], ["rejection", "OBSERVATION", 508, 517], ["fungal", "OBSERVATION_MODIFIER", 530, 536], ["infection", "OBSERVATION", 537, 546], ["non-pathogenic molds", "OBSERVATION", 563, 583]]], ["Definitions of fungal pneumonia, tracheobronchitis, bronchial anastomotic infection and colonization in CTTX are given in Tables 4a, 4b, 4c , and 4d, respectively.Other infectious syndromes in cardiothoracic organ transplant recipientsNon-CTTX-specific infections, such as urinary tract infection (UTI), surgical site infection (SSI), bloodstream infection (BSI), infective endocarditis (IE), Clostridium difficile infection (CDI) and skin and soft tissue infections (SSTIs), are not included herein.", [["bronchial", "ANATOMY", 52, 61], ["organ", "ANATOMY", 208, 213], ["urinary tract", "ANATOMY", 273, 286], ["site", "ANATOMY", 313, 317], ["bloodstream", "ANATOMY", 335, 346], ["skin", "ANATOMY", 435, 439], ["soft tissue", "ANATOMY", 444, 455], ["fungal pneumonia", "DISEASE", 15, 31], ["tracheobronchitis", "DISEASE", 33, 50], ["bronchial anastomotic infection", "DISEASE", 52, 83], ["infectious syndromes", "DISEASE", 169, 189], ["infections", "DISEASE", 253, 263], ["urinary tract infection", "DISEASE", 273, 296], ["UTI", "DISEASE", 298, 301], ["surgical site infection", "DISEASE", 304, 327], ["SSI", "DISEASE", 329, 332], ["bloodstream infection", "DISEASE", 335, 356], ["BSI", "DISEASE", 358, 361], ["infective endocarditis", "DISEASE", 364, 386], ["IE", "DISEASE", 388, 390], ["Clostridium difficile infection", "DISEASE", 393, 424], ["CDI", "DISEASE", 426, 429], ["skin and soft tissue infections", "DISEASE", 435, 466], ["SSTIs", "DISEASE", 468, 473], ["bronchial anastomotic", "MULTI-TISSUE_STRUCTURE", 52, 73], ["organ", "ORGAN", 208, 213], ["urinary tract", "ORGANISM_SUBDIVISION", 273, 286], ["Clostridium difficile", "ORGANISM", 393, 414], ["skin", "ORGAN", 435, 439], ["soft tissue", "TISSUE", 444, 455], ["Clostridium difficile", "SPECIES", 393, 414], ["Clostridium difficile", "SPECIES", 393, 414], ["fungal pneumonia", "PROBLEM", 15, 31], ["tracheobronchitis", "PROBLEM", 33, 50], ["bronchial anastomotic infection", "PROBLEM", 52, 83], ["colonization in CTTX", "PROBLEM", 88, 108], ["Other infectious syndromes", "PROBLEM", 163, 189], ["cardiothoracic organ transplant recipients", "TREATMENT", 193, 235], ["specific infections", "PROBLEM", 244, 263], ["urinary tract infection", "PROBLEM", 273, 296], ["UTI", "PROBLEM", 298, 301], ["surgical site infection", "PROBLEM", 304, 327], ["bloodstream infection (BSI", "PROBLEM", 335, 361], ["infective endocarditis", "PROBLEM", 364, 386], ["Clostridium difficile infection", "PROBLEM", 393, 424], ["CDI", "PROBLEM", 426, 429], ["skin and soft tissue infections", "PROBLEM", 435, 466], ["SSTIs", "PROBLEM", 468, 473], ["fungal", "OBSERVATION_MODIFIER", 15, 21], ["pneumonia", "OBSERVATION", 22, 31], ["tracheobronchitis", "OBSERVATION", 33, 50], ["bronchial", "ANATOMY", 52, 61], ["anastomotic infection", "OBSERVATION", 62, 83], ["colonization", "OBSERVATION_MODIFIER", 88, 100], ["infectious", "OBSERVATION", 169, 179], ["cardiothoracic organ", "ANATOMY", 193, 213], ["transplant recipients", "OBSERVATION", 214, 235], ["infections", "OBSERVATION", 253, 263], ["urinary tract", "ANATOMY", 273, 286], ["infection", "OBSERVATION", 287, 296], ["UTI", "OBSERVATION", 298, 301], ["infection", "OBSERVATION", 318, 327], ["bloodstream", "ANATOMY", 335, 346], ["infection", "OBSERVATION", 347, 356], ["infective", "OBSERVATION_MODIFIER", 364, 373], ["endocarditis", "OBSERVATION", 374, 386], ["Clostridium", "OBSERVATION_MODIFIER", 393, 404], ["difficile", "OBSERVATION_MODIFIER", 405, 414], ["infection", "OBSERVATION", 415, 424], ["skin", "ANATOMY", 435, 439], ["soft tissue", "ANATOMY", 444, 455], ["infections", "OBSERVATION", 456, 466]]], ["2,86 -94 The consensus opinion of the ISHLT ID council encourages the use of previously published international definitions for these infections, which have been well established outside of the CTTX population.", [["2,86 -94", "CHEMICAL", 0, 8], ["infections", "DISEASE", 134, 144], ["these infections", "PROBLEM", 128, 144], ["infections", "OBSERVATION", 134, 144]]], ["The use of these standard definitions will allow for intercenter comparisons of rates and types of infections that should not be significantly impacted by the transplant.", [["infections", "DISEASE", 99, 109], ["infections", "PROBLEM", 99, 109], ["the transplant", "TREATMENT", 155, 169], ["infections", "OBSERVATION", 99, 109], ["transplant", "OBSERVATION", 159, 169]]]], "821ffc1f3233eaf9bfb4a56ee7d135b9760de8f7": [["In the past 40 years, healthcare epidemiologists have led responses to community and healthcare outbreaks of novel pathogens, including human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), novel influenza A virus (H1N1), and Ebola virus, in addition to the increased prevalence of antibiotic-resistant pathogens.", [["human immunodeficiency virus (HIV)", "DISEASE", 136, 170], ["acute respiratory syndrome coronavirus", "DISEASE", 179, 217], ["SARS-CoV)", "DISEASE", 219, 228], ["Middle East respiratory syndrome coronavirus", "DISEASE", 230, 274], ["influenza A virus", "DISEASE", 293, 310], ["Ebola virus", "DISEASE", 323, 334], ["human immunodeficiency virus", "ORGANISM", 136, 164], ["HIV", "ORGANISM", 166, 169], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 172, 217], ["SARS-CoV", "ORGANISM", 219, 227], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 230, 274], ["MERS-CoV", "ORGANISM", 276, 284], ["novel influenza A virus", "ORGANISM", 287, 310], ["Ebola virus", "ORGANISM", 323, 334], ["human immunodeficiency virus (HIV", "SPECIES", 136, 169], ["influenza A virus (H1N1", "SPECIES", 293, 316], ["Ebola virus", "SPECIES", 323, 334], ["human immunodeficiency virus", "SPECIES", 136, 164], ["HIV", "SPECIES", 166, 169], ["severe acute respiratory syndrome coronavirus", "SPECIES", 172, 217], ["SARS-CoV", "SPECIES", 219, 227], ["Middle East respiratory syndrome coronavirus", "SPECIES", 230, 274], ["MERS-CoV", "SPECIES", 276, 284], ["influenza A virus", "SPECIES", 293, 310], ["Ebola virus", "SPECIES", 323, 334], ["novel pathogens", "PROBLEM", 109, 124], ["human immunodeficiency virus", "PROBLEM", 136, 164], ["HIV", "PROBLEM", 166, 169], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 172, 217], ["SARS", "PROBLEM", 219, 223], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 230, 274], ["novel influenza A virus (H1N1)", "PROBLEM", 287, 317], ["Ebola virus", "PROBLEM", 323, 334], ["antibiotic", "TREATMENT", 379, 389], ["resistant pathogens", "PROBLEM", 390, 409], ["severe", "OBSERVATION_MODIFIER", 172, 178], ["acute", "OBSERVATION_MODIFIER", 179, 184], ["respiratory syndrome coronavirus", "OBSERVATION", 185, 217], ["Middle", "ANATOMY_MODIFIER", 230, 236], ["respiratory syndrome", "ANATOMY", 242, 262]]], ["Now they are handling novel coronavirus disease 2019 (COVID-19) pandemic responses in facilities across the world, adapting infection prevention and control practices rapidly to save lives while optimizing the use of supplies essential to patient care and healthcare worker safety.", [["coronavirus disease", "DISEASE", 28, 47], ["pandemic", "DISEASE", 64, 72], ["infection", "DISEASE", 124, 133], ["patient", "ORGANISM", 239, 246], ["patient", "SPECIES", 239, 246], ["handling novel coronavirus disease", "PROBLEM", 13, 47], ["infection prevention", "TREATMENT", 124, 144], ["coronavirus disease", "OBSERVATION", 28, 47], ["infection", "OBSERVATION", 124, 133]]]], "cbb2d62e148f5747c7fc7da256ab5fe98c0f2158": [["INTRODUCTIONused to determine the relationships with the gene sets of SARS-CoV/SARS-CoV-2-infected cells.", [["cells", "ANATOMY", 99, 104], ["SARS", "DISEASE", 70, 74], ["SARS-CoV", "ORGANISM", 70, 78], ["SARS-CoV-2", "ORGANISM", 79, 89], ["cells", "CELL", 99, 104], ["infected cells", "CELL_TYPE", 90, 104], ["SARS-CoV", "SPECIES", 70, 78], ["SARS", "TEST", 70, 74], ["CoV/SARS", "TEST", 75, 83], ["CoV", "TEST", 84, 87], ["infected cells", "PROBLEM", 90, 104], ["infected cells", "OBSERVATION", 90, 104]]], ["Among 420 gene sets (as of June, 2020), the gene sets for GSE147507 [9] and GSE148729 and GSE30589 [15] [NCBI`s Gene Expression Omnibus (GEO) Series IDs] (https://www.ncbi.nlm.nih.gov/geo/) were selected. infection/replication, the response observed in IAV-CT_down also suggests that CT could attenuate viral infection and/or replication.INTRODUCTIONIn this study, genes encoding chemokines, some of which are characteristic of cytokine storm, were downregulated in response to CT.", [["infection", "DISEASE", 205, 214], ["viral infection", "DISEASE", 303, 318], ["IAV-CT_down", "ORGANISM", 253, 264], ["chemokines", "PROTEIN", 380, 390], ["cytokine", "PROTEIN", 428, 436], ["the gene sets", "TEST", 40, 53], ["GSE30589", "TEST", 90, 98], ["NCBI`s", "TEST", 105, 111], ["Series IDs", "TEST", 142, 152], ["infection", "PROBLEM", 205, 214], ["replication", "PROBLEM", 215, 226], ["IAV", "PROBLEM", 253, 256], ["CT", "TEST", 284, 286], ["viral infection", "PROBLEM", 303, 318], ["replication", "PROBLEM", 326, 337], ["this study", "TEST", 353, 363], ["cytokine storm", "PROBLEM", 428, 442], ["CT", "TEST", 478, 480], ["viral", "OBSERVATION_MODIFIER", 303, 308], ["infection", "OBSERVATION", 309, 318], ["cytokine storm", "OBSERVATION", 428, 442]]], ["Among these molecules, CCL5 and CXCL9 have been shown to be elevated in response to SARS-CoV-2, SARS-CoV or MERS-CoV infections[9] [21] .", [["infections", "DISEASE", 117, 127], ["CCL5", "GENE_OR_GENE_PRODUCT", 23, 27], ["CXCL9", "GENE_OR_GENE_PRODUCT", 32, 37], ["SARS-CoV-2", "ORGANISM", 84, 94], ["SARS-CoV", "ORGANISM", 96, 104], ["MERS-CoV", "ORGANISM", 108, 116], ["CCL5", "PROTEIN", 23, 27], ["CXCL9", "PROTEIN", 32, 37], ["SARS-CoV", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 96, 104], ["MERS-CoV", "SPECIES", 108, 116], ["CCL5", "TEST", 23, 27], ["CXCL9", "TEST", 32, 37], ["elevated", "PROBLEM", 60, 68], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92], ["SARS", "PROBLEM", 96, 100], ["MERS", "PROBLEM", 108, 112], ["CoV infections", "PROBLEM", 113, 127]]], ["The IAV-CT_down signature also contained CXCL12 and CXCR4, which are thought to be involved in the activation of Th17 cells [22] [23] .INTRODUCTIONOur study has some limitations.", [["Th17 cells", "ANATOMY", 113, 123], ["IAV", "ORGANISM", 4, 7], ["CXCL12", "GENE_OR_GENE_PRODUCT", 41, 47], ["CXCR4", "GENE_OR_GENE_PRODUCT", 52, 57], ["Th17 cells", "CELL", 113, 123], ["IAV-CT_down signature", "DNA", 4, 25], ["CXCL12", "PROTEIN", 41, 47], ["CXCR4", "PROTEIN", 52, 57], ["Th17 cells", "CELL_TYPE", 113, 123], ["CXCL12", "TEST", 41, 47], ["CXCR4", "TEST", 52, 57], ["Th17 cells", "PROBLEM", 113, 123], ["INTRODUCTIONOur study", "TEST", 135, 156], ["thought to be", "UNCERTAINTY", 69, 82], ["Th17 cells", "OBSERVATION", 113, 123]]], ["For instance, we compared IAV and IAV-CT samples and therefore did not observe transcriptome changes in response to CT alone.", [["IAV", "ORGANISM", 26, 29], ["IAV", "ORGANISM", 34, 37], ["IAV", "SPECIES", 26, 29], ["IAV-CT samples", "TEST", 34, 48], ["transcriptome changes", "PROBLEM", 79, 100], ["CT", "TEST", 116, 118]]], ["Although we showed the downregulation of chemokine genes and virus-responsive genes, these changes could be due to the reduction of IAV infection and/or replication.", [["infection", "DISEASE", 136, 145], ["IAV", "ORGANISM", 132, 135], ["chemokine genes", "DNA", 41, 56], ["virus-responsive genes", "DNA", 61, 83], ["IAV", "SPECIES", 132, 135], ["the downregulation of chemokine genes and virus-responsive genes", "PROBLEM", 19, 83], ["IAV infection", "PROBLEM", 132, 145], ["chemokine genes", "OBSERVATION", 41, 56], ["responsive genes", "OBSERVATION", 67, 83], ["IAV", "OBSERVATION_MODIFIER", 132, 135], ["infection", "OBSERVATION", 136, 145]]], ["Further work is needed to clarify the detailed mechanisms of the antiviral effects of CT.INTRODUCTIONIn conclusion, the present study demonstrated the unique gene signatures in response to orally administered CT in IAV-infected mouse spleen tissues.", [["spleen tissues", "ANATOMY", 234, 248], ["IAV", "ORGANISM", 215, 218], ["mouse", "ORGANISM", 228, 233], ["spleen tissues", "TISSUE", 234, 248], ["mouse", "SPECIES", 228, 233], ["IAV", "SPECIES", 215, 218], ["mouse", "SPECIES", 228, 233], ["the present study", "TEST", 116, 133], ["CT", "TEST", 209, 211], ["infected mouse spleen tissues", "OBSERVATION", 219, 248]]], ["Upregulated signatures included redox-related genes, and downregulated genes included chemokines.", [["redox-related genes", "DNA", 32, 51], ["downregulated genes", "DNA", 57, 76], ["chemokines", "PROTEIN", 86, 96], ["Upregulated signatures", "PROBLEM", 0, 22], ["redox-related genes", "PROBLEM", 32, 51], ["downregulated genes included chemokines", "PROBLEM", 57, 96]]], ["Based on a comparison with COVID-19-related public gene set data, CT may attenuate viral infection, replication and the cytokine storm related to COVID-19.", [["viral infection", "DISEASE", 83, 98], ["COVID-19", "DNA", 27, 35], ["cytokine", "PROTEIN", 120, 128], ["COVID-19", "DNA", 146, 154], ["COVID", "TEST", 27, 32], ["CT", "TEST", 66, 68], ["viral infection", "PROBLEM", 83, 98], ["the cytokine storm", "PROBLEM", 116, 134], ["COVID", "TEST", 146, 151], ["viral", "OBSERVATION_MODIFIER", 83, 88], ["infection", "OBSERVATION", 89, 98]]], ["IAV-CON data (see Fig. 1B ) is overlaid with redox-related genes (red circles), chemokine/chemokine receptor genes (blue circles), HMC class I/II genes (purple squares), ISGs (green triangles) and HSP genes (red open triangles).", [["blue circles", "GENE_OR_GENE_PRODUCT", 116, 128], ["HMC class I/II", "GENE_OR_GENE_PRODUCT", 131, 145], ["green triangles)", "GENE_OR_GENE_PRODUCT", 176, 192], ["HSP", "GENE_OR_GENE_PRODUCT", 197, 200], ["red circles", "DNA", 66, 77], ["chemokine/chemokine receptor genes", "DNA", 80, 114], ["blue circles", "DNA", 116, 128], ["HMC class I/II genes", "DNA", 131, 151], ["purple squares", "DNA", 153, 167], ["ISGs", "DNA", 170, 174], ["green triangles", "DNA", 176, 191], ["HSP genes", "DNA", 197, 206], ["red open triangles", "DNA", 208, 226], ["chemokine/chemokine receptor genes", "TREATMENT", 80, 114], ["ISGs (green triangles", "TREATMENT", 170, 191], ["HSP genes", "PROBLEM", 197, 206]]]], "22828ae7e5ade2da9032b49690fb85db80947137": [["The computer can provide fast facts: The Internet was invaluable in allowing me to tell dates of birth and death for persons mentioned in the various chapters; it permitted me to do a lot of important fact-checking.", [["death", "DISEASE", 107, 112], ["persons", "ORGANISM", 117, 124], ["persons", "SPECIES", 117, 124]]], ["On the last (and curiously unnumbered) page of the book, the one item in the book (other than the preface) that is not a record of an address is Osler's recommendations for a \"Bedside Library for Medical Students\" (Osler, last page):Osler's Recommendations\"A liberal education may be had at a very slight cost of time and money.", [["A liberal education", "TREATMENT", 257, 276]]], ["Well filled though the day be with appointed tasks, to make the best possible use of your one or of your ten talents, rest not satisfied with this professional training, but try to get the education, if not of a scholar, at least of a gentleman.", [["this professional training", "TREATMENT", 142, 168]]], ["Before going to sleep read for half an hour, and in the morning have a book open on the dressing table.", [["the dressing table", "TREATMENT", 84, 102]]], ["OldLandmarks in Medical HistoryA good friend once told me, \"There are two kinds of people in the worldthose who travel and those who don't.\"", [["people", "ORGANISM", 83, 89], ["people", "SPECIES", 83, 89]]], ["Sometimes they are a little hard to find; the typical tourist is probably not likely to seek out the Semmelweis Museum in Budapest or the Museum of Questionable Medical Devices at the Science Museum in St. Paul, Minnesota.", [["Medical Devices", "TREATMENT", 161, 176], ["probably not likely", "UNCERTAINTY", 65, 84]]], ["However, visiting the site of an important medical event or a collection of medical artifacts can become the highlight of a trip.Landmarks in Medical HistoryHere is a list of some suggested medical landmarks to visit.", [["medical artifacts", "PROBLEM", 76, 93]]], ["460-377 BCE), and here we visited the two chief medical history attractions of the island.Europe and GreeceThe first, in a quiet city square, is the Plane tree-or at least a descendent of the original tree-under whose branches Hippocrates taught his pupils.", [["tree", "ANATOMY_MODIFIER", 201, 205], ["branches", "ANATOMY_MODIFIER", 218, 226]]], ["The other awe-inspiring medical site is the Aesculapion, the temple of healing built in the fourth century BCE.", [["healing", "OBSERVATION", 71, 78]]], ["Here was built the Aesculapion, a center of healing well known throughout Greece (mentioned in chapter 11).", [["healing", "OBSERVATION", 44, 51]]], ["Sick persons came to spend the night in the sleeping hall, the enkoimitiria, where during the night Aesculapius might help them find their way back to health.", [["persons", "ORGANISM", 5, 12], ["persons", "SPECIES", 5, 12]]], ["The pilgrims to the Aesculapion brought riches to the city and allowed the construction of the nearby amphitheater, famous for its remarkable acoustics.Baths of CaracallaSome may hold that the Baths of Caracalla in Rome are not truly a medical attraction, but I include them to highlight that public health measuresincluding providing clean water and other advances in sanitation-were the chief medical contributions of the ancient Romans.", [["CaracallaSome", "TREATMENT", 161, 174]]], ["Built in the early third century CE during the reign of Emperor Caracalla, the baths are worth a visit during the day or perhaps on a summer evening when the ruins are the backdrop for the Teatro del Opera di Roma.Anatomy Theater in PaduaThe oldest anatomy theater in the world is in Padua, Italy, and it was here that Andreas Vesalius (1514-1564) conducted his anatomic dissections.", [["CE", "CHEMICAL", 33, 35], ["his anatomic dissections", "PROBLEM", 358, 382], ["early", "OBSERVATION_MODIFIER", 13, 18], ["third", "OBSERVATION_MODIFIER", 19, 24], ["century", "OBSERVATION", 25, 32], ["oldest", "OBSERVATION_MODIFIER", 242, 248], ["anatomy", "OBSERVATION", 249, 256], ["anatomic dissections", "OBSERVATION", 362, 382]]], ["Among the other noteworthy persons who taught at the University were Copernicus, Galileo, and Giovanni Battista Morgagni.", [["persons", "ORGANISM", 27, 34], ["persons", "SPECIES", 27, 34], ["Giovanni Battista Morgagni", "TREATMENT", 94, 120]]], ["You will probably need a guide to find this well-preserved architectural treasure among the many halls and rooms of the university.The Hunterian Museum in LondonIn 1783, our own ubiquitous John Hunter, recalled for making surgery a scientific discipline as well as for his syphilitic misadventure and his eventually fatal temper, began what is now the Hunterian Collection of the Royal College of Surgeons in London.", [["surgery", "TREATMENT", 222, 229], ["his syphilitic misadventure", "PROBLEM", 269, 296]]], ["The collection holds thousands of specimens, including 3,500 of Hunter's original preparations, such as a specimen showing his successful ligation of the femoral artery for popliteal aneurysm.Semmelweis Museum in BudapestThe home of Ignaz Semmelweis (1818-1865) in Budapest, Hungary, is now the site of a small museum showing artifacts from his life and a selection of other antique medical items.The Handleless Pump in LondonWe recall that, in 1854, John Snow (1813-1858) helped stop a cholera epidemic in the Broad Street neighborhood of London (see chapter 1).", [["specimens", "ANATOMY", 34, 43], ["specimen", "ANATOMY", 106, 114], ["femoral artery", "ANATOMY", 154, 168], ["popliteal aneurysm", "ANATOMY", 173, 191], ["popliteal aneurysm", "DISEASE", 173, 191], ["cholera", "DISEASE", 487, 494], ["specimens", "CANCER", 34, 43], ["femoral artery", "MULTI-TISSUE_STRUCTURE", 154, 168], ["popliteal aneurysm", "MULTI-TISSUE_STRUCTURE", 173, 191], ["specimens", "TEST", 34, 43], ["a specimen", "TEST", 104, 114], ["his successful ligation of the femoral artery", "TREATMENT", 123, 168], ["popliteal aneurysm", "PROBLEM", 173, 191], ["collection", "OBSERVATION", 4, 14], ["ligation", "OBSERVATION", 138, 146], ["femoral artery", "ANATOMY", 154, 168], ["popliteal", "ANATOMY", 173, 182], ["aneurysm", "OBSERVATION", 183, 191], ["small", "OBSERVATION_MODIFIER", 305, 310], ["museum", "OBSERVATION", 311, 317], ["artifacts", "OBSERVATION", 326, 335]]], ["A short walk from Leicester Square in Soho is Broadwick Street; in 1936, the suffix \"wick\" was added to the name of historic Broad Street-in my opinion, a sad distortion of historical nomenclature.", [["a sad distortion of historical nomenclature", "PROBLEM", 153, 196], ["historical nomenclature", "OBSERVATION", 173, 196]]], ["What is there may be even better: There is a handleless pump, a commemorative plaque, and the John Snow Pub, with some framed memorabilia of Snow's work.", [["plaque", "ANATOMY", 78, 84], ["plaque", "DISEASE", 78, 84], ["a handleless pump", "TREATMENT", 43, 60], ["a commemorative plaque", "PROBLEM", 62, 84], ["handleless pump", "OBSERVATION", 45, 60], ["commemorative", "OBSERVATION_MODIFIER", 64, 77], ["plaque", "OBSERVATION", 78, 84]]], ["Ironically, Snow did not drink alcohol, and yet the only building honoring his memory is a tavern.Pasteur Museum in ParisNestled in the Pasteur Institute in Paris is the Pasteur Museum, opened in 1936.", [["alcohol", "CHEMICAL", 31, 38], ["alcohol", "CHEMICAL", 31, 38], ["alcohol", "SIMPLE_CHEMICAL", 31, 38]]], ["You can view the apartment where Pasteur and his wife lived, and you can visit Pasteur's tomb.Asia and the Middle EastNational Museum of Medical Science History of the Islamic Republic of Iran This museum, opened just a few years ago in Tehran, presents Iran's historical contributions to medical science.", [["Middle", "ANATOMY_MODIFIER", 107, 113]]], ["In 1980, I visited one such medical college and hospital in Beijing, where I witnessed acupuncture, moxibus-tion, cupping using short pieces of bamboo, and cauterization of enlarged tonsils in children.", [["tonsils", "ANATOMY", 182, 189], ["cupping", "DISEASE", 114, 121], ["tonsils", "ORGAN", 182, 189], ["children", "ORGANISM", 193, 201], ["children", "SPECIES", 193, 201], ["bamboo", "TREATMENT", 144, 150], ["cauterization", "TREATMENT", 156, 169], ["enlarged tonsils", "PROBLEM", 173, 189], ["enlarged", "OBSERVATION_MODIFIER", 173, 181], ["tonsils", "OBSERVATION", 182, 189]]], ["(The children, wide awake during the procedure, felt no pain.", [["pain", "DISEASE", 56, 60], ["children", "ORGANISM", 5, 13], ["children", "SPECIES", 5, 13], ["the procedure", "TREATMENT", 33, 46], ["pain", "PROBLEM", 56, 60]]], ["The tonsils have no nerve fibers that conduct pain.)", [["tonsils", "ANATOMY", 4, 11], ["nerve fibers", "ANATOMY", 20, 32], ["pain", "DISEASE", 46, 50], ["tonsils", "ORGAN", 4, 11], ["nerve fibers", "MULTI-TISSUE_STRUCTURE", 20, 32], ["nerve fibers", "PROBLEM", 20, 32], ["pain", "PROBLEM", 46, 50], ["tonsils", "ANATOMY", 4, 11], ["no", "UNCERTAINTY", 17, 19], ["nerve fibers", "OBSERVATION", 20, 32]]], ["Shanghai, for example, has the Museum of Medical History of Shanghai College of Traditional Chinese Medicine.", [["Traditional Chinese Medicine", "TREATMENT", 80, 108]]], ["If the Chinese city you are visiting has a traditional medical college, a tour of the facilities will be memorable.Thoughts Upon (Almost) Completing the Manuscript for This BookThis section is a personal indulgence, and it is risky for two reasons.", [["This BookThis section", "TREATMENT", 168, 189]]], ["Wilhelm Roentgen took the first x-ray film-of his wife's hand.", [["hand", "ANATOMY", 57, 61], ["hand", "ORGANISM_SUBDIVISION", 57, 61], ["the first x-ray film", "TEST", 22, 42], ["hand", "ANATOMY", 57, 61]]], ["Jonas Salk injected his whole family, as well as himself, with his new polio vaccine.", [["Jonas Salk", "ORGANISM", 0, 10], ["his new polio vaccine", "TREATMENT", 63, 84]]], ["The days of heroically putting one's health, and that of one's family, at risk are gone and should not be lamented.The Age of Self-Experimentation Is OverToday, human experimentation is performed under tight control.", [["human", "ORGANISM", 161, 166], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166]]], ["We in academic medicine sometimes grumble about the administrative hurdles placed in our path by institutional review boards and government agencies, but they help to ensure that episodes such as the Tuskegee Syphilis Study will not be repeated.In the Future, Most Discoveries That Change the Course of Medical History Will Be Made by TeamsAs I worked on this book and looked for the name of the single pioneering scientist responsible for breakthroughs in the mapping of the human genome, the control of the hemorrhagic fevers, and the new advances in treating acquired immunodeficiency syndrome (AIDS), I found lists of team members, but no Pasteur, Ehrlich, or Salk.", [["Ehrlich", "ANATOMY", 652, 659], ["Syphilis", "DISEASE", 209, 217], ["hemorrhagic fevers", "DISEASE", 509, 527], ["acquired immunodeficiency syndrome", "DISEASE", 562, 596], ["AIDS", "DISEASE", 598, 602], ["human", "ORGANISM", 476, 481], ["Ehrlich", "CANCER", 652, 659], ["human genome", "DNA", 476, 488], ["human", "SPECIES", 476, 481], ["human", "SPECIES", 476, 481], ["episodes", "PROBLEM", 179, 187], ["the Tuskegee Syphilis Study", "TEST", 196, 223], ["the human genome", "TREATMENT", 472, 488], ["the hemorrhagic fevers", "PROBLEM", 505, 527], ["acquired immunodeficiency syndrome", "PROBLEM", 562, 596], ["hemorrhagic", "OBSERVATION_MODIFIER", 509, 520], ["fevers", "OBSERVATION", 521, 527]]], ["More than 20 years ago, Portland, Oregon otolaryngologist John Epley, MD developed what he believed was an effective and non-invasive treatment for benign paroxysmal positional vertigo.", [["paroxysmal positional vertigo", "DISEASE", 155, 184], ["non-invasive treatment", "TREATMENT", 121, 143], ["benign paroxysmal positional vertigo", "PROBLEM", 148, 184], ["positional vertigo", "OBSERVATION", 166, 184]]], ["It was a simple maneuver involving moving the body to reposition particles in the inner ear canals.", [["body", "ANATOMY", 46, 50], ["inner ear canals", "ANATOMY", 82, 98], ["body", "ORGANISM_SUBDIVISION", 46, 50], ["inner ear canals", "MULTI-TISSUE_STRUCTURE", 82, 98], ["a simple maneuver", "TREATMENT", 7, 24], ["simple", "OBSERVATION_MODIFIER", 9, 15], ["maneuver", "OBSERVATION", 16, 24], ["body", "ANATOMY", 46, 50], ["reposition particles", "OBSERVATION", 54, 74], ["inner", "ANATOMY_MODIFIER", 82, 87], ["ear canals", "ANATOMY", 88, 98]]], ["No surgery and no medication were needed.", [["surgery", "TREATMENT", 3, 10], ["medication", "TREATMENT", 18, 28], ["surgery", "OBSERVATION", 3, 10], ["no", "UNCERTAINTY", 15, 17]]], ["The technique came to be called the Epley maneuver and eventually involved a rotating, computer-controlled chair used to standardize movement of the patient.", [["patient", "ORGANISM", 149, 156], ["patient", "SPECIES", 149, 156], ["a rotating, computer-controlled chair", "TREATMENT", 75, 112]]], ["Nevertheless, Dr. John Eng must have had an \"Aha\" experience when he first realized that a drug for diabetes, now marketed as exenatide (Byetta), might possibly be derived from the venom of the Gila monster.", [["venom", "ANATOMY", 181, 186], ["diabetes", "DISEASE", 100, 108], ["exenatide", "CHEMICAL", 126, 135], ["Byetta", "CHEMICAL", 137, 143], ["exenatide", "SIMPLE_CHEMICAL", 126, 135], ["Byetta", "SIMPLE_CHEMICAL", 137, 143], ["venom", "ORGANISM_SUBSTANCE", 181, 186], ["Gila monster", "ORGANISM", 194, 206], ["Dr. John", "SPECIES", 14, 22], ["diabetes", "PROBLEM", 100, 108], ["exenatide (Byetta)", "TREATMENT", 126, 144]]], ["Because he was a Veteran's Administration (VA) employee and because the VA was not interested in seeking a patent, Eng paid for the patent himself and subsequently licensed the patent to a pharmaceutical company (5) .", [["patent", "OBSERVATION", 107, 113], ["patent", "OBSERVATION", 132, 138], ["patent", "OBSERVATION", 177, 183]]], ["Eng shows that there is still a place in medical science for the persistent, intuitive entrepreneur.Medicine's Linguistic Treasury Continues to GrowThe language of medicine is far from dead.", [["persistent", "OBSERVATION_MODIFIER", 65, 75]]], ["Every year, we create new medical words, phases, syndromes, abbreviations, acronyms, euphemisms, jargon, and slang.", [["euphemisms", "DISEASE", 85, 95], ["syndromes", "PROBLEM", 49, 58], ["euphemisms", "PROBLEM", 85, 95], ["jargon, and slang", "PROBLEM", 97, 114], ["jargon", "OBSERVATION", 97, 103]]], ["During my lifetime, and perhaps yours, we have had the following additions to medicalese: AIDS, human immunodeficiency virus, prion, erectile dysfunction (well known to all who view television today), nutraceutical, telemedicine, and eHealth.", [["erectile", "ANATOMY", 133, 141], ["AIDS", "DISEASE", 90, 94], ["human immunodeficiency virus", "DISEASE", 96, 124], ["erectile dysfunction", "DISEASE", 133, 153], ["human immunodeficiency virus", "ORGANISM", 96, 124], ["erectile", "TISSUE", 133, 141], ["human", "SPECIES", 96, 101], ["immunodeficiency virus", "SPECIES", 102, 124], ["human immunodeficiency virus", "SPECIES", 96, 124], ["AIDS", "PROBLEM", 90, 94], ["human immunodeficiency virus", "PROBLEM", 96, 124], ["erectile dysfunction", "PROBLEM", 133, 153]]], ["In prior chapters, I described jersey finger, runner's knee, Legionnaires disease, Fred Astaire legs, and the Salk vaccine.", [["knee", "ANATOMY", 55, 59], ["Legionnaires disease", "DISEASE", 61, 81], ["finger", "ORGANISM_SUBDIVISION", 38, 44], ["knee", "ORGANISM_SUBDIVISION", 55, 59], ["legs", "ORGANISM_SUBDIVISION", 96, 100], ["Legionnaires disease", "PROBLEM", 61, 81], ["Fred Astaire legs", "TREATMENT", 83, 100], ["the Salk vaccine", "TREATMENT", 106, 122], ["knee", "ANATOMY", 55, 59], ["Legionnaires", "OBSERVATION", 61, 73], ["legs", "ANATOMY", 96, 100]]], ["A few paragraphs ago, I told of the Epley maneuver; this technique is not in my current edition of Stedman's Electronic Medical Dictionary but probably will be at some point in the future.", [["the Epley maneuver", "TREATMENT", 32, 50], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["We have developed a host of new abbreviations, acronyms, and slang expressions: WASP (wait-and-see prescription), PET (positron emission tomography), SARS (severe acute respiratory syndrome), and EMR (electronic medical record).", [["SARS", "DISEASE", 150, 154], ["acute respiratory syndrome", "DISEASE", 163, 189], ["WASP", "GENE_OR_GENE_PRODUCT", 80, 84], ["WASP", "PROTEIN", 80, 84], ["new abbreviations", "PROBLEM", 28, 45], ["PET (positron emission tomography", "TEST", 114, 147], ["SARS (severe acute respiratory syndrome", "PROBLEM", 150, 189], ["host", "OBSERVATION_MODIFIER", 20, 24], ["new", "OBSERVATION_MODIFIER", 28, 31], ["abbreviations", "OBSERVATION", 32, 45], ["severe", "OBSERVATION_MODIFIER", 156, 162], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["respiratory syndrome", "OBSERVATION", 169, 189]]], ["We also have learned the meanings of commonly used abbreviations such as NSAID (non-steroidal anti-inflammatory drug) and some that are more specialized, such as UVAL (ultraviolet argon laser).", [["UVAL", "CHEMICAL", 162, 166], ["UVAL", "CHEMICAL", 162, 166], ["NSAID", "SIMPLE_CHEMICAL", 73, 78], ["UVAL", "SIMPLE_CHEMICAL", 162, 166], ["NSAID (non-steroidal anti-inflammatory drug", "TREATMENT", 73, 116], ["UVAL (ultraviolet argon laser", "TREATMENT", 162, 191]]], ["Medicine can take less pride in the creation of squash (brain), fascinoma (an interesting and unexpected clinical finding), and positive gown sign (painting a somewhat graphic image of a patient who exits the hospital with neither permission nor street clothes).Medicine's Linguistic Treasury Continues to GrowHow rapidly is medicine's vocabulary growing?", [["brain", "ANATOMY", 56, 61], ["fascinoma", "ANATOMY", 64, 73], ["fascinoma", "DISEASE", 64, 73], ["squash", "ORGANISM_SUBDIVISION", 48, 54], ["brain", "ORGAN", 56, 61], ["fascinoma", "CANCER", 64, 73], ["patient", "ORGANISM", 187, 194], ["patient", "SPECIES", 187, 194], ["Medicine", "TREATMENT", 0, 8], ["fascinoma", "PROBLEM", 64, 73], ["positive gown sign", "PROBLEM", 128, 146], ["brain", "ANATOMY", 56, 61]]], ["By 2000, when the 29th edition of Dorland's was published, the book had ballooned to 2,088 pages describing 121,000 items.", [["Dorland's", "TREATMENT", 34, 43]]], ["In four short years, we added 4,000 new medical words, phrases, and abbreviations.Medicine's Linguistic Treasury Continues to GrowYes, staying current in medicine today involves knowing not only new tests, drugs, and procedures, but new medical words and their permutations.A Medical Scholar Can Do a Lot of Research Quickly on the Internet; Not Everything Found There Is AccurateFor example, I told above about Dr. John Eng paying for the patent for what is now the drug exenatide with his own money.", [["exenatide", "CHEMICAL", 472, 481], ["exenatide", "SIMPLE_CHEMICAL", 472, 481], ["drugs", "TREATMENT", 206, 211], ["procedures", "TREATMENT", 217, 227], ["the drug exenatide", "TREATMENT", 463, 481], ["patent", "OBSERVATION", 440, 446]]], ["Although the Internet has several sites telling about Eng and his discovery, the only source I could find telling about his personal payment for the patent was http://www. mendosa.com/monster.htm (5) .", [["patent", "OBSERVATION", 149, 155]]], ["This Web site is entitled Mendosa.com, with the subtitle: Your On-Line Diabetes Resource.", [["Diabetes", "DISEASE", 71, 79]]], ["The author isDavid Mendosa.", [["David Mendosa", "OBSERVATION", 13, 26]]], ["I like Mendosa's story about Dr. Eng and his patent.", [["patent", "OBSERVATION", 45, 51]]], ["Because Mendosa's piece provides no reference citations, I am not quite sure.", [["Mendosa's piece", "TREATMENT", 8, 23]]], ["With appropriate skepticism, I pondered facts presented by Web sites maintained by advocacy groups, such as organizations concerned with single diseases (e.g., Morgellon disease), and I skipped by Web sites whose URL (uniform resource locator) contains words such as Aquarius, underground, and celestial.Some of the Heroes Described in This Book Lived and Died During My LifetimeThese include Alexander Fleming (died in 1955), Abraham Flexner (died in 1959), and Jonas Salk (died in 1995).", [["Morgellon disease", "DISEASE", 160, 177], ["single diseases (e.g., Morgellon disease)", "PROBLEM", 137, 178], ["skepticism", "OBSERVATION", 17, 27]]], ["I wish that I had met these men.", [["men", "ORGANISM", 28, 31], ["men", "SPECIES", 28, 31]]], ["While in private practice in upstate New York, I met cardiologist Paul Dudley White when he spoke at a county medical society meeting; he struck me as a kind, humble man.", [["man", "ORGANISM", 166, 169], ["man", "SPECIES", 166, 169]]], ["I won't try to be Nostradamus and predict specific events in the future, but during the lifetimes of today's young physicians, we can hope to see effective vaccines for the infectious diseases to which we are currently vulnerable (e.g., AIDS), some means to prevent cancers of various types, and interventions to help patients avoid chronic diseases such as diabetes mellitus and hypertension.Until Medical Schools and Residencies Offer Courses in Medical History, Culture, and Linguistics, There Will Be a Need for Books Like ThisFrom time to time, I mention an event in medical history to a medical student or resident.", [["cancers", "ANATOMY", 266, 273], ["infectious diseases", "DISEASE", 173, 192], ["AIDS", "DISEASE", 237, 241], ["cancers", "DISEASE", 266, 273], ["diabetes mellitus", "DISEASE", 358, 375], ["hypertension", "DISEASE", 380, 392], ["cancers", "CANCER", 266, 273], ["patients", "ORGANISM", 318, 326], ["patients", "SPECIES", 318, 326], ["effective vaccines", "TREATMENT", 146, 164], ["the infectious diseases", "PROBLEM", 169, 192], ["cancers of various types", "PROBLEM", 266, 290], ["interventions", "TREATMENT", 296, 309], ["chronic diseases", "PROBLEM", 333, 349], ["diabetes mellitus", "PROBLEM", 358, 375], ["hypertension", "PROBLEM", 380, 392], ["Culture", "TEST", 465, 472], ["hypertension", "OBSERVATION", 380, 392]]], ["Every month, when I teach a headache seminar for third-year students, I tell the story of ergot and St. Anthony's fire.", [["headache", "DISEASE", 28, 36]]], ["I describe how Lewis Carroll might have visualized some characters in Alice's Adventures in Wonderland as part of a migraine aura visual distortion.", [["migraine aura visual distortion", "DISEASE", 116, 147], ["a migraine aura visual distortion", "PROBLEM", 114, 147], ["migraine aura", "OBSERVATION", 116, 129], ["visual distortion", "OBSERVATION", 130, 147]]], ["Only a few synaptic connections.Until Medical Schools and Residencies Offer Courses in Medical History, Culture, and Linguistics, There Will Be a Need for Books Like ThisFortunately, when I attended Temple Medical School long ago, we had some excellent lectures in medical history.", [["synaptic", "ANATOMY", 11, 19], ["Culture", "TEST", 104, 111], ["few", "OBSERVATION_MODIFIER", 7, 10], ["synaptic connections", "OBSERVATION", 11, 31]]], ["I recall the image of Joseph Auenbrugger (1722-1809), inventor of percussion as a diagnostic maneuver, tapping on wine barrels filled to various levels.", [["percussion", "TREATMENT", 66, 76], ["a diagnostic maneuver", "TEST", 80, 101]]], ["Embarrassed to place his ear directly on the chest of a young woman he was examining, Laennec rolled several sheets of paper to make a tube that could carry sound from her chest to his ear.", [["ear", "ANATOMY", 25, 28], ["chest", "ANATOMY", 45, 50], ["tube", "ANATOMY", 135, 139], ["chest", "ANATOMY", 172, 177], ["ear", "ANATOMY", 185, 188], ["ear", "ORGAN", 25, 28], ["chest", "ORGANISM_SUBDIVISION", 45, 50], ["woman", "ORGANISM", 62, 67], ["tube", "TISSUE", 135, 139], ["chest", "ORGANISM_SUBDIVISION", 172, 177], ["ear", "ORGAN", 185, 188], ["woman", "SPECIES", 62, 67], ["a tube", "TREATMENT", 133, 139], ["ear", "ANATOMY", 25, 28], ["chest", "ANATOMY", 45, 50], ["chest", "ANATOMY", 172, 177], ["ear", "ANATOMY", 185, 188]]], ["1 suspect not many.", [["not", "UNCERTAINTY", 10, 13], ["many", "OBSERVATION_MODIFIER", 14, 18]]], ["Until we senior physicians once again assume responsibility for passing on the oral history of our discipline, books like this will be needed.Some Medical Truths Are Best Learned From Patients, Not From BooksI will share one example, humorously encapsulated by Woody Allen: \"Eighty percent of life is showing up.\" 1 remember one day that-counter to all logic-I drove 18 miles over snowy roads to make a very routine hospital visit to an elderly patient.", [["oral", "ANATOMY", 79, 83], ["oral", "ORGANISM_SUBDIVISION", 79, 83], ["Patients", "ORGANISM", 184, 192], ["patient", "ORGANISM", 445, 452], ["Patients", "SPECIES", 184, 192], ["patient", "SPECIES", 445, 452]]], ["That day 1 felt especially proud to be a physician, and the snowy drive home didn't seem as long as the trip to the hospital.Some Medical Truths Are Best Learned From Patients, Not From BooksA less happy lesson was learned in my very first year in practice.", [["Patients", "ORGANISM", 167, 175], ["Patients", "SPECIES", 167, 175]]], ["My patient, an older man, quite overweight and severely diabetic, was dying.", [["overweight", "DISEASE", 32, 42], ["diabetic", "DISEASE", 56, 64], ["patient", "ORGANISM", 3, 10], ["man", "ORGANISM", 21, 24], ["patient", "SPECIES", 3, 10], ["man", "SPECIES", 21, 24], ["severely diabetic", "PROBLEM", 47, 64], ["diabetic", "OBSERVATION", 56, 64]]], ["I kept seeing my scheduled patients and dispatched the \"house call\" doctor to my patient's home.", [["patients", "ORGANISM", 27, 35], ["patient", "ORGANISM", 81, 88], ["patients", "SPECIES", 27, 35], ["patient", "SPECIES", 81, 88]]], ["He pronounced the patient dead, doing the job that needed to be done.Some Medical Truths Are Best Learned From Patients, Not From BooksThe next time I saw the widow, she began to weep.", [["patient", "ORGANISM", 18, 25], ["Patients", "ORGANISM", 111, 119], ["patient", "SPECIES", 18, 25], ["Patients", "SPECIES", 111, 119], ["weep", "OBSERVATION", 179, 183]]], ["He was your patient.\"", [["patient", "ORGANISM", 12, 19], ["patient", "SPECIES", 12, 19]]], ["If there are ever times when persons remember every detail of what happens, it is at times of major life events; death is one of these.Some Medical Truths Are Best Learned From Patients, Not From BooksYou really can't learn lessons such as these from books.Physicians Enjoy the Trust and Privilege We Do Today Because of the Dedication and Sacrifice of Generation of Healers That Have Gone Before Us-Only a Few of Whom Are Described in These PagesMedical students and young physicians often do not understand this simple truth and seem to assume that the faith and respect that patients accord them is something that they somehow merit.", [["death", "DISEASE", 113, 118], ["persons", "ORGANISM", 29, 36], ["Patients", "ORGANISM", 177, 185], ["patients", "ORGANISM", 578, 586], ["persons", "SPECIES", 29, 36], ["Patients", "SPECIES", 177, 185], ["patients", "SPECIES", 578, 586], ["death", "PROBLEM", 113, 118]]], ["With few exceptions, our patients do trust us.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["For the experienced physician, the trust comes from past actions, but it comes also from patients' subconscious memories of their childhood physicians, the legends of Hippocrates and Maimonides, the discoveries of Pasteur and Fleming, and the clinical skills of Freud and Osler.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["Maimonides", "TREATMENT", 183, 193]]], ["We must be hardworking, resourceful, and patient-centered.", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48]]], ["As Phillips and Haynes wrote (see chapter 8), we must \"be there\" when our patients need us.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82]]], ["We must always act with integrity and do what is right for the patient, striving to be the physician our patients believe us to be.Tomorrow's White Coat TalesSome of the tales we will tell young physicians in the future will be about what happens today and tomorrow-perhaps in your examination room or hospital.", [["patient", "ORGANISM", 63, 70], ["patients", "ORGANISM", 105, 113], ["patient", "SPECIES", 63, 70], ["patients", "SPECIES", 105, 113]]], ["Some of these stories will concern AIDS, which Oldstone calls \"a plague as bad as any ever known\" (p.", [["AIDS", "DISEASE", 35, 39]]], ["Other viruses also threaten us, including Ebola, Marburg, and Ranta viruses.", [["Ebola, Marburg, and Ranta viruses", "DISEASE", 42, 75], ["Ebola", "ORGANISM", 42, 47], ["Ranta viruses", "ORGANISM", 62, 75], ["Ebola", "PROBLEM", 42, 47], ["viruses", "OBSERVATION", 6, 13]]], ["Could one of them mutate in a way that matches or even exceeds the devastation caused by the 1918 influenza pandemic?", [["influenza", "DISEASE", 98, 107]]], ["Then there is the concern that avian influenza (R5N1) will become a pandemic with human-to-human transmission.Tomorrow's White Coat TalesOn the more positive side, we can expect many new developments in genetic screening and gene therapy.", [["avian influenza", "DISEASE", 31, 46], ["human-to-human transmission", "DISEASE", 82, 109], ["avian influenza", "ORGANISM", 31, 46], ["human", "ORGANISM", 82, 87], ["human", "ORGANISM", 91, 96], ["avian influenza", "SPECIES", 31, 46], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 91, 96], ["R5N1", "SPECIES", 48, 52], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 91, 96], ["avian influenza", "PROBLEM", 31, 46], ["genetic screening", "TEST", 203, 220], ["gene therapy", "TREATMENT", 225, 237]]], ["Electronic technology promises to revolutionize day-by-day patient care, with electronic medical records serving as the platform.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66]]], ["In years to come, we will see innovations in messaging between patients and physicians, virtual office visits and home visits, online group therapy, and much more.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["online group therapy", "TREATMENT", 127, 147]]], ["Robotic surgery is already a reality, and we will see innovations that are difficult to imagine today.", [["Robotic surgery", "TREATMENT", 0, 15]]], ["In the end, perhaps we will even begin to conquer some of America's actual causes of death, which include tobacco use, poor diet and physical inactivity, excessive alcohol consumption, motor vehicle accidents, careless sexual behavior, and illicit drug use (6) .Tomorrow and YouIn the meantime, while the dramas that will generate tomorrow's tales are unfolding, what should you and I do?", [["death", "DISEASE", 85, 90], ["alcohol", "CHEMICAL", 164, 171], ["motor vehicle accidents", "DISEASE", 185, 208], ["careless sexual behavior", "DISEASE", 210, 234], ["alcohol", "CHEMICAL", 164, 171], ["tobacco", "ORGANISM", 106, 113], ["tobacco", "SPECIES", 106, 113], ["death", "PROBLEM", 85, 90]]], ["Medicine is much more than seeing your 20 patients in the office tomorrow, more than performing three operations or passing an endoscope four times in the morning, more than making hospital rounds or visiting a patient in the nursing home or whatever else your specialty calls for you to do in your workday.", [["patients", "ORGANISM", 42, 50], ["patient", "ORGANISM", 211, 218], ["patients", "SPECIES", 42, 50], ["patient", "SPECIES", 211, 218], ["an endoscope", "TREATMENT", 124, 136]]], ["How can we-in some small way-help pass on the history of medicine to the next generation?", [["medicine", "TREATMENT", 57, 65]]], ["Begin a program of reading about medical giants, language, and culture.", [["culture", "TEST", 63, 70]]], ["Keep an enrichment book at your bedside and read a little each night. \u2022 Make the extra effort to learn about newly encountered medical terms and syndromes.", [["syndromes", "PROBLEM", 145, 154]]], ["Look up clinical word origins and search out the life stories of persons for whom diseases and syndromes are named.", [["persons", "ORGANISM", 65, 72], ["persons", "SPECIES", 65, 72], ["syndromes", "PROBLEM", 95, 104]]], ["You may have noted a previously unreported cluster of diseases or an unusual manifestation of an illness.", [["diseases", "PROBLEM", 54, 62], ["an illness", "PROBLEM", 94, 104], ["diseases", "OBSERVATION", 54, 62], ["illness", "OBSERVATION", 97, 104]]], ["When you have a thought worth sharing, consider writing a short piece and submitting it for publication.", [["a short piece", "TREATMENT", 56, 69]]], ["Your medical knowledge and mine also has its roots in the lore of medicine.", [["roots", "ANATOMY", 45, 50], ["roots", "ORGAN", 45, 50]]], ["I urge you to stop often and reflect that every diagnostic maneuver, every therapeutic intervention, and every word and phrase in medicine come from some source, some person, or some event in history.", [["person", "SPECIES", 167, 173], ["therapeutic intervention", "TREATMENT", 75, 99]]], ["200):Tomorrow and YouIn your future work, you will be in good company.", [["You", "SPECIES", 18, 21]]], ["The great physicians of history, the glorious figures of the past, will always be near you.", [["great", "OBSERVATION_MODIFIER", 4, 9]]], ["When you perform a dissection, a red-bearded young man with flashing eyes, Andreas Vesalius, will be peering over your shoulder; when you conduct a physiological experiment, the melancholy, pensive eyes of William Harvey will be watching you; when you teach medicine, the venerable figure of William Osler with his Apollonian head will come and sit like a medical Goethe beside you; and when you approach the sickbed, the shades of Hippocrates, Sydenham, and Fleming will gather round to counsel you, the young princes [and princesses] of our profession.", [["eyes", "ANATOMY", 69, 73], ["eyes", "ANATOMY", 198, 202], ["man", "ORGANISM", 51, 54], ["eyes", "ORGAN", 69, 73], ["shoulder", "ORGANISM_SUBDIVISION", 119, 127], ["eyes", "ORGAN", 198, 202], ["head", "ORGANISM_SUBDIVISION", 326, 330], ["man", "SPECIES", 51, 54], ["a dissection", "TREATMENT", 17, 29], ["flashing eyes", "PROBLEM", 60, 73], ["dissection", "OBSERVATION", 19, 29], ["shoulder", "ANATOMY", 119, 127]]]], "PMC7112338": [["Human airway epithelia reconstituted in\u00a0vitro (MucilAir) ::: MethodsMucilAir tissues (Epithelix S\u00e0rl, Geneva, Switzerland) were cultured at the air-liquid interface from a mixture of nasal polyp epithelial cells originating from 14 healthy donors, as previously described.16", [["airway epithelia", "ANATOMY", 6, 22], ["MethodsMucilAir tissues", "ANATOMY", 61, 84], ["nasal polyp epithelial cells", "ANATOMY", 183, 211], ["Human", "ORGANISM", 0, 5], ["airway epithelia", "TISSUE", 6, 22], ["MethodsMucilAir tissues", "TISSUE", 61, 84], ["nasal polyp epithelial cells", "CELL", 183, 211], ["donors", "ORGANISM", 240, 246], ["nasal polyp epithelial cells", "CELL_TYPE", 183, 211], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["MethodsMucilAir tissues", "TREATMENT", 61, 84], ["nasal polyp epithelial cells", "PROBLEM", 183, 211], ["airway epithelia", "ANATOMY", 6, 22], ["nasal", "ANATOMY", 183, 188], ["polyp epithelial cells", "OBSERVATION", 189, 211]]]], "a20dd414ae35d60f68f110278416af7f783f8800": [["Die Auswirkungen auf die Allgemein-und Viszeralchirurgie waren besonders deutlich: Um Krankenhauskapazit\u00e4ten f\u00fcr COVID-19-Patienten bereitzustellen, mussten elektive Operationen ausgesetzt und verschoben werden.", [["Die Auswirkungen auf die Allgemein-und Viszeralchirurgie waren besonders deutlich: Um Krankenhauskapazit\u00e4ten f\u00fcr COVID-19-Patienten bereitzustellen, mussten elektive Operationen ausgesetzt und verschoben werden", "SPECIES", 0, 210], ["COVID", "TEST", 113, 118]]], ["Nun d\u00fcrfen die Bettenkapazit\u00e4ten schrittweise wieder f\u00fcr elektive Eingriffe freigegeben und genutzt werden.", [["Nun", "TREATMENT", 0, 3]]], ["In diesem Beitrag werden die Wahrnehmungen und Erfahrungswerte der Ordinarien f\u00fcr Allgemein-und Viszeralchirurgie in Deutschland in dieser fr\u00fchen Pandemiephase vorgestellt.HintergrundEnde Dezember 2019 wurde in der Stadt Wuhan, China, erstmalig eine durch ein neuartiges Coronavirus (SARS-CoV-2) verursachte Lungenerkrankung beschrieben, die am 11.02.2020 von der Die Autoren C. St\u00f6\u00df und H. Haffer haben zu gleichen Teilen zur Arbeit beigetragen.HintergrundAus Gr\u00fcnden der besseren Lesbarkeit wird in diesem Beitrag \u00fcberwiegend das generische Maskulinum verwendet.", [["erstmalig eine durch ein neuartiges Coronavirus (SARS-CoV-2) verursachte Lungenerkrankung beschrieben, die am 11.02.2020 von der Die Autoren C. St\u00f6\u00df und H. Haffer haben zu gleichen Teilen zur Arbeit beigetragen", "SPECIES", 235, 445], ["Coronavirus", "PROBLEM", 271, 282]]], ["Dies impliziert immer beide Formen, schlie\u00dft also die weibliche Form mit ein.HintergrundWorld Health Organization (WHO) als \"coronavirus disease 2019\" (COVID-19) bezeichnet wurde [1] [2] [3] .", [["coronavirus disease", "DISEASE", 125, 144], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 179, 190], ["als \"coronavirus disease", "PROBLEM", 120, 144], ["COVID", "TEST", 152, 157]]], ["Um Krankenhauskapazit\u00e4ten, Schutzausr\u00fcstungen und Beatmungsger\u00e4te f\u00fcr eine steigende Zahl von COVID-19-Patienten bereitzustellen, wurden die chirurgischen Fachdisziplinen angewiesen, alle elektiven Operationen zu verschieben und Personal bei Bedarf auf Intensiv-und COVID-19-Stationen umzuverteilen [5] .", [["Schutzausr\u00fcstungen und Beatmungsger\u00e4te f\u00fcr eine steigende Zahl von COVID-19-Patienten bereitzustellen, wurden die chirurgischen Fachdisziplinen angewiesen, alle elektiven Operationen zu verschieben und Personal bei Bedarf auf Intensiv-und COVID-19-Stationen umzuverteilen", "SPECIES", 27, 298], ["Schutzausr\u00fcstungen", "TREATMENT", 27, 45]]], ["Die Deutsche Gesellschaft f\u00fcr Allgemein-und Viszeralchirurgie ver\u00f6ffentlichte am 22.03.2020 eine Stellungnahme mit einem \u00dcberblick dringlicher Operationseingriffe, die als noch durchf\u00fchrbar anzusehen waren [6] .", [["Die Deutsche Gesellschaft f\u00fcr Allgemein-und Viszeralchirurgie ver\u00f6ffentlichte am 22.03.2020 eine Stellungnahme mit einem \u00dcberblick dringlicher Operationseingriffe, die als noch durchf\u00fchrbar anzusehen waren", "SPECIES", 0, 205]]], ["Ende April nach Abschluss der vorliegenden Befragung beschloss die deutsche BundesregierungStatistische AnalyseDie deskriptive Datenanalyse wurde mit Microsoft Excel 2019 (Microsoft, Redmond, WA, USA) durchgef\u00fchrt.", [["Ende April nach Abschluss der vorliegenden Befragung beschloss die deutsche BundesregierungStatistische AnalyseDie deskriptive Datenanalyse wurde mit Microsoft Excel 2019 (Microsoft, Redmond, WA, USA) durchgef\u00fchrt", "SPECIES", 0, 213]]], ["Die Angaben erfolgen als absolute sowie relative Zahlen und als Mittelwert (\u00b1 Standardabweichung).Allgemeine CharakteristikenInsgesamt nahmen 73 % der Befragten an der Umfrage teil.", [["Allgemeine CharakteristikenInsgesamt nahmen", "TREATMENT", 98, 141]]], ["Die Teilnehmer waren zu 93 % m\u00e4nnlich.", [["Die Teilnehmer waren zu 93", "SPECIES", 0, 26]]], ["Acht (28 %) der 29 Befragten waren unter 50 Jahre alt, 21 (72 %) waren \u00e4lter als 50 Jahre.", [["Acht", "TEST", 0, 4], ["Jahre alt", "TEST", 44, 53]]], ["Hinsichtlich der Krankenhausgr\u00f6\u00dfe (Anzahl an Betten) gaben 20 der 29 Befragten (69 %) eine Gr\u00f6\u00dfe von \u00fcber 1000 Betten an.", [["Hinsichtlich der Krankenhausgr\u00f6\u00dfe (Anzahl an Betten) gaben", "TREATMENT", 0, 58]]], ["Sieben (24 %) gaben an, unter 50 Intensivbetten im Krankenhaus zur Verf\u00fcgung zu haben.", [["Sieben", "CHEMICAL", 0, 6], ["gaben", "CHEMICAL", 14, 19], ["Sieben", "CHEMICAL", 0, 6]]], ["Zehn (34 %) bzw.", [["Zehn", "TEST", 0, 4]]], ["12 (41 %) gaben eine Gesamtzahl verf\u00fcgbarer Intensivbetten von 51 bis 100 bzw. \u00fcber 100 an.", [["bis", "TEST", 66, 69]]], ["Tab.", [["Tab", "GENE_OR_GENE_PRODUCT", 0, 3]]], ["1).Wahrnehmung der Politik und Kooperation mit den Beh\u00f6rdenDer Aussage, dass die Informationsvermittlung der Politik zur SARS-CoV-2-Pandemie ausreichend war, stimmten 10 % und 59 % der Klinikdirektoren voll zu bzw. zu (.", [["Wahrnehmung der Politik und Kooperation mit den Beh\u00f6rdenDer Aussage, dass die Informationsvermittlung der Politik zur SARS-CoV-2-Pandemie ausreichend war, stimmten 10 % und 59 % der Klinikdirektoren voll zu bzw", "SPECIES", 3, 213], ["CoV", "TEST", 126, 129]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["Die Informationspolitik der Gesundheitsbeh\u00f6rden empfanden 48 % der Befragten als angemessen (Schl\u00fcsselw\u00f6rterDeutsches Gesundheitssystem \u00b7 Allgemeinund Viszeralchirurgie \u00b7 Umstrukturierungen \u00b7 Versorgungsqualit\u00e4t \u00b7 Universit\u00e4tsmedizin Effects of the SARS-CoV-2 pandemic on surgery -a national crosssectional study Abstract Background and aims.", [["SARS", "DISEASE", 249, 253], ["Die Informationspolitik der Gesundheitsbeh\u00f6rden empfanden 48 % der Befragten als angemessen (Schl\u00fcsselw\u00f6rterDeutsches Gesundheitssystem \u00b7 Allgemeinund Viszeralchirurgie \u00b7 Umstrukturierungen \u00b7 Versorgungsqualit\u00e4t \u00b7 Universit\u00e4tsmedizin", "SPECIES", 0, 233], ["Versorgungsqualit\u00e4t", "TREATMENT", 192, 211], ["the SARS", "PROBLEM", 245, 253], ["surgery", "TREATMENT", 272, 279], ["a national crosssectional study", "TEST", 281, 312]]], ["From the beginning of the SARS-CoV-2 pandemic the German healthcare system focused on the treatment of COVID-19 patients.", [["SARS", "DISEASE", 26, 30], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["COVID", "TEST", 103, 108]]], ["This was accompanied by the suspension of all elective operations.", [["all elective operations", "TREATMENT", 42, 65], ["suspension", "OBSERVATION_MODIFIER", 28, 38], ["elective", "OBSERVATION_MODIFIER", 46, 54], ["operations", "OBSERVATION", 55, 65]]], ["The aim of this study was to investigate the impact of the SARS-CoV-2 pandemic on general and visceral surgery in university hospitals in Germany.", [["visceral", "ANATOMY", 94, 102], ["SARS", "DISEASE", 59, 63], ["CoV-2", "ORGANISM", 64, 69], ["visceral", "ORGANISM_SUBDIVISION", 94, 102], ["this study", "TEST", 11, 21], ["the SARS", "PROBLEM", 55, 63], ["general and visceral surgery", "TREATMENT", 82, 110], ["visceral", "ANATOMY", 94, 102]]], ["This cross-sectional study was based on an anonymous survey, which was accessible online from 3 April 2020 to 17 April 2020 for the surgical departments of university hospitals in Germany.", [["This cross-sectional study", "TEST", 0, 26], ["an anonymous survey", "TEST", 40, 59]]], ["Cooperation with the authorities and the hospital administration was generally considered adequate; however, only 3% (1/29) and 7% (2/29) fully agreed with the statement that the health authorities at the federal and state level, respectively, were supportive of general and visceral surgery.", [["visceral", "ANATOMY", 275, 283], ["visceral", "TISSUE", 275, 283], ["general and visceral surgery", "TREATMENT", 263, 291], ["visceral", "ANATOMY", 275, 283], ["surgery", "OBSERVATION", 284, 291]]], ["The hospital directors expect an average loss of revenues of 28 \u00b1 16%.", [["average", "OBSERVATION_MODIFIER", 33, 40], ["loss", "OBSERVATION_MODIFIER", 41, 45]]], ["There was an average reduction in beds or operating room capacity of 38% and 45%, respectively.", [["operating room capacity", "TEST", 42, 65], ["average", "OBSERVATION_MODIFIER", 13, 20], ["reduction", "OBSERVATION_MODIFIER", 21, 30]]], ["In addition, 11% of the medical personnel in general and visceral surgery were reallocated to other departments.", [["visceral", "ANATOMY", 57, 65], ["visceral", "ORGANISM_SUBDIVISION", 57, 65], ["visceral surgery", "TREATMENT", 57, 73], ["visceral", "ANATOMY", 57, 65]]], ["The SARS-CoV-2 pandemic has a significant impact on academic general and visceral surgery in Germany.", [["visceral", "ANATOMY", 73, 81], ["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["visceral", "TISSUE", 73, 81], ["The SARS", "TEST", 0, 8], ["visceral surgery", "TREATMENT", 73, 89], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["impact", "OBSERVATION_MODIFIER", 42, 48], ["visceral", "ANATOMY", 73, 81], ["surgery", "OBSERVATION", 82, 89]]], ["The reduction in beds and operating room capacity can lead to considerable delays in urgent surgical interventions and financial burdens in 2020 and subsequent years.KeywordsGerman healthcare system \u00b7 General and visceral surgery \u00b7 Restructuring \u00b7 Quality of care \u00b7 University medicineDer ChirurgAbb.", [["visceral", "ANATOMY", 213, 221], ["visceral", "TISSUE", 213, 221], ["The reduction in beds", "TREATMENT", 0, 21], ["considerable delays", "PROBLEM", 62, 81], ["urgent surgical interventions", "TREATMENT", 85, 114], ["General and visceral surgery", "TREATMENT", 201, 229], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["visceral", "ANATOMY", 213, 221]]], ["1 8 \u00dcbersicht der Ergebnisse der Fragenbl\u00f6cke a \"Politik\", b \"Gesundheitsbeh\u00f6rden\", c \"Krankenhausleitung\" und d \"Kommunikation mit anderen Fachbereichen\"Zusammenarbeit mit anderen FachabteilungenZwischen 75 und 86 % der Befragten stimmten den jeweiligen Aussagen zu, einen interdisziplin\u00e4ren Austausch mit der An\u00e4sthesie, Intensivmedizin, Infektiologie, Virologie, Onkologie und der Gastroenterologie zu f\u00fchren (.", [["\u00dcbersicht der Ergebnisse der Fragenbl\u00f6cke a \"Politik\", b \"Gesundheitsbeh\u00f6rden\", c \"Krankenhausleitung\" und d \"Kommunikation mit anderen Fachbereichen\"Zusammenarbeit mit anderen FachabteilungenZwischen 75 und 86 % der Befragten stimmten den jeweiligen Aussagen zu, einen interdisziplin\u00e4ren Austausch mit der An\u00e4sthesie, Intensivmedizin, Infektiologie, Virologie, Onkologie und der Gastroenterologie zu f\u00fchren", "SPECIES", 4, 411], ["Zusammenarbeit mit anderen FachabteilungenZwischen", "TREATMENT", 154, 204], ["Intensivmedizin", "TREATMENT", 323, 338]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["1).DiskussionDie vorliegende Querschnittsstudie liefert erste Daten zur Auswirkungen der SARS-CoV-2-Pandemie auf die Allgemein-und Viszeralchirurgie der Universit\u00e4tskliniken w\u00e4hrend der Aussetzung aller Elektivoperationen.", [["DiskussionDie vorliegende Querschnittsstudie liefert erste Daten zur Auswirkungen der SARS-CoV-2-Pandemie auf die Allgemein-und Viszeralchirurgie der Universit\u00e4tskliniken w\u00e4hrend der Aussetzung aller Elektivoperationen", "SPECIES", 3, 221], ["Pandemie auf die Allgemein", "TREATMENT", 100, 126]]], ["Die Teilnahmerate von 73 % weist auf die gro\u00dfe Bedeutung der Thematik f\u00fcr die Ordinarien der Allgemein-und Viszeralchirurgie hin.", [["Die Teilnahmerate von 73 % weist auf die gro\u00dfe Bedeutung der Thematik f\u00fcr die Ordinarien der Allgemein-und Viszeralchirurgie hin", "SPECIES", 0, 128]]], ["Die Ergebnisse zeigen, dass die Ma\u00dfnahmen zur Eind\u00e4mmung der SARS-CoV-2-Pandemie \u00fcberwiegend positiv seitens der Ordinarien aufgenommen wurden.", [["Die Ergebnisse zeigen, dass die Ma\u00dfnahmen zur Eind\u00e4mmung der SARS-CoV-2-Pandemie \u00fcberwiegend positiv seitens der Ordinarien aufgenommen wurden", "SPECIES", 0, 142], ["CoV", "TEST", 66, 69], ["Pandemie", "TREATMENT", 72, 80]]], ["Die Zusammenarbeit der Allgemein-und Viszeralchirurgie mit der Krankenhausverwaltung und anderen Fachdisziplinen erfolgte \u00fcberwiegend erfolgreich.", [["Die Zusammenarbeit der Allgemein-und Viszeralchirurgie mit der Krankenhausverwaltung und anderen Fachdisziplinen erfolgte \u00fcberwiegend erfolgreich", "SPECIES", 0, 145]]], ["Hervorzuheben sind auch die Ergebnisse zur Nachrangigkeit der finanziellen Zielvorgaben.", [["Hervorzuheben", "TREATMENT", 0, 13]]], ["Die Arbeit der Gesundheitsbeh\u00f6rden im Hinblick auf den Schutz der Mitarbeiter in den Krankenh\u00e4usern wurde \u00fcberwiegend als ausreichend empfunden.", [["Die Arbeit der Gesundheitsbeh\u00f6rden im Hinblick auf den Schutz der Mitarbeiter in den Krankenh\u00e4usern wurde \u00fcberwiegend als ausreichend empfunden", "SPECIES", 0, 143]]], ["So herrscht aufgrund der SARS-CoV-2-Pandemie weltweit in immer mehr Gesundheitseinrichtungen ein Mangel an wichtiger Ausr\u00fcstung wie Desinfektionsmittel und pers\u00f6nlicher Schutzausr\u00fcstung [10] .", [["CoV", "TEST", 30, 33], ["Pandemie weltweit", "TREATMENT", 36, 53]]], ["Daraus folgt die Erkenntnis und Forderung, Reserven f\u00fcr k\u00fcnftige Pandemien aufzubauen, um sie z\u00fcgiger bereitstellen zu k\u00f6nnen.DiskussionDie chirurgischen Kliniken wurden am 16.", [["Daraus folgt die Erkenntnis und Forderung, Reserven f\u00fcr k\u00fcnftige Pandemien aufzubauen, um sie z\u00fcgiger bereitstellen zu k\u00f6nnen", "SPECIES", 0, 125]]], ["M\u00e4rz 2020 aufgefordert, alle medizinisch nicht zwingend notwendigen planbaren Aufnahmen und Operationen zu verschieben [11] .", [["alle medizinisch", "TREATMENT", 24, 40]]], ["Die jetzige Situation k\u00f6nnte als Wendepunkt dienen, um den Pflegebereich nachhaltig zu st\u00e4rken.", [["Die jetzige Situation k\u00f6nnte als Wendepunkt dienen, um den Pflegebereich nachhaltig zu st\u00e4rken", "SPECIES", 0, 94]]], ["Es bleibt zu hoffen, dass nach R\u00fcckbau der COVID-19-Kapazit\u00e4ten noch gen\u00fcgend Pflegekr\u00e4fte zur Verf\u00fcgung stehen, da in der Pandemiehochphase die Neurekrutierung nicht im Vordergrund stand und es weiterhin schwierig bleibt, in Ballungsgebieten ausreichend Pflegepersonal zu finden.DiskussionDie vorliegende Querschnittsstudie geht mit Limitationen einher.", [["Es bleibt zu hoffen, dass nach R\u00fcckbau der COVID-19-Kapazit\u00e4ten noch gen\u00fcgend Pflegekr\u00e4fte zur Verf\u00fcgung stehen, da in der Pandemiehochphase die Neurekrutierung nicht im Vordergrund stand und es weiterhin schwierig bleibt", "SPECIES", 0, 221], ["DiskussionDie vorliegende Querschnittsstudie geht mit Limitationen einher", "SPECIES", 280, 353], ["Kapazit\u00e4ten", "TREATMENT", 52, 63]]], ["Der Befragungszeitraum erfolgte w\u00e4hrend des vorerst ersten H\u00f6hepunkts der SARS-CoV-2-Pandemie, sodass die Ergebnisse als vorl\u00e4ufig zu betrachten sind und die weitere Entwicklung bzw. die abschlie\u00dfenden Auswirkungen in geplanten Folgeumfragen evaluiert werden sollten.DiskussionUnseres Wissens ist dies bislang die erste Umfrage, die die Einfl\u00fcsse der SARS-CoV-2-Pandemie auf die Allgemein-und Viszeralchirurgie der deutschen Universit\u00e4tsklinika umfassend darstellt und somit einen \u00dcberblick \u00fcber die Herausforderungen in der universit\u00e4ren, chirurgischen Versorgungsrealit\u00e4t gibt.", [["Der Befragungszeitraum erfolgte w\u00e4hrend des vorerst ersten H\u00f6hepunkts der SARS-CoV-2-Pandemie, sodass die Ergebnisse als vorl\u00e4ufig zu betrachten sind und die weitere Entwicklung bzw", "SPECIES", 0, 181], ["DiskussionUnseres Wissens ist dies bislang die erste Umfrage, die die Einfl\u00fcsse der SARS-CoV-2-Pandemie auf die Allgemein-und Viszeralchirurgie der deutschen Universit\u00e4tsklinika umfassend darstellt und somit einen \u00dcberblick \u00fcber die Herausforderungen in der universit\u00e4ren, chirurgischen Versorgungsrealit\u00e4t gibt", "SPECIES", 267, 578]]], ["W\u00e4hrend des Befragungszeitraums befand sich Deutschland noch in einem fr\u00fchen Stadium der SARS-CoV-2-Pandemie, sodass zuk\u00fcnftige Auswirkungen derzeit noch schwer absehbar sind.", [["CoV", "TEST", 94, 97], ["Pandemie", "PROBLEM", 100, 108]]], ["Offen bleibt, ob die Reduktion der Operationskapazit\u00e4t und das Aussetzen der elektiven Operationen zu einer Minderung der chirurgischen Versorgungsqualit\u00e4t in Deutschland f\u00fchren und ob es zu Nachteilen in der Versorgung und den Ergebnissen bei onkologischen Patienten kommen wird.", [["Reduktion der Operationskapazit\u00e4t und das Aussetzen der elektiven Operationen zu einer Minderung der chirurgischen Versorgungsqualit\u00e4t in Deutschland f\u00fchren und ob es zu Nachteilen in der Versorgung und den Ergebnissen bei onkologischen Patienten kommen wird", "SPECIES", 21, 279]]], ["Folgeerhebungen m\u00fcssen hierzu zuk\u00fcnftig weitere Evidenz liefern.", [["Folgeerhebungen m\u00fcssen hierzu zuk\u00fcnftig weitere Evidenz liefern", "SPECIES", 0, 63], ["Folgeerhebungen", "TREATMENT", 0, 15]]], ["Betrachtet man die Ergebnisse zur Bereitstellung der Schutzausr\u00fcstung f\u00fcr das Personal, zur Bezahlung der Pflegekr\u00e4fte und zu den finanziellen Belastungen f\u00fcr die Kliniken, muss man von der Politik L\u00f6sungsvorschl\u00e4ge erwarten.", [["man", "SPECIES", 11, 14], ["Betrachtet man die Ergebnisse zur Bereitstellung der Schutzausr\u00fcstung f\u00fcr das Personal, zur Bezahlung der Pflegekr\u00e4fte und zu den finanziellen Belastungen f\u00fcr die Kliniken, muss man von der Politik L\u00f6sungsvorschl\u00e4ge erwarten", "SPECIES", 0, 224]]], ["Dabei sollte auch eine m\u00f6gliche n\u00e4chste SARS-CoV-2-Pandemiewelle ber\u00fccksichtigt werden, die nach Lockerung der Eind\u00e4mmungsma\u00dfnahmen m\u00f6glich erscheint.", [["Dabei sollte auch eine m\u00f6gliche n\u00e4chste SARS-CoV-2-Pandemiewelle ber\u00fccksichtigt werden, die nach Lockerung der Eind\u00e4mmungsma\u00dfnahmen m\u00f6glich erscheint", "SPECIES", 0, 149], ["Pandemiewelle ber\u00fccksichtigt werden", "TREATMENT", 51, 86]]], ["Dabei muss das Ausma\u00df der Vorhaltungen f\u00fcr Universit\u00e4tsklinika und nichtuniversit\u00e4re Krankenh\u00e4user pr\u00e4zise definiert werden, um Planungssicherheiten zu bieten.", [["Dabei muss das Ausma\u00df der Vorhaltungen f\u00fcr Universit\u00e4tsklinika und nichtuniversit\u00e4re Krankenh\u00e4user pr\u00e4zise definiert werden, um Planungssicherheiten zu bieten", "SPECIES", 0, 158]]], ["Zudem steht zur Diskussion, ob eine Konzentrierung", [["Zudem steht zur Diskussion, ob eine Konzentrierung", "SPECIES", 0, 50]]]], "PMC7112492": [["IntroductionSince Nov 1, 2002, an outbreak of severe acute respiratory syndrome (SARS) has affected 33 countries in five continents, with 7053 reported cases and 506 deaths at the time of writing.1 Local transmission has occurred in at least six countries.", [["acute respiratory syndrome", "DISEASE", 53, 79], ["SARS", "DISEASE", 81, 85], ["deaths", "DISEASE", 166, 172], ["severe acute respiratory syndrome", "PROBLEM", 46, 79], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["respiratory syndrome", "OBSERVATION", 59, 79]]], ["The first cases of SARS in Hong Kong Special Administrative Region were recognised in February, 2003.", [["SARS", "DISEASE", 19, 23], ["SARS", "PROBLEM", 19, 23]]], ["As of May 8, 2003, there had been 1661 cases and 208 deaths in the region.IntroductionClinically, the disease is characterised by fever, dyspnoea, lymphopenia, and rapidly progressing changes on radiography.23 Upper-respiratory-tract symptoms are not prominent, but diarrhoea has been reported by some patients.", [["deaths", "DISEASE", 53, 59], ["fever", "DISEASE", 130, 135], ["dyspnoea", "DISEASE", 137, 145], ["lymphopenia", "DISEASE", 147, 158], ["Upper-respiratory-tract symptoms", "DISEASE", 210, 242], ["diarrhoea", "DISEASE", 266, 275], ["tract", "ORGANISM_SUBDIVISION", 228, 233], ["patients", "ORGANISM", 302, 310], ["patients", "SPECIES", 302, 310], ["the disease", "PROBLEM", 98, 109], ["fever", "PROBLEM", 130, 135], ["dyspnoea", "PROBLEM", 137, 145], ["lymphopenia", "PROBLEM", 147, 158], ["rapidly progressing changes", "PROBLEM", 164, 191], ["radiography", "TEST", 195, 206], ["tract symptoms", "PROBLEM", 228, 242], ["diarrhoea", "PROBLEM", 266, 275], ["region", "ANATOMY_MODIFIER", 67, 73], ["disease", "OBSERVATION", 102, 109], ["fever", "OBSERVATION", 130, 135], ["lymphopenia", "OBSERVATION", 147, 158], ["rapidly", "OBSERVATION_MODIFIER", 164, 171], ["progressing", "OBSERVATION_MODIFIER", 172, 183], ["not", "UNCERTAINTY", 247, 250], ["prominent", "OBSERVATION_MODIFIER", 251, 260]]], ["There is no response to conventional antibiotics used to treat atypical pneumonia.", [["pneumonia", "DISEASE", 72, 81], ["conventional antibiotics", "TREATMENT", 24, 48], ["atypical pneumonia", "PROBLEM", 63, 81], ["no", "UNCERTAINTY", 9, 11], ["response", "OBSERVATION_MODIFIER", 12, 20], ["atypical", "OBSERVATION_MODIFIER", 63, 71], ["pneumonia", "OBSERVATION", 72, 81]]], ["The SARS-associated coronavirus (SARS-CoV) has been consistently associated with this disease.3 Although this virus seems to be necessary for the development of SARS, it has not been localised at the site of lung pathology.3, 4 Poutanen and colleagues5 found human metapneumovirus (HMPV) as a second pathogen in patients with SARS and postulated that HMPV potentiates the progression or severity of coronavirus infection.IntroductionThe use of steroids together with ribavirin has been reported to confer clinical benefit, although randomised clinical trials to support its clinical efficacy are not available.", [["lung", "ANATOMY", 208, 212], ["SARS", "DISEASE", 4, 8], ["SARS", "DISEASE", 161, 165], ["human metapneumovirus (HMPV)", "DISEASE", 259, 287], ["SARS", "DISEASE", 326, 330], ["HMPV", "DISEASE", 351, 355], ["coronavirus infection", "DISEASE", 399, 420], ["steroids", "CHEMICAL", 444, 452], ["ribavirin", "CHEMICAL", 467, 476], ["steroids", "CHEMICAL", 444, 452], ["ribavirin", "CHEMICAL", 467, 476], ["SARS-associated coronavirus", "ORGANISM", 4, 31], ["SARS-CoV", "ORGANISM", 33, 41], ["lung", "ORGAN", 208, 212], ["colleagues5", "ORGANISM", 241, 252], ["human metapneumovirus", "ORGANISM", 259, 280], ["HMPV", "ORGANISM", 282, 286], ["patients", "ORGANISM", 312, 320], ["HMPV", "ORGANISM", 351, 355], ["coronavirus", "ORGANISM", 399, 410], ["steroids", "SIMPLE_CHEMICAL", 444, 452], ["ribavirin", "SIMPLE_CHEMICAL", 467, 476], ["human", "SPECIES", 259, 264], ["metapneumovirus", "SPECIES", 265, 280], ["patients", "SPECIES", 312, 320], ["SARS-CoV", "SPECIES", 33, 41], ["human metapneumovirus", "SPECIES", 259, 280], ["HMPV", "SPECIES", 282, 286], ["HMPV", "SPECIES", 351, 355], ["The SARS-associated coronavirus (SARS-CoV", "PROBLEM", 0, 41], ["this disease", "PROBLEM", 81, 93], ["this virus", "PROBLEM", 105, 115], ["SARS", "PROBLEM", 161, 165], ["lung pathology", "PROBLEM", 208, 222], ["colleagues5", "TREATMENT", 241, 252], ["human metapneumovirus (HMPV", "PROBLEM", 259, 286], ["a second pathogen", "PROBLEM", 291, 308], ["SARS", "PROBLEM", 326, 330], ["HMPV", "PROBLEM", 351, 355], ["coronavirus infection", "PROBLEM", 399, 420], ["steroids", "TREATMENT", 444, 452], ["ribavirin", "TREATMENT", 467, 476], ["randomised clinical trials", "TREATMENT", 532, 558], ["coronavirus", "OBSERVATION_MODIFIER", 20, 31], ["consistently associated with", "UNCERTAINTY", 52, 80], ["SARS", "OBSERVATION", 161, 165], ["lung", "ANATOMY", 208, 212], ["pathology", "OBSERVATION", 213, 222], ["metapneumovirus", "OBSERVATION", 265, 280], ["HMPV", "OBSERVATION", 351, 355], ["coronavirus", "OBSERVATION_MODIFIER", 399, 410], ["infection", "OBSERVATION", 411, 420]]], ["To aid understanding of the pathogenesis of the disease and the relation to current therapy, we report the pathological and virological findings in six patients with SARS who died.Selection of patients and autopsy material ::: MethodsAll patients who met a modified WHO case definition of SARS6 and who underwent lung biopsy or post-mortem examination during March, 2003, at four major hospitals in the Kowloon hospital cluster were eligible for inclusion.", [["lung", "ANATOMY", 313, 317], ["SARS", "DISEASE", 166, 170], ["patients", "ORGANISM", 152, 160], ["patients", "ORGANISM", 193, 201], ["patients", "ORGANISM", 238, 246], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 313, 324], ["patients", "SPECIES", 152, 160], ["patients", "SPECIES", 193, 201], ["patients", "SPECIES", 238, 246], ["the disease", "PROBLEM", 44, 55], ["current therapy", "TREATMENT", 76, 91], ["Methods", "TREATMENT", 227, 234], ["lung biopsy", "TEST", 313, 324], ["post-mortem examination", "TEST", 328, 351], ["disease", "OBSERVATION", 48, 55], ["lung", "ANATOMY", 313, 317], ["biopsy", "OBSERVATION", 318, 324]]], ["The case definition was fever (temperature 38\u00b0C or higher), cough or shortness of breath, new pulmonary infiltrates on chest radiograph, and either a history of exposure to a patient with SARS or a lack of response to empirical antimicrobial coverage for typical and atypical pneumonia (beta-lactams and macrolides, fluoroquinolones or tetracyclines).3 Owing to the potentially infectious nature of the disorder, full autopsy was done in only one case.", [["pulmonary", "ANATOMY", 94, 103], ["chest", "ANATOMY", 119, 124], ["fever", "DISEASE", 24, 29], ["cough", "DISEASE", 60, 65], ["shortness of breath", "DISEASE", 69, 88], ["SARS", "DISEASE", 188, 192], ["pneumonia", "DISEASE", 276, 285], ["beta-lactams", "CHEMICAL", 287, 299], ["macrolides", "CHEMICAL", 304, 314], ["fluoroquinolones", "CHEMICAL", 316, 332], ["tetracyclines", "CHEMICAL", 336, 349], ["macrolides", "CHEMICAL", 304, 314], ["fluoroquinolones", "CHEMICAL", 316, 332], ["tetracyclines", "CHEMICAL", 336, 349], ["pulmonary", "ORGAN", 94, 103], ["patient", "ORGANISM", 175, 182], ["beta-lactams", "SIMPLE_CHEMICAL", 287, 299], ["macrolides", "SIMPLE_CHEMICAL", 304, 314], ["fluoroquinolones", "SIMPLE_CHEMICAL", 316, 332], ["tetracyclines", "SIMPLE_CHEMICAL", 336, 349], ["patient", "SPECIES", 175, 182], ["fever", "PROBLEM", 24, 29], ["temperature", "TEST", 31, 42], ["cough", "PROBLEM", 60, 65], ["shortness of breath", "PROBLEM", 69, 88], ["new pulmonary infiltrates", "PROBLEM", 90, 115], ["chest radiograph", "TEST", 119, 135], ["SARS", "PROBLEM", 188, 192], ["empirical antimicrobial coverage", "TREATMENT", 218, 250], ["typical and atypical pneumonia", "PROBLEM", 255, 285], ["beta-lactams", "TREATMENT", 287, 299], ["macrolides", "TREATMENT", 304, 314], ["fluoroquinolones", "TREATMENT", 316, 332], ["tetracyclines", "TREATMENT", 336, 349], ["the disorder", "PROBLEM", 399, 411], ["full autopsy", "TEST", 413, 425], ["new", "OBSERVATION_MODIFIER", 90, 93], ["pulmonary", "ANATOMY", 94, 103], ["infiltrates", "OBSERVATION", 104, 115], ["chest", "ANATOMY", 119, 124], ["atypical", "OBSERVATION_MODIFIER", 267, 275], ["pneumonia", "OBSERVATION", 276, 285], ["infectious", "OBSERVATION", 378, 388]]], ["In the other cases, the post-mortem examination was limited to the lungs.", [["lungs", "ANATOMY", 67, 72], ["lungs", "ORGAN", 67, 72], ["the post-mortem examination", "TEST", 20, 47], ["lungs", "ANATOMY", 67, 72]]], ["We included only those patients for whom paired serum samples were submitted for virological studies during the course of the illness.", [["serum samples", "ANATOMY", 48, 61], ["illness", "DISEASE", 126, 133], ["patients", "ORGANISM", 23, 31], ["serum samples", "ORGANISM_SUBSTANCE", 48, 61], ["patients", "SPECIES", 23, 31], ["paired serum samples", "TEST", 41, 61], ["virological studies", "TEST", 81, 100], ["the illness", "PROBLEM", 122, 133]]], ["Patients with only needle-biopsy samples of organs available were excluded.", [["samples", "ANATOMY", 33, 40], ["organs", "ANATOMY", 44, 50], ["Patients", "ORGANISM", 0, 8], ["biopsy samples", "MULTI-TISSUE_STRUCTURE", 26, 40], ["organs", "ORGAN", 44, 50], ["Patients", "SPECIES", 0, 8], ["needle-biopsy samples of organs", "TEST", 19, 50], ["organs", "ANATOMY", 44, 50]]], ["During the period under study, there were six patients with pathological and virological investigation; one of these also underwent lung biopsy earlier in the course of the illness.Selection of patients and autopsy material ::: MethodsIn all cases the autopsy material was fixed in 10% neutral buffered formalin and later processed for electron microscopy.", [["lung", "ANATOMY", 132, 136], ["illness", "DISEASE", 173, 180], ["formalin", "CHEMICAL", 303, 311], ["patients", "ORGANISM", 46, 54], ["lung", "ORGAN", 132, 136], ["patients", "ORGANISM", 194, 202], ["formalin", "SIMPLE_CHEMICAL", 303, 311], ["patients", "SPECIES", 46, 54], ["patients", "SPECIES", 194, 202], ["virological investigation", "TEST", 77, 102], ["lung biopsy", "TEST", 132, 143], ["Methods", "TREATMENT", 228, 235], ["electron microscopy", "TEST", 336, 355], ["lung", "ANATOMY", 132, 136], ["biopsy", "OBSERVATION", 137, 143]]], ["Separate pieces of fresh tissue were sent for virological study; if sufficient quantity was available, they were stored at \u201370\u00b0C for immunofluorescence studies.Patients ::: MethodsPatient 1, a 37-year-old woman, had good health before the illness.", [["tissue", "ANATOMY", 25, 31], ["tissue", "TISSUE", 25, 31], ["C", "GENE_OR_GENE_PRODUCT", 127, 128], ["Patients", "ORGANISM", 160, 168], ["woman", "ORGANISM", 205, 210], ["Patients", "SPECIES", 160, 168], ["woman", "SPECIES", 205, 210], ["fresh tissue", "PROBLEM", 19, 31], ["virological study", "TEST", 46, 63], ["immunofluorescence studies", "TEST", 133, 159], ["fresh tissue", "OBSERVATION", 19, 31]]], ["She was admitted on March 13, 2003, with a history of fever, cough, and general muscle pain for 10 days.", [["muscle", "ANATOMY", 80, 86], ["fever", "DISEASE", 54, 59], ["cough", "DISEASE", 61, 66], ["muscle pain", "DISEASE", 80, 91], ["muscle", "ORGAN", 80, 86], ["fever", "PROBLEM", 54, 59], ["cough", "PROBLEM", 61, 66], ["general muscle pain", "PROBLEM", 72, 91], ["fever", "OBSERVATION", 54, 59], ["cough", "OBSERVATION", 61, 66], ["muscle", "ANATOMY", 80, 86], ["pain", "OBSERVATION", 87, 91]]], ["Oxygen saturation on admission was 89% on 50% oxygen.", [["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 46, 52], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 46, 52], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["Oxygen saturation", "TEST", 0, 17], ["50% oxygen", "TREATMENT", 42, 52]]], ["The chest radiograph showed patchy haziness.", [["chest", "ANATOMY", 4, 9], ["The chest radiograph", "TEST", 0, 20], ["patchy haziness", "PROBLEM", 28, 43], ["chest", "ANATOMY", 4, 9], ["patchy", "OBSERVATION_MODIFIER", 28, 34], ["haziness", "OBSERVATION", 35, 43]]], ["The patient soon developed respiratory failure necessitating mechanical ventilation; ribavirin and antibiotic treatment was then started.", [["respiratory", "ANATOMY", 27, 38], ["respiratory failure", "DISEASE", 27, 46], ["ribavirin", "CHEMICAL", 85, 94], ["ribavirin", "CHEMICAL", 85, 94], ["patient", "ORGANISM", 4, 11], ["ribavirin", "SIMPLE_CHEMICAL", 85, 94], ["patient", "SPECIES", 4, 11], ["respiratory failure", "PROBLEM", 27, 46], ["mechanical ventilation", "TREATMENT", 61, 83], ["ribavirin", "TREATMENT", 85, 94], ["antibiotic treatment", "TREATMENT", 99, 119], ["respiratory failure", "OBSERVATION", 27, 46], ["mechanical ventilation", "OBSERVATION", 61, 83]]], ["The ratio of partial arterial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2) was 24\u00b72 kPa on the day before death.", [["arterial", "ANATOMY", 21, 29], ["oxygen", "CHEMICAL", 42, 48], ["oxygen", "CHEMICAL", 80, 86], ["death", "DISEASE", 125, 130], ["oxygen", "CHEMICAL", 42, 48], ["PaO2", "CHEMICAL", 50, 54], ["oxygen", "CHEMICAL", 80, 86], ["FiO2", "CHEMICAL", 88, 92], ["arterial", "MULTI-TISSUE_STRUCTURE", 21, 29], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["PaO2", "SIMPLE_CHEMICAL", 50, 54], ["oxygen", "SIMPLE_CHEMICAL", 80, 86], ["FiO2", "SIMPLE_CHEMICAL", 88, 92], ["The ratio", "TEST", 0, 9], ["partial arterial pressure of oxygen", "TREATMENT", 13, 48], ["PaO2", "TEST", 50, 54], ["inspired oxygen (FiO2", "TREATMENT", 71, 92], ["death", "PROBLEM", 125, 130], ["partial arterial", "OBSERVATION", 13, 29], ["pressure", "OBSERVATION_MODIFIER", 30, 38], ["oxygen", "OBSERVATION_MODIFIER", 42, 48]]], ["She died on March 23, after 10 days of assisted ventilation.Patients ::: MethodsPatient 2, a 39-year-old woman who was previously well, had indirect contact with a person who developed fever after return from Guangzhou, China.", [["fever", "DISEASE", 185, 190], ["Patients", "ORGANISM", 60, 68], ["woman", "ORGANISM", 105, 110], ["Patients", "SPECIES", 60, 68], ["woman", "SPECIES", 105, 110], ["person", "SPECIES", 164, 170], ["assisted ventilation", "TREATMENT", 39, 59], ["fever", "PROBLEM", 185, 190], ["fever", "OBSERVATION", 185, 190]]], ["She subsequently developed fever with shortness of breath and diarrhoea.", [["fever", "DISEASE", 27, 32], ["shortness of breath", "DISEASE", 38, 57], ["diarrhoea", "DISEASE", 62, 71], ["fever", "PROBLEM", 27, 32], ["shortness of breath", "PROBLEM", 38, 57], ["diarrhoea", "PROBLEM", 62, 71], ["fever", "OBSERVATION", 27, 32], ["diarrhoea", "OBSERVATION", 62, 71]]], ["She had lymphopenia at admission, and the chest radiograph showed infiltrates in the left upper zone.", [["chest", "ANATOMY", 42, 47], ["left upper zone", "ANATOMY", 85, 100], ["lymphopenia", "DISEASE", 8, 19], ["upper", "ORGANISM_SUBDIVISION", 90, 95], ["lymphopenia", "PROBLEM", 8, 19], ["the chest radiograph", "TEST", 38, 58], ["infiltrates in the left upper zone", "PROBLEM", 66, 100], ["lymphopenia", "OBSERVATION", 8, 19], ["chest", "ANATOMY", 42, 47], ["infiltrates", "OBSERVATION", 66, 77], ["left", "ANATOMY_MODIFIER", 85, 89], ["upper", "ANATOMY_MODIFIER", 90, 95], ["zone", "ANATOMY_MODIFIER", 96, 100]]], ["Treatment with ribavirin and steroids was started on March 21.", [["ribavirin", "CHEMICAL", 15, 24], ["steroids", "CHEMICAL", 29, 37], ["ribavirin", "CHEMICAL", 15, 24], ["steroids", "CHEMICAL", 29, 37], ["ribavirin", "SIMPLE_CHEMICAL", 15, 24], ["steroids", "SIMPLE_CHEMICAL", 29, 37], ["ribavirin", "TREATMENT", 15, 24], ["steroids", "TREATMENT", 29, 37]]], ["She developed respiratory failure the next day and was intubated.", [["respiratory", "ANATOMY", 14, 25], ["respiratory failure", "DISEASE", 14, 33], ["respiratory failure", "PROBLEM", 14, 33], ["intubated", "TREATMENT", 55, 64], ["respiratory failure", "OBSERVATION", 14, 33]]], ["She had repeated cardiac arrests and died on March 24.Patients ::: MethodsPatient 3, a 64-year-old man, developed influenza-like symptoms and left pleuritic chest pain on Feb 15.", [["cardiac", "ANATOMY", 17, 24], ["chest", "ANATOMY", 157, 162], ["cardiac arrests", "DISEASE", 17, 32], ["influenza-like symptoms", "DISEASE", 114, 137], ["chest pain", "DISEASE", 157, 167], ["Patients", "ORGANISM", 54, 62], ["man", "ORGANISM", 99, 102], ["chest", "ORGANISM_SUBDIVISION", 157, 162], ["Patients", "SPECIES", 54, 62], ["man", "SPECIES", 99, 102], ["repeated cardiac arrests", "PROBLEM", 8, 32], ["influenza", "PROBLEM", 114, 123], ["like symptoms", "PROBLEM", 124, 137], ["left pleuritic chest pain", "PROBLEM", 142, 167], ["cardiac", "ANATOMY", 17, 24], ["arrests", "OBSERVATION", 25, 32], ["influenza", "OBSERVATION", 114, 123], ["left", "ANATOMY_MODIFIER", 142, 146], ["pleuritic", "ANATOMY", 147, 156], ["chest", "ANATOMY", 157, 162]]], ["A chest radiograph taken a day later showed haziness in the left lower zone.", [["chest", "ANATOMY", 2, 7], ["left lower zone", "ANATOMY", 60, 75], ["A chest radiograph", "TEST", 0, 18], ["haziness in the left lower zone", "PROBLEM", 44, 75], ["chest", "ANATOMY", 2, 7], ["haziness", "OBSERVATION", 44, 52], ["left", "ANATOMY_MODIFIER", 60, 64], ["lower", "ANATOMY_MODIFIER", 65, 70], ["zone", "ANATOMY_MODIFIER", 71, 75]]], ["He subjectively improved after self-medication with levofloxacin and penicillin.", [["levofloxacin", "CHEMICAL", 52, 64], ["penicillin", "CHEMICAL", 69, 79], ["levofloxacin", "CHEMICAL", 52, 64], ["penicillin", "CHEMICAL", 69, 79], ["He", "ORGANISM", 0, 2], ["levofloxacin", "SIMPLE_CHEMICAL", 52, 64], ["penicillin", "SIMPLE_CHEMICAL", 69, 79], ["self-medication", "TREATMENT", 31, 46], ["levofloxacin", "TREATMENT", 52, 64], ["penicillin", "TREATMENT", 69, 79]]], ["He was admitted directly to the intensive-care unit and intubated on Feb 22.", [["He", "ORGANISM", 0, 2], ["intubated", "TREATMENT", 56, 65]]], ["Investigation showed diffuse bilateral ground-glass changes on chest radiograph and severe oxygen desaturation.", [["chest", "ANATOMY", 63, 68], ["oxygen", "CHEMICAL", 91, 97], ["desaturation", "DISEASE", 98, 110], ["oxygen", "CHEMICAL", 91, 97], ["oxygen", "SIMPLE_CHEMICAL", 91, 97], ["Investigation", "TEST", 0, 13], ["diffuse bilateral ground-glass changes", "PROBLEM", 21, 59], ["chest radiograph", "TEST", 63, 79], ["severe oxygen desaturation", "PROBLEM", 84, 110], ["diffuse", "OBSERVATION_MODIFIER", 21, 28], ["bilateral", "ANATOMY_MODIFIER", 29, 38], ["ground-glass changes", "OBSERVATION", 39, 59], ["chest", "ANATOMY", 63, 68], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["oxygen desaturation", "OBSERVATION", 91, 110]]], ["Despite empirical antimicrobial coverage for typical, atypical, and hospital-acquired pneumonia, his condition continued to deteriorate.", [["pneumonia", "DISEASE", 86, 95], ["empirical antimicrobial coverage", "TREATMENT", 8, 40], ["hospital-acquired pneumonia", "PROBLEM", 68, 95], ["his condition", "PROBLEM", 97, 110], ["atypical", "OBSERVATION_MODIFIER", 54, 62], ["pneumonia", "OBSERVATION", 86, 95]]], ["He was empirically treated with oseltamivir, foscarnet, intravenous immunoglobulin and, at a later stage, ribavirin and steroids.", [["intravenous", "ANATOMY", 56, 67], ["oseltamivir", "CHEMICAL", 32, 43], ["foscarnet", "CHEMICAL", 45, 54], ["ribavirin", "CHEMICAL", 106, 115], ["steroids", "CHEMICAL", 120, 128], ["oseltamivir", "CHEMICAL", 32, 43], ["foscarnet", "CHEMICAL", 45, 54], ["ribavirin", "CHEMICAL", 106, 115], ["steroids", "CHEMICAL", 120, 128], ["He", "ORGANISM", 0, 2], ["oseltamivir", "SIMPLE_CHEMICAL", 32, 43], ["foscarnet", "SIMPLE_CHEMICAL", 45, 54], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 67], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 68, 82], ["ribavirin", "SIMPLE_CHEMICAL", 106, 115], ["steroids", "SIMPLE_CHEMICAL", 120, 128], ["immunoglobulin", "PROTEIN", 68, 82], ["oseltamivir", "TREATMENT", 32, 43], ["foscarnet", "TREATMENT", 45, 54], ["intravenous immunoglobulin", "TREATMENT", 56, 82], ["ribavirin", "TREATMENT", 106, 115], ["steroids", "TREATMENT", 120, 128]]], ["After ventilation for 10 days with a peak airway pressure of 36 cm water, tidal volume of 730 mL, and PaO2/FiO2 9\u00b78 kPa, he died on March 4 with acute respiratory distress syndrome and multiorgan failure.Patients ::: MethodsPatient 4 was a 53-year-old man with a history of hypertension.", [["airway", "ANATOMY", 42, 48], ["respiratory", "ANATOMY", 151, 162], ["multiorgan", "ANATOMY", 185, 195], ["acute respiratory distress syndrome", "DISEASE", 145, 180], ["multiorgan failure", "DISEASE", 185, 203], ["hypertension", "DISEASE", 274, 286], ["airway", "MULTI-TISSUE_STRUCTURE", 42, 48], ["multiorgan", "ORGAN", 185, 195], ["Patients", "ORGANISM", 204, 212], ["man", "ORGANISM", 252, 255], ["Patients", "SPECIES", 204, 212], ["man", "SPECIES", 252, 255], ["ventilation", "TREATMENT", 6, 17], ["a peak airway pressure", "TEST", 35, 57], ["tidal volume", "TEST", 74, 86], ["PaO2", "TEST", 102, 106], ["FiO2", "TREATMENT", 107, 111], ["acute respiratory distress syndrome", "PROBLEM", 145, 180], ["multiorgan failure", "PROBLEM", 185, 203], ["hypertension", "PROBLEM", 274, 286], ["airway", "ANATOMY", 42, 48], ["pressure", "OBSERVATION_MODIFIER", 49, 57], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["respiratory distress", "OBSERVATION", 151, 171], ["multiorgan failure", "OBSERVATION", 185, 203], ["hypertension", "OBSERVATION", 274, 286]]], ["He had developed influenza-like symptoms a few days before admission on Feb 28 with chest radiographic changes of diffuse bilateral pneumonia and respiratory failure.", [["chest", "ANATOMY", 84, 89], ["respiratory", "ANATOMY", 146, 157], ["influenza-like symptoms", "DISEASE", 17, 40], ["pneumonia", "DISEASE", 132, 141], ["respiratory failure", "DISEASE", 146, 165], ["He", "ORGANISM", 0, 2], ["influenza", "PROBLEM", 17, 26], ["like symptoms", "PROBLEM", 27, 40], ["chest radiographic changes", "PROBLEM", 84, 110], ["diffuse bilateral pneumonia", "PROBLEM", 114, 141], ["respiratory failure", "PROBLEM", 146, 165], ["influenza", "OBSERVATION", 17, 26], ["chest", "ANATOMY", 84, 89], ["diffuse", "OBSERVATION_MODIFIER", 114, 121], ["bilateral", "ANATOMY_MODIFIER", 122, 131], ["pneumonia", "OBSERVATION", 132, 141], ["respiratory failure", "OBSERVATION", 146, 165]]], ["He did not respond to doxycycline, amantadine, and cefotaxime.", [["doxycycline", "CHEMICAL", 22, 33], ["amantadine", "CHEMICAL", 35, 45], ["cefotaxime", "CHEMICAL", 51, 61], ["doxycycline", "CHEMICAL", 22, 33], ["amantadine", "CHEMICAL", 35, 45], ["cefotaxime", "CHEMICAL", 51, 61], ["doxycycline", "SIMPLE_CHEMICAL", 22, 33], ["amantadine", "SIMPLE_CHEMICAL", 35, 45], ["cefotaxime", "SIMPLE_CHEMICAL", 51, 61], ["doxycycline", "TREATMENT", 22, 33], ["amantadine", "TREATMENT", 35, 45], ["cefotaxime", "TREATMENT", 51, 61]]], ["An open lung biopsy was done on March 4.", [["lung", "ANATOMY", 8, 12], ["lung", "ORGAN", 8, 12], ["An open lung biopsy", "TEST", 0, 19], ["open", "OBSERVATION_MODIFIER", 3, 7], ["lung", "ANATOMY", 8, 12], ["biopsy", "OBSERVATION", 13, 19]]], ["Routine microbiological and virological investigations were negative.", [["Routine microbiological and virological investigations", "TEST", 0, 54]]], ["He was empirically treated with oseltamivir, steroids, and ribavirin.", [["oseltamivir", "CHEMICAL", 32, 43], ["steroids", "CHEMICAL", 45, 53], ["ribavirin", "CHEMICAL", 59, 68], ["oseltamivir", "CHEMICAL", 32, 43], ["steroids", "CHEMICAL", 45, 53], ["ribavirin", "CHEMICAL", 59, 68], ["He", "ORGANISM", 0, 2], ["oseltamivir", "SIMPLE_CHEMICAL", 32, 43], ["steroids", "SIMPLE_CHEMICAL", 45, 53], ["ribavirin", "SIMPLE_CHEMICAL", 59, 68], ["oseltamivir", "TREATMENT", 32, 43], ["steroids", "TREATMENT", 45, 53], ["ribavirin", "TREATMENT", 59, 68]]], ["Non-oliguric renal failure developed and was later complicated by nosocomial pneumonia due to Pseudomonas aeruginosa.", [["renal", "ANATOMY", 13, 18], ["Non-oliguric renal failure", "DISEASE", 0, 26], ["pneumonia", "DISEASE", 77, 86], ["Pseudomonas aeruginosa", "DISEASE", 94, 116], ["renal", "ORGAN", 13, 18], ["Pseudomonas aeruginosa", "ORGANISM", 94, 116], ["Pseudomonas aeruginosa", "SPECIES", 94, 116], ["Pseudomonas aeruginosa", "SPECIES", 94, 116], ["Non-oliguric renal failure", "PROBLEM", 0, 26], ["nosocomial pneumonia", "PROBLEM", 66, 86], ["Pseudomonas aeruginosa", "PROBLEM", 94, 116], ["renal", "ANATOMY", 13, 18], ["failure", "OBSERVATION", 19, 26], ["nosocomial", "OBSERVATION_MODIFIER", 66, 76], ["pneumonia", "OBSERVATION", 77, 86], ["Pseudomonas aeruginosa", "OBSERVATION", 94, 116]]], ["He died on March 19, after ventilation for 16 days with a peak airway pressure of 34 cm water, tidal volume of 640 mL, and PaO2/FiO2 17\u00b70 kPaPatients ::: MethodsPatient 5 was a 49-year-old businessman who had a history of hepatitis B liver cirrhosis and portal hypertension.", [["airway", "ANATOMY", 63, 69], ["liver", "ANATOMY", 234, 239], ["portal", "ANATOMY", 254, 260], ["hepatitis B liver cirrhosis", "DISEASE", 222, 249], ["portal hypertension", "DISEASE", 254, 273], ["airway", "MULTI-TISSUE_STRUCTURE", 63, 69], ["businessman", "ORGANISM", 189, 200], ["liver", "ORGAN", 234, 239], ["portal", "MULTI-TISSUE_STRUCTURE", 254, 260], ["ventilation", "TREATMENT", 27, 38], ["a peak airway pressure", "TEST", 56, 78], ["tidal volume", "TEST", 95, 107], ["PaO2", "TEST", 123, 127], ["FiO2", "TREATMENT", 128, 132], ["hepatitis B liver cirrhosis", "PROBLEM", 222, 249], ["portal hypertension", "PROBLEM", 254, 273], ["airway", "ANATOMY", 63, 69], ["pressure", "OBSERVATION_MODIFIER", 70, 78], ["hepatitis", "OBSERVATION", 222, 231], ["liver", "ANATOMY", 234, 239], ["cirrhosis", "OBSERVATION", 240, 249], ["portal", "ANATOMY", 254, 260], ["hypertension", "OBSERVATION", 261, 273]]], ["He developed influenza-like symptoms while in Hong Kong but still travelled overseas on Feb 26.", [["influenza-like symptoms", "DISEASE", 13, 36], ["influenza", "PROBLEM", 13, 22], ["symptoms", "PROBLEM", 28, 36], ["influenza", "OBSERVATION", 13, 22]]], ["Investigation at his destination showed lymphopenia and thrombocytopenia in the peripheral blood examination, and bilateral pulmonary infiltrates on chest radiograph.", [["peripheral blood", "ANATOMY", 80, 96], ["pulmonary", "ANATOMY", 124, 133], ["lymphopenia", "DISEASE", 40, 51], ["thrombocytopenia", "DISEASE", 56, 72], ["peripheral blood", "ORGANISM_SUBSTANCE", 80, 96], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 124, 145], ["lymphopenia", "PROBLEM", 40, 51], ["thrombocytopenia", "PROBLEM", 56, 72], ["the peripheral blood examination", "TEST", 76, 108], ["bilateral pulmonary infiltrates", "PROBLEM", 114, 145], ["chest radiograph", "TEST", 149, 165], ["lymphopenia", "OBSERVATION", 40, 51], ["thrombocytopenia", "OBSERVATION", 56, 72], ["peripheral", "ANATOMY_MODIFIER", 80, 90], ["blood", "ANATOMY", 91, 96], ["bilateral", "ANATOMY_MODIFIER", 114, 123], ["pulmonary", "ANATOMY", 124, 133], ["infiltrates", "OBSERVATION", 134, 145], ["chest", "ANATOMY", 149, 154]]], ["He went into respiratory failure on March 2, and on March 5 was transferred back to Hong Kong, where he was ventilated.", [["respiratory", "ANATOMY", 13, 24], ["respiratory failure", "DISEASE", 13, 32], ["respiratory failure", "PROBLEM", 13, 32], ["respiratory", "ANATOMY", 13, 24], ["failure", "OBSERVATION", 25, 32], ["ventilated", "OBSERVATION", 108, 118]]], ["The ventilation pressure was 20/10 cm water most of the time.", [["The ventilation pressure", "TEST", 0, 24], ["ventilation pressure", "OBSERVATION", 4, 24]]], ["Positive end-expiratory pressure was 15\u201317 cm water.", [["end-expiratory pressure", "TEST", 9, 32], ["end", "OBSERVATION_MODIFIER", 9, 12], ["expiratory pressure", "OBSERVATION", 13, 32]]], ["The tidal volume was generally kept at 450\u2013650 mL, and the PaO2 was between 70% and 90% and FiO2 between 80% and 100%.", [["The tidal volume", "TEST", 0, 16], ["the PaO2", "TEST", 55, 63], ["FiO2", "TEST", 92, 96], ["tidal volume", "OBSERVATION", 4, 16]]], ["His renal function deteriorated progressively from March 9 to March 12, and at the time of death the urea concentration was 10\u00b76 mmol/L and creatinine 218 \u03bcmol/L. Total bilirubin varied between 18 \u03bcmol/L and 27 \u03bcmol/L. Despite intensive support and antimicrobial coverage with piperacillin-tazobactam, azithromycin, and oseltamivir, he died on March 13.Patients ::: MethodsPatient 6 was a 77-year-old man with good health previously.", [["renal", "ANATOMY", 4, 9], ["death", "DISEASE", 91, 96], ["urea", "CHEMICAL", 101, 105], ["creatinine", "CHEMICAL", 140, 150], ["bilirubin", "CHEMICAL", 169, 178], ["piperacillin-tazobactam", "CHEMICAL", 277, 300], ["azithromycin", "CHEMICAL", 302, 314], ["oseltamivir", "CHEMICAL", 320, 331], ["urea", "CHEMICAL", 101, 105], ["creatinine", "CHEMICAL", 140, 150], ["bilirubin", "CHEMICAL", 169, 178], ["piperacillin-tazobactam", "CHEMICAL", 277, 300], ["azithromycin", "CHEMICAL", 302, 314], ["oseltamivir", "CHEMICAL", 320, 331], ["renal", "ORGAN", 4, 9], ["urea", "SIMPLE_CHEMICAL", 101, 105], ["creatinine", "SIMPLE_CHEMICAL", 140, 150], ["bilirubin", "GENE_OR_GENE_PRODUCT", 169, 178], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 277, 300], ["azithromycin", "SIMPLE_CHEMICAL", 302, 314], ["oseltamivir", "SIMPLE_CHEMICAL", 320, 331], ["Patients", "ORGANISM", 353, 361], ["man", "ORGANISM", 401, 404], ["Patients", "SPECIES", 353, 361], ["man", "SPECIES", 401, 404], ["the urea concentration", "TEST", 97, 119], ["creatinine", "TEST", 140, 150], ["Total bilirubin", "TEST", 163, 178], ["intensive support", "TREATMENT", 227, 244], ["antimicrobial coverage", "TREATMENT", 249, 271], ["piperacillin", "TREATMENT", 277, 289], ["tazobactam", "TREATMENT", 290, 300], ["azithromycin", "TREATMENT", 302, 314], ["oseltamivir", "TREATMENT", 320, 331], ["renal", "ANATOMY", 4, 9], ["function", "OBSERVATION", 10, 18], ["deteriorated", "OBSERVATION_MODIFIER", 19, 31]]], ["On March 2 he was admitted to hospital for increasing shortness of breath, fever, and cough for 2 days.", [["shortness of breath", "DISEASE", 54, 73], ["fever", "DISEASE", 75, 80], ["cough", "DISEASE", 86, 91], ["increasing shortness of breath", "PROBLEM", 43, 73], ["fever", "PROBLEM", 75, 80], ["cough", "PROBLEM", 86, 91], ["fever", "OBSERVATION", 75, 80], ["cough", "OBSERVATION", 86, 91]]], ["Investigations showed bilateral patchy consolidations of lower zones on chest radiograph and oxygen desaturation.", [["lower zones", "ANATOMY", 57, 68], ["chest", "ANATOMY", 72, 77], ["oxygen", "CHEMICAL", 93, 99], ["oxygen", "CHEMICAL", 93, 99], ["oxygen", "SIMPLE_CHEMICAL", 93, 99], ["Investigations", "TEST", 0, 14], ["bilateral patchy consolidations of lower zones", "PROBLEM", 22, 68], ["chest radiograph", "TEST", 72, 88], ["oxygen desaturation", "PROBLEM", 93, 112], ["bilateral", "ANATOMY_MODIFIER", 22, 31], ["patchy", "OBSERVATION_MODIFIER", 32, 38], ["consolidations", "OBSERVATION", 39, 53], ["lower", "ANATOMY_MODIFIER", 57, 62], ["zones", "ANATOMY_MODIFIER", 63, 68], ["chest", "ANATOMY", 72, 77], ["oxygen desaturation", "OBSERVATION", 93, 112]]], ["He was intubated and ventilated by positive end-expiratory pressure mode in the intensive-care unit 2 days after admission.", [["He", "ORGANISM", 0, 2], ["intubated", "TREATMENT", 7, 16], ["ventilated", "TREATMENT", 21, 31], ["positive end-expiratory pressure mode", "TREATMENT", 35, 72]]], ["His clinical course was complicated by pneumonia due to meticillin-resistant Staphylococcus aureus.", [["pneumonia", "DISEASE", 39, 48], ["meticillin", "CHEMICAL", 56, 66], ["Staphylococcus aureus", "DISEASE", 77, 98], ["meticillin", "CHEMICAL", 56, 66], ["Staphylococcus aureus", "ORGANISM", 77, 98], ["Staphylococcus aureus", "SPECIES", 77, 98], ["Staphylococcus aureus", "SPECIES", 77, 98], ["pneumonia", "PROBLEM", 39, 48], ["meticillin", "PROBLEM", 56, 66], ["resistant Staphylococcus aureus", "PROBLEM", 67, 98], ["pneumonia", "OBSERVATION", 39, 48], ["Staphylococcus aureus", "OBSERVATION", 77, 98]]], ["He was ventilated for 12 days with a peak airway pressure of 30 cm water, tidal volume of 540 mL, and PaO2/FiO2 9\u00b74 kPa, but he died on March 15, despite extensive antimicrobial coverage for typical, atypical, and hospital-acquired pneumonia.Patients ::: MethodsThe clinical presentations of two of these patients (patients 3 and 4) have been reported previously.2", [["airway", "ANATOMY", 42, 48], ["pneumonia", "DISEASE", 232, 241], ["He", "ORGANISM", 0, 2], ["airway", "MULTI-TISSUE_STRUCTURE", 42, 48], ["Patients", "ORGANISM", 242, 250], ["patients", "ORGANISM", 305, 313], ["patients", "ORGANISM", 315, 323], ["Patients", "SPECIES", 242, 250], ["patients", "SPECIES", 305, 313], ["patients", "SPECIES", 315, 323], ["a peak airway pressure", "TEST", 35, 57], ["tidal volume", "TEST", 74, 86], ["PaO2", "TEST", 102, 106], ["FiO2", "TREATMENT", 107, 111], ["extensive antimicrobial coverage", "TREATMENT", 154, 186], ["hospital-acquired pneumonia", "PROBLEM", 214, 241], ["Methods", "TREATMENT", 255, 262], ["ventilated", "OBSERVATION", 7, 17], ["atypical", "OBSERVATION_MODIFIER", 200, 208], ["pneumonia", "OBSERVATION", 232, 241]]]], "178b05b40a3bd594194e23fd8ad3165b2431b505": [["B U I L D I N G O N E X P E R I E N C E : L E A R N I N G L E S S O N S F R O M P A S T F R A M E W O R K P R O G R A M M E SBuilding on past experience via ex-post evaluation is an increasingly important element in the design of research programmes and policies, notably at the European level.", [["O N", "CHEMICAL", 16, 19], ["O N", "CHEMICAL", 66, 69], ["B U I L D I", "TEST", 0, 11], ["G", "TEST", 14, 15], ["S S", "TEST", 62, 65], ["S F", "TEST", 70, 73], ["A S", "TEST", 82, 85], ["ex-post evaluation", "TEST", 157, 175]]], ["1 Being aware of the strength and weaknesses of past Framework Programmes, knowing their impacts and realising in which fields potential impacts could not be achieved, is a precondition for the improvement of any new programme.B U I L D I N G O N E X P E R I E N C E : L E A R N I N G L E S S O N S F R O M P A S T F R A M E W O R K P R O G R A M M E SBased on the evidence of ex-post evaluations, this chapter looks back at past Framework Programmes and shows what lessons were helpful for the design of the 7th Framework Programme.", [["O N", "CHEMICAL", 243, 246], ["O N", "CHEMICAL", 293, 296], ["U I L D I", "TEST", 229, 238], ["G", "TEST", 241, 242], ["S S", "TEST", 289, 292], ["S F", "TEST", 297, 300], ["A S", "TEST", 309, 312], ["ex-post evaluations", "TEST", 377, 396]]], ["The chapter starts with some methodological considerations linked to the evaluation of Framework Programmes (Section 1).", [["the evaluation", "TEST", 69, 83]]], ["Turning to the outcomes and impacts of Framework Programmes, the accumulated evidence convincingly shows that the Framework Programme has had a clear positive impact not only on participants' immediate competitive position, but also on their capabilities, behaviour, and ability to compete.", [["participants", "SPECIES", 178, 190], ["Framework Programmes", "TREATMENT", 39, 59]]], ["It has improved Europe's scientific, technological, and innovative performance (Section 2).", [["improved", "OBSERVATION_MODIFIER", 7, 15]]], ["And it has strengthened Europe's human capital (Section 3) and integrated European research infrastructures (Section 4), and enhanced the coordination of Member State research policies and actions (Section 5).", [["human", "ORGANISM", 33, 38], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38]]], ["It has also generated wider economic, social, and environmental benefits (Section 6).Evaluating research projects is complexIdentifying the outputs and economic, social, and environmental impacts of individual research projects is complex.", [["wider", "OBSERVATION_MODIFIER", 22, 27], ["complex", "OBSERVATION_MODIFIER", 117, 124], ["outputs", "OBSERVATION_MODIFIER", 140, 147], ["economic", "OBSERVATION_MODIFIER", 152, 160], ["complex", "OBSERVATION_MODIFIER", 231, 238]]], ["The first reason is the difficulty of attribution, which concerns the key question at the heart of every impact study: to what 1 The Union, in response to its desire to regulate better, calls for transparency and accountability, as well as budget constraints, wants to know what impacts past policies and programmes have generated, and how it can increase those of future ones.", [["heart", "ANATOMY", 90, 95], ["heart", "ORGAN", 90, 95], ["heart", "ANATOMY", 90, 95]]], ["2 Over the years, an extensive and highly diverse body of Framework Programme ex-post evaluation literature has emerged.", [["ex-post evaluation", "TEST", 78, 96], ["extensive", "OBSERVATION_MODIFIER", 21, 30], ["highly", "OBSERVATION_MODIFIER", 35, 41], ["diverse", "OBSERVATION_MODIFIER", 42, 49]]], ["The spotlight of Commission studies was sometimes on the Framework Programme as a whole, sometimes on just one or a few Specific Programmes.", [["Commission studies", "TEST", 17, 35]]], ["Past Framework Programme evaluations were sometimes of an ad hoc and one-off nature, and sometimes carried out repeatedly within the context of the formal Framework Programme ex-post evaluation system extent are measurable effects really the result of -that is causally attributable to -the project under review? 3 Usually it is not just the individual research project financed which has produced the solution to a particular problem or a certain impact.", [["Framework Programme evaluations", "TEST", 5, 36]]], ["Project participants may have received funding from other sources as well.", [["participants", "SPECIES", 8, 20]]], ["Next, factors other than research itself may have contributed to an impact.", [["impact", "OBSERVATION", 68, 74]]], ["5 Finally, attribution is hindered by the usually long period 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 of time between the funding and carrying out of research on the one hand, and the results of that research becoming visible on the other hand.", [["hand", "ORGANISM_SUBDIVISION", 274, 278], ["visible", "OBSERVATION", 253, 260]]], ["6 The second reason for the complexity involved in identifying the outputs and impacts of individual research projects is the need to assess additionality or what it is that would have happened anyway even without public support.", [["public support", "TREATMENT", 214, 228]]], ["Or did it just replace and crowd out inputs that would have been made anyway?); behavioural additionality (did researchers change their behaviour (importance attached to research and research collaboration, project management) as a result of receiving public support and participating in the project?); and output additionality (would the same outputs have been obtained without the policy action?).The Framework Programme has evolved in terms of rationale, content, and budgetIn addition to the methodological problems discussed in the previous section, puzzling together a consistent picture of past Framework Programmes and their outputs and impacts is hampered by the programme's main characteristics having evolved rather substantially over time.", [["project management", "TREATMENT", 207, 225], ["public support", "TREATMENT", 252, 266], ["the methodological problems", "PROBLEM", 492, 519]]], ["The start of the Framework Programmes constituted a radical break with what came before.", [["a radical break", "TREATMENT", 50, 65], ["radical break", "OBSERVATION", 52, 65]]], ["Because it was tied to particular sectors (agriculture, coal, nuclear energy, steel, etc.), it was also fragmented.", [["nuclear", "ANATOMY", 62, 69], ["fragmented", "OBSERVATION_MODIFIER", 104, 114]]], ["10 The 2nd Framework Programme (1987) (1988) (1989) (1990) (1991) was intended to strengthen the research base of European industry in response to fierce Japanese competition.", [["European industry", "TREATMENT", 114, 131]]], ["Developing information and communication technologies was high on the political agenda.", [["communication technologies", "TEST", 27, 53]]], ["The number of thematic priorities has multiplied.", [["number", "OBSERVATION_MODIFIER", 4, 10]]], ["And new instruments have been introduced.The Framework Programme has evolved in terms of rationale, content, and budgetAnother indicator of substantial change has been the growth of the Framework Programme budget, which reached about Before (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) Ad hoc approach Energy oriented -FP1 (1984) (1985) (1986) (1987) Coordination of Community RTD actions Energy and ICT oriented Environment, international cooperation human capital and mobility FP2 (1987) (1988) (1989) (1990) (1991) Information society ICT oriented Biotechnologies, marine resources, dissemination FP3 (1990 FP3 ( -1994 Industrial Programmes, different and not always compatible databases were in use managed by different Commission services in charge of a particular Framework Programme component, making it difficult to arrive at one integrated dataset for a single Framework Programme.", [["human", "ORGANISM", 470, 475], ["human", "SPECIES", 470, 475], ["human", "SPECIES", 470, 475], ["new instruments", "TREATMENT", 4, 19], ["substantial change", "PROBLEM", 140, 158], ["a single Framework Programme", "TREATMENT", 879, 907], ["new", "OBSERVATION_MODIFIER", 4, 7], ["instruments", "OBSERVATION", 8, 19], ["substantial", "OBSERVATION_MODIFIER", 140, 151], ["change", "OBSERVATION", 152, 158], ["growth", "OBSERVATION_MODIFIER", 172, 178]]], ["As instruments and rules of participation evolved from one Framework Programme to the next, the labels attached in the databases to Framework Programme participants also changed, which makes it difficult to analyse, for instance, the evolution of the participant type structure (e.g. evolution of industrial participation).", [["participants", "SPECIES", 152, 164]]], ["Some data on project outputs have been collected in the past via end-of-project reports, but these have tended to be incomplete, and this is not helped by the frequent perception that reporting such outputs represents a significant administrative burden on Framework Programme participants.The Framework Programme monitoring and evaluation systemThe European Commission has been involved in research programme evaluation since the late 1970s.", [["participants", "SPECIES", 277, 289], ["project outputs", "TEST", 13, 28], ["such outputs", "PROBLEM", 194, 206], ["a significant administrative burden", "PROBLEM", 218, 253], ["The Framework Programme monitoring", "TEST", 290, 324], ["evaluation system", "TEST", 329, 346], ["research programme evaluation", "TEST", 391, 420], ["significant", "OBSERVATION_MODIFIER", 220, 231]]], ["Yet it was only in the early 1980s, when evaluation became a legislative requirement, that the institutionalisation of Commission research evaluation practices picked up pace.", [["evaluation", "TEST", 41, 51], ["a legislative requirement", "PROBLEM", 59, 84], ["Commission research evaluation", "TEST", 119, 149]]], ["15The Framework Programme monitoring and evaluation systemThe ex-post evaluation system The Framework Programme ex-post evaluation system was introduced in the mid-nineties.", [["The Framework Programme monitoring", "TEST", 2, 36], ["evaluation system", "TEST", 41, 58], ["The ex-post evaluation system", "TEST", 58, 87], ["evaluation system", "TEST", 120, 137]]], ["16 Its two main components are yearly monitoring exercises and five-yearly in-depth assessments (the so-called \"Five-Year Assessments\") carried out at overall and usually also specific programme level.", [["depth assessments", "TEST", 78, 95], ["two", "OBSERVATION_MODIFIER", 7, 10], ["main", "OBSERVATION_MODIFIER", 11, 15], ["components", "OBSERVATION_MODIFIER", 16, 26]]], ["The annual monitoring exercise is intended to be rather light and enable a quick response to issues arising from ongoing programme implementation.", [["The annual monitoring exercise", "TEST", 0, 30], ["ongoing programme implementation", "TREATMENT", 113, 145]]], ["The objective of the Five-Year Assessments, on the other hand, is to provide input for policy formulation and decision-making on the basis of feedback obtained from programme implementation.", [["policy formulation", "TREATMENT", 87, 105]]], ["17 The current Framework Programme ex-post evaluation system has obvious strengths, for example its independence and legitimacy.", [["ex-post evaluation system", "TEST", 35, 60]]], ["However, the literature has also identified some important weaknesses which go beyond the issues plaguing all research evaluations (time lag, attribution, additionality, difficulties of measuring qualitative effects, etc.).", [["all research evaluations", "TEST", 106, 130]]], ["According to some evaluation experts, the main problem affecting the current system relates to FP design: \"The intervention logic that connects the high-level and operational goals of the FP is poorly articulated, making an overall evaluation of the FP difficult.", [["some evaluation", "TEST", 13, 28], ["The intervention logic", "TREATMENT", 107, 129], ["an overall evaluation", "TEST", 221, 242]]], ["The Framework needs more systematic planning, clearer objectives and a stronger link to an evidence base.", [["systematic planning", "TREATMENT", 25, 44], ["base", "ANATOMY_MODIFIER", 100, 104]]], ["This would ease evaluation and, arguably, improve FP performance\".", [["evaluation", "TEST", 16, 26]]], ["The same difficulties apply when it comes to establishing quantifiable ex-ante objectives for programme evaluation at the national level.The Framework Programme monitoring and evaluation systemOther (potential) problems have been identified mainly with regard to the available evidence base and the use of expert panels.", [["programme evaluation", "TEST", 94, 114], ["The Framework Programme monitoring", "TEST", 137, 171], ["evaluation", "TEST", 176, 186], ["expert panels", "TEST", 306, 319]]], ["A strong and timely evidence base constitutes the main tool for Five-year Assessment expert panels on which to base their assessment and recommendations.", [["their assessment", "TEST", 116, 132], ["main", "OBSERVATION_MODIFIER", 50, 54]]], ["Yet a number of studies have highlighted weaknesses in the evidence base available.", [["highlighted weaknesses", "PROBLEM", 29, 51]]], ["19 Sometimes thematic expost evaluations have not (yet) been completed, or they focus on different issues, cover different periods, or have been carried out according to different methodologies.", [["thematic expost evaluations", "TEST", 13, 40]]], ["Especially in recent years substantial efforts have been made to address this issue.The Framework Programme monitoring and evaluation systemIn Framework Programme ex-post evaluation, use is often made of external expert panels.", [["The Framework Programme monitoring", "TEST", 84, 118], ["evaluation", "TEST", 123, 133], ["ex-post evaluation", "TEST", 163, 181], ["external expert panels", "TEST", 204, 226]]], ["However, some observers have considered them to be time-and 17 The careful timing of the Five-Year Assessments allows for the combination of an ex-post evaluation of the previous Framework Programme with a mid-term appraisal of the ongoing one to formulate recommendations for the next Framework Programme.", [["an ex-post evaluation", "TEST", 141, 162]]], ["And with regard to the 2000 Five-Year Assessment, one scholar noted that \"many of the recommendations drew not so much on an evaluation of past FP activities, but on the collective opinions and assessments of the panel member concerning the general structure, and organisation of RTD in Europe\".", [["an evaluation", "TEST", 122, 135]]], ["22 It should however be borne in mind that these problems are not unique to the Framework Programme, but exist in many other industrialised countries' R&D programmes as well.The Framework Programme monitoring and evaluation systemThe above observations on Framework Programme evaluation are all well known and well documented.", [["The Framework Programme monitoring", "TEST", 174, 208], ["evaluation system", "TEST", 213, 230], ["Framework Programme evaluation", "TEST", 256, 286]]], ["But this is also one of the greatest strengths of the system, because transparent and constructive criticism is one of the main vehicles for promoting programme improvement.", [["system", "ANATOMY", 54, 60], ["constructive", "OBSERVATION_MODIFIER", 86, 98], ["criticism", "OBSERVATION", 99, 108], ["main", "OBSERVATION_MODIFIER", 123, 127]]], ["And indeed many important improvements to the Framework Programme in the past have emanated from comments made at the evaluation stage.The Framework Programme monitoring and evaluation systemTopics, sources, and methodologies Above we have argued that, except for the recent introduction of impact assessment, the Commission's research evaluation system has remained relatively stable over the past decade.", [["the evaluation stage", "TEST", 114, 134], ["The Framework Programme monitoring", "TEST", 135, 169], ["evaluation systemTopics", "TEST", 174, 197], ["impact assessment", "TEST", 291, 308], ["the Commission's research evaluation system", "TEST", 310, 353], ["relatively", "OBSERVATION_MODIFIER", 367, 377], ["stable", "OBSERVATION_MODIFIER", 378, 384]]], ["Greater change has characterised the evaluation studies carried out.", [["the evaluation studies", "TEST", 33, 55]]], ["New topics are being explored, studies are based on new kinds of sources, and use is made of innovative methodologies.The Framework Programme monitoring and evaluation systemIn past Framework Programme ex-post evaluations, substantial attention used to be paid to analysing participant characteristics (e.g. type of institutional actor, country of origin, region of origin, etc.) and R&D inputs.", [["The Framework Programme monitoring", "TEST", 118, 152], ["evaluation", "TEST", 157, 167], ["ex-post evaluations", "TEST", 202, 221]]], ["This has not disappeared.", [["not disappeared", "UNCERTAINTY", 9, 24]]], ["But attempts are now made to profile programme participants in more innovative ways.", [["participants", "SPECIES", 47, 59]]], ["From merely counting project outputs, the emphasis has also shifted to assessing 20 Framework Programme aggregate impacts on Europe's scientific and technological performance, and on research capacity, or on the European economy and society.The Framework Programme monitoring and evaluation systemThe study of such more challenging topics can be embarked upon because of the mining of new data sources.", [["The Framework Programme monitoring", "TEST", 241, 275], ["evaluation system", "TEST", 280, 297], ["The study", "TEST", 297, 306]]], ["Framework Programme ex-post evaluations used to be based mainly on surveys (interviews or written questionnaires) and end-ofproject reports.", [["ex-post evaluations", "TEST", 20, 39]]], ["However, attempts are now made, for instance, to create cleaned and consolidated participant databases at the individual scientist level rather than just the institutional level, and to link them with bibliometric and patent databases.", [["patent", "OBSERVATION", 218, 224]]], ["The use of bibliometric and patent data almost by definition also entails the use of new methodological approaches and techniques.", [["new methodological approaches", "TREATMENT", 85, 114], ["patent", "OBSERVATION", 28, 34]]], ["Within this context, mention should be made of the use of econometric models to estimate the impact of the Framework Programme on the European economy, as was done in the impact assessment on the Commission's proposal for the Seventh Framework Programme.", [["econometric models", "TREATMENT", 58, 76]]], ["23The Framework Programme monitoring and evaluation systemThe way forward Against this background, several steps are envisaged to improve the Framework Programme's evaluation system.", [["The Framework Programme monitoring", "TEST", 2, 36], ["evaluation system", "TEST", 41, 58]]], ["A clearer formulation of the intervention logic in the 7th Framework Programme proposal with clear and measurable objectives and the monitoring of their progress will facilitate the ex-post evaluation of the 7th Framework Programme.", [["the intervention logic", "TREATMENT", 25, 47], ["the ex-post evaluation", "TEST", 178, 200], ["clearer", "OBSERVATION_MODIFIER", 2, 9]]], ["A comprehensive effort will be made under the next Framework Programme to ensure that the ex-post evaluation will be based on a wide range of completed, focussed and methodologically standardised ex-post evaluation studies.", [["the ex-post evaluation", "TEST", 86, 108], ["methodologically standardised ex-post evaluation studies", "TEST", 166, 222]]], ["Also, what constitutes a project of critical mass?", [["critical mass", "PROBLEM", 36, 49], ["mass", "OBSERVATION", 45, 49]]], ["How does critical mass interrelate with flexibility, with cohesion, with excellence?", [["critical mass", "PROBLEM", 9, 22], ["mass", "OBSERVATION", 18, 22]]], ["But external networking is also needed so as to achieve complementarity between European Commission and national level Framework Programme evaluations.", [["Framework Programme evaluations", "TEST", 119, 150]]], ["25 Those networks also allow sharing and comparing hard evidence of the impact of research policies at regional, national and EU levels and will help identify what is done best at each level, and how to design the S&T governance model in the most efficient and effective way.The size of collaborative research projectsThe added value of European funded collaborative research projects is among other things to be found in the fact that they allow for pooling financial resources and knowledge across national frontiers.", [["the S&T governance model", "TREATMENT", 210, 234], ["size", "OBSERVATION_MODIFIER", 279, 283]]], ["This allows research projects to attain the appropriate size or \"critical mass\" needed to achieve scientific breakthroughs.", [["\"critical mass\"", "PROBLEM", 64, 79], ["size", "OBSERVATION_MODIFIER", 56, 60], ["mass", "OBSERVATION", 74, 78]]], ["The average number of participations per project increased from 4.7 in the 2nd Framework Programme to 6.5 in the 5th Framework Programme, while the average Commission funding per project increased from E1.2 million to E1.4 million.", [["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["The 6th Framework Programme appears to have initiated a trend towards decisively larger projects with more participations per project, and with higher funding per project and per participation (Table 4 .2).The size of collaborative research projectsSo the trend appears to be towards larger projects.", [["size", "OBSERVATION_MODIFIER", 210, 214], ["appears to be", "UNCERTAINTY", 262, 275], ["larger", "OBSERVATION_MODIFIER", 284, 290]]], ["But a better understanding has to be gained of what \"critical mass\" means, and of how it can be achieved.", [["mass", "OBSERVATION", 62, 66]]], ["For example, does it refer to the number of participants in and the size of the funding allocated to a collaborative research project?", [["participants", "SPECIES", 44, 56], ["size", "OBSERVATION_MODIFIER", 68, 72]]], ["If that is the case, what do we know about the ideal number of participants and the ideal size of funding?", [["participants", "SPECIES", 63, 75]]], ["Is the relation between project scale and project achievement a simple linear one, or is there a minimum efficient project scale above which there is a disproportionately higher level of achievement? 28 Is it possible to make general statements about it, or is it Participation pattern by type of institution Available data indicate that over time the pattern of participation in collaborative research projects by type of institution has become more balanced.", [["project scale", "TREATMENT", 24, 37], ["disproportionately", "OBSERVATION_MODIFIER", 152, 170], ["higher", "OBSERVATION_MODIFIER", 171, 177]]], ["30 Whereas business enterprises initially accounted for the largest share of funding and participations, that is no longer true.", [["largest", "OBSERVATION_MODIFIER", 60, 67], ["funding", "OBSERVATION", 77, 84], ["no longer", "UNCERTAINTY", 113, 122]]], ["Higher education institutes and research centres now also account for sizeable participation and funding shares (Figs 4.4 and 4.5).", [["Figs", "TEST", 113, 117]]], ["31 Several factors could explain the growth of the collaborative research participation and funding shares held by higher education institutes and research centres.", [["growth", "OBSERVATION_MODIFIER", 37, 43]]], ["The wider trend in OECD countries is to put renewed emphasis on funding basic research.", [["wider", "OBSERVATION_MODIFIER", 4, 9], ["trend", "OBSERVATION_MODIFIER", 10, 15]]], ["8: \"The literature deals poorly with the question of 'critical mass,' providing no ready-reckoner to check whether more or better capacity is necessary.\" 30 It is not possible to trace in a definitive manner across Framework Programmes the evolution of the collaborative research participation structure by type of institution.", [["'critical mass", "PROBLEM", 53, 67], ["mass", "OBSERVATION", 63, 67], ["not possible", "UNCERTAINTY", 163, 175]]], ["Therefore, definitions of especially industrial types of participants have also changed.", [["participants", "ORGANISM", 57, 69], ["participants", "SPECIES", 57, 69]]], ["31 See European Commission, Second Report on S&T Indicators, 1997 -Report, Luxembourg, 1997, pp. 520-522, for a discussion on the drop between FP2 and FP3 and the seeming stabilisation between FP3 and FP4 of the industrial share of participations, and of the drop between FP3 and FP4 of the industrial share of funding.", [["FP2", "TEST", 143, 146], ["FP3", "TEST", 272, 275]]], ["6, the assessment panel, commenting on FP6, states having encountered \"significant evidence of industrial discontent and reports from different regions of industry dropping out in unusually high numbers from the Sixth Framework Programme\", but does not find supporting statistics.", [["the assessment panel", "TEST", 3, 23], ["industrial discontent", "PROBLEM", 95, 116], ["industrial discontent", "OBSERVATION", 95, 116]]], ["34 Some observers question the appropriateness of the Framework Programme's mix of participants in terms of type of institution.", [["participants", "SPECIES", 83, 95]]], ["The supposedly too low participation of SMEs in the Framework Programme, for instance, is a constant in the Framework Programme ex-post evaluation literature.", [["ex-post evaluation", "TEST", 128, 146], ["too low", "OBSERVATION_MODIFIER", 15, 22]]], ["Less than 3 per cent is involved in leading-edge research, however.", [["edge", "OBSERVATION_MODIFIER", 44, 48]]], ["Theory does not offer much insight beyond the one that it is quite natural for SMEs to be more irregular participants in the Framework Programme than large firms.", [["participants", "SPECIES", 105, 117], ["large", "OBSERVATION_MODIFIER", 150, 155], ["firms", "OBSERVATION", 156, 161]]], ["Given their scale, the relative cost of participation is higher.", [["higher", "OBSERVATION_MODIFIER", 57, 63]]], ["And there is no learning effect from regular participation.", [["no", "UNCERTAINTY", 13, 15], ["learning effect", "OBSERVATION", 16, 31]]], ["37 On the other hand, there are no appropriate national or international points of comparison as the thematic coverage and instruments of these schemes differ from those of the Framework Programme.The size of collaborative research projectsParticipation pattern by country of origin Framework Programme funding is awarded not on the basis of the nationalities of the applicants, but on the basis of their scientific excellence and the European added value of the research proposal.", [["the thematic coverage", "TREATMENT", 97, 118], ["no", "UNCERTAINTY", 32, 34], ["size", "OBSERVATION_MODIFIER", 201, 205], ["collaborative", "OBSERVATION_MODIFIER", 209, 222], ["research", "OBSERVATION_MODIFIER", 223, 231]]], ["Framework Programme funding is important to the Member States, however, especially the smaller ones, so that national stakeholders take an understandable interest in the amounts they receive.The size of collaborative research projectsThe Framework Programme evaluation literature does not dwell much on the countries of origin of Framework Programme participants.", [["participants", "SPECIES", 350, 362], ["The Framework Programme evaluation", "TEST", 234, 268], ["size", "OBSERVATION_MODIFIER", 195, 199]]], ["38 This is confirmed by an empirical check.", [["an empirical check", "TEST", 24, 42]]], ["Fig. 4 .6 displays for each EU-15 Member State (the highest ranking being 15 and the lowest 1) its ranking for three variables: the number of shared-cost action participations in the 5th Framework Programme, the shared-cost action funding received under the 5th Framework Programme, and the share of European GDP in 2000.", [["GDP", "CHEMICAL", 309, 312]]], ["It is clear that a Member State's Framework Programme participation is more or less in line with its share of European GDP.", [["GDP", "CHEMICAL", 119, 122], ["GDP", "SIMPLE_CHEMICAL", 119, 122], ["clear", "OBSERVATION", 6, 11]]], ["In other words, Member States accounting for large shares of European GDP participate most often in the Framework Programme and obtain most Framework Programme funding while the reverse is true for Member States accounting for small shares of European GDP.", [["GDP", "CHEMICAL", 252, 255], ["GDP", "SIMPLE_CHEMICAL", 70, 73], ["GDP", "SIMPLE_CHEMICAL", 252, 255]]], ["An important exception is Greece, which participates in the Framework Programme to a larger extent and obtains more funding from the Framework Programme than one would expect on the basis of its share of European GDP.", [["GDP", "CHEMICAL", 213, 216], ["GDP", "SIMPLE_CHEMICAL", 213, 216], ["larger extent", "OBSERVATION_MODIFIER", 85, 98]]], ["Similar results are obtained when the comparison is made not with the share of European GDP but with the number of researchers ( Fig. 4.7) .", [["GDP", "CHEMICAL", 88, 91], ["GDP", "SIMPLE_CHEMICAL", 88, 91], ["European GDP", "TEST", 79, 91]]], ["Then it becomes clear that smaller Member States participate more intensely in the Framework Programme than larger ones.", [["clear", "OBSERVATION", 16, 21], ["smaller", "OBSERVATION_MODIFIER", 27, 34]]], ["New Member States, however, have usually been able to rapidly increase their number of participations across Framework Programmes (See e.g. Sweden, Austria and Finland in Fig. 4 .10).The size of collaborative research projectsIn addition to intra-European collaboration, the Framework Programme supports international collaboration beyond Europe's borders.", [["size", "OBSERVATION_MODIFIER", 187, 191]]], ["The number Participation pattern by region of origin The pattern of Framework Programme participation can be traced not just at national level, but also in Europe's regions.", [["origin", "ANATOMY_MODIFIER", 46, 52]]], ["A close look at the map of Europe reveals the great diversity in research capacity and innovation performance among its regions.", [["great", "OBSERVATION_MODIFIER", 46, 51], ["diversity", "OBSERVATION", 52, 61]]], ["40 R&D \"hot spots\" generating above average high-tech employment rates exist alongside pockets of poverty and entrepreneurial deprivation.", [["entrepreneurial deprivation", "TREATMENT", 110, 137]]], ["42 40 Andr\u00e9s Rodr\u00edguez-Pose, The Dynamics of Regional Growth in Europe: Social A pilot study based on 15 years of Framework Programme data (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) has analysed in more detail the regional distribution of Framework Programme participation and funding.", [["A pilot study", "TEST", 79, 92], ["Regional", "OBSERVATION_MODIFIER", 45, 53], ["Growth", "OBSERVATION_MODIFIER", 54, 60]]], ["43 There have been a number of interesting findings, in particular for Europe's less favoured regions.", [["number", "OBSERVATION_MODIFIER", 21, 27]]], ["Successive FP programmes have created networks of research in less favoured regions which are at the base of the diffusion of knowledge spillovers and which undoubtedly have eased the diffusion of knowledge from the centre to the periphery.", [["Successive FP programmes", "TREATMENT", 0, 24], ["less favoured", "OBSERVATION_MODIFIER", 62, 75], ["base", "ANATOMY_MODIFIER", 101, 105], ["periphery", "ANATOMY_MODIFIER", 230, 239]]], ["In terms of study findings, the study confirms firstly and not surprisingly that, in absolute terms, participations and funding are concentrated in the \"usual suspects\": London and the South-East in the United Kingdom; \u00cele de France and Rh\u00f4ne-Alpes in France; the Stuttgart-Karlsruhe-Lower Bavaria axis in Germany; the Randstad in the Netherlands; the greater Brussels area in Belgium; and the North of Italy.", [["study findings", "TEST", 12, 26], ["the study", "TEST", 28, 37], ["Rh\u00f4ne", "TEST", 237, 242], ["the Stuttgart", "TEST", 260, 273], ["Lower", "ANATOMY_MODIFIER", 284, 289], ["Bavaria axis", "ANATOMY", 290, 302], ["greater", "OBSERVATION_MODIFIER", 352, 359], ["Brussels", "OBSERVATION_MODIFIER", 360, 368], ["area", "OBSERVATION_MODIFIER", 369, 373]]], ["44 Secondly, within peripheral countries, European research activity is often, though not always, concentrated in those areas with the highest levels of GDP per capita and the greatest concentration of researchers and research activity (e.g. Helsinki, Lisbon, Madrid, Athens).", [["GDP", "CHEMICAL", 153, 156], ["GDP", "CHEMICAL", 153, 156], ["GDP", "SIMPLE_CHEMICAL", 153, 156], ["peripheral", "ANATOMY_MODIFIER", 20, 30]]], ["Thirdly and most interestingly, a significant number of peripheral regions obtain a share of European research funds which is larger than one would expect on the basis of their overall R&D effort, the size of their economy, or their relative wealth (e.g. Scotland in the United Kingdom; Catalonia and Murcia in Spain; Steiermark in Austria).", [["most interestingly", "OBSERVATION_MODIFIER", 12, 30], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["number", "OBSERVATION_MODIFIER", 46, 52], ["peripheral", "ANATOMY_MODIFIER", 56, 66], ["regions", "ANATOMY_MODIFIER", 67, 74], ["larger", "OBSERVATION_MODIFIER", 126, 132], ["size", "OBSERVATION_MODIFIER", 201, 205], ["economy", "OBSERVATION_MODIFIER", 215, 222]]], ["Given the fact that they often face a more limited choice of funding possibilities than more advanced regions, this study indicates that the Framework Programme plays an encouraging role in reducing the research investment gap in less favoured regions.", [["this study", "TEST", 111, 121], ["less favoured", "OBSERVATION_MODIFIER", 230, 243]]], ["From the viewpoint of the more advanced -in terms of research endowment and innovation performance -regions it can be said that successive Framework Programmes have supported excellent research without being detrimental to cohesion (Fig. 4.11) .The size of collaborative research projectsThe degree of concentration of collaborative research participation In the previous two sections, we have looked at the distribution of Framework Programme participations and funding across countries and regions.", [["size", "OBSERVATION_MODIFIER", 249, 253], ["concentration", "OBSERVATION_MODIFIER", 302, 315]]], ["This section considers how participation is dispersed at the level of individual organisations.", [["This section", "TREATMENT", 0, 12]]], ["Many institutions are present in the system only one or a few times, but a small number of universities achieve a high number of participations.", [["small", "OBSERVATION_MODIFIER", 75, 80], ["high number", "OBSERVATION_MODIFIER", 114, 125]]], ["45 summary of a series of Framework Programme ex-post evaluations comes to the same conclusion: many organisations' participation in Framework Programme is short-lived, but there is a core of frequent participants.", [["participants", "SPECIES", 201, 213], ["Framework Programme ex-post evaluations", "TEST", 26, 65]]], ["48 Finally, a recent network analysis of partial data on the 6th Framework Programme found skewed distributions of connectedness, with a central core of highly linked organisations and a periphery of less well connected entities.", [["skewed", "OBSERVATION_MODIFIER", 91, 97], ["distributions", "OBSERVATION_MODIFIER", 98, 111], ["central core", "OBSERVATION_MODIFIER", 137, 149], ["organisations", "OBSERVATION", 167, 180], ["periphery", "OBSERVATION_MODIFIER", 187, 196], ["less", "OBSERVATION_MODIFIER", 200, 204], ["well connected", "OBSERVATION_MODIFIER", 205, 219]]], ["49 A certain degree of concentration of participation in a selective funding scheme based primarily on scientific excellence is inevitable, and a certain degree of continuity of participation is indeed to be welcomed.", [["a selective funding scheme", "TREATMENT", 57, 83], ["certain degree", "OBSERVATION_MODIFIER", 5, 19], ["concentration", "OBSERVATION_MODIFIER", 23, 36]]], ["Large institutions are more likely to apply multiple times to research programmes as they have more staff, and to internationally collaborative research programmes as they are more likely to have prior experience with international research collaboration.", [["more likely", "UNCERTAINTY", 23, 34]]], ["50 Large, well-known institutions are better placed than small, lesser-known ones to put together research consortia.", [["Large", "OBSERVATION_MODIFIER", 3, 8]]], ["51 More than small institutions, large organisations have the institutional capacity to handle complex application and project management procedures, and to do so multiple times.", [["complex application", "TREATMENT", 95, 114], ["project management procedures", "TREATMENT", 119, 148], ["large", "OBSERVATION_MODIFIER", 33, 38]]], ["52 Research project proposals submitted by consortia involving a large, well-known institution with a well-established research reputation are more likely to get selected.", [["large", "OBSERVATION_MODIFIER", 65, 70], ["more likely", "UNCERTAINTY", 143, 154]]], ["53 A lock-in effect then ensues.", [["A lock", "TREATMENT", 3, 9]]], ["This results first of all from the fact that successful applicants can familiarise themselves even more with complex application and project management procedures, which remain stable to a certain extent over time.", [["complex application", "TREATMENT", 109, 128], ["project management procedures", "TREATMENT", 133, 162], ["stable", "OBSERVATION_MODIFIER", 177, 183]]], ["Successful participation, on the basis of which scientific and technological outputs can be produced, further consolidates the participant's scientific reputation and reinforces the information signalling effect to both potential consortia participants and proposal evaluators on the occasion of a next application.", [["participants", "SPECIES", 240, 252], ["a next application", "TREATMENT", 296, 314]]], ["54 It is not possible to judge now whether the degree of concentration of Framework Programme participation is appropriate.", [["not possible", "UNCERTAINTY", 9, 21]]], ["A study would be required of the evolution 48 of the degree of concentration of participation over time.", [["A study", "TEST", 0, 7]]], ["And an assessment would have to be made of the relationship between programme participant and network characteristics on the one hand, and project outputs and impacts on the other hand.The size of collaborative research projectsIn the meantime, the Commission is aware of the importance of not discouraging small innovative institutions from participating regularly in the Framework Programme.", [["hand", "ORGANISM_SUBDIVISION", 180, 184], ["an assessment", "TEST", 4, 17], ["size", "OBSERVATION_MODIFIER", 189, 193]]], ["These networks embody the unique European added value of the Framework Programme, which is to bring together different types of high-quality participants from different countries and with complementary expertise in productive partnerships, thus overcoming the sectoral and national fragmentation of the European research system.", [["participants", "SPECIES", 141, 153]]], ["Over the past two decades, the number of links established between participants in FP-supported collaborative research projects has increased substantially to reach 160 000 under the 5th Framework Programme (Fig. 4.12) .", [["participants", "SPECIES", 67, 79], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["substantially", "OBSERVATION_MODIFIER", 142, 155]]], ["55 Collaborative research project participants do not just establish collaborative links within their own sectors (businesses just collaborating with businesses, universities just with universities, etc.).", [["participants", "SPECIES", 34, 46]]], ["56 At the heart of these networks, however, still lies science-industry collaboration.", [["heart", "ANATOMY", 10, 15], ["heart", "ORGAN", 10, 15], ["heart", "ANATOMY", 10, 15]]], ["This is a feature greatly appreciated by Framework Programme shared-cost action participants.", [["participants", "SPECIES", 80, 92]]], ["57 It is also a key component of innovation systems.", [["innovation", "OBSERVATION", 33, 43]]], ["58 The average number of different Member States per project has increased from Framework Programme to Framework Programme.", [["average", "OBSERVATION_MODIFIER", 7, 14], ["number", "OBSERVATION_MODIFIER", 15, 21]]], ["Starting from an average of 3 different Member States per project in the 2nd Framework Programme, interim data for the 6th Framework Programme show an average of 6.5 ( Over time, the configuration of intra-European transnational collaboration has also changed (Figs 4.13-4.15 ).", [["Figs", "TEST", 261, 265]]], ["No less than eight Member States are now situated at the core (Austria, Belgium, Greece, Ireland, Netherlands, Portugal, Spain, and Sweden).", [["less", "OBSERVATION_MODIFIER", 3, 7]]], ["Finally, a strong cohesion effect is evident.", [["a strong cohesion effect", "PROBLEM", 9, 33], ["strong", "OBSERVATION_MODIFIER", 11, 17], ["cohesion effect", "OBSERVATION", 18, 33]]], ["In the 6th Framework Programme, formerly \"peripheral\" countries -Austria, Ireland, and Luxemburg -joined the two inner circles of collaboration.", [["peripheral", "ANATOMY_MODIFIER", 42, 52]]], ["Modern mainstream innovation theory recognises the importance of networks bringing together different types of actors (e.g. science and industry) in regional, national, and supranational systems of innovation.", [["mainstream innovation", "OBSERVATION", 7, 28]]], ["One question concerns the optimal size of networks, as some have suggested 59 Is network stability beneficial?", [["size", "OBSERVATION_MODIFIER", 34, 38]]], ["Certainly one of the aims of Framework Programme support is to tackle the fragmentation of the EU research system by encouraging the formation of transnational consortia.", [["Framework Programme support", "TREATMENT", 29, 56], ["fragmentation", "OBSERVATION", 74, 87], ["transnational consortia", "OBSERVATION", 146, 169]]], ["If the networks thus created are durable, then, one could argue, a real contribution has been made to the long-term restructuring of research in Europe.", [["long-term", "OBSERVATION_MODIFIER", 106, 115]]], ["Continuity over successive Framework Programmes can allow complex research fields to advance within a stable cooperative structure.", [["Continuity over successive Framework Programmes", "TREATMENT", 0, 47], ["stable", "OBSERVATION_MODIFIER", 102, 108]]], ["However, there are also some important caveats.", [["some", "OBSERVATION_MODIFIER", 24, 28], ["important", "OBSERVATION_MODIFIER", 29, 38], ["caveats", "OBSERVATION", 39, 46]]], ["In such instances, there would be no \"behavioural additionality\" from repeated Framework Programme support (although there may still be input or output additionality).", [["repeated Framework Programme support", "TREATMENT", 70, 106]]], ["Finding the right balance between stability and dynamism is therefore important and merits ongoing analysis.The characteristics of collaborative research networksFrom financial to knowledge returns -the multiplier effect of collaborative research via networks A Member State's net returns from the Framework Programme are traditionally calculated by subtracting its contribution to the Framework Programme budget from the combined value of its Framework Programme participations.", [["merits ongoing analysis", "TEST", 84, 107], ["right", "ANATOMY_MODIFIER", 12, 17], ["stability", "OBSERVATION_MODIFIER", 34, 43]]], ["In other words, a single project participant benefits from and thus accesses the funding of all project participants combined.The characteristics of collaborative research networksThe question is how to calculate these knowledge returns.", [["participants", "SPECIES", 104, 116]]], ["This is an issue which so far has barely been explored and deserves further investigation.", [["further investigation", "TEST", 68, 89]]], ["For example, if a country contributes E1 to the Framework Programme budget, the combined value of its Framework Programme participations is E2, and the combined value of the Framework Programme contracts in which it participates is E10, then that country's net financial return is E1 while its net knowledge return is E9, and thus the multiplier effect is of a factor 9.The characteristics of collaborative research networksCalculations carried out by DG Research show that for each Euro invested in the 5th Framework Programme, countries' net knowledge return averaged E19.8 for the EU-25 (Fig. 4.16) .", [["E2", "CHEMICAL", 140, 142], ["E9", "PROTEIN", 318, 320], ["Calculations", "TEST", 424, 436], ["the EU", "TEST", 580, 586]]], ["However, the size of these returns tended to be inversely related to a country's number of Framework Programme participations.", [["size", "OBSERVATION_MODIFIER", 13, 17]]], ["This probably happened because a smaller number of Framework Programme participations translates into a pattern of widely dispersed single participations per project, while a larger number of Framework Programme participations translates into a pattern where regularly two or three participations from the same country can be found in the same project, which partially dampens the net knowledge return. successive Framework Programmes (Fig. 4.17) .", [["smaller", "OBSERVATION_MODIFIER", 33, 40], ["widely", "OBSERVATION_MODIFIER", 115, 121], ["dispersed", "OBSERVATION_MODIFIER", 122, 131]]], ["70 Within this context, it is legitimate to ask whether the Framework Programme's increasingly comprehensive coverage may have led to a degree of fragmentation in the sense that Framework Programme resources may be spread too thinly across too many priorities.", [["fragmentation", "PROBLEM", 146, 159], ["fragmentation", "OBSERVATION", 146, 159]]], ["This is always an important consideration because, to make a real difference, the level of support in a particular S&T area should be sufficient to achieve critical mass and a minimum efficient scale of research.", [["support", "TREATMENT", 91, 98], ["a particular S&T area", "TREATMENT", 102, 123], ["critical mass", "PROBLEM", 156, 169], ["mass", "OBSERVATION", 165, 169]]], ["However, there are no indications as yet in the Framework Programme evaluation literature or elsewhere that this is a major cause for concern.Themes, quality, and riskiness of collaborative researchA rigid predefined thematic priority structure can make it more difficult to accommodate important scientific advances and new needs which emerge during the life-time of the programme.", [["Programme evaluation", "TEST", 58, 78], ["collaborative researchA rigid predefined thematic priority structure", "PROBLEM", 176, 244], ["no", "UNCERTAINTY", 19, 21]]], ["Programme experience that adjustments to meet new needs, or to reflect new scientific advances, required a tortuous and time-consuming legal process.", [["tortuous", "OBSERVATION_MODIFIER", 107, 115]]], ["71 In the recent ICT Five-Year Assessment, the Panel was of the opinion that, in a fast-moving area such as ICT research, the programme should be willing and able to respond rapidlyif justified -to changes in the economic, technological, or even policy context.", [["the Panel", "TEST", 43, 52]]], ["The 6th Framework Programme, for instance, has been able to fund research on, for example, SARS and avian flu.", [["SARS", "DISEASE", 91, 95], ["avian flu", "DISEASE", 100, 109], ["avian flu", "ORGANISM", 100, 109], ["SARS", "PROBLEM", 91, 95]]], ["Under the EU-supported SEPSDA (Sino-European Project on SARS Diagnostics and Antivirals), scientists from across Europe and China have spent the past years screening over 8 000 existing drugs to find prime candidates for combating SARS, and identified a number of promising anti-SARS compounds.", [["SARS", "DISEASE", 231, 235], ["anti-SARS compounds", "SIMPLE_CHEMICAL", 274, 293], ["Antivirals", "TREATMENT", 77, 87], ["drugs", "TREATMENT", 186, 191], ["SARS", "PROBLEM", 231, 235]]], ["73 The European Commission recently also announced that it would be making a further E20 million available for research into avian and pandemic influenza.", [["influenza", "DISEASE", 144, 153], ["avian", "ORGANISM", 125, 130], ["a further E20 million", "TREATMENT", 75, 96], ["pandemic influenza", "PROBLEM", 135, 153]]], ["Relating to animal health, the relevant call for proposals would cover issues such as developing vaccines for avian species, improved diagnosis and early warning systems, and technology transfer to third countries.", [["developing vaccines", "TREATMENT", 86, 105], ["avian species", "PROBLEM", 110, 123]]], ["Relating to human health, it would cover issues such as clinical research on pandemic influenza vaccines, better understanding of the influenza virus, and strengthening support to surveillance.", [["influenza", "DISEASE", 86, 95], ["influenza", "DISEASE", 134, 143], ["human", "ORGANISM", 12, 17], ["influenza virus", "ORGANISM", 134, 149], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["influenza virus", "SPECIES", 134, 149], ["pandemic influenza vaccines", "TREATMENT", 77, 104], ["the influenza virus", "PROBLEM", 130, 149], ["strengthening support", "TREATMENT", 155, 176], ["surveillance", "TEST", 180, 192]]], ["74 In terms of quality, FP-supported collaborative research has generally been found to be of a high standard.", [["FP", "TEST", 24, 26]]], ["75 Industrial participants have reported that Framework Programme projects are of relatively high scientific and technological complexity, while university participants have identified major benefits in the form of knowledge enhancement.", [["participants", "SPECIES", 14, 26], ["participants", "SPECIES", 156, 168]]], ["76 A first important factor underlying the high quality of FP-funded research is the well-functioning Framework Programme proposal assessment and project monitoring system.", [["proposal assessment", "TEST", 122, 141], ["project monitoring system", "TEST", 146, 171]]], ["78 Another crucial factor is that Framework Programme participants themselves are generally of high quality.", [["participants", "SPECIES", 54, 66]]], ["A recent study on the networks resulting from funding under the 6th Framework Programme in the field of ICT concluded that networks under this Framework Programme attract knowledge leaders from corporate and academic centres of excellence, evidenced by the rate at which relevant patent holders and institutions participate.", [["A recent study", "TEST", 0, 14], ["patent", "OBSERVATION", 280, 286]]], ["79 A recent bibliometric study on participants in the 5th Framework Programme in the fields of the life sciences and nanotechnology convincingly demonstrated that the level of Framework Programme participants is generally above world level and that they reach citation impact scores higher than what could be expected on the basis of the journals in which they publish or the fields in which they are active.", [["participants", "SPECIES", 34, 46], ["participants", "SPECIES", 196, 208], ["A recent bibliometric study", "TEST", 3, 30], ["active", "OBSERVATION_MODIFIER", 401, 407]]], ["80 A substantial number of Nobel Prize laureates in medicine, chemistry, and physics are involved in research projects and networks under the 6th Framework Programme, many of them oriented towards medical purposes.", [["substantial", "OBSERVATION_MODIFIER", 5, 16], ["number", "OBSERVATION_MODIFIER", 17, 23]]], ["81 Although Framework Programme collaborative research is of high quality, it has been observed that it can often be too mainstream and insufficiently risky and \"at the frontier\".", [["high quality", "OBSERVATION_MODIFIER", 61, 73]]], ["The Five-Year Assessment 1995-99 found that the Framework Programme should retain its overarching emphasis on excellence, but make extra efforts to ensure that \"risky\" projects are not excluded.", [["not excluded", "UNCERTAINTY", 181, 193]]], ["82 Efforts were made to address this in the NEST programme under the 6th Framework Programme, and while this was welcomed by the subsequent Five-Year Assessment panel, they felt it was still a too narrow approach.", [["Assessment panel", "TEST", 150, 166], ["a too narrow approach", "PROBLEM", 191, 212]]], ["The panel therefore recommended that an ambition to fund more risky projects should be embedded in the Framework Programme objectives, instruments and implementation as well as in the assessment of achievements and impacts.", [["The panel", "TEST", 0, 9], ["the assessment", "TEST", 180, 194]]], ["In other words, in the absence of the Framework Programme collaborative research component, would projects have been carried out at all or would they have been carried out differently?The additionality of collaborative researchThe consensus appears to be that Framework Programme collaborative research funding schemes are characterised by a high degree of additionality. out or they would have been carried out differently, often entailing substantial losses in terms of efficiency and effectiveness.", [["appears to be", "UNCERTAINTY", 241, 254], ["high degree", "OBSERVATION_MODIFIER", 342, 353], ["substantial", "OBSERVATION_MODIFIER", 441, 452], ["losses", "OBSERVATION", 453, 459]]], ["Typical is the conclusion of a UK study on the EU Framework Programmes, which reported a broad agreement that Framework provides considerable added value.", [["a UK study", "TEST", 29, 39]]], ["It provides UK participants with access to foreign researchers and research outputs in a way that national funds cannot.", [["participants", "SPECIES", 15, 27]]], ["By pooling financial resources, it boosts investment in important research topics, and by pooling competencies it increases the likelihood of a breakthrough in a given area.", [["a breakthrough", "PROBLEM", 142, 156]]], ["Complex issues are resolved more quickly and more thoroughly as a result of larger projects and portfolios and multiple projects across successive Frameworks.", [["Complex issues", "PROBLEM", 0, 14], ["multiple projects across successive Frameworks", "TREATMENT", 111, 157], ["larger", "OBSERVATION_MODIFIER", 76, 82], ["multiple", "OBSERVATION_MODIFIER", 111, 119]]], ["85 Supportive evidence is wide-ranging and convincing.", [["wide", "OBSERVATION_MODIFIER", 26, 30]]], ["Almost 95 per cent of respondents to a survey of Norwegian participants in the 5th Framework Programme answered that EU-funding was very important for getting the project started, 90 per cent that it was important for the size of the project, and over 80 per cent that it was important for how fast the project could be carried through.", [["participants", "SPECIES", 59, 71]]], ["86 Among Irish participants in the 4th Framework Programme responding to a survey, 82 per cent would not have proceeded with their project without Framework Programme funding.", [["participants", "SPECIES", 15, 27]]], ["87 An Austrian study found very high additionality of the EU Framework Programmes.", [["An Austrian study", "TEST", 3, 20]]], ["Typical adjustments entailed a modified goal orientation, a reduced number of project partners, and a different project volume.", [["a modified goal orientation", "TREATMENT", 29, 56]]], ["88 Of Finnish participants in the 5th Framework Programme, 70 per cent would not have carried out the project without EU funding, 40 per cent would have carried it out on a smaller scale, and 35 per cent would have carried it out more slowly.", [["participants", "SPECIES", 14, 26]]], ["The evidence is considerable that the Framework Programme helps to improve participants' research capabilities, and modifies their behaviour, in addition to generating significant scientific and technological outputs, and contributing to competitiveness and innovation by boosting productivity and encouraging the development of new products and processes.The impact of collaborative researchImpact on capabilities, behaviour, and ability to compete FP-funded collaborative research projects strengthen participants' research capabilities by enhancing their knowledge base, and improving the skills of staff.", [["participants", "SPECIES", 75, 87], ["participants", "SPECIES", 503, 515], ["considerable", "OBSERVATION_MODIFIER", 16, 28], ["new", "OBSERVATION_MODIFIER", 329, 332], ["products", "OBSERVATION", 333, 341]]], ["For example, participants able to achieve short-term networking goals are more likely to carry out research through networks in the future.", [["participants", "SPECIES", 13, 25]]], ["91 An analysis of the Third Community Innovation Survey (CIS-3) shows that Framework Programme participating enterprises are more likely to engage in innovation cooperation with other partners in the innovation system, such as other firms and universities (Fig. 4.18 ).", [["An analysis", "TEST", 3, 14], ["CIS", "TEST", 57, 60], ["more likely", "UNCERTAINTY", 125, 136]]], ["Impact on scientific performance The extension of the knowledge base is to some extent codified and made explicit through scientific publications.", [["base", "ANATOMY_MODIFIER", 64, 68]]], ["Framework Programme projects generate many publications and thereby contribute directly to Europe's total output in terms of scientific publications, an important indicator of scientific performance.The impact of collaborative researchThe publication of peer-reviewed scientific work is an important goal for Framework Programme participants, especially those from universities and research institutes, now accounting for most Framework Programme participations and funding.", [["participants", "SPECIES", 329, 341]]], ["93 And a study in Ireland showed that Framework Programme participants from the public sector ranked publications as one of the ten most important goals.", [["participants", "SPECIES", 58, 70], ["a study", "TEST", 7, 14]]], ["94 Framework Programme participants generally achieve their publication goals, and thus generate large numbers of scientific publications.", [["participants", "SPECIES", 23, 35], ["large", "OBSERVATION_MODIFIER", 97, 102], ["numbers", "OBSERVATION_MODIFIER", 103, 110]]], ["For instance, 92 per cent of Finnish university participants in the 4th Framework Programme (and 91 per cent of such participants in the 5th Framework Programme) had achieved their publication goals.", [["participants", "SPECIES", 48, 60], ["participants", "SPECIES", 117, 129]]], ["95 And 85 per cent of 3rd/4th Framework Programme public sector participants declared that they had achieved their publication goals.", [["participants", "SPECIES", 64, 76]]], ["96 In a study of Irish participants in the 4th Framework Programme, 83 per cent of university/research institute respondents listed publications in refereed journals as important outputs.", [["participants", "SPECIES", 23, 35]]], ["97 Over 80 per cent of Austrian university participants in the 4th Framework Programme responding to a survey (and over 70 per cent of such research institute participants) had already reached their publication goals or expected to do so within the next three years.", [["participants", "SPECIES", 43, 55], ["participants", "SPECIES", 159, 171]]], ["98 A recent IST impact study obtained for publications a score for goal achievement of over 3 (important goal achieved as expected).", [["A recent IST impact study", "TEST", 3, 28]]], ["100 An analysis of impact variables resulting from research projects in the fisheries and aquaculture domain of the FAIR programme under the 4th Framework Programme identified 711 publications in 219 peer-reviewed journals by the participants of 82 projects, an average of 8.7 peer-reviewed publications per project.", [["participants", "SPECIES", 230, 242], ["An analysis", "TEST", 4, 15], ["impact variables", "PROBLEM", 19, 35]]], ["101 Participants in the BRITE-EURAM II programme under the 3rd Framework Programme reported 3 621 publications for 454 projects, an average of 8 publications per project.", [["Participants", "SPECIES", 4, 16]]], ["102 Participants in the transport programme under the 4th Framework Programme reported 3 766 publications for 269 shared-cost projects, an average of 14 publications per project.", [["Participants", "SPECIES", 4, 16]]], ["103 The scientific publications resulting from FP-funded collaborative research projects are often intra-European international co-publications, which points once more to the integrating effect of these projects.", [["FP", "PROBLEM", 47, 49]]], ["Direct evidence for this comes from a recently completed bibliometric study on participants in the 5th Framework Programme in the life sciences and nanotechnology, which found that for those Framework Programme participants the growth in intra-European international co-publications was much larger than that in international copublications with US authors or in the overall number of scientific publications.", [["participants", "SPECIES", 79, 91], ["participants", "SPECIES", 211, 223], ["bibliometric study", "TEST", 57, 75], ["the growth in intra-European international co-publications", "PROBLEM", 224, 282], ["growth", "OBSERVATION_MODIFIER", 228, 234]]], ["104 This may explain the fact that also at the aggregate level the share of intra-European international co-publications in Europe's international co-publications has increased, while that of international co-publications with the United States has decreased.", [["increased", "OBSERVATION_MODIFIER", 167, 176], ["decreased", "OBSERVATION_MODIFIER", 249, 258]]], ["105 The scientific publications resulting from Framework Programme collaborative research are generally of high quality.", [["high quality", "OBSERVATION_MODIFIER", 107, 119]]], ["It is well known that the citation impact score of international co-publications is generally higher than that of purely national publications.", [["higher", "OBSERVATION_MODIFIER", 94, 100]]], ["106 Direct evidence, however, also comes from the aforementioned recently completed bibliometric study on participants in the 5th Framework Programme, which found that the citation impact scores of those Framework Programme participants were higher than could be expected on the basis of the journals in which they published, and that they scored above world level when allocated to specific fields.", [["participants", "SPECIES", 106, 118], ["participants", "SPECIES", 224, 236], ["bibliometric study", "TEST", 84, 102]]], ["109 The results show that firms participating in the Framework Programme, irrespective of their size, tend to be more innovative than those that do not participate.", [["firms", "OBSERVATION", 26, 31], ["size", "OBSERVATION_MODIFIER", 96, 100]]], ["Although no causal links can be \"proven\" by these results, they nevertheless provide a strong indication that public funding for research strengthens innovation performance.", [["public funding", "TREATMENT", 110, 124]]], ["110 FP-funded collaborative research projects also generate a large number of patents, once more exerting a positive influence on an important S&T indicator.", [["S&T", "CANCER", 143, 146], ["a positive influence", "PROBLEM", 106, 126], ["large", "OBSERVATION_MODIFIER", 62, 67], ["number", "OBSERVATION_MODIFIER", 68, 74], ["patents", "OBSERVATION", 78, 85]]], ["A 2002 assessment of nearly 1 900 non-nuclear energy research and demonstration projects under the 4th Framework Programme found that they had resulted in about 400 product/process innovative companies as a proportion of companies with FP funding product/process innovative companies as a proportion of companies without FP funding Fig. 4.19 .", [["A 2002 assessment", "TEST", 0, 17]]], ["FP participants are more likely to produce product/process innovations Source: DG Research, Eurostat Data: Eurostat Note: Results here are for firms in the manufacturing sector patent applications.", [["participants", "SPECIES", 3, 15], ["more likely", "UNCERTAINTY", 20, 31], ["patent", "OBSERVATION", 177, 183]]], ["In Germany, for example, FP-funded firms submit three times as many patent applications as non-participating firms.", [["FP", "TEST", 25, 27], ["many patent applications", "TREATMENT", 63, 87], ["patent", "OBSERVATION", 68, 74]]], ["Nevertheless they provide a strong indication that public funding for research strengthens innovation performance.The micro-economic benefits of collaborative research The FrameworkProgramme not only strengthens participants' mid-to long-term ability to compete, but also directly enhances their competitive position.", [["participants", "SPECIES", 212, 224], ["public funding", "TREATMENT", 51, 65], ["long-term", "OBSERVATION_MODIFIER", 233, 242]]], ["A wide range of ex-post evaluation studies show that as a result of Framework Programme participation firms are able to realise increased turnover and profitability, enhanced productivity, improved market share, access to new markets, reorientation of the commercial strategy, enhanced competitive position, enhanced reputation and image, and reduced commercial risk.", [["ex-post evaluation studies", "TEST", 16, 42], ["increased turnover and profitability", "PROBLEM", 128, 164], ["image", "TEST", 332, 337], ["wide", "OBSERVATION_MODIFIER", 2, 6]]], ["112 Companies that applied for a patent as a proportion of companies with FP funding Companies that applied for a patent as a proportion of companies without FP fundingT H E I M P A C T O F T H E F R A M E W O R K P R O G R A M M E O N H U M A N R E S O U R C E SOne of the important effects of Framework Programme collaborative research projects is the enhancement of skills of participating research staff, which helps to strengthen research capabilities.", [["O N H", "CHEMICAL", 232, 237], ["FP funding", "TREATMENT", 74, 84], ["H", "TEST", 170, 171], ["G", "TEST", 220, 221], ["U M", "TEST", 238, 241], ["A", "TEST", 242, 243], ["E S", "TEST", 248, 251], ["patent", "OBSERVATION", 33, 39], ["patent", "OBSERVATION", 114, 120], ["enhancement", "OBSERVATION_MODIFIER", 354, 365]]], ["The purpose of the Framework Programme human resources schemes is to enable researchers to participate in top transnational teams and high-level projects, and benefit from training and knowledge sharing.", [["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44]]], ["This should ultimately lead to better R&D, while also having a positive impact on the attractiveness of the EU as a place to pursue a scientific career for European and third country researchers.T H E I M P A C T O F T H E F R A M E W O R K P R O G R A M M E O N H U M A N R E S O U R C E SThe Framework Programme human resources schemes are very much in demand.", [["O", "CHEMICAL", 235, 236], ["O N H", "CHEMICAL", 259, 264], ["human", "ORGANISM", 314, 319], ["human", "SPECIES", 314, 319], ["human", "SPECIES", 314, 319], ["T", "TEST", 195, 196], ["H", "TEST", 219, 220], ["K", "TEST", 239, 240], ["G", "TEST", 247, 248], ["U M", "TEST", 265, 268], ["A", "TEST", 269, 270], ["E S", "TEST", 275, 278], ["Framework Programme human resources schemes", "TREATMENT", 294, 337]]], ["113 The 6th Framework Programme is characterised by high numbers of applications as well.", [["high numbers", "OBSERVATION_MODIFIER", 52, 64]]], ["About one-fifth of fellows were engaged in university-industry collaboration during their fellowship.T H E I M P A C T O F T H E F R A M E W O R K P R O G R A M M E O N H U M A N R E S O U R C E SMarie Curie fellows identified as most important impacts for themselves having gained international research experience, having had dedicated time to carry out research, and having developed research skills.", [["O N H", "CHEMICAL", 165, 170], ["T", "TEST", 101, 102], ["H", "TEST", 125, 126], ["F", "TEST", 129, 130], ["K", "TEST", 145, 146], ["G", "TEST", 153, 154], ["U M", "TEST", 171, 174]]], ["Of those on fellowships of up to 6 months (for 94 per cent at postgraduate level), 57 per cent produced at least one publication.", [["publication", "OBSERVATION", 117, 128]]], ["Supervisors were of the opinion that in 43 per cent of cases, the work of the fellow had led to the creation of new technologies.T H E I M P A C T O F T H E F R A M E W O R K P R O G R A M M E O N H U M A N R E S O U R C E SAfter their fellowship, a majority of fellows eventually returned to their home country, though planning a new mobility experience within five years.", [["O N H", "CHEMICAL", 193, 198], ["T", "TEST", 129, 130], ["H", "TEST", 153, 154], ["F", "TEST", 157, 158], ["R", "TEST", 159, 160], ["K", "TEST", 173, 174]]], ["Over 70 per cent of fellows reported that their stay abroad generated new contacts influential for subsequent career progression, and 86 per cent maintained contacts with their Marie Curie host institution after the fellowship.T H E I M P A C T O F T H E F R A M E W O R K P R O G R A M M E O N R E S E A R C H I N F R A S T R U C T U R E SIf Europe's research teams are to remain at the forefront of all fields of science and technology, then they will have to be supported by state-of-the-art infrastructures.", [["O", "CHEMICAL", 267, 268], ["O N", "CHEMICAL", 291, 294], ["C H", "CHEMICAL", 307, 310], ["T", "TEST", 227, 228], ["A", "TEST", 239, 240], ["T", "TEST", 249, 250], ["E", "TEST", 253, 254], ["K", "TEST", 271, 272], ["G", "TEST", 279, 280], ["A S", "TEST", 319, 322], ["U C", "TEST", 327, 330], ["Europe's research teams", "TEST", 343, 366]]], ["The successive Framework Programmes have been active in this sense, promoting the development of a fabric of research infrastructures of the highest quality and performance in Europe, and their optimum use.", [["active", "OBSERVATION_MODIFIER", 46, 52], ["fabric", "OBSERVATION_MODIFIER", 99, 105]]], ["Examples of research infrastructures include large-scale research installations, collections, special habitats, libraries, databases, integrated arrays of small research installations, highcapacity/high-speed communications networks (e.g. G\u00e9ant), networks of computing facilities (e.g. Grids), and infrastructural centres of competence, which provide a service for the wider research community based on an assembly of techniques and know-how.T H E I M P A C T O F T H E F R A M E W O R K P R O G R A M M E O N R E S E A R C H I N F R A S T R U C T U R E STo develop a strategic approach for research infrastructures at European level, comprehensive and up-to-date information about the current pattern of existing infrastructures is essential.", [["O", "CHEMICAL", 482, 483], ["O N", "CHEMICAL", 506, 509], ["C H", "CHEMICAL", 522, 525], ["research infrastructures", "PROBLEM", 12, 36], ["large-scale research installations", "TREATMENT", 45, 79], ["collections", "PROBLEM", 81, 92], ["small research installations", "TREATMENT", 155, 183], ["A S", "TEST", 534, 537], ["R U C", "TEST", 540, 545], ["a strategic approach", "TREATMENT", 566, 586], ["research infrastructures", "PROBLEM", 591, 615], ["large", "OBSERVATION_MODIFIER", 45, 50], ["small", "OBSERVATION_MODIFIER", 155, 160], ["infrastructures", "OBSERVATION", 714, 729]]], ["Existing research infrastructures of clear European dimension, as well as a certain number of infrastructures under construction, were invited to participate The first round of the survey resulted in feedback from 585 existing research infrastructures and 157 under construction, that is, in total 742 research infrastructures were reported.T H E I M P A C T O F T H E F R A M E W O R K P R O G R A M M E O N R E S E A R C H I N F R A S T R U C T U R E SThe technical review panel for the access to research infrastructures action under the 5th Framework Programme concluded that it succeeded in providing researchers with access to unique or outstanding infrastructures in a broad range of disciplines, and thus contributed to the production of high quality research.", [["O", "CHEMICAL", 381, 382], ["O N", "CHEMICAL", 405, 408], ["C H", "CHEMICAL", 421, 424], ["H", "TEST", 365, 366], ["A S", "TEST", 433, 436], ["technical review panel", "TEST", 458, 480], ["the access", "TREATMENT", 485, 495], ["clear", "OBSERVATION_MODIFIER", 37, 42], ["European dimension", "OBSERVATION_MODIFIER", 43, 61]]], ["116 It also noted that the Framework Programme helped to develop interdisciplinary approaches between several areas as well as cooperation between European researchers, while giving a European dimension to several national facilities and, in several cases, organising more efficiently their networking.", [["interdisciplinary approaches", "TREATMENT", 65, 93]]], ["Through infrastructure RTD projects, it also contributed to improving the technical performance of several categories of infrastructures and thus to enhancing European scientific competitiveness in several fields.T H E I M P A C T O F T H E F R A M E W O R K P R O G R A M M E O N R E S E A R C H I N F R A S T R U C T U R E SA questionnaire to participants who received 5th Framework Programme funding for transnational access to infrastructures, carried out as part of this technical review, found that 88 per cent of respondents would have been unable to carry out their project at this research infrastructure without EU support.", [["O N", "CHEMICAL", 277, 280], ["participants", "SPECIES", 345, 357], ["T", "TEST", 213, 214], ["H", "TEST", 237, 238], ["F", "TEST", 241, 242], ["K", "TEST", 257, 258], ["A S", "TEST", 305, 308], ["transnational access", "TREATMENT", 407, 427], ["EU support", "TREATMENT", 622, 632]]], ["Of these, 71 per cent indicated that they would have been unable to pay for travel and subsistence, while 41 per cent could not have afforded the user fees.T H E F R A M E W O R K P R O G R A M M E A N D I N T E R G O V E R N M E N T A L C O O P E R A T I O N A T T H E P R O G R A M M E L E V E LAlthough the vast bulk of public R&D spending in Europe is still carried out at national or regional level, these substantial resources remain fragmented and poorly coordinated.", [["O O P E", "CHEMICAL", 240, 247], ["O N", "CHEMICAL", 256, 259], ["T", "TEST", 156, 157], ["G", "TEST", 214, 215], ["E L E V E", "TEST", 286, 295], ["the vast bulk", "TEST", 306, 319], ["E V", "ANATOMY_MODIFIER", 290, 293], ["E", "ANATOMY_MODIFIER", 294, 295], ["substantial", "OBSERVATION_MODIFIER", 411, 422], ["fragmented", "OBSERVATION", 440, 450]]], ["This fragmentation, isolation and compartmentalisation of national research efforts and systems and the disparity of regulatory and administrative systems only serve to compound the impact of lower global investment in knowledge\".", [["This fragmentation", "PROBLEM", 0, 18], ["isolation", "TREATMENT", 20, 29], ["fragmentation", "OBSERVATION", 5, 18]]], ["The main tools proposed under the 6th Framework Programme for promoting the coordination of national and regional research at programme level were the ERA-NET scheme and the application of Article 169 of the EC Treaty.T H E F R A M E W O R K P R O G R A M M E A N D I N T E R G O V E R N M E N T A L C O O P E R A T I O N A T T H E P R O G R A M M E L E V E LIn early 2002, EU research ministers recognised the importance of the mutual opening of national research programmes.", [["N D I N", "CHEMICAL", 262, 269], ["O O P E", "CHEMICAL", 302, 309], ["O N", "CHEMICAL", 318, 321], ["EC", "CELL", 208, 210], ["T", "TEST", 218, 219], ["G", "TEST", 276, 277], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The ERA-NET scheme was considered to be the most suitable mechanism for pursuing the first stages of coordination.T H E F R A M E W O R K P R O G R A M M E A N D I N T E R G O V E R N M E N T A L C O O P E R A T I O N A T T H E P R O G R A M M E L E V E LThe ERA-NET scheme was a highly innovative component of the 6th Framework Programme.", [["O O P E", "CHEMICAL", 198, 205], ["O N", "CHEMICAL", 214, 217], ["The ERA-NET scheme", "TREATMENT", 0, 18], ["T", "TEST", 114, 115], ["G", "TEST", 172, 173], ["ERA", "TEST", 259, 262], ["NET scheme", "TEST", 263, 273], ["NET scheme", "OBSERVATION", 263, 273]]], ["119 Its objective was to contribute to the creation of the European Research Area by facilitating practical initiatives to coordinate regional, national and European research programmes in specific fields, and to pool fragmented human and financial resources in order to improve both the efficiency and the effectiveness of Europe's research efforts.", [["human", "ORGANISM", 229, 234], ["human", "SPECIES", 229, 234], ["human", "SPECIES", 229, 234], ["financial resources", "TREATMENT", 239, 258]]], ["The scheme's participants were programme funders and managers working in national and regional ministries and funding agencies rather than universities or enterprises.", [["participants", "SPECIES", 13, 25]]], ["Ultimately ERA-NETs were expected to lead to collaboration of major significance, including the strategic planning and design of joint research programmes, the reciprocal opening of national research programmes to researchers from other member countries, and the launch of fully transnational programmes jointly funded by more than one country.", [["joint research programmes", "TREATMENT", 129, 154], ["joint", "ANATOMY", 129, 134]]], ["Interest in the scheme was large, which is evidenced by the fact that by 2006A S S E S S I N G T H E W I D E R I M P A C T S O F T H E F R A M E W O R K P R O G R A M M EThe above sections have dealt mainly with impacts that are produced within a relatively short period of time, and that are \"manageable\" from a data collection point of view because they are situated at the project level.", [["O", "CHEMICAL", 125, 126], ["O", "CHEMICAL", 147, 148], ["K", "TEST", 151, 152], ["EThe above sections", "TEST", 169, 188], ["large", "OBSERVATION_MODIFIER", 27, 32], ["relatively", "OBSERVATION_MODIFIER", 247, 257], ["short", "OBSERVATION_MODIFIER", 258, 263]]], ["Much more complex, however, is the assessment of the Framework Programme's wider impacts.", [["the assessment", "TEST", 31, 45], ["more complex", "OBSERVATION_MODIFIER", 5, 17]]], ["Moreover, the benefits of research are not confined to the R&D actors themselves, or to the beneficiaries of public funding (such as Framework Programme participants), but spill over across many actors, sectors of society, and the economy.Wider economic impacts of community research policyMeasuring the economic impact of research is extremely difficult.", [["participants", "SPECIES", 153, 165], ["economic", "OBSERVATION_MODIFIER", 304, 312]]], ["Among the complicating factors are the long lead time between R&D activity and the eventual economic exploitation of the results, and the problem of unambiguously attributing effects on a firm's turnover to specific research projects.", [["a firm's turnover", "TREATMENT", 186, 203]]], ["For example, a recent UK study estimated the impact of the Framework Programme on the United Kingdom's total factor productivity using a model developed at the OECD.", [["a recent UK study", "TEST", 13, 30]]], ["It was found that application of the formula generated an estimated annual contribution to UK industrial output of over \u00a3 3 billion, a manifold return on UK Framework activity in economic terms.", [["the formula", "TREATMENT", 33, 44], ["industrial output", "OBSERVATION", 94, 111]]], ["123 The European Commission's Joint Research Centre at Ispra subsequently extended the analysis to all Member States for which data were available.", [["Joint", "ANATOMY", 30, 35]]], ["The results seem to indicate significant effects on total factor productivity ( Fig. 4.21) .", [["total factor productivity", "PROBLEM", 52, 77], ["significant", "OBSERVATION_MODIFIER", 29, 40]]], ["It is estimated that on average E1 of Framework Programme funding leads to an (long-term) increase in industry added value of between E7 and E14, depending on the assumptions and parameters used.", [["E7", "ORGANISM", 134, 136], ["E7", "PROTEIN", 134, 136], ["an (long-term)", "TREATMENT", 75, 89]]], ["Of course, it is also important to stress that econometrics is not an exact science, and that such results must be treated with a large degree of caution.", [["a large degree of caution", "TREATMENT", 128, 153]]], ["124Wider social and environmental impacts of community research policyIt is not possible to present -like in the case of macro-economic impacts -in an aggregate way the many social and environmental societal challenges to the meeting of which FP-funded research projects have contributed directly.", [["macro-economic impacts", "PROBLEM", 121, 143], ["not possible", "UNCERTAINTY", 76, 88]]], ["Only an extensive enumeration of case studies would be able to provide a proper insight into the vast range of areas in which valuable contributions have been made.", [["case studies", "TEST", 33, 45], ["extensive", "OBSERVATION_MODIFIER", 8, 17], ["enumeration", "OBSERVATION", 18, 29]]], ["It is important to note, however, that ever since the 5th Framework Programme the Framework Programme has been more explicitly positioned as having to contribute to the solution of such societal problems.", [["such societal problems", "PROBLEM", 181, 203]]], ["Some examples of the contribution made by the Framework Programme to societal and environmental goals include the following:Wider social and environmental impacts of community research policy\u2022 Developing the sophisticated analytical tools needed to predict and optimise the net environmental, economic, and social impacts of new policy measures.", [["new policy measures", "TREATMENT", 325, 344]]], ["For example, 3E -a powerful computer model of interdependent economic, environmental, and energy variables -enabled EU negotiators at Kyoto to calculate the cost implication of different policy scenarios on the spot; \u2022 Producing forecasting systems to give early warning of flooding, improving water treatment technologies, and planning tools to protect coastal zones against erosion and pollution; \u2022 Creating many of the new technologies on which sustainable development will depend -for instance, new sensor systems to monitor levels of pollutants in the rivers that supply our drinking water; \u2022 Strengthening the environmental research infrastructures which underpin European work in priority areas like climate change, encouraging coordinated transnational use of complex data sets, and state-of-the-art facilities.", [["erosion", "DISEASE", 376, 383], ["water treatment technologies", "TREATMENT", 294, 322], ["erosion", "PROBLEM", 376, 383], ["new sensor systems", "TEST", 499, 517], ["erosion", "OBSERVATION", 376, 383]]], ["Third, there is the increasing willingness to base the development of new policies on the results of FP-funded research projects.Wider social and environmental impacts of community research policyResearch serves more and more as the knowledge-base referred to in key policy documents.", [["increasing", "OBSERVATION_MODIFIER", 20, 30], ["new", "OBSERVATION_MODIFIER", 70, 73]]], ["125 The key internal provider of such scientific support for EC policies is the Joint Research Centre (JRC).", [["EC", "ANATOMY", 61, 63], ["EC", "CELL", 61, 63], ["such scientific support", "TREATMENT", 33, 56], ["EC policies", "TREATMENT", 61, 72], ["internal", "OBSERVATION_MODIFIER", 12, 20], ["Joint", "ANATOMY", 80, 85]]], ["Its role as a Community reference for EU policy in scientific and technological questions is epitomised by the increasing volume of legislation which is based on the work of (and which mentions) the JRC.", [["JRC", "CANCER", 199, 202], ["increasing", "OBSERVATION_MODIFIER", 111, 121], ["volume", "OBSERVATION_MODIFIER", 122, 128]]], ["126 Thus European BSE (Bovine Spongiform Encephalopathy) research, to which the Community contributed E90 million in the period 1996-2003, provided the basis for close to 300 scientific opinions in support of almost 40 pieces of Community legislation in the fields of consumer protection, public health, and risk management.", [["Bovine Spongiform Encephalopathy", "DISEASE", 23, 55], ["Bovine", "ORGANISM", 23, 29], ["Bovine", "SPECIES", 23, 29], ["European BSE", "TEST", 9, 21], ["Bovine Spongiform Encephalopathy", "PROBLEM", 23, 55], ["risk management", "TREATMENT", 308, 323], ["Spongiform", "OBSERVATION_MODIFIER", 30, 40]]], ["In fact, the announcement in March 1996 of the links between BSE and the new variant Creutzfeld-Jacob Disease was the result of Community-funded collaborative research.", [["BSE", "DISEASE", 61, 64], ["Creutzfeld-Jacob Disease", "DISEASE", 85, 109], ["Jacob Disease", "PROBLEM", 96, 109], ["new", "OBSERVATION_MODIFIER", 73, 76], ["Jacob Disease", "OBSERVATION", 96, 109]]], ["Even more recently, with the outbreak of the SARS epidemics, Community action proved extremely adaptive and prompt.", [["SARS", "DISEASE", 45, 49], ["the SARS epidemics", "PROBLEM", 41, 59]]], ["126 In 2003, the JRC provided scientific and technical support to over 80 pieces of EU legislation.", [["the JRC", "TEST", 13, 20], ["technical support", "TREATMENT", 45, 62]]], ["Thematically, the focal points are spelled out in the Specific Programmes (nuclear and non-nuclear parts) and are further defined in the Multi-Annual and Annual Work Programmes.", [["nuclear", "CELLULAR_COMPONENT", 75, 82], ["focal", "OBSERVATION_MODIFIER", 18, 23]]], ["To a lesser degree the JRC also uses Indirect Actions under the FPs, additional work for customer DGs, Enlargement Actions and Third Party Work to implement its mission.", [["lesser degree", "OBSERVATION_MODIFIER", 5, 18], ["Enlargement", "OBSERVATION", 103, 114]]], ["This provides an indication of the actual exploitation of research results for policy support.", [["policy support", "TREATMENT", 79, 93]]], ["128 A number of societal issues (ethics, gender issues, environmental issues) have also been put on the agenda via the Framework Programme proposal evaluation process.", [["societal issues", "PROBLEM", 16, 31]]], ["This plays an important role in the evaluation and selection of projects to be funded.", [["the evaluation", "TEST", 32, 46]]], ["Nonetheless, the detail provided on these targets and objectives is seldom sufficient to allow for subsequent systematic monitoring and evaluation at the programme level.", [["subsequent systematic monitoring", "TEST", 99, 131], ["evaluation", "TEST", 136, 146]]], ["Therefore, it is difficult to quantitatively assess the environmental effects of these projects (e.g. in the form of reduced emissions, or decreased health risks, etc.) at an aggregate level.", [["reduced emissions", "PROBLEM", 117, 134], ["decreased health risks", "PROBLEM", 139, 161]]], ["A study commissioned by the Australian Government Department of Education, Science and Training (DEST) on Australian science and technology cooperation with Europe, for instance, concluded that Australian researchers want to work with Europe because it is seen as a site of leading-edge collaboration, and that there is a large potential for expanded collaboration.The Framework Programme and the EU's international standingInternational S&T cooperation with developing countries via the Specific International Scientific Cooperation Activities (INCO) programme of the Framework Programme established in 1983 starts from the concept of sustainable development and the idea that poverty and social marginalisation can be overcome successfully by investing in human and institutional resources. based on dialogue and promotes the development of long-term durable research partnerships, with four main regions: Latin America, Asia, and Africa; the Mediterranean countries; the Western Balkans; and the Newly Independent States.", [["human", "ORGANISM", 758, 763], ["human", "SPECIES", 758, 763], ["human", "SPECIES", 758, 763], ["A study", "TEST", 0, 7], ["large", "OBSERVATION_MODIFIER", 322, 327], ["expanded", "OBSERVATION_MODIFIER", 342, 350], ["collaboration", "OBSERVATION", 351, 364]]], ["129 Though difficult to quantify, the impact of the Framework Programme in these regions is fourfold.", [["regions", "ANATOMY_MODIFIER", 81, 88], ["fourfold", "OBSERVATION_MODIFIER", 92, 100]]], ["Positive impacts concern, for instance, scientific job creation, substitution of imported goods, improved food quality, and environmental protection from rapid industrialisation and urbanisation.", [["environmental protection", "TREATMENT", 124, 148]]], ["Impacts of Asian and African INCO-funded projects in the fields of agriculture, food, and health concern improvements in farmer incomes, gender equality, public health, education, employment, protection against erosion, conservation of natural resources, and training and professional improvement.", [["erosion", "DISEASE", 211, 218], ["erosion", "PROBLEM", 211, 218]]], ["131 And fourth, Framework Programme projects promote regional collaboration.C O N C L U S I O NAssessing the impacts of research programmes is complex, and even more difficult in the case of the Framework Programme.", [["C", "CHEMICAL", 76, 77], ["O N C", "CHEMICAL", 78, 83], ["S I O", "CHEMICAL", 88, 93], ["research programmes", "TREATMENT", 120, 139], ["regional collaboration", "OBSERVATION", 53, 75]]], ["Across Framework Programmes, the collaborative research component has been characterised more by growth in the number of projects and participations than by growth in the average size of the project, raising the issue of the optimal size of projects and critical mass.", [["critical mass", "PROBLEM", 254, 267], ["growth", "OBSERVATION_MODIFIER", 97, 103], ["growth", "OBSERVATION_MODIFIER", 157, 163], ["average", "OBSERVATION_MODIFIER", 171, 178], ["size", "OBSERVATION_MODIFIER", 179, 183], ["size", "OBSERVATION_MODIFIER", 233, 237], ["critical", "OBSERVATION_MODIFIER", 254, 262], ["mass", "OBSERVATION", 263, 267]]], ["The degree of industrial participation has become smaller, while that of universities and research institutes has increased.", [["degree", "OBSERVATION_MODIFIER", 4, 10], ["industrial participation", "OBSERVATION", 14, 38], ["smaller", "OBSERVATION_MODIFIER", 50, 57], ["increased", "OBSERVATION_MODIFIER", 114, 123]]], ["The by-country ranking in terms of participations and funding is more or less in line with that in terms of GDP or number of researchers, although smaller countries prove to be more \"efficient\" in obtaining funding than larger ones.", [["GDP", "SIMPLE_CHEMICAL", 108, 111]]], ["However, a large number of peripheral regions are allocated a larger share of European research funds than could be expected on the basis of their R&D effort, economic importance, and so on.", [["large", "OBSERVATION_MODIFIER", 11, 16], ["number", "OBSERVATION_MODIFIER", 17, 23], ["peripheral", "ANATOMY_MODIFIER", 27, 37], ["regions", "ANATOMY_MODIFIER", 38, 45], ["larger", "OBSERVATION_MODIFIER", 62, 68]]], ["Regarding individual participants, it was shown that a relatively small number of organisations participate in a relatively large number of projects across calls and across Framework Programmes, collecting most participations and most funding.", [["participants", "SPECIES", 21, 33], ["small", "OBSERVATION_MODIFIER", 66, 71]]], ["Networks remain remarkably stable after the end of projects and have a multiplier effect on a country's returns from the Framework Programme.", [["remarkably", "OBSERVATION_MODIFIER", 16, 26], ["stable", "OBSERVATION", 27, 33]]], ["Collaborative research has been characterised by an ever-increasing number of thematic priorities, avoiding major gaps in terms of coverage, though this does not seem to have caused fragmentation.", [["fragmentation", "PROBLEM", 182, 195], ["fragmentation", "OBSERVATION", 182, 195]]], ["Community-funded collaborative research is characterised by a very high degree of additionality.", [["a very high degree of additionality", "PROBLEM", 60, 95], ["very high degree", "OBSERVATION_MODIFIER", 62, 78]]], ["In the absence of Framework Programme funding, projects would not have been carried out at all or would have been carried out in a very different manner with reduced objectives and a smaller number of partners.", [["smaller", "OBSERVATION_MODIFIER", 183, 190]]], ["Framework Programme collaborative research has clear impacts on capabilities, behaviour, and competitivity, and on scientific and innovative performance.", [["clear", "OBSERVATION_MODIFIER", 47, 52], ["impacts", "OBSERVATION_MODIFIER", 53, 60]]], ["The Framework Programme also contributes to human resources development and has a structuring effect through its coordination of national research programmes.C O N C L U S I O NWe have seen in this chapter that learning from past experiences and identifying the strengths and weaknesses of previous Framework Programmes draws upon the evidence of ex-post evaluations.", [["C", "CHEMICAL", 158, 159], ["O N C", "CHEMICAL", 160, 165], ["S I O", "CHEMICAL", 170, 175], ["human", "ORGANISM", 44, 49], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["ex-post evaluations", "TEST", 347, 366]]], ["And such evaluations rely to a large extent on good and robust data.", [["such evaluations", "TEST", 4, 20]]], ["132 When conceiving its new Framework Programme, the Commission did not only look backwards to the experiences gained with previous Framework Programmes.", [["previous Framework Programmes", "TREATMENT", 123, 152]]]], "79a2eb4d2a995fcbf39b2857b3402c5433f7f932": [["Dear Editor, Morelli et al. [1] reported decreased prevalence of stroke during the COVID-19 pandemic era according to their observation from a single center (Guglielmo da Saliceto Hospital, Piacenza, northern Italy).", [["stroke", "DISEASE", 65, 71], ["stroke", "PROBLEM", 65, 71], ["stroke", "OBSERVATION", 65, 71]]], ["They considered phobia of admission in COVID-affiliated hospitals and the probability of missing minor strokes in seriously involved respiratory distress patients.", [["respiratory", "ANATOMY", 133, 144], ["phobia", "DISEASE", 16, 22], ["strokes", "DISEASE", 103, 110], ["respiratory distress", "DISEASE", 133, 153], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["phobia", "PROBLEM", 16, 22], ["missing minor strokes", "PROBLEM", 89, 110], ["respiratory distress", "PROBLEM", 133, 153], ["strokes", "OBSERVATION", 103, 110], ["respiratory distress", "OBSERVATION", 133, 153]]], ["Meanwhile, they hypothesized that increased interleukin-6 and thrombocytopenia may result in decreased prevalence of stroke.", [["thrombocytopenia", "DISEASE", 62, 78], ["stroke", "DISEASE", 117, 123], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 44, 57], ["interleukin-6", "PROTEIN", 44, 57], ["increased interleukin", "PROBLEM", 34, 55], ["thrombocytopenia", "PROBLEM", 62, 78], ["stroke", "PROBLEM", 117, 123], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["decreased", "OBSERVATION_MODIFIER", 93, 102], ["stroke", "OBSERVATION", 117, 123]]], ["They concluded that the association of stroke and viral infection, which has been reported previously [2] , might not be true for SARS-CoV-2 infection.", [["stroke", "DISEASE", 39, 45], ["viral infection", "DISEASE", 50, 65], ["SARS-CoV-2 infection", "DISEASE", 130, 150], ["SARS-CoV-2", "ORGANISM", 130, 140], ["SARS-CoV-2", "SPECIES", 130, 140], ["stroke", "PROBLEM", 39, 45], ["viral infection", "PROBLEM", 50, 65], ["SARS", "PROBLEM", 130, 134], ["CoV", "PROBLEM", 135, 138], ["2 infection", "PROBLEM", 139, 150], ["stroke", "OBSERVATION", 39, 45], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["infection", "OBSERVATION", 56, 65], ["infection", "OBSERVATION", 141, 150]]]], "PMC4944999": [["IntroductionInfluenza A virus is an enveloped virus belonging to the Orthomyxoviridae family.", [["Influenza A virus", "DISEASE", 12, 29], ["Influenza A virus", "ORGANISM", 12, 29], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 69, 85], ["Influenza A virus", "SPECIES", 12, 29], ["Influenza A virus", "SPECIES", 12, 29], ["IntroductionInfluenza A virus", "PROBLEM", 0, 29]]], ["It can cause annual epidemics and infrequent pandemics [1].", [["annual epidemics", "PROBLEM", 13, 29]]], ["The Spanish flu pandemic of 1918 as well as the Asian flu of 1957 and the Hongkong flu in 1968 pandemics caused the death of millions of people [2].", [["pandemics", "DISEASE", 95, 104], ["death", "DISEASE", 116, 121], ["people", "ORGANISM", 137, 143], ["people", "SPECIES", 137, 143], ["Asian flu", "SPECIES", 48, 57]]], ["In 2009 the pandemic swine origin influenza A H1N1 virus as well as the outbreak of H7N9 in China in 2013 has reminded the world of the threat of pandemic influenza [3\u20136].IntroductionThe genome of influenza virus consists of eight segmented negative RNA strands.", [["influenza A H1N1 virus", "DISEASE", 34, 56], ["H7N9", "CHEMICAL", 84, 88], ["influenza", "DISEASE", 155, 164], ["swine origin", "ORGANISM", 21, 33], ["influenza A H1N1 virus", "ORGANISM", 34, 56], ["influenza virus", "ORGANISM", 197, 212], ["segmented negative RNA strands", "RNA", 231, 261], ["swine", "SPECIES", 21, 26], ["influenza A H1N1 virus", "SPECIES", 34, 56], ["influenza virus", "SPECIES", 197, 212], ["A H1N1 virus", "SPECIES", 44, 56], ["H7N9", "SPECIES", 84, 88], ["influenza virus", "SPECIES", 197, 212], ["influenza", "PROBLEM", 34, 43], ["A H1N1 virus", "PROBLEM", 44, 56], ["H7N9", "PROBLEM", 84, 88], ["pandemic influenza", "PROBLEM", 146, 164], ["influenza virus", "PROBLEM", 197, 212], ["influenza virus", "OBSERVATION", 197, 212], ["RNA strands", "OBSERVATION", 250, 261]]], ["The envelope bilayer harbors the two spike glycoproteins hemagglutinin (HA) and neuraminidase (NA), and the M2 proton channel.", [["HA", "GENE_OR_GENE_PRODUCT", 72, 74], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 80, 93], ["spike glycoproteins", "PROTEIN", 37, 56], ["hemagglutinin", "PROTEIN", 57, 70], ["HA", "PROTEIN", 72, 74], ["neuraminidase", "PROTEIN", 80, 93], ["NA", "PROTEIN", 95, 97], ["M2 proton channel", "PROTEIN", 108, 125], ["The envelope bilayer harbors", "TREATMENT", 0, 28], ["glycoproteins hemagglutinin (HA)", "TREATMENT", 43, 75], ["neuraminidase (NA)", "TREATMENT", 80, 98], ["the M2 proton channel", "TREATMENT", 104, 125]]], ["The homotrimeric HA is the most abundant protein on the viral surface.", [["surface", "ANATOMY", 62, 69], ["homotrimeric HA", "GENE_OR_GENE_PRODUCT", 4, 19], ["homotrimeric HA", "PROTEIN", 4, 19], ["The homotrimeric HA", "PROBLEM", 0, 19], ["most abundant", "OBSERVATION_MODIFIER", 27, 40], ["protein", "OBSERVATION", 41, 48], ["viral surface", "OBSERVATION_MODIFIER", 56, 69]]], ["It mediates attachment to the host cell surface via binding to sialic acid (SA) residues of cellular receptors, and upon endocytic virus uptake it triggers fusion of the envelope with the endosomal membrane releasing the viral genome into the cytoplasm.", [["cell surface", "ANATOMY", 35, 47], ["cellular", "ANATOMY", 92, 100], ["endosomal membrane", "ANATOMY", 188, 206], ["cytoplasm", "ANATOMY", 243, 252], ["sialic acid", "CHEMICAL", 63, 74], ["sialic acid", "CHEMICAL", 63, 74], ["cell surface", "CELLULAR_COMPONENT", 35, 47], ["sialic acid", "SIMPLE_CHEMICAL", 63, 74], ["cellular", "CELL", 92, 100], ["endosomal membrane", "CELLULAR_COMPONENT", 188, 206], ["cytoplasm", "ORGANISM_SUBSTANCE", 243, 252], ["sialic acid (SA) residues", "PROTEIN", 63, 88], ["cellular receptors", "PROTEIN", 92, 110], ["viral genome", "DNA", 221, 233], ["sialic acid", "TEST", 63, 74], ["cellular receptors", "PROBLEM", 92, 110], ["endocytic virus uptake", "PROBLEM", 121, 143], ["the endosomal membrane", "TREATMENT", 184, 206], ["host cell", "OBSERVATION", 30, 39], ["surface", "OBSERVATION_MODIFIER", 40, 47], ["cellular receptors", "OBSERVATION", 92, 110], ["endocytic virus", "OBSERVATION", 121, 136], ["endosomal membrane", "OBSERVATION", 188, 206], ["viral genome", "OBSERVATION", 221, 233], ["cytoplasm", "OBSERVATION_MODIFIER", 243, 252]]], ["NA cleaves glycosidic bonds with terminal SA facilitating the release of budding virions from the cell.IntroductionIn diagnostics, antibodies against spike proteins are the preferred tool for identification and serotyping of viruses.", [["cell", "ANATOMY", 98, 102], ["NA", "CHEMICAL", 0, 2], ["SA", "CHEMICAL", 42, 44], ["NA", "SIMPLE_CHEMICAL", 0, 2], ["glycosidic bonds", "SIMPLE_CHEMICAL", 11, 27], ["terminal SA", "SIMPLE_CHEMICAL", 33, 44], ["cell", "CELL", 98, 102], ["antibodies against spike proteins", "GENE_OR_GENE_PRODUCT", 131, 164], ["antibodies", "PROTEIN", 131, 141], ["spike proteins", "PROTEIN", 150, 164], ["terminal SA", "PROBLEM", 33, 44], ["antibodies", "TEST", 131, 141], ["spike proteins", "PROBLEM", 150, 164], ["identification", "TEST", 192, 206], ["viruses", "PROBLEM", 225, 232], ["glycosidic bonds", "OBSERVATION", 11, 27], ["terminal", "OBSERVATION_MODIFIER", 33, 41], ["SA", "OBSERVATION_MODIFIER", 42, 44], ["budding virions", "OBSERVATION", 73, 88], ["cell", "ANATOMY", 98, 102]]], ["Development of therapeutic antibodies against influenza is a challenge, as the high viral mutation rate (antigenic drift) and genetic reassortment of the virus genome (antigenic shift) continuously lead to new strains escaping from neutralization by antibodies [7, 8].", [["influenza", "DISEASE", 46, 55], ["therapeutic antibodies", "PROTEIN", 15, 37], ["virus genome", "DNA", 154, 166], ["antibodies", "PROTEIN", 250, 260], ["therapeutic antibodies", "TREATMENT", 15, 37], ["influenza", "PROBLEM", 46, 55], ["the high viral mutation rate", "PROBLEM", 75, 103], ["antigenic drift", "PROBLEM", 105, 120], ["the virus genome", "PROBLEM", 150, 166], ["new strains escaping", "PROBLEM", 206, 226], ["therapeutic", "OBSERVATION_MODIFIER", 15, 26], ["antibodies", "OBSERVATION", 27, 37]]], ["This goes along with adaptation to small molecule inhibitors (e.g. oseltamivir) [9].IntroductionVaccines can only temporarily control the recurring epidemics of influenza, because antigenic changes are typical for HA and NA.", [["oseltamivir", "CHEMICAL", 67, 78], ["influenza", "DISEASE", 161, 170], ["NA", "CHEMICAL", 221, 223], ["oseltamivir", "CHEMICAL", 67, 78], ["oseltamivir", "SIMPLE_CHEMICAL", 67, 78], ["Vaccines", "ORGANISM", 96, 104], ["small molecule inhibitors", "TREATMENT", 35, 60], ["oseltamivir)", "TREATMENT", 67, 79], ["IntroductionVaccines", "TREATMENT", 84, 104], ["influenza", "PROBLEM", 161, 170], ["antigenic changes", "PROBLEM", 180, 197], ["HA", "PROBLEM", 214, 216], ["NA", "PROBLEM", 221, 223], ["influenza", "OBSERVATION", 161, 170]]], ["16 avian and 2 bat serotypes of influenza A virus HA (H1\u2014H18) are known, but only three (H1, H2, and H3) have been adapted to humans.", [["bat serotypes", "ORGANISM", 15, 28], ["influenza A virus HA", "ORGANISM", 32, 52], ["H1\u2014H18", "ORGANISM", 54, 60], ["H3", "GENE_OR_GENE_PRODUCT", 101, 103], ["humans", "ORGANISM", 126, 132], ["H3", "PROTEIN", 101, 103], ["influenza A virus", "SPECIES", 32, 49], ["humans", "SPECIES", 126, 132], ["influenza A virus", "SPECIES", 32, 49], ["H1", "SPECIES", 54, 56], ["humans", "SPECIES", 126, 132], ["influenza A virus HA", "PROBLEM", 32, 52]]], ["Antibodies binding to regions of hemagglutinin conserved among serotypes have been developed which demonstrated broad specificity and neutralization potency [10\u201315].", [["hemagglutinin", "PROTEIN", 33, 46], ["Antibodies binding", "PROBLEM", 0, 18], ["hemagglutinin", "PROBLEM", 33, 46], ["neutralization potency", "TEST", 134, 156], ["broad", "OBSERVATION_MODIFIER", 112, 117]]], ["However, development, production and quality control of antibodies is expensive and time consuming.IntroductionAs an alternative, short peptides binding specifically to the spike proteins can be produced in automated high-throughput synthesis at low costs.", [["antibodies", "PROTEIN", 56, 66], ["spike proteins", "PROTEIN", 173, 187], ["short peptides binding", "PROBLEM", 130, 152], ["the spike proteins", "PROBLEM", 169, 187]]], ["HA-binding peptides have been recently obtained by phage display, lead structure optimization of natural products and specific toxins, bioinformatics tools and discovery from side effects of known anti-inflammatory peptides [16\u201323].", [["HA-binding peptides", "GENE_OR_GENE_PRODUCT", 0, 19], ["HA-binding peptides", "PROBLEM", 0, 19], ["natural products", "TREATMENT", 97, 113], ["specific toxins", "PROBLEM", 118, 133], ["bioinformatics tools", "TEST", 135, 155], ["known anti-inflammatory peptides", "PROBLEM", 191, 223]]], ["Some of them showed antiviral activity [17, 19\u201323].", [["antiviral activity", "OBSERVATION", 20, 38]]], ["A more epitope-oriented accession to binding peptides is the search for paratope-derived peptides from variable regions of specific antibodies [24].", [["paratope", "PROTEIN", 72, 80], ["specific antibodies", "PROTEIN", 123, 142], ["A more epitope", "PROBLEM", 0, 14], ["binding peptides", "PROBLEM", 37, 53], ["paratope", "TEST", 72, 80], ["derived peptides", "PROBLEM", 81, 97], ["specific antibodies", "TEST", 123, 142]]], ["Antibodies against HA have been described, and at least 6 antigenic sites (A-F) on the HA-trimer have been identified, localized either at the receptor binding site, the interface of the three HA-monomers, or at other sites like the stalk [8, 11, 25].", [["HA", "GENE_OR_GENE_PRODUCT", 19, 21], ["A-F", "GENE_OR_GENE_PRODUCT", 75, 78], ["HA", "PROTEIN", 19, 21], ["HA-trimer", "PROTEIN", 87, 96], ["receptor binding site", "PROTEIN", 143, 164], ["HA", "PROTEIN", 193, 195], ["HA", "PROBLEM", 19, 21]]], ["Several structures of HA\u2013antibody complexes have been published deposited in the protein data bank (PDB) [11\u201314].", [["HA\u2013antibody", "GENE_OR_GENE_PRODUCT", 22, 33], ["HA\u2013antibody complexes", "PROTEIN", 22, 43], ["Several structures of HA\u2013antibody complexes", "PROBLEM", 0, 43], ["HA\u2013antibody complexes", "OBSERVATION", 22, 43]]], ["Indeed, an antibody was described, whose HA binding is mediated mainly by one CDR, namely HCDR3 [12].IntroductionInspired by this finding, we chose linear peptides corresponding to the CDRs of VH of monoclonal antibody HC19, having the majority of contacts with the HA1 domain of the strain A/Aichi/2/1968 [26, 27].", [["HA", "GENE_OR_GENE_PRODUCT", 41, 43], ["CDR", "PROTEIN", 78, 81], ["VH", "PROTEIN", 193, 195], ["monoclonal antibody HC19", "PROTEIN", 199, 223], ["HA1 domain", "PROTEIN", 266, 276], ["A/Aichi/2/1968", "SPECIES", 291, 305], ["an antibody", "TEST", 8, 19], ["linear peptides", "PROBLEM", 148, 163], ["monoclonal antibody HC19", "PROBLEM", 199, 223], ["monoclonal antibody", "OBSERVATION", 199, 218]]], ["The antibody and the derived peptides bind to HA at the SA binding site, in particular to the 130-loop and the 190-helix, which belong to the antigenic sites A and B, respectively.", [["HA", "GENE_OR_GENE_PRODUCT", 46, 48], ["B", "GENE_OR_GENE_PRODUCT", 164, 165], ["SA binding site", "DNA", 56, 71], ["130-loop", "DNA", 94, 102], ["The antibody", "TEST", 0, 12], ["HA", "PROBLEM", 46, 48]]], ["This binding site is conserved among several HA serotypes providing a basis for a peptide with broader specificity [28].IntroductionWe used complementary experimental and theoretical approaches to select HA binding VH-CDR peptides and to improve their potential to inhibit binding, and finally, infection of cells by influenza A virus.", [["cells", "ANATOMY", 308, 313], ["infection", "DISEASE", 295, 304], ["cells", "CELL", 308, 313], ["influenza A virus", "ORGANISM", 317, 334], ["influenza A virus", "SPECIES", 317, 334], ["influenza A virus", "SPECIES", 317, 334], ["This binding site", "PROBLEM", 0, 17], ["several HA serotypes", "TREATMENT", 37, 57], ["a peptide", "TREATMENT", 80, 89], ["broader specificity", "TEST", 95, 114], ["theoretical approaches", "TREATMENT", 171, 193], ["HA binding VH", "TREATMENT", 204, 217], ["CDR peptides", "TREATMENT", 218, 230], ["inhibit binding", "PROBLEM", 265, 280], ["infection of cells", "PROBLEM", 295, 313], ["influenza A virus", "PROBLEM", 317, 334]]], ["The inhibitory potential of the most efficient CDR-peptide was improved by microarray-based site-directed substitutions of amino acids.", [["amino acids", "CHEMICAL", 123, 134], ["amino acids", "CHEMICAL", 123, 134], ["CDR-peptide", "SIMPLE_CHEMICAL", 47, 58], ["amino acids", "AMINO_ACID", 123, 134], ["microarray", "TEST", 75, 85], ["amino acids", "TREATMENT", 123, 134]]], ["We could demonstrate a broader specificity of the selected peptides as they bound to HA of human and avian pathogenic influenza strains.Virus material ::: Material and MethodsInfluenza strain A/Aichi/2/68 H3N2 X31 (Aichi H3N2), reassorted with A/PuertoRico/8/1934 H1N1, and low pathogenic A/Mute Swan/Rostock/R901/2006 H7N1 K3141 (Rostock H7N1) were harvested from allantoic fluid of hen eggs.", [["allantoic fluid", "ANATOMY", 365, 380], ["eggs", "ANATOMY", 388, 392], ["influenza", "DISEASE", 118, 127], ["HA", "GENE_OR_GENE_PRODUCT", 85, 87], ["human", "ORGANISM", 91, 96], ["avian pathogenic influenza strains", "ORGANISM", 101, 135], ["Virus", "ORGANISM", 136, 141], ["Influenza strain A/", "ORGANISM", 175, 194], ["Aichi/2/68 H3N2 X31", "ORGANISM", 194, 213], ["Aichi H3N2", "ORGANISM", 215, 225], ["PuertoRico/8/1934 H1N1", "ORGANISM", 246, 268], ["R901/2006 H7N1 K3141", "ORGANISM", 309, 329], ["Rostock H7N1", "ORGANISM", 331, 343], ["allantoic fluid", "ORGANISM_SUBSTANCE", 365, 380], ["hen", "ORGANISM", 384, 387], ["eggs", "ORGANISM_SUBSTANCE", 388, 392], ["human", "SPECIES", 91, 96], ["H3N2", "SPECIES", 205, 209], ["Aichi H3N2", "SPECIES", 215, 225], ["hen", "SPECIES", 384, 387], ["human", "SPECIES", 91, 96], ["A/Aichi/2/68 H3N2 X31", "SPECIES", 192, 213], ["Aichi H3N2", "SPECIES", 215, 225], ["A/PuertoRico/8/1934 H1N1", "SPECIES", 244, 268], ["A/Mute Swan/Rostock/R901/2006 H7N1 K3141", "SPECIES", 289, 329], ["hen", "SPECIES", 384, 387], ["avian pathogenic influenza strains", "PROBLEM", 101, 135], ["H3N2", "PROBLEM", 205, 209], ["H1N1", "PROBLEM", 264, 268], ["influenza strains", "OBSERVATION", 118, 135]]], ["Virus isolates were clarified upon low speed centrifugation (300 x g, 10 min) and concentrated by ultracentrifugation (100 000 x g, 1 h).", [["Virus", "ORGANISM", 0, 5], ["Virus isolates", "PROBLEM", 0, 14], ["low speed centrifugation", "TREATMENT", 35, 59]]], ["For safety reasons, viruses prepared for SPR experiments were inactivated by 5 min irradiation with UV-light on ice.", [["viruses", "PROBLEM", 20, 27], ["UV", "TREATMENT", 100, 102], ["ice", "TREATMENT", 112, 115]]], ["Infectivity of inactivated virus was precluded using MDCK II based cell-assays, remaining binding ability of HA was proven using standard hemagglutination assay (HA) with human red blood cells [29].", [["cell", "ANATOMY", 67, 71], ["red blood cells", "ANATOMY", 177, 192], ["MDCK II", "CELL", 53, 60], ["cell", "CELL", 67, 71], ["HA", "SIMPLE_CHEMICAL", 109, 111], ["human", "ORGANISM", 171, 176], ["red blood cells", "CELL", 177, 192], ["MDCK II", "CELL_LINE", 53, 60], ["human red blood cells", "CELL_TYPE", 171, 192], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176], ["inactivated virus", "PROBLEM", 15, 32], ["MDCK II based cell", "TEST", 53, 71], ["HA", "PROBLEM", 109, 111], ["standard hemagglutination assay", "TEST", 129, 160], ["human red blood cells", "TEST", 171, 192], ["virus", "OBSERVATION", 27, 32]]], ["For SPR measurements, also monovalent split vaccine influenza strains A/NewYork/55/2004 H3N2, NIH accession No.", [["NewYork/55/2004 H3N2", "ORGANISM", 72, 92], ["A/NewYork/55/2004 H3N2", "SPECIES", 70, 92], ["SPR measurements", "TEST", 4, 20], ["H3N2", "PROBLEM", 88, 92]]], ["ABO37541 (New York H3N2), A/Victoria/210/2009 H3N2, NIH accession No.", [["ABO37541", "CHEMICAL", 0, 8], ["New York H3N2", "ORGANISM", 10, 23], ["A/Victoria/210/2009 H3N2", "ORGANISM", 26, 50], ["A/Victoria/210/2009 H3N2", "SPECIES", 26, 50], ["H3N2", "PROBLEM", 46, 50]]], ["AFM71802 (Victoria H3N2) and the split vaccine Pandemrix (GlaxoSmithKline) of influenza strain A/California/7/2009 H1N1, NIH accession No.", [["AFM71802", "CHEMICAL", 0, 8], ["Pandemrix", "CHEMICAL", 47, 56], ["GlaxoSmithKline", "CHEMICAL", 58, 73], ["AFM71802", "SIMPLE_CHEMICAL", 0, 8], ["Victoria H3N2", "ORGANISM", 10, 23], ["influenza strain A/California/7/2009 H1N1", "ORGANISM", 78, 119], ["A/California/7/2009 H1N1", "SPECIES", 95, 119], ["the split vaccine Pandemrix", "TREATMENT", 29, 56], ["influenza strain", "PROBLEM", 78, 94], ["H1N1", "PROBLEM", 115, 119]]], ["ACP44189 (California H1N1) were used.", [["ACP44189", "CHEMICAL", 0, 8], ["ACP44189", "SIMPLE_CHEMICAL", 0, 8], ["California H1N1", "ORGANISM", 10, 25], ["California H1N1)", "TREATMENT", 10, 26]]], ["Protein concentrations were determined using standard BCA assay (Thermo Fisher Scientific).", [["Protein concentrations", "TEST", 0, 22]]], ["Additionally viruses were titrated for HA units.", [["Additionally viruses", "PROBLEM", 0, 20], ["HA units", "TREATMENT", 39, 47], ["viruses", "OBSERVATION", 13, 20]]], ["Here, 50 \u03bcl virus concentrate was serially diluted twofold in PBS using 96-well microtiter plates.", [["PBS", "TEST", 62, 65]]], ["Then, 50 \u03bcl of 1% human red blood cells (German Red Cross, Berlin, AB+) were added to each well, followed by an incubation of 60 min at room temperature.", [["red blood cells", "ANATOMY", 24, 39], ["human", "ORGANISM", 18, 23], ["red blood cells", "CELL", 24, 39], ["human red blood cells", "CELL_TYPE", 18, 39], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["1% human red blood cells", "TREATMENT", 15, 39]]], ["The last well showing hemagglutination provided the HA units per 50 \u03bcl virus solution.", [["hemagglutination", "PROBLEM", 22, 38], ["the HA units", "TREATMENT", 48, 60]]], ["For the Rostock H7N1 strain turkey erythrocytes have been used.", [["erythrocytes", "ANATOMY", 35, 47], ["turkey", "ORGANISM", 28, 34], ["erythrocytes", "CELL", 35, 47], ["turkey erythrocytes", "CELL_TYPE", 28, 47], ["turkey", "SPECIES", 28, 34], ["Rostock H7N1", "SPECIES", 8, 20], ["turkey", "SPECIES", 28, 34], ["the Rostock H7N1 strain turkey erythrocytes", "TREATMENT", 4, 47]]], ["Additional material used was HA from Aichi H3N2 (Sino Biological, 11707-V08H).Cell lines ::: Material and MethodsFor infection and cytotoxicity assays Madin-Darby Canine Kidney Epithelial Cells (MDCK II, NBL-2, CCL-34) were used (ATCC).", [["Cell lines", "ANATOMY", 78, 88], ["Kidney Epithelial Cells", "ANATOMY", 170, 193], ["MDCK", "ANATOMY", 195, 199], ["NBL-2", "ANATOMY", 204, 209], ["CCL-34", "ANATOMY", 211, 217], ["ATCC", "ANATOMY", 230, 234], ["infection", "DISEASE", 117, 126], ["Aichi H3N2", "ORGANISM", 37, 47], ["Cell lines", "CELL", 78, 88], ["Kidney Epithelial Cells", "CELL", 170, 193], ["MDCK II", "CELL", 195, 202], ["NBL-2", "CELL", 204, 209], ["CCL-34", "CELL", 211, 217], ["ATCC", "CELL", 230, 234], ["Madin-Darby Canine Kidney Epithelial Cells", "CELL_LINE", 151, 193], ["MDCK II", "CELL_LINE", 195, 202], ["CCL-34", "CELL_LINE", 211, 217], ["Aichi H3N2", "SPECIES", 37, 47], ["HA", "PROBLEM", 29, 31], ["Methods", "TEST", 106, 113], ["infection", "PROBLEM", 117, 126], ["cytotoxicity assays", "TEST", 131, 150], ["Madin", "TEST", 151, 156], ["Darby Canine Kidney Epithelial Cells", "TEST", 157, 193], ["MDCK II", "TEST", 195, 202], ["NBL", "TEST", 204, 207], ["CCL", "TEST", 211, 214], ["infection", "OBSERVATION", 117, 126], ["Kidney", "ANATOMY", 170, 176], ["Epithelial Cells", "OBSERVATION", 177, 193]]], ["Cells were cultivated under standard cell culture conditions with DMEM (supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine) in humid atmosphere at 37\u00b0C and 5% CO2.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 37, 41], ["fetal calf serum", "ANATOMY", 94, 110], ["DMEM", "CHEMICAL", 66, 70], ["L-glutamine", "CHEMICAL", 123, 134], ["CO2", "CHEMICAL", 171, 174], ["L-glutamine", "CHEMICAL", 123, 134], ["CO2", "CHEMICAL", 171, 174], ["Cells", "CELL", 0, 5], ["cell", "CELL", 37, 41], ["calf", "ORGANISM", 100, 104], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["FCS", "ORGANISM_SUBSTANCE", 112, 115], ["L-glutamine", "SIMPLE_CHEMICAL", 123, 134], ["CO2", "SIMPLE_CHEMICAL", 171, 174], ["calf", "SPECIES", 100, 104], ["FCS", "TEST", 112, 115], ["2 mM L-glutamine", "TREATMENT", 118, 134]]], ["Hemagglutination inhibition assays (HAI) were performed using either human erythrocytes (\u03b1-2,6\u2019-sialosugars) for Aichi H3N2, or turkey erythrocytes (\u03b1-2,3\u2019-sialosugars) for Rostock H7N1 [29].Peptides ::: Material and MethodsPeptides were synthesized with a linker for immobilization or without linker for in vitro inhibition assays.", [["erythrocytes", "ANATOMY", 75, 87], ["erythrocytes", "ANATOMY", 135, 147], ["\u03b1-2,6\u2019-sialosugars", "CHEMICAL", 89, 107], ["\u03b1-2,3\u2019-sialosugars", "CHEMICAL", 149, 167], ["\u03b1-2,6\u2019-sialosugars", "CHEMICAL", 89, 107], ["\u03b1-2,3\u2019-sialosugars", "CHEMICAL", 149, 167], ["human", "ORGANISM", 69, 74], ["erythrocytes", "CELL", 75, 87], ["\u03b1-2,6\u2019-sialosugars", "SIMPLE_CHEMICAL", 89, 107], ["Aichi H3N2", "ORGANISM", 113, 123], ["turkey", "ORGANISM", 128, 134], ["erythrocytes", "CELL", 135, 147], ["\u03b1-2,3\u2019-sialosugars", "SIMPLE_CHEMICAL", 149, 167], ["MethodsPeptides", "SIMPLE_CHEMICAL", 217, 232], ["human erythrocytes", "CELL_TYPE", 69, 87], ["turkey erythrocytes", "CELL_TYPE", 128, 147], ["human", "SPECIES", 69, 74], ["turkey", "SPECIES", 128, 134], ["human", "SPECIES", 69, 74], ["Aichi H3N2", "SPECIES", 113, 123], ["turkey", "SPECIES", 128, 134], ["Hemagglutination inhibition assays", "TEST", 0, 34], ["human erythrocytes", "TEST", 69, 87], ["Aichi H3N2", "PROBLEM", 113, 123], ["turkey erythrocytes", "TEST", 128, 147], ["MethodsPeptides", "TREATMENT", 217, 232], ["a linker for immobilization", "TREATMENT", 255, 282], ["linker", "TREATMENT", 294, 300], ["vitro inhibition assays", "TEST", 308, 331]]], ["For SPR based binding experiments, antibody derived peptides were extended with an N-terminal lysine linker: KKKK-SGFLLISN-amide (PeA-Lys), KKKK-FYDYDVFY-amide (PeB-Lys), KK-\u00dfA\u00dfA-LGVIWAGGNTNY-amide (PeC-Lys).", [["KKKK-SGFLLISN-amide", "CHEMICAL", 109, 128], ["PeA-Lys", "CHEMICAL", 130, 137], ["KKKK-FYDYDVFY-amide", "CHEMICAL", 140, 159], ["PeB-Lys", "CHEMICAL", 161, 168], ["KK-\u00dfA\u00dfA-LGVIWAGGNTNY-amide", "CHEMICAL", 171, 197], ["PeC-Lys", "CHEMICAL", 199, 206], ["N", "CHEMICAL", 83, 84], ["lysine", "CHEMICAL", 94, 100], ["KKKK-SGFLLISN-amide", "CHEMICAL", 109, 128], ["PeA-Lys", "CHEMICAL", 130, 137], ["KKKK-FYDYDVFY-amide", "CHEMICAL", 140, 159], ["PeB-Lys", "CHEMICAL", 161, 168], ["KK-\u00dfA\u00dfA-LGVIWAGGNTNY-amide", "CHEMICAL", 171, 197], ["PeC", "CHEMICAL", 199, 202], ["Lys", "CHEMICAL", 203, 206], ["KKKK-SGFLLISN-amide", "SIMPLE_CHEMICAL", 109, 128], ["PeA-Lys", "SIMPLE_CHEMICAL", 130, 137], ["KKKK-FYDYDVFY-amide", "SIMPLE_CHEMICAL", 140, 159], ["PeB-Lys", "SIMPLE_CHEMICAL", 161, 168], ["KK-\u00dfA\u00dfA-LGVIWAGGNTNY-amide", "SIMPLE_CHEMICAL", 171, 197], ["PeC-Lys", "SIMPLE_CHEMICAL", 199, 206], ["N-terminal lysine linker", "PROTEIN", 83, 107], ["SPR based binding experiments", "PROBLEM", 4, 33], ["antibody derived peptides", "PROBLEM", 35, 60], ["an N-terminal lysine linker", "TREATMENT", 80, 107], ["KKKK", "TEST", 109, 113], ["PeA", "TEST", 130, 133], ["KKKK", "TEST", 140, 144]]], ["In the SPR based screen for virus binding, single and double mutated variants of PeB-Lys were used.", [["PeB-Lys", "CHEMICAL", 81, 88], ["Lys", "CHEMICAL", 85, 88], ["PeB-Lys", "GENE_OR_GENE_PRODUCT", 81, 88], ["PeB", "PROTEIN", 81, 84], ["the SPR", "TEST", 3, 10], ["virus binding", "PROBLEM", 28, 41], ["PeB-Lys", "TREATMENT", 81, 88]]], ["All lysine variants were purchased from Biosyntan or Genecust with >95% purity.", [["lysine", "CHEMICAL", 4, 10], ["Biosyntan", "CHEMICAL", 40, 49], ["Genecust", "CHEMICAL", 53, 61], ["lysine", "CHEMICAL", 4, 10], ["Biosyntan", "SIMPLE_CHEMICAL", 40, 49], ["Genecust", "SIMPLE_CHEMICAL", 53, 61], ["All lysine variants", "PROBLEM", 0, 19], ["lysine variants", "OBSERVATION", 4, 19]]], ["These peptides were dissolved in water and diluted in appropriate buffers for immobilization on SPR sensor chips.", [["water", "SIMPLE_CHEMICAL", 33, 38], ["These peptides", "TREATMENT", 0, 14], ["immobilization on SPR sensor chips", "TREATMENT", 78, 112], ["dissolved", "OBSERVATION_MODIFIER", 20, 29]]], ["SPR based binding inhibition assays were performed with the full length peptides SGFLLISNGVHWV-amide (PeA), ARDFYDYDVFYYAMD-amide (PeB), and its double mutant ARDFYGYDVFFYAMD-amide (PeBGF).", [["SGFLLISNGVHWV-amide", "CHEMICAL", 81, 100], ["PeA", "CHEMICAL", 102, 105], ["ARDFYDYDVFYYAMD-amide", "CHEMICAL", 108, 129], ["PeB", "CHEMICAL", 131, 134], ["ARDFYGYDVFFYAMD-amide", "CHEMICAL", 159, 180], ["SGFLLISNGVHWV-amide", "CHEMICAL", 81, 100], ["PeA", "CHEMICAL", 102, 105], ["ARDFYDYDVFYYAMD-amide", "CHEMICAL", 108, 129], ["PeB", "CHEMICAL", 131, 134], ["amide", "CHEMICAL", 175, 180], ["PeBGF", "CHEMICAL", 182, 187], ["SGFLLISNGVHWV-amide", "SIMPLE_CHEMICAL", 81, 100], ["PeA", "SIMPLE_CHEMICAL", 102, 105], ["ARDFYDYDVFYYAMD-amide", "SIMPLE_CHEMICAL", 108, 129], ["PeB", "SIMPLE_CHEMICAL", 131, 134], ["ARDFYGYDVFFYAMD-amide", "SIMPLE_CHEMICAL", 159, 180], ["PeBGF", "SIMPLE_CHEMICAL", 182, 187], ["PeBGF", "PROTEIN", 182, 187], ["SPR based binding inhibition assays", "TEST", 0, 35], ["ARDFYDYDVFYYAMD-amide (PeB)", "TREATMENT", 108, 135], ["its double mutant ARDFYGYDVFFYAMD-amide (PeBGF)", "TREATMENT", 141, 188]]], ["For the biological assays PeB, PeBGF and the control peptide ARDFYDPDVFYYAMD-amide (PeBP) were applied.", [["PeBGF", "CHEMICAL", 31, 36], ["ARDFYDPDVFYYAMD-amide", "CHEMICAL", 61, 82], ["ARDFYDPDVFYYAMD-amide", "CHEMICAL", 61, 82], ["PeBP", "CHEMICAL", 84, 88], ["PeB", "SIMPLE_CHEMICAL", 26, 29], ["PeBGF", "SIMPLE_CHEMICAL", 31, 36], ["ARDFYDPDVFYYAMD-amide", "SIMPLE_CHEMICAL", 61, 82], ["PeBP", "SIMPLE_CHEMICAL", 84, 88], ["PeB", "PROTEIN", 26, 29], ["PeBGF", "PROTEIN", 31, 36], ["the biological assays", "TEST", 4, 25], ["PeBGF", "TREATMENT", 31, 36], ["the control peptide ARDFYDPDVFYYAMD-amide (PeBP)", "TREATMENT", 41, 89]]], ["These peptides, and the peptides EB, s2(1\u20135), Phage 1 (P1) H5N1 and Phage 1 (L-P1) H9N2, Mucroporin M-1were synthesized by Rudolf Volkmer (Charit\u00e9, Berlin).", [["Mucroporin M-1were", "CHEMICAL", 89, 107], ["P1) H5N1", "ORGANISM", 55, 63], ["Mucroporin M-1were", "SIMPLE_CHEMICAL", 89, 107], ["H9N2", "SPECIES", 83, 87], ["These peptides", "TEST", 0, 14], ["the peptides EB", "TEST", 20, 35], ["Phage", "TEST", 46, 51], ["H5N1", "TEST", 59, 63], ["Phage", "TEST", 68, 73], ["H9N2", "TREATMENT", 83, 87], ["Mucroporin M", "TREATMENT", 89, 101]]], ["HPLC purification and analysis were achieved using a linear solvent gradient (A: 0.05% TFA in water; B: 0.05% TFA in acetonitrile; gradient: 5\u201360% B over 30 min; UV detector at 214 nm; RP-18 column).", [["TFA", "CHEMICAL", 87, 90], ["TFA", "CHEMICAL", 110, 113], ["acetonitrile", "CHEMICAL", 117, 129], ["TFA", "SIMPLE_CHEMICAL", 87, 90], ["TFA", "SIMPLE_CHEMICAL", 110, 113], ["acetonitrile", "SIMPLE_CHEMICAL", 117, 129], ["HPLC purification", "TEST", 0, 17], ["analysis", "TEST", 22, 30], ["a linear solvent gradient", "TREATMENT", 51, 76], ["acetonitrile", "TEST", 117, 129], ["gradient", "TEST", 131, 139], ["UV detector", "TEST", 162, 173], ["RP", "TEST", 185, 187]]], ["The identities of the peptides were validated by mass spectrometry using MALDI-TOF (microflex LT, Bruker Daltonik), and ESI (Q-TOF micro, Micromass).", [["mass spectrometry", "TEST", 49, 66], ["MALDI", "TEST", 73, 78], ["TOF", "TEST", 79, 82], ["microflex LT", "TEST", 84, 96], ["ESI", "TEST", 120, 123], ["LT", "ANATOMY", 94, 96]]], ["Lyophilized peptides could be stored for at least one year at -20\u00b0C as controlled by HPLC/MS analysis.", [["C", "SIMPLE_CHEMICAL", 66, 67], ["HPLC/MS analysis", "TEST", 85, 101]]], ["Stock solutions of PeB, PeBGF and PeBP were prepared by initial dissolving in DMSO, followed by dilution in PBS (8 mM peptide with 10% DMSO v/v).", [["PeB", "CHEMICAL", 19, 22], ["PeBGF", "CHEMICAL", 24, 29], ["PeBP", "CHEMICAL", 34, 38], ["DMSO", "CHEMICAL", 78, 82], ["PeB", "CHEMICAL", 19, 22], ["PeBGF", "CHEMICAL", 24, 29], ["PeBP", "CHEMICAL", 34, 38], ["DMSO", "CHEMICAL", 78, 82], ["PeB", "SIMPLE_CHEMICAL", 19, 22], ["PeBGF", "SIMPLE_CHEMICAL", 24, 29], ["PeBP", "SIMPLE_CHEMICAL", 34, 38], ["DMSO", "SIMPLE_CHEMICAL", 78, 82], ["PeBP", "PROTEIN", 34, 38], ["PeB", "TREATMENT", 19, 22], ["PeBGF", "TREATMENT", 24, 29], ["PeBP", "TREATMENT", 34, 38], ["DMSO", "TREATMENT", 78, 82], ["dilution in PBS", "TREATMENT", 96, 111]]], ["Stock solutions could be stored for several weeks at 4\u00b0C.Peptides ::: Material and MethodsCircular Dichroism (CD) spectroscopy for determination of secondary structure and melting temperature was performed (S1 Fig) using a Jasco J-715 CD spectrometer.", [["Stock solutions", "TREATMENT", 0, 15], ["MethodsCircular Dichroism (CD) spectroscopy", "TREATMENT", 83, 126], ["secondary structure", "PROBLEM", 148, 167], ["melting temperature", "PROBLEM", 172, 191], ["a Jasco J", "TREATMENT", 221, 230], ["MethodsCircular Dichroism", "OBSERVATION", 83, 108]]], ["CD spectra of 100 \u03bcg ml-1 peptide solutions were recorded at 1 nm wavelength steps.", [["CD spectra", "TEST", 0, 10], ["1 peptide solutions", "TREATMENT", 24, 43]]], ["The primary signal in millidegrees (mdeg) was recorded over 4 s, and then the molar ellipticity (\u03b8mrw, [deg cm2 dmol-1 10\u22123]) was calculated.Surface preparation for surface plasmon resonance ::: Material and MethodsMeasurements were performed on a Biacore\u2122 T200 (GE-Healthcare Bio-Sciences AB) using CM5 chips, and running buffer HBSP (10 mM Hepes, 150 mM NaCl, 0.05% Tween 20, pH 7.4) at 25\u00b0C. Peptides and proteins were immobilized via amine coupling with EDC/NHS at a flow rate of 10 \u03bcl min-1, according to the manufacturer\u2019s instructions (GE Healthcare).", [["HBSP", "CHEMICAL", 330, 334], ["NaCl", "CHEMICAL", 356, 360], ["amine", "CHEMICAL", 438, 443], ["EDC", "CHEMICAL", 458, 461], ["NaCl", "CHEMICAL", 356, 360], ["Tween 20", "CHEMICAL", 368, 376], ["amine", "CHEMICAL", 438, 443], ["EDC", "CHEMICAL", 458, 461], ["HBSP", "SIMPLE_CHEMICAL", 330, 334], ["amine", "SIMPLE_CHEMICAL", 438, 443], ["EDC", "SIMPLE_CHEMICAL", 458, 461], ["NHS", "SIMPLE_CHEMICAL", 462, 465], ["surface plasmon resonance", "TEST", 165, 190], ["MethodsMeasurements", "TEST", 208, 227], ["a Biacore\u2122 T200", "TREATMENT", 246, 261], ["CM5 chips", "TREATMENT", 300, 309], ["running buffer HBSP", "TREATMENT", 315, 334], ["Hepes", "TEST", 342, 347], ["NaCl", "TEST", 356, 360], ["pH", "TEST", 378, 380], ["EDC/NHS", "TREATMENT", 458, 465], ["a flow rate", "TREATMENT", 469, 480]]], ["Optimum preconcentration was evaluated before, using acetate and phosphate buffers (10 mM) of pH 4 to 7, and ligand concentrations of 10 \u03bcg ml-1.", [["acetate", "CHEMICAL", 53, 60], ["phosphate", "CHEMICAL", 65, 74], ["acetate", "CHEMICAL", 53, 60], ["phosphate", "CHEMICAL", 65, 74], ["acetate", "SIMPLE_CHEMICAL", 53, 60], ["phosphate buffers", "SIMPLE_CHEMICAL", 65, 82], ["Optimum preconcentration", "TREATMENT", 0, 24], ["acetate and phosphate buffers", "TREATMENT", 53, 82], ["pH", "TEST", 94, 96], ["ligand concentrations", "TEST", 109, 130]]], ["For the immobilization of biotinylated sialyllactose (Lectinity), neutravidin (Thermo Fisher Scientific) (100 \u03bcg ml-1) was immobilized by amine coupling at pH 5.5 enabling high ligand density.", [["sialyllactose", "CHEMICAL", 39, 52], ["neutravidin", "CHEMICAL", 66, 77], ["amine", "CHEMICAL", 138, 143], ["sialyllactose", "CHEMICAL", 39, 52], ["neutravidin", "CHEMICAL", 66, 77], ["amine", "CHEMICAL", 138, 143], ["sialyllactose", "SIMPLE_CHEMICAL", 39, 52], ["Lectinity", "SIMPLE_CHEMICAL", 54, 63], ["neutravidin", "SIMPLE_CHEMICAL", 66, 77], ["amine", "SIMPLE_CHEMICAL", 138, 143], ["biotinylated sialyllactose (Lectinity)", "TREATMENT", 26, 64], ["neutravidin (Thermo Fisher Scientific)", "TREATMENT", 66, 104], ["pH", "TEST", 156, 158], ["high ligand density", "OBSERVATION", 172, 191]]], ["Biotinylated sialyllactose was then injected at a concentration of 10 \u03bcg ml-1 in HBSP for 3 min.Binding experiments ::: Material and MethodsSeveral concentrations of analyte (HA, virus) were applied at least onto two channels with generally 500 s association and a 600 s dissociation time, followed by a 60 s regeneration step with 50 mM NaOH.", [["sialyllactose", "CHEMICAL", 13, 26], ["NaOH", "CHEMICAL", 338, 342], ["sialyllactose", "CHEMICAL", 13, 26], ["NaOH", "CHEMICAL", 338, 342], ["sialyllactose", "SIMPLE_CHEMICAL", 13, 26], ["HBSP", "SIMPLE_CHEMICAL", 81, 85], ["NaOH", "SIMPLE_CHEMICAL", 338, 342], ["Biotinylated sialyllactose", "TREATMENT", 0, 26], ["Material", "TREATMENT", 120, 128], ["MethodsSeveral concentrations of analyte (HA, virus)", "TREATMENT", 133, 185]]], ["A flow rate of 10 \u03bcl min-1 was used.", [["A flow rate", "TEST", 0, 11]]], ["Quantitative data were obtained by extracting the amount of bound material 10 s after injection was terminated (mean value over 5 s).", [["Quantitative data", "TEST", 0, 17]]], ["Reverse peptide binding experiments were run, with immobilized HA or Aichi H3N2, under the same conditions.", [["Aichi H3N2", "ORGANISM", 69, 79], ["Aichi H3N2", "SPECIES", 69, 79], ["Reverse peptide binding experiments", "PROBLEM", 0, 35], ["immobilized HA", "PROBLEM", 51, 65], ["Aichi H3N2", "PROBLEM", 69, 79]]], ["Double referencing of binding curves was performed, using a control flow cell without ligand, and using control injections of buffer, in order to eliminate bulk refractive index effects and unspecific binding to the sensor surface.", [["cell", "ANATOMY", 73, 77], ["surface", "CELLULAR_COMPONENT", 223, 230], ["Double referencing of binding curves", "TEST", 0, 36], ["control injections of buffer", "TREATMENT", 104, 132], ["bulk refractive index effects", "PROBLEM", 156, 185], ["bulk", "OBSERVATION", 156, 160], ["refractive index", "OBSERVATION", 161, 177]]], ["The dissociation constant (KD) was calculated from a plot of steady state binding levels against analyte concentration, using a Biacore T200 Evaluation Software.Solid-state binding competition experiments ::: Material and MethodsA constant concentration of 50 or 100 \u03bcg ml-1 Aichi H3N2 virus was used as analyte, while the concentration of the inhibitors was varied.", [["Aichi H3N2 virus", "ORGANISM", 275, 291], ["Aichi H3N2 virus", "SPECIES", 275, 291], ["Aichi H3N2 virus", "SPECIES", 275, 291], ["The dissociation constant", "PROBLEM", 0, 25], ["Material and MethodsA constant concentration", "TREATMENT", 209, 253], ["Aichi H3N2 virus", "TREATMENT", 275, 291], ["the inhibitors", "TREATMENT", 340, 354]]], ["The suspensions of virus and inhibitor were mixed and subsequently incubated on a Thriller\u00ae thermoshaker at 500 rpm and 37\u00b0C for at least 15 min to reach equilibrium before injection on the SPR surface.", [["surface", "ANATOMY", 194, 201], ["C", "SIMPLE_CHEMICAL", 123, 124], ["virus and inhibitor", "TREATMENT", 19, 38], ["virus", "OBSERVATION", 19, 24]]], ["The inhibitors used were peptides or \u03b1-2,3\u2019- and \u03b1-2,6\u2019-sialyllactose (Carbosynth).", [["\u03b1-2,3\u2019- and \u03b1-2,6\u2019-sialyllactose", "CHEMICAL", 37, 69], ["Carbosynth", "CHEMICAL", 71, 81], ["\u03b1-2,3\u2019- and \u03b1-2,6\u2019-sialyllactose", "CHEMICAL", 37, 69], ["Carbosynth", "CHEMICAL", 71, 81], ["\u03b1-2,3\u2019", "SIMPLE_CHEMICAL", 37, 43], ["\u03b1-2,6\u2019-sialyllactose", "SIMPLE_CHEMICAL", 49, 69], ["Carbosynth", "SIMPLE_CHEMICAL", 71, 81], ["The inhibitors", "TREATMENT", 0, 14], ["peptides", "TEST", 25, 33], ["\u03b1", "TEST", 37, 38], ["\u03b1", "TEST", 49, 50]]], ["The suspensions of virus and inhibitor were mixed and subsequently incubated for at least 15 min to reach equilibrium before injection on the SPR surface.", [["virus and inhibitor", "TREATMENT", 19, 38], ["virus", "OBSERVATION", 19, 24]]], ["All data were referenced against buffer or inhibitor injection of identical concentration.", [["All data", "TEST", 0, 8], ["buffer or inhibitor injection", "TREATMENT", 33, 62]]], ["The decrease of binding capacity of the chip over time was considered by referencing against multiple virus injections at various time points during the experiment.", [["The decrease of binding capacity", "PROBLEM", 0, 32], ["multiple virus injections", "TREATMENT", 93, 118], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["binding capacity", "OBSERVATION", 16, 32]]], ["Inhibition was calculated against the mean value of at least five binding events with the virus alone, using the sigmoidal four parameter logistic fit (Origin).Microarray based substitutional analysis ::: Material and MethodsMicroarray-based substitutional analysis of peptide PeB was performed using a PepStar\u00ae peptide library spotted on glass slides by JPT Peptide Technologies.", [["the virus", "PROBLEM", 86, 95], ["MethodsMicroarray", "TEST", 218, 235], ["peptide PeB", "TREATMENT", 269, 280], ["a PepStar\u00ae peptide library", "TREATMENT", 301, 327]]], ["The slides were used without additional treatment.", [["The slides", "TREATMENT", 0, 10], ["additional treatment", "TREATMENT", 29, 49]]], ["For the labeling of proteins with a fluorescent dye, Dyomics DY-634 (\u03bbex = 635 nm, \u03bbem = 654 nm, Fluorospin 634 Kit (emp Biotech) was used, according to the manufacturer\u00b4s instructions.", [["Dyomics DY-634", "CHEMICAL", 53, 67], ["DY-634", "CHEMICAL", 61, 67], ["a fluorescent dye", "TEST", 34, 51], ["Dyomics DY", "TEST", 53, 63], ["\u03bbex", "TEST", 69, 72], ["\u03bbem", "TEST", 83, 86], ["Fluorospin", "TEST", 97, 107], ["Kit (emp Biotech", "TREATMENT", 112, 128]]], ["The following materials were labeled: NewYork H3N2, Victoria H3N2, Aichi H3N2, and California H1N1.", [["Aichi H3N2, and California H1N1", "DISEASE", 67, 98], ["NewYork H3N2", "ORGANISM", 38, 50], ["Victoria H3N2", "ORGANISM", 52, 65], ["Aichi H3N2", "ORGANISM", 67, 77], ["California H1N1", "ORGANISM", 83, 98], ["Aichi H3N2", "SPECIES", 67, 77], ["California H1N1", "SPECIES", 83, 98], ["Aichi H3N2", "SPECIES", 67, 77], ["H3N2", "PROBLEM", 46, 50], ["Aichi H3N2", "PROBLEM", 67, 77], ["Aichi H3N2", "OBSERVATION", 67, 77], ["California H1N1", "OBSERVATION", 83, 98]]], ["Labeled analytes were incubated several hours or overnight at indicated concentrations using Femtotip buffer (FTP) (20 mM Tris, 30% glycerol, 3% polyvinylpyrrolidon 90, 0.1% Tween 20, pH 8.4) for dilution.", [["FTP", "CHEMICAL", 110, 113], ["glycerol", "CHEMICAL", 132, 140], ["polyvinylpyrrolidon", "CHEMICAL", 145, 164], ["Tris", "CHEMICAL", 122, 126], ["glycerol", "CHEMICAL", 132, 140], ["polyvinylpyrrolidon", "CHEMICAL", 145, 164], ["Tween 20", "CHEMICAL", 174, 182], ["glycerol", "SIMPLE_CHEMICAL", 132, 140], ["polyvinylpyrrolidon", "SIMPLE_CHEMICAL", 145, 164], ["Femtotip buffer (FTP)", "TREATMENT", 93, 114], ["20 mM Tris", "TREATMENT", 116, 126], ["glycerol", "TREATMENT", 132, 140], ["3% polyvinylpyrrolidon", "TREATMENT", 142, 164], ["pH", "TEST", 184, 186]]], ["The slides were washed twice in FTP and twice in ultrapure water and subsequently dried under a stream of nitrogen.", [["nitrogen", "CHEMICAL", 106, 114], ["nitrogen", "CHEMICAL", 106, 114], ["FTP", "TREATMENT", 32, 35], ["ultrapure water", "TREATMENT", 49, 64], ["a stream of nitrogen", "TREATMENT", 94, 114]]], ["Fluorescence measurements were performed using an Axon 4200A Laser Scanner (Molecular Devices).", [["Fluorescence measurements", "TEST", 0, 25], ["an Axon 4200A Laser Scanner (Molecular Devices", "TREATMENT", 47, 93]]], ["Fluorescence intensity was evaluated using GenePix Pro 6.0 software.", [["Fluorescence intensity", "TEST", 0, 22], ["GenePix Pro", "TREATMENT", 43, 54]]], ["For evaluation of binding efficiency the contrast (C) was calculated fromC=IS-INCIS+INCwhere IS represents the relative fluorescence intensity (background subtracted) of a sample spot and INC the relative fluorescence intensity of an appropriate negative control spot.", [["INCIS", "DNA", 78, 83], ["evaluation", "TEST", 4, 14], ["a sample spot", "TEST", 170, 183], ["fluorescence intensity", "OBSERVATION", 120, 142], ["negative control spot", "OBSERVATION", 246, 267]]], ["Mean values of triplicate experiments for mutant peptides (CM) are given relative to contrast of positive control fetuin (CM x 100/Cfetuin) in percent with CPeB set to zero.", [["fetuin", "GENE_OR_GENE_PRODUCT", 114, 120], ["fetuin", "PROTEIN", 114, 120], ["CPeB", "PROTEIN", 156, 160], ["Mean values", "TEST", 0, 11], ["mutant peptides", "PROBLEM", 42, 57], ["positive control fetuin", "TREATMENT", 97, 120], ["CPeB", "OBSERVATION", 156, 160]]], ["Experimental data can be obtained from GEO accession GSE78700, ID 200078700.Neuraminidase activity assay ::: Material and MethodsThe assay was performed according to Potier et al. [30].", [["Neuraminidase", "SIMPLE_CHEMICAL", 76, 89], ["MethodsThe assay", "TEST", 122, 138]]], ["Recombinant neuraminidase of Influenza A virus (A/Aichi/2/1968, H3N2) was purchased from antibodies-online (ABIN2007091).", [["Influenza A virus", "ORGANISM", 29, 46], ["A/Aichi/2/1968", "ORGANISM", 48, 62], ["H3N2", "ORGANISM", 64, 68], ["antibodies", "PROTEIN", 89, 99], ["Influenza A virus", "SPECIES", 29, 46], ["Influenza A virus", "SPECIES", 29, 46], ["A/Aichi/2/1968, H3N2", "SPECIES", 48, 68], ["Influenza A virus", "PROBLEM", 29, 46], ["H3N2", "PROBLEM", 64, 68], ["Influenza", "OBSERVATION", 29, 38]]], ["The substrate 4-Methylumbelliferyl-N-acetyl-\u03b1-D-neuraminic acid sodium salt (MUNANA) was obtained from Carbosynth.", [["4-Methylumbelliferyl-N-acetyl-\u03b1-D-neuraminic acid sodium salt", "CHEMICAL", 14, 75], ["MUNANA", "CHEMICAL", 77, 83], ["Carbosynth", "CHEMICAL", 103, 113], ["4-Methylumbelliferyl-N-acetyl-\u03b1-D-neuraminic acid sodium salt", "CHEMICAL", 14, 75], ["MUNANA", "CHEMICAL", 77, 83], ["4-Methylumbelliferyl-N-acetyl-\u03b1-D-neuraminic acid sodium salt", "SIMPLE_CHEMICAL", 14, 75], ["MUNANA", "SIMPLE_CHEMICAL", 77, 83], ["The substrate", "TEST", 0, 13], ["Methylumbelliferyl-N-acetyl-\u03b1-D-neuraminic acid sodium salt (MUNANA)", "TREATMENT", 16, 84], ["Carbosynth", "TREATMENT", 103, 113]]], ["The assays were done in MES buffer, containing 32.5 mM 2-(N-morpholino-) ethane sulfonic acid and 4 mM CaCl2.", [["2-(N-morpholino-) ethane sulfonic acid", "CHEMICAL", 55, 93], ["CaCl2", "CHEMICAL", 103, 108], ["2-(N-morpholino-) ethane sulfonic acid", "CHEMICAL", 55, 93], ["CaCl2", "CHEMICAL", 103, 108], ["2-(N-morpholino-) ethane sulfonic acid", "SIMPLE_CHEMICAL", 55, 93], ["CaCl2", "SIMPLE_CHEMICAL", 103, 108], ["The assays", "TEST", 0, 10], ["N-morpholino", "TEST", 58, 70], ["ethane sulfonic acid", "TREATMENT", 73, 93], ["4 mM CaCl2", "TREATMENT", 98, 108]]], ["The fluorescence of the cleaved product 5-Methyl-umbelliferone was detected by the FLUOstar Omega Microplate Reader (BMG LABTECH, Ortenberg, Germany) at excitation wavelength 320 nm and emission wavelength 510 nm.", [["5-Methyl-umbelliferone", "CHEMICAL", 40, 62], ["5-Methyl-umbelliferone", "CHEMICAL", 40, 62], ["5-Methyl-umbelliferone", "SIMPLE_CHEMICAL", 40, 62], ["the cleaved product", "TREATMENT", 20, 39], ["Methyl-umbelliferone", "TREATMENT", 42, 62]]], ["The well-known inhibitor N-acetyl-2,3-dehydro-2-deoxy- neuraminic acid disodium salt (DANA, Carbosynth) was used as a positive control for the inhibition assay.", [["N-acetyl-2,3-dehydro-2-deoxy- neuraminic acid disodium salt", "CHEMICAL", 25, 84], ["DANA", "CHEMICAL", 86, 90], ["Carbosynth", "CHEMICAL", 92, 102], ["N-acetyl-2,3-dehydro-2-deoxy- neuraminic acid disodium salt", "CHEMICAL", 25, 84], ["DANA", "CHEMICAL", 86, 90], ["Carbosynth", "CHEMICAL", 92, 102], ["N-acetyl-2,3-dehydro-2-deoxy- neuraminic acid disodium salt", "SIMPLE_CHEMICAL", 25, 84], ["DANA", "SIMPLE_CHEMICAL", 86, 90], ["Carbosynth", "SIMPLE_CHEMICAL", 92, 102], ["N-acetyl", "TEST", 25, 33], ["dehydro", "TREATMENT", 38, 45], ["deoxy- neuraminic acid disodium salt (DANA, Carbosynth)", "TREATMENT", 48, 103], ["a positive control", "TREATMENT", 116, 134], ["the inhibition assay", "TEST", 139, 159]]], ["The microtiter plate wells were filled with 50 \u03bcl containing 15 ng neuraminidase, 200 \u03bcM substrate and various concentrations of inhibitor, and incubated at 37\u00b0C for 30 min.", [["The microtiter plate wells", "TREATMENT", 0, 26], ["15 ng neuraminidase", "TREATMENT", 61, 80], ["various concentrations of inhibitor", "TREATMENT", 103, 138]]], ["Assays were also performed with Aichi H3N2, UV inactivated, 100 ng per well.Hemagglutination inhibition assay ::: Material and MethodsAichi H3N2 or Rostock H7N1 viruses were incubated with human or turkey erythrocytes, respectively, to yield agglutination (in the absence of an inhibitor) and concentration-dependent inhibition of agglutination (in the presence of an inhibitor).", [["erythrocytes", "ANATOMY", 205, 217], ["Aichi H3N2", "ORGANISM", 32, 42], ["MethodsAichi H3N2", "ORGANISM", 127, 144], ["Rostock H7N1 viruses", "ORGANISM", 148, 168], ["human", "ORGANISM", 189, 194], ["turkey", "ORGANISM", 198, 204], ["erythrocytes", "CELL", 205, 217], ["human or turkey erythrocytes", "CELL_TYPE", 189, 217], ["human", "SPECIES", 189, 194], ["turkey", "SPECIES", 198, 204], ["Aichi H3N2", "SPECIES", 32, 42], ["Rostock H7N1 viruses", "SPECIES", 148, 168], ["human", "SPECIES", 189, 194], ["turkey", "SPECIES", 198, 204], ["Assays", "TEST", 0, 6], ["Aichi H3N2", "TREATMENT", 32, 42], ["UV", "TREATMENT", 44, 46], ["Hemagglutination inhibition assay", "TEST", 76, 109], ["Material", "TEST", 114, 122], ["MethodsAichi H3N2", "TREATMENT", 127, 144], ["Rostock H7N1 viruses", "PROBLEM", 148, 168], ["agglutination", "TEST", 242, 255], ["an inhibitor", "TREATMENT", 275, 287], ["dependent inhibition of agglutination", "PROBLEM", 307, 344], ["an inhibitor", "TREATMENT", 365, 377], ["MethodsAichi H3N2", "OBSERVATION", 127, 144]]], ["Inhibitors were twofold serially diluted in PBS.", [["Inhibitors", "TREATMENT", 0, 10]]], ["Then, 2 hemagglutination units (HAU) containing 2\u2219107 virus particles were added to all wells.", [["2 hemagglutination units (HAU) containing 2\u2219107 virus particles", "TREATMENT", 6, 69]]], ["Viral particle concentration was estimated as described by Desselberger et al. [31].", [["Viral", "ORGANISM", 0, 5], ["Viral particle concentration", "PROBLEM", 0, 28], ["particle concentration", "OBSERVATION", 6, 28]]], ["After 30 min incubation at room temperature, 50 \u03bcl of a 1% erythrocyte solution (~2\u2219106 cells \u03bcl-1) was added, gently mixed and incubated for 60 min at room temperature.", [["erythrocyte", "ANATOMY", 59, 70], ["cells", "ANATOMY", 88, 93], ["erythrocyte", "CELL", 59, 70], ["a 1% erythrocyte solution", "TREATMENT", 54, 79], ["cells \u03bcl", "TREATMENT", 88, 96]]], ["For Aichi H3N2 human erythrocytes (\u03b1-2,6\u2019-sialosugars), for Rostock H7N1 turkey erythrocytes (\u03b1-2,3\u2019-sialosugars) have been used.", [["erythrocytes", "ANATOMY", 21, 33], ["erythrocytes", "ANATOMY", 80, 92], ["\u03b1-2,6\u2019-sialosugars", "CHEMICAL", 35, 53], ["\u03b1-2,3\u2019-sialosugars", "CHEMICAL", 94, 112], ["\u03b1-2,6\u2019-sialosugars", "CHEMICAL", 35, 53], ["\u03b1-2,3\u2019-sialosugars", "CHEMICAL", 94, 112], ["Aichi H3N2", "ORGANISM", 4, 14], ["human", "ORGANISM", 15, 20], ["erythrocytes", "CELL", 21, 33], ["\u03b1-2,6\u2019-sialosugars", "SIMPLE_CHEMICAL", 35, 53], ["turkey", "ORGANISM", 73, 79], ["erythrocytes", "ORGANISM_SUBSTANCE", 80, 92], ["\u03b1-2,3\u2019-sialosugars", "SIMPLE_CHEMICAL", 94, 112], ["Aichi H3N2 human erythrocytes", "CELL_LINE", 4, 33], ["Aichi H3N2", "SPECIES", 4, 14], ["human", "SPECIES", 15, 20], ["turkey", "SPECIES", 73, 79], ["Aichi H3N2 human", "SPECIES", 4, 20], ["Rostock H7N1 turkey", "SPECIES", 60, 79], ["Aichi H3N2 human erythrocytes", "TEST", 4, 33], ["\u03b1", "TEST", 35, 36], ["erythrocytes", "TEST", 80, 92], ["\u03b1", "TEST", 94, 95]]], ["The inhibitor constant Ki(HAI), reflects the lowest inhibitor concentration, which is necessary to achieve complete inhibition of hemagglutination caused by the influenza virus.", [["influenza virus", "DISEASE", 161, 176], ["influenza virus", "ORGANISM", 161, 176], ["influenza virus", "SPECIES", 161, 176], ["The inhibitor constant Ki(HAI)", "TREATMENT", 0, 30], ["the lowest inhibitor concentration", "TREATMENT", 41, 75], ["hemagglutination", "PROBLEM", 130, 146], ["the influenza virus", "PROBLEM", 157, 176], ["influenza virus", "OBSERVATION", 161, 176]]], ["To check for full hemagglutination inhibition, the microtiter plate was tilted by 60\u00b0 to cause droplet formation from the red blood cell pellet [29].Infection inhibition assay ::: Material and MethodsThe experiment has been assessed using an MTS reagent (Promega) according to the manufacturer\u2019s protocol: 15,000 MDCK II cells were seeded the day before infection.", [["droplet", "ANATOMY", 95, 102], ["red blood cell", "ANATOMY", 122, 136], ["MDCK II cells", "ANATOMY", 313, 326], ["infection", "DISEASE", 354, 363], ["blood cell", "ORGANISM_SUBSTANCE", 126, 136], ["MDCK II cells", "CELL", 313, 326], ["15,000 MDCK II cells", "CELL_LINE", 306, 326], ["full hemagglutination inhibition", "TREATMENT", 13, 45], ["the microtiter plate", "TEST", 47, 67], ["droplet formation", "PROBLEM", 95, 112], ["the red blood cell pellet", "TEST", 118, 143], ["an MTS reagent (Promega)", "TREATMENT", 239, 263], ["MDCK II cells", "TREATMENT", 313, 326], ["infection", "PROBLEM", 354, 363], ["infection", "OBSERVATION", 354, 363]]], ["Aichi H3N2 or Rostock H7N1 were pretreated with peptides in a twofold dilution series for 30 min at room temperature under slight agitation.", [["agitation", "DISEASE", 130, 139], ["Aichi H3N2", "ORGANISM", 0, 10], ["Rostock H7N1", "ORGANISM", 14, 26], ["Aichi H3N2", "SPECIES", 0, 10], ["Rostock H7N1", "SPECIES", 14, 26], ["Aichi H3N2", "PROBLEM", 0, 10], ["peptides", "TREATMENT", 48, 56], ["a twofold dilution series", "TREATMENT", 60, 85], ["slight agitation", "PROBLEM", 123, 139], ["slight", "OBSERVATION_MODIFIER", 123, 129], ["agitation", "OBSERVATION", 130, 139]]], ["Cells were washed once with PBS (supplemented with 0.49 mM Mg2+, 0.90 mM Ca2+), before pretreated virus (MOI 0.05) was added to the cells and maintained for 1 h at room temperature to allow binding.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 132, 137], ["Mg2", "CHEMICAL", 59, 62], ["Ca2", "CHEMICAL", 73, 76], ["Mg2+", "CHEMICAL", 59, 63], ["Ca2+", "CHEMICAL", 73, 77], ["Cells", "CELL", 0, 5], ["PBS", "SIMPLE_CHEMICAL", 28, 31], ["Mg2+", "SIMPLE_CHEMICAL", 59, 63], ["Ca2+", "SIMPLE_CHEMICAL", 73, 77], ["cells", "CELL", 132, 137], ["PBS", "TEST", 28, 31], ["Mg2", "TEST", 59, 62], ["pretreated virus (MOI", "TREATMENT", 87, 108]]], ["Unbound virus was removed by washing once with infection medium (DMEM, 2 mM L-glutamine, 0.1% FCS, 0.1% bovine serum albumin (BSA), 2.5 \u03bcg ml-1 L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK) treated trypsin, 100 U ml-1 penicillin and 100 \u03bcg ml-1 streptomycin), and subsequently incubated for 24 h at 37\u00b0C. Then, 20 \u03bcl MTS solution was added to each well followed by 2 hours incubation at 37\u00b0C. Finally, absorbance at 490 nm was recorded and data were normalized as follows:Infection inhibition(%)=(Infectedtreated-Infecteduntreated)(Uninfecteduntreated-Infecteduntreated)x100Infection inhibition assay ::: Material and MethodsExperiments have been performed for both virus strains in at least triplicate experiments.Microneutralization assay ::: Material and MethodsThe microneutralization assay was performed according to the protocol of Klimov et al. [32] with minor modifications.", [["serum", "ANATOMY", 111, 116], ["infection", "DISEASE", 47, 56], ["L-glutamine", "CHEMICAL", 76, 87], ["FCS", "CHEMICAL", 94, 97], ["BSA", "CHEMICAL", 126, 129], ["L-(tosylamido-2-phenyl) ethyl chloromethyl ketone", "CHEMICAL", 144, 193], ["TPCK", "CHEMICAL", 195, 199], ["penicillin", "CHEMICAL", 229, 239], ["streptomycin", "CHEMICAL", 256, 268], ["MTS", "CHEMICAL", 328, 331], ["L-glutamine", "CHEMICAL", 76, 87], ["L-(tosylamido-2-phenyl) ethyl chloromethyl ketone", "CHEMICAL", 144, 193], ["TPCK", "CHEMICAL", 195, 199], ["penicillin", "CHEMICAL", 229, 239], ["streptomycin", "CHEMICAL", 256, 268], ["MTS", "CHEMICAL", 328, 331], ["L-glutamine", "SIMPLE_CHEMICAL", 76, 87], ["bovine", "ORGANISM", 104, 110], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["albumin", "SIMPLE_CHEMICAL", 117, 124], ["BSA", "SIMPLE_CHEMICAL", 126, 129], ["L-(tosylamido-2-phenyl) ethyl chloromethyl ketone", "SIMPLE_CHEMICAL", 144, 193], ["TPCK", "SIMPLE_CHEMICAL", 195, 199], ["trypsin", "SIMPLE_CHEMICAL", 209, 216], ["penicillin", "SIMPLE_CHEMICAL", 229, 239], ["streptomycin", "SIMPLE_CHEMICAL", 256, 268], ["trypsin", "PROTEIN", 209, 216], ["bovine", "SPECIES", 104, 110], ["Unbound virus", "PROBLEM", 0, 13], ["infection", "PROBLEM", 47, 56], ["glutamine", "TREATMENT", 78, 87], ["FCS", "TEST", 94, 97], ["bovine serum albumin", "TEST", 104, 124], ["BSA", "TEST", 126, 129], ["tosylamido", "TEST", 147, 157], ["phenyl) ethyl chloromethyl ketone (TPCK", "TREATMENT", 160, 199], ["trypsin", "TREATMENT", 209, 216], ["penicillin", "TREATMENT", 229, 239], ["streptomycin", "TREATMENT", 256, 268], ["20 \u03bcl MTS solution", "TREATMENT", 322, 340], ["Infection inhibition", "PROBLEM", 483, 503], ["MethodsExperiments", "TREATMENT", 629, 647], ["both virus strains", "PROBLEM", 672, 690], ["Microneutralization assay", "TEST", 726, 751], ["The microneutralization assay", "TEST", 776, 805], ["minor modifications", "TREATMENT", 873, 892], ["virus", "OBSERVATION", 8, 13]]], ["Briefly, peptide dilutions were mixed with either 200 TCID50 Aichi H3N2 or 50 TCID50 Rostock H7N1 in infection medium for 30 min at room temperature.", [["infection", "DISEASE", 101, 110], ["Aichi H3N2", "ORGANISM", 61, 71], ["Aichi H3N2", "SPECIES", 61, 71], ["peptide dilutions", "TREATMENT", 9, 26], ["infection", "OBSERVATION", 101, 110]]], ["Subsequently, 30,000 MDCK II cells were added to each well, followed by incubation for 18 h at 37\u00b0C. Next, the medium was removed, washed with PBS and fixed with ice cold acetone (80% v/v).", [["MDCK II cells", "ANATOMY", 21, 34], ["ice cold acetone", "CHEMICAL", 162, 178], ["acetone", "CHEMICAL", 171, 178], ["MDCK II cells", "CELL", 21, 34], ["acetone", "SIMPLE_CHEMICAL", 171, 178], ["30,000 MDCK II cells", "CELL_LINE", 14, 34], ["MDCK II cells", "TREATMENT", 21, 34], ["PBS", "TREATMENT", 143, 146], ["ice cold acetone", "TREATMENT", 162, 178]]], ["After removal of the fixative, plates were dried and undergone immunostaining.", [["removal", "TREATMENT", 6, 13], ["the fixative, plates", "TREATMENT", 17, 37], ["immunostaining", "TEST", 63, 77]]], ["Cells were stained with IgG primary antibody against the influenza A nucleoprotein (Millipore, Cat. # MAB8257, mouse monoclonal, 1:1000 in antibody diluent: PBS, 0.3% Tween 20 (v/v) and 5% (w/v) nonfat, dry milk) for 1 h at room temperature.", [["Cells", "ANATOMY", 0, 5], ["milk", "ANATOMY", 207, 211], ["Tween 20", "CHEMICAL", 167, 175], ["Cells", "CELL", 0, 5], ["influenza A nucleoprotein", "ORGANISM", 57, 82], ["mouse", "ORGANISM", 111, 116], ["nonfat", "ORGANISM_SUBSTANCE", 195, 201], ["milk", "ORGANISM_SUBSTANCE", 207, 211], ["IgG primary antibody", "PROTEIN", 24, 44], ["influenza A nucleoprotein", "PROTEIN", 57, 82], ["mouse", "SPECIES", 111, 116], ["mouse", "SPECIES", 111, 116], ["Cells", "TEST", 0, 5], ["IgG primary antibody", "TEST", 24, 44], ["Cat.", "TEST", 95, 99], ["mouse monoclonal", "TEST", 111, 127], ["PBS", "TEST", 157, 160], ["Tween", "TEST", 167, 172], ["v/v", "TEST", 177, 180]]], ["Following, cells were washed with washing buffer (PBS, 0.3% Tween 20), before a secondary antibody (1:1000 goat anti-mouse IgG, KPL, Cat. # 074\u20131802 in antibody diluent) conjugated to horseradish peroxidase (HRP) was added for another hour at room temperature.", [["cells", "ANATOMY", 11, 16], ["Cat. # 074\u20131802", "CHEMICAL", 133, 148], ["Tween 20", "CHEMICAL", 60, 68], ["cells", "CELL", 11, 16], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 184, 206], ["HRP", "SIMPLE_CHEMICAL", 208, 211], ["secondary antibody", "PROTEIN", 80, 98], ["1:1000 goat anti-mouse IgG", "PROTEIN", 100, 126], ["KPL", "PROTEIN", 128, 131], ["horseradish peroxidase", "PROTEIN", 184, 206], ["HRP", "PROTEIN", 208, 211], ["goat", "SPECIES", 107, 111], ["anti-mouse", "SPECIES", 112, 122], ["horseradish", "SPECIES", 184, 195], ["goat", "SPECIES", 107, 111], ["washing buffer", "TREATMENT", 34, 48], ["PBS", "TEST", 50, 53], ["a secondary antibody", "TEST", 78, 98], ["IgG", "TEST", 123, 126], ["KPL", "TEST", 128, 131], ["Cat.", "TEST", 133, 137], ["antibody diluent", "TREATMENT", 152, 168], ["horseradish peroxidase (HRP", "TREATMENT", 184, 211]]], ["Next, the antibody was removed and the cells were washed with washing buffer.", [["cells", "ANATOMY", 39, 44], ["cells", "CELL", 39, 44], ["the antibody", "TREATMENT", 6, 18], ["the cells", "TREATMENT", 35, 44], ["washing buffer", "TREATMENT", 62, 76]]], ["Finally, \u03c3-phenylenediamine dihydrochloride (OPD) in citrate (0.05 M phosphate-citrate, 0.03% sodium perborate, pH 5.0 at 25\u00b0C), was added for approximately 30 minutes until the supernatant turned yellow.", [["supernatant", "ANATOMY", 178, 189], ["\u03c3-phenylenediamine dihydrochloride", "CHEMICAL", 9, 43], ["citrate", "CHEMICAL", 53, 60], ["phosphate-citrate", "CHEMICAL", 69, 86], ["sodium perborate", "CHEMICAL", 94, 110], ["\u03c3-phenylenediamine dihydrochloride", "CHEMICAL", 9, 43], ["OPD", "CHEMICAL", 45, 48], ["citrate", "CHEMICAL", 53, 60], ["phosphate-citrate", "CHEMICAL", 69, 86], ["sodium perborate", "CHEMICAL", 94, 110], ["\u03c3-phenylenediamine dihydrochloride", "SIMPLE_CHEMICAL", 9, 43], ["OPD", "SIMPLE_CHEMICAL", 45, 48], ["citrate", "SIMPLE_CHEMICAL", 53, 60], ["0.05 M phosphate-citrate", "SIMPLE_CHEMICAL", 62, 86], ["sodium perborate", "SIMPLE_CHEMICAL", 94, 110], ["\u03c3-phenylenediamine dihydrochloride (OPD)", "TREATMENT", 9, 49], ["citrate (0.05 M phosphate", "TREATMENT", 53, 78], ["citrate", "TREATMENT", 79, 86], ["0.03% sodium perborate", "TREATMENT", 88, 110], ["pH", "TEST", 112, 114]]], ["The reaction was stopped with 0.5 M sulfuric acid and absorbance of the reaction product in the microwell plate was recorded at 490 nm.", [["sulfuric acid", "CHEMICAL", 36, 49], ["sulfuric acid", "CHEMICAL", 36, 49], ["sulfuric acid", "SIMPLE_CHEMICAL", 36, 49], ["The reaction", "PROBLEM", 0, 12], ["0.5 M sulfuric acid", "TREATMENT", 30, 49], ["the reaction product", "TREATMENT", 68, 88], ["the microwell plate", "TEST", 92, 111], ["reaction product", "OBSERVATION", 72, 88]]], ["After subtraction of the background of non-infected cells, neutralization was calculated in ratio to untreated, infected cells.Cell viability assay ::: Material and MethodsOne day before treatment 15,000 MDCK II cells were seeded.", [["cells", "ANATOMY", 52, 57], ["cells", "ANATOMY", 121, 126], ["Cell", "ANATOMY", 127, 131], ["MDCK II cells", "ANATOMY", 204, 217], ["cells", "CELL", 52, 57], ["cells", "CELL", 121, 126], ["Cell", "CELL", 127, 131], ["MDCK II cells", "CELL", 204, 217], ["non-infected cells", "CELL_TYPE", 39, 57], ["infected cells", "CELL_TYPE", 112, 126], ["MDCK II cells", "CELL_LINE", 204, 217], ["non-infected cells", "PROBLEM", 39, 57], ["neutralization", "TREATMENT", 59, 73], ["infected cells", "PROBLEM", 112, 126], ["treatment", "TREATMENT", 187, 196], ["MDCK II cells", "TREATMENT", 204, 217], ["non-infected cells", "OBSERVATION", 39, 57], ["infected cells", "OBSERVATION", 112, 126]]], ["On the following day media was removed and replaced with a twofold serial dilution of either PeB, PeBGF or PeBP in supplemented DMEM (see above).", [["PeB", "CHEMICAL", 93, 96], ["PeBGF", "CHEMICAL", 98, 103], ["PeBP", "CHEMICAL", 107, 111], ["PeBGF", "CHEMICAL", 98, 103], ["PeBP", "CHEMICAL", 107, 111], ["PeB", "SIMPLE_CHEMICAL", 93, 96], ["PeBGF", "SIMPLE_CHEMICAL", 98, 103], ["PeBP", "SIMPLE_CHEMICAL", 107, 111], ["a twofold serial dilution of either PeB", "TREATMENT", 57, 96], ["PeBGF", "TREATMENT", 98, 103], ["PeBP in supplemented DMEM", "TREATMENT", 107, 132]]], ["Next, cells have been incubated in the presence of inhibitor for 24 h at 37\u00b0C. Then, 20 \u03bcl MTS solution was added to each well.", [["cells", "ANATOMY", 6, 11], ["MTS", "CHEMICAL", 91, 94], ["cells", "CELL", 6, 11], ["inhibitor", "TREATMENT", 51, 60], ["20 \u03bcl MTS solution", "TREATMENT", 85, 103]]], ["Finally, absorbance at 490 nm was measured and data were normalized to untreated cells as follows:Cell viability(%)=(Treated Cells-Medium Background)(Untreated Cells-Medium Background)x100Molecular dynamics simulations ::: Material and MethodsAn ensemble of configurations for the complexes HA-PeA, HA-PeB, HA-PeC and HA-PeBGF was built using the AMBER14 package of programs [33].", [["cells", "ANATOMY", 81, 86], ["Cell", "ANATOMY", 98, 102], ["Cells", "ANATOMY", 125, 130], ["cells", "CELL", 81, 86], ["Cell", "CELL", 98, 102], ["HA-PeA", "SIMPLE_CHEMICAL", 291, 297], ["HA-PeB", "SIMPLE_CHEMICAL", 299, 305], ["HA-PeC", "SIMPLE_CHEMICAL", 307, 313], ["HA-PeBGF", "SIMPLE_CHEMICAL", 318, 326], ["PeA", "PROTEIN", 294, 297], ["HA", "PROTEIN", 299, 301], ["PeB", "PROTEIN", 302, 305], ["HA", "PROTEIN", 307, 309], ["PeC", "PROTEIN", 310, 313], ["HA", "PROTEIN", 318, 320], ["PeBGF", "PROTEIN", 321, 326], ["absorbance", "TEST", 9, 19], ["Cell viability", "TEST", 98, 112], ["Cells", "TEST", 125, 130], ["Untreated Cells", "PROBLEM", 150, 165], ["the complexes HA", "PROBLEM", 277, 293], ["PeA", "PROBLEM", 294, 297], ["HA", "PROBLEM", 299, 301], ["PeB", "TREATMENT", 302, 305], ["HA", "PROBLEM", 307, 309], ["PeC", "PROBLEM", 310, 313], ["HA", "PROBLEM", 318, 320], ["PeBGF", "PROBLEM", 321, 326], ["PeC", "ANATOMY", 310, 313]]], ["In each case, the antibody moiety excepting the sequence of the peptide under study was erased.", [["antibody moiety", "PROTEIN", 18, 33], ["the antibody moiety", "TREATMENT", 14, 33], ["the peptide under study", "TEST", 60, 83]]], ["In the case of PeBGF, in silico D6G and Y11F mutations were performed.", [["PeBGF", "GENE_OR_GENE_PRODUCT", 15, 20], ["D6G", "GENE_OR_GENE_PRODUCT", 32, 35], ["Y11F", "GENE_OR_GENE_PRODUCT", 40, 44], ["PeBGF", "PROTEIN", 15, 20]]], ["Systems were then solvated using the TIP3P water molecule model [34], extending at least 10 \u00c5 from the complex.", [["the TIP3P water molecule model", "TREATMENT", 33, 63]]], ["Nearly 18250 water molecules were added to solvate the complex and the resulting truncated octahedral box size was nearly 108 \u00c5 x 108 \u00c5 x 108 \u00c5.", [["the resulting truncated octahedral box size", "PROBLEM", 67, 110], ["size", "OBSERVATION_MODIFIER", 106, 110]]], ["An appropriate number of chloride ions were added to keep the total system charge neutral.", [["chloride", "CHEMICAL", 25, 33], ["chloride", "CHEMICAL", 25, 33], ["chloride ions", "SIMPLE_CHEMICAL", 25, 38], ["chloride ions", "TREATMENT", 25, 38], ["the total system charge neutral", "TREATMENT", 58, 89]]], ["All bond lengths involving hydrogen atoms were constrained using the SHAKE algorithm allowing the usage of a 2 fs time-step [35].", [["hydrogen", "CHEMICAL", 27, 35], ["hydrogen", "CHEMICAL", 27, 35], ["hydrogen atoms", "SIMPLE_CHEMICAL", 27, 41], ["All bond lengths involving hydrogen atoms", "TREATMENT", 0, 41], ["the SHAKE algorithm", "TREATMENT", 65, 84], ["bond", "OBSERVATION_MODIFIER", 4, 8], ["lengths", "OBSERVATION_MODIFIER", 9, 16], ["hydrogen atoms", "OBSERVATION", 27, 41]]], ["The temperature was fixed at 300 K using a Langevin thermostat with a collision frequency of 2 ps-1.", [["The temperature", "TEST", 0, 15], ["a Langevin thermostat", "TREATMENT", 41, 62], ["a collision frequency", "TEST", 68, 89]]], ["The electrostatic interactions were treated using the particle-mesh Ewald (PME) scheme with a fourth-order B-spline interpolation and a tolerance of 10-5 [36].", [["The electrostatic interactions", "PROBLEM", 0, 30], ["the particle-mesh Ewald (PME) scheme", "TREATMENT", 50, 86], ["B-spline interpolation", "TREATMENT", 107, 129]]], ["The non-bonded cut-off was 8 \u00c5 and the non-bonded pair list was updated every 50 fs.Molecular dynamics simulations ::: Material and MethodsSimulations were carried out according to the same protocol that has been used in our previous studies [37\u201341], with the Amber FF99SB force field [42].", [["MethodsSimulations", "TREATMENT", 132, 150], ["non-bonded", "OBSERVATION_MODIFIER", 4, 14], ["cut", "OBSERVATION_MODIFIER", 15, 18]]], ["Briefly, each complex configuration was first optimized by 1000 steps of steepest descent followed by another 1000 steps of conjugate gradient minimization, keeping all atoms of the complex restrained to their initial position with a weak harmonic potential.", [["conjugate gradient minimization", "TREATMENT", 124, 155]]], ["Each system was then simulated for 50 ps at constant volume with a 2 kcal mol-1 \u00c5-2 restraint on the complex, in order to equilibrate the solvent at 300 K without undesirable drifts of the structure.", [["a 2 kcal mol", "TREATMENT", 65, 77], ["undesirable drifts of the structure", "PROBLEM", 163, 198]]], ["Subsequently, a 50 ps MD simulation with a 2 kcal mol-1 \u00c5-2 restraint on each complex at a pressure of 101,325 kPa was conducted to relax the density using Berendsen's barostat.", [["barostat", "SIMPLE_CHEMICAL", 168, 176], ["a 2 kcal mol", "TREATMENT", 41, 53], ["1 \u00c5-2 restraint", "TREATMENT", 54, 69], ["Berendsen's barostat", "TREATMENT", 156, 176]]], ["After 1 ns without restraint equilibration phase, a 10 ns simulation at constant pressure was carried out and the coordinates were stored every 10 ps, resulting in 1000 configurations for each simulation.", [["restraint equilibration phase", "TEST", 19, 48], ["a 10 ns simulation at constant pressure", "TREATMENT", 50, 89]]], ["Subsequently, Molecular Mechanics-Poisson-Boltzmann Surface Area (MM-PBSA) calculations were performed.Molecular Mechanics\u2014Poisson-Boltzmann Surface Area calculations ::: Material and MethodsIn the MM-PBSA method, the binding free energy of the receptor-ligand complex, \u0394Gbind, is determined from\u0394Gbind=Gcom-Grec-Gligwhere Gcom, Grec, and Glig denote the absolute free energies of the complex, receptor and the ligand, respectively.", [["\u0394Gbind", "SIMPLE_CHEMICAL", 270, 276], ["Grec", "SIMPLE_CHEMICAL", 329, 333], ["Glig", "SIMPLE_CHEMICAL", 339, 343], ["receptor-ligand complex", "PROTEIN", 245, 268], ["\u0394Gbind", "PROTEIN", 270, 276], ["Gcom-Grec", "PROTEIN", 303, 312], ["Molecular Mechanics", "TREATMENT", 14, 33], ["Poisson-Boltzmann Surface Area (MM-PBSA) calculations", "TREATMENT", 34, 87], ["Molecular Mechanics", "TREATMENT", 103, 122], ["Gcom-Grec", "TEST", 303, 312], ["Grec", "TEST", 329, 333], ["free energies", "OBSERVATION", 364, 377], ["ligand", "ANATOMY", 411, 417]]], ["This method has been discussed elsewhere [37\u201341].Molecular Mechanics\u2014Poisson-Boltzmann Surface Area calculations ::: Material and MethodsThe free energy G for each species is estimated fromG=EMM-Gsolv-TMMSMolecular Mechanics\u2014Poisson-Boltzmann Surface Area calculations ::: Material and MethodsHere, EMM is the molecular mechanical energy in the gas phase, Gsolv the solvation free energy, and -TSMM the contribution from the conformational entropy.", [["Gsolv", "SIMPLE_CHEMICAL", 356, 361], ["Molecular Mechanics", "TREATMENT", 49, 68], ["The free energy G", "TREATMENT", 137, 154], ["each species", "PROBLEM", 159, 171], ["the gas phase", "TEST", 341, 354], ["the conformational entropy", "PROBLEM", 421, 447], ["gas phase", "OBSERVATION", 345, 354], ["conformational entropy", "OBSERVATION", 425, 447]]], ["The term EMM is comprised of the internal (bond, angle, dihedral) (Eint), electrostatic (Eelec), and van der Waals energies (EvdW), according toEMM=Eint+Eelec+EvdWandEint=Ebond+Eangle+EtorsionMolecular Mechanics\u2014Poisson-Boltzmann Surface Area calculations ::: Material and MethodsTo incorporate all possible nonbonded interactions, the term EMM was estimated for each snapshot with no cut-offs.", [["Eint", "PROTEIN", 148, 152], ["Eelec", "PROTEIN", 153, 158], ["EvdWandEint=Ebond", "PROTEIN", 159, 176], ["Eangle", "PROTEIN", 177, 183], ["toEMM", "TEST", 142, 147], ["Eint", "TEST", 148, 152], ["Eelec", "TEST", 153, 158], ["EtorsionMolecular Mechanics", "TREATMENT", 184, 211], ["Methods", "TREATMENT", 273, 280], ["nonbonded interactions", "PROBLEM", 308, 330], ["term EMM", "OBSERVATION", 4, 12], ["internal", "ANATOMY_MODIFIER", 33, 41]]], ["The solvation free energy, Gsolv, is approximated as the sum of the polar (Gpol) and the nonpolar contribution (Gnp) using a continuum representation of the solvent according toGsolv=Gpol+GnpGnp=\u03b3xSASA+bMolecular Mechanics\u2014Poisson-Boltzmann Surface Area calculations ::: Material and MethodsHere, \u03b3 = 0.00378 kcal mol-1 \u00c5-2 and b = -0.5692 kcal mol-1.", [["Gsolv", "SIMPLE_CHEMICAL", 27, 32], ["a continuum representation", "TREATMENT", 123, 149], ["the solvent according toGsolv=Gpol+GnpGnp=\u03b3xSASA+bMolecular Mechanics", "TREATMENT", 153, 222]]], ["The popular linear Poisson-Boltzmann method was used to estimate the polar component of the solvation free energy.", [["The popular linear Poisson-Boltzmann method", "TREATMENT", 0, 43], ["popular", "OBSERVATION_MODIFIER", 4, 11], ["linear", "OBSERVATION_MODIFIER", 12, 18], ["polar", "OBSERVATION_MODIFIER", 69, 74], ["component", "OBSERVATION_MODIFIER", 75, 84], ["solvation", "OBSERVATION", 92, 101], ["free energy", "OBSERVATION", 102, 113]]], ["Here, SASA is the solvent accessible surface area estimated by the linear combination of pairwise overlap (LCPO) algorithm using a probe radius of 1.4 \u00c5 [43].Molecular Mechanics\u2014Poisson-Boltzmann Surface Area calculations ::: Material and MethodsThe electrostatic contribution to the solvation free energy was estimated from the Poisson-Boltzmann (PB) approach using the pbsa solver implemented in Amber.", [["surface area", "ANATOMY", 37, 49], ["a probe radius", "TEST", 129, 143], ["Molecular Mechanics", "TREATMENT", 158, 177], ["the solvation free energy", "PROBLEM", 280, 305], ["Boltzmann (PB) approach", "TREATMENT", 337, 360], ["the pbsa solver", "TREATMENT", 367, 382], ["Amber", "OBSERVATION", 398, 403]]], ["In order to solve the PB equation the grid spacing was set to 0.5 \u00c5 in all dimensions and the relative dielectric constants in the protein and in the water were chosen to be 1 and 80, respectively.", [["the PB equation the grid spacing", "TREATMENT", 18, 50], ["grid spacing", "OBSERVATION", 38, 50], ["dielectric constants", "OBSERVATION", 103, 123]]], ["The ionic strength was set to 0.15 M. The ratio between the longest dimension of the rectangular finite-difference grid and that of the solute was chosen to be 4.0.", [["ionic strength", "OBSERVATION_MODIFIER", 4, 18], ["rectangular", "OBSERVATION_MODIFIER", 85, 96], ["finite", "OBSERVATION_MODIFIER", 97, 103]]], ["The linear PB equation was solved with a maximum of 1000 iterations.Molecular Mechanics\u2014Poisson-Boltzmann Surface Area calculations ::: Material and MethodsIn order to understand the inhibitor-residue interaction in more detail, the interaction energy was further decomposed into the contributions from each residue of the peptide by using the theory of free energy decomposition [44].", [["The linear PB equation", "TREATMENT", 0, 22], ["Molecular Mechanics", "TREATMENT", 68, 87], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["PB equation", "OBSERVATION", 11, 22]]], ["The peptide-residue interaction is approximated by\u0394Gpeptide-residue=\u0394Evdw+\u0394Eelec+\u0394GPBwhere \u0394EvdW and \u0394Eelec are the contributions from the van der Waals and electrostatic interactions between the inhibitor and each residue in the gas phase.", [["\u0394Eelec", "SIMPLE_CHEMICAL", 101, 107], ["\u0394Evdw", "PROTEIN", 68, 73], ["\u0394Eelec", "PROTEIN", 74, 80], ["\u0394EvdW", "PROTEIN", 91, 96], ["\u0394Eelec", "PROTEIN", 101, 107], ["The peptide-residue interaction", "PROBLEM", 0, 31], ["the van der Waals", "TREATMENT", 135, 152], ["the inhibitor", "TREATMENT", 192, 205], ["the gas phase", "TEST", 226, 239], ["gas phase", "OBSERVATION", 230, 239]]], ["The polar solvation free energy, \u0394GPB, was estimated using the pbsa module of Amber.Modeling based selection of HA binding peptides ::: ResultsThe 3D structure of the Fab-hemagglutinin complex of the antibody HC19 (PDB: 2vir; complex of immunoglobulin IgG1 with HA of Aichi H3N2) was analyzed to identify peptide sequences of the Fab fragment at the HA contact area [26].", [["Fab-hemagglutinin", "GENE_OR_GENE_PRODUCT", 167, 184], ["PDB: 2vir", "GENE_OR_GENE_PRODUCT", 215, 224], ["immunoglobulin IgG1", "GENE_OR_GENE_PRODUCT", 237, 256], ["Aichi H3N2", "ORGANISM", 268, 278], ["Fab", "GENE_OR_GENE_PRODUCT", 330, 333], ["Fab-hemagglutinin complex", "PROTEIN", 167, 192], ["antibody HC19", "PROTEIN", 200, 213], ["PDB: 2vir; complex", "PROTEIN", 215, 233], ["immunoglobulin IgG1", "PROTEIN", 237, 256], ["HA", "PROTEIN", 262, 264], ["Fab fragment", "PROTEIN", 330, 342], ["Aichi H3N2", "SPECIES", 268, 278], ["Aichi H3N2", "SPECIES", 268, 278], ["\u0394GPB", "TREATMENT", 33, 37], ["the antibody HC19", "TEST", 196, 213], ["PDB", "TEST", 215, 218], ["immunoglobulin IgG1", "TREATMENT", 237, 256], ["HA", "PROBLEM", 262, 264], ["Aichi H3N2", "TREATMENT", 268, 278], ["the Fab fragment", "PROBLEM", 326, 342], ["polar", "OBSERVATION_MODIFIER", 4, 9], ["Amber", "OBSERVATION", 78, 83], ["Fab fragment", "OBSERVATION", 330, 342]]], ["Essentially, three hypervariable complementarity determining regions (CDR) of the heavy chain variable domain (VH) of Fab interact with HA (Fig 1A, 1B and 1C).", [["Fab", "GENE_OR_GENE_PRODUCT", 118, 121], ["hypervariable complementarity determining regions", "PROTEIN", 19, 68], ["CDR", "DNA", 70, 73], ["heavy chain variable domain", "PROTEIN", 82, 109], ["VH", "PROTEIN", 111, 113], ["Fab", "PROTEIN", 118, 121], ["HA", "PROTEIN", 136, 138], ["Fig 1A, 1B and 1C", "PROTEIN", 140, 157], ["three hypervariable complementarity determining regions", "PROBLEM", 13, 68], ["HA", "PROBLEM", 136, 138], ["hypervariable", "OBSERVATION_MODIFIER", 19, 32], ["complementarity", "OBSERVATION", 33, 48], ["heavy", "OBSERVATION_MODIFIER", 82, 87], ["chain", "OBSERVATION_MODIFIER", 88, 93]]], ["From these three loop-like organized sequences interacting with the SA binding pocket of HA, peptides PeA, PeB and PeC (Fig 1D) were derived containing as a core the CDR sequences (Table 1).Modeling based selection of HA binding peptides ::: ResultsIn order to predict and compare binding affinities to HA of the three peptides, corresponding peptide-HA complexes were simulated in explicit water model for 10 ns using MD.", [["PeA", "GENE_OR_GENE_PRODUCT", 102, 105], ["PeB", "GENE_OR_GENE_PRODUCT", 107, 110], ["SA binding pocket", "PROTEIN", 68, 85], ["HA", "PROTEIN", 89, 91], ["PeA", "PROTEIN", 102, 105], ["PeB", "PROTEIN", 107, 110], ["PeC", "PROTEIN", 115, 118], ["CDR sequences", "DNA", 166, 179], ["HA complexes", "PROTEIN", 351, 363], ["the SA binding pocket", "PROBLEM", 64, 85], ["HA", "PROBLEM", 89, 91], ["peptides PeA", "TREATMENT", 93, 105], ["PeB and PeC (Fig 1D)", "TREATMENT", 107, 127], ["a core the CDR sequences", "TEST", 155, 179], ["HA complexes", "PROBLEM", 351, 363], ["loop", "OBSERVATION_MODIFIER", 17, 21]]], ["As deduced from the root-mean-square deviation for PeB already after three ns a steady state for binding was observed (Fig 2A).", [["PeB", "SIMPLE_CHEMICAL", 51, 54], ["PeB", "PROTEIN", 51, 54], ["PeB", "TREATMENT", 51, 54], ["root", "ANATOMY", 20, 24]]], ["In contrast, peptide PeA dissociated from HA within the simulation time of 10 ns.", [["PeA", "GENE_OR_GENE_PRODUCT", 21, 24], ["peptide PeA", "PROBLEM", 13, 24], ["HA", "PROBLEM", 42, 44]]], ["Gibbs free energies of peptide binding to HA were -20.4 and -5.3 kcal mol-1 for PeB and PeC, respectively (Table 1).", [["PeB", "SIMPLE_CHEMICAL", 80, 83], ["PeC", "SIMPLE_CHEMICAL", 88, 91], ["PeB", "PROTEIN", 80, 83], ["peptide binding", "PROBLEM", 23, 38], ["HA", "TEST", 42, 44], ["PeB and PeC", "TREATMENT", 80, 91]]], ["Even though absolute values for free energy changes derived from MD simulation have been proven not to correlate exactly with experimental values, a comparison between MD derived values implicates a stronger binding of PeB to HA.", [["PeB", "SIMPLE_CHEMICAL", 219, 222], ["HA", "GENE_OR_GENE_PRODUCT", 226, 228], ["PeB", "PROTEIN", 219, 222], ["absolute values", "PROBLEM", 12, 27], ["free energy changes", "PROBLEM", 32, 51], ["HA", "PROBLEM", 226, 228]]], ["Also, as shown in Fig 1B and 1C, PeB fits best the conserved SA binding site of Aichi H3N2 HA.", [["PeB", "GENE_OR_GENE_PRODUCT", 33, 36], ["Aichi H3N2 HA", "ORGANISM", 80, 93], ["PeB", "PROTEIN", 33, 36], ["SA binding site", "DNA", 61, 76], ["Aichi H3N2", "SPECIES", 80, 90], ["Aichi H3N2 HA", "PROBLEM", 80, 93], ["Aichi H3N2", "OBSERVATION", 80, 90]]], ["Based on this and experimental results (see below) we selected PeB as a potential inhibitor of virus binding to host cells.", [["cells", "ANATOMY", 117, 122], ["PeB", "CHEMICAL", 63, 66], ["PeB", "GENE_OR_GENE_PRODUCT", 63, 66], ["host cells", "CELL", 112, 122], ["PeB", "PROTEIN", 63, 66], ["host cells", "CELL_TYPE", 112, 122], ["PeB", "TREATMENT", 63, 66], ["a potential inhibitor of virus binding", "TREATMENT", 70, 108]]], ["As expected for its short primary sequence, and revealed experimentally by CD spectroscopy, PeB displayed no secondary structure elements in solution at physiological pH (S1A and S1B Fig).Modeling based selection of HA binding peptides ::: ResultsTo unravel the molecular basis of PeB binding to HA, an analysis of energetic contribution was conducted by a combined MD/MM-PBSA approach.", [["PeB", "CHEMICAL", 92, 95], ["PeB", "CHEMICAL", 281, 284], ["PeB", "CHEMICAL", 92, 95], ["PeB", "SIMPLE_CHEMICAL", 92, 95], ["PeB", "SIMPLE_CHEMICAL", 281, 284], ["PeB", "PROTEIN", 92, 95], ["PeB", "PROTEIN", 281, 284], ["its short primary sequence", "TEST", 16, 42], ["CD spectroscopy", "TEST", 75, 90], ["secondary structure elements", "PROBLEM", 109, 137], ["physiological pH", "TEST", 153, 169], ["PeB binding", "PROBLEM", 281, 292], ["HA", "PROBLEM", 296, 298], ["an analysis", "TEST", 300, 311], ["a combined MD/MM-PBSA approach", "TREATMENT", 355, 385], ["no", "UNCERTAINTY", 106, 108], ["secondary", "OBSERVATION", 109, 118], ["structure elements", "OBSERVATION", 119, 137]]], ["Molecular configurations obtained from MD simulations of the complexes in explicit water were used for calculation of binding free energies using an implicit solvation scheme.", [["explicit water", "TREATMENT", 74, 88], ["binding free energies", "PROBLEM", 118, 139], ["an implicit solvation scheme", "TREATMENT", 146, 174]]], ["The binding free energy was decomposed into contributions of the individual peptide residues (Fig 2B, PeB).", [["the individual peptide residues", "PROBLEM", 61, 92]]], ["Residues within and close to the loop (Y5 to Y12) provide the largest contributions to the binding free energy.", [["loop", "ANATOMY_MODIFIER", 33, 37], ["largest", "OBSERVATION_MODIFIER", 62, 69]]], ["Significant attractive contributions to the binding free energy change arise from F4 (-0.6 kcal mol-1), Y7 (-3.9 kcal mol-1), and F10 (-3.0 kcal mol-1).", [["the binding free energy change", "PROBLEM", 40, 70]]], ["Hence, exchanging D8 and D6 to other amino acids would predict to reduce the repulsive interactions of these residues and, thus, to increase the affinity of the modified PeB to HA.", [["amino acids", "CHEMICAL", 37, 48], ["amino acids", "CHEMICAL", 37, 48], ["amino acids", "AMINO_ACID", 37, 48], ["PeB", "SIMPLE_CHEMICAL", 170, 173], ["HA", "GENE_OR_GENE_PRODUCT", 177, 179], ["PeB", "PROTEIN", 170, 173], ["D8", "TREATMENT", 18, 20], ["D6", "TREATMENT", 25, 27], ["other amino acids", "TREATMENT", 31, 48], ["the modified PeB to HA", "TREATMENT", 157, 179], ["repulsive", "OBSERVATION", 77, 86]]], ["The detailed analysis of electrostatic, van der Waals and polar contributions to the free energy change of each residue is presented in S3 Fig.Modeling based selection of HA binding peptides ::: ResultsWe have also analyzed the contributions of the individual residues of HA to this complex.", [["HA", "GENE_OR_GENE_PRODUCT", 272, 274], ["The detailed analysis", "TEST", 0, 21], ["electrostatic, van der Waals", "TREATMENT", 25, 53], ["each residue", "PROBLEM", 107, 119], ["HA", "PROBLEM", 272, 274], ["S3 Fig", "OBSERVATION", 136, 142]]], ["Attractive contributions mainly originate from residues S136 (-3.0 kcal mol-1), N137 (-1.8 kcal mol-1), and L194 (-1.0 kcal mol-1), whereas the most significant repulsive contribution is caused by E190 (1.1 kcal mol-1) (numbering according to PDB 2vir) (S4 Fig).", [["E190", "CHEMICAL", 197, 201], ["E190", "CHEMICAL", 197, 201], ["PDB 2vir", "PROTEIN", 243, 251], ["residues", "TEST", 47, 55], ["repulsive", "OBSERVATION", 161, 170]]], ["The attractive contributions from the polar residues S136 and N137 arise mainly from the intermolecular electrostatic interaction energy, whereas the hydrophobic residue L194 derives most of its contribution from van der Waals interactions.Binding of peptides to hemagglutinin ::: ResultsBinding of Aichi H3N2 virus to surface immobilized peptides was measured using SPR.", [["surface", "ANATOMY", 319, 326], ["S136", "CHEMICAL", 53, 57], ["N137", "CHEMICAL", 62, 66], ["N137", "AMINO_ACID", 62, 66], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 263, 276], ["Aichi H3N2 virus", "ORGANISM", 299, 315], ["hemagglutinin", "PROTEIN", 263, 276], ["Aichi H3N2 virus", "SPECIES", 299, 315], ["Aichi H3N2 virus", "SPECIES", 299, 315], ["the polar residues", "TEST", 34, 52], ["the hydrophobic residue", "PROBLEM", 146, 169], ["Aichi H3N2 virus", "PROBLEM", 299, 315], ["surface immobilized peptides", "TREATMENT", 319, 347], ["polar residues", "OBSERVATION", 38, 52], ["Aichi H3N2", "OBSERVATION", 299, 309]]], ["For this purpose, peptides PeA-Lys, PeB-Lys, and PeC-Lys, containing lysine residues at the amino terminus, acting as spacer were used.", [["PeA-Lys", "CHEMICAL", 27, 34], ["PeB-Lys", "CHEMICAL", 36, 43], ["PeC-Lys", "CHEMICAL", 49, 56], ["lysine", "CHEMICAL", 69, 75], ["PeA", "CHEMICAL", 27, 30], ["Lys", "CHEMICAL", 31, 34], ["PeB", "CHEMICAL", 36, 39], ["Lys", "CHEMICAL", 40, 43], ["PeC", "CHEMICAL", 49, 52], ["Lys", "CHEMICAL", 53, 56], ["lysine", "CHEMICAL", 69, 75], ["amino", "CHEMICAL", 92, 97], ["PeA-Lys", "SIMPLE_CHEMICAL", 27, 34], ["PeB-Lys", "SIMPLE_CHEMICAL", 36, 43], ["PeC-Lys", "SIMPLE_CHEMICAL", 49, 56], ["lysine", "AMINO_ACID", 69, 75], ["amino terminus", "AMINO_ACID", 92, 106], ["PeC", "PROTEIN", 49, 52], ["amino terminus", "PROTEIN", 92, 106], ["peptides PeA", "TEST", 18, 30], ["Lys", "TEST", 31, 34], ["PeB-Lys", "TREATMENT", 36, 43], ["PeC-Lys", "TREATMENT", 49, 56], ["lysine residues at the amino terminus", "TREATMENT", 69, 106], ["acting as spacer", "TREATMENT", 108, 124], ["lysine residues", "OBSERVATION", 69, 84]]], ["As deduced from MD simulations, the N-terminus of PeB does not significantly contribute to binding of the peptide to HA, as the contribution of these residues to the total free energy change is close to 0 kcal mol-1 (Fig 2B, PeB).", [["PeB", "CHEMICAL", 50, 53], ["PeB", "GENE_OR_GENE_PRODUCT", 50, 53], ["HA", "GENE_OR_GENE_PRODUCT", 117, 119], ["PeB", "PROTEIN", 50, 53], ["HA", "PROBLEM", 117, 119], ["these residues", "PROBLEM", 144, 158], ["the total free energy change", "TREATMENT", 162, 190]]], ["Binding responses are shown in Fig 3, deduced from the SPR sensorgrams for the binding of Aichi H3N2 to peptide-covered surfaces (S5 Fig).Binding of peptides to hemagglutinin ::: ResultsSignificant virus binding was observed on PeB- and PeC-, but not on PeA-modified surfaces consistent with our MD simulations.", [["PeB", "CHEMICAL", 228, 231], ["Aichi H3N2", "ORGANISM", 90, 100], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 161, 174], ["PeB", "SIMPLE_CHEMICAL", 228, 231], ["PeC", "SIMPLE_CHEMICAL", 237, 240], ["PeA", "SIMPLE_CHEMICAL", 254, 257], ["hemagglutinin", "PROTEIN", 161, 174], ["PeB", "PROTEIN", 228, 231], ["PeC", "PROTEIN", 237, 240], ["PeA", "PROTEIN", 254, 257], ["Aichi H3N2", "SPECIES", 90, 100], ["the SPR sensorgrams", "TEST", 51, 70], ["Aichi H3N2 to peptide", "TREATMENT", 90, 111], ["ResultsSignificant virus binding", "PROBLEM", 179, 211], ["PeB", "TEST", 228, 231], ["PeC", "TEST", 237, 240], ["virus", "OBSERVATION", 198, 203]]], ["The minimum detection level, corresponding to the lowest virus concentration, and showing binding 3 times above the SPR response of a buffer control, was 0.19 \u03bcg and 6.25 \u03bcg Aichi H3N2 virus protein ml-1 for immobilized PeB and PeC, respectively.", [["PeB", "SIMPLE_CHEMICAL", 220, 223], ["PeC", "SIMPLE_CHEMICAL", 228, 231], ["PeB", "PROTEIN", 220, 223], ["PeC", "PROTEIN", 228, 231], ["Aichi H3N2 virus", "SPECIES", 174, 190], ["Aichi H3N2 virus", "SPECIES", 174, 190], ["The minimum detection level", "TEST", 0, 27], ["the lowest virus concentration", "TEST", 46, 76], ["a buffer control", "TREATMENT", 132, 148], ["Aichi H3N2 virus protein ml", "TREATMENT", 174, 201], ["immobilized PeB", "TREATMENT", 208, 223]]], ["The higher sensitivity of PeB in the viral binding assay confirms the selection of this CDR derived peptide for further experiments, as mentioned above.", [["PeB", "CHEMICAL", 26, 29], ["PeB", "SIMPLE_CHEMICAL", 26, 29], ["PeB", "PROTEIN", 26, 29], ["PeB", "TREATMENT", 26, 29], ["the viral binding assay", "TEST", 33, 56], ["higher", "OBSERVATION_MODIFIER", 4, 10]]], ["To confirm specificity three PeB variants containing single amino acid residue exchanges, which were immobilized with the same ligand density, were investigated.", [["amino acid", "CHEMICAL", 60, 70], ["amino acid", "CHEMICAL", 60, 70], ["PeB", "GENE_OR_GENE_PRODUCT", 29, 32], ["amino acid", "AMINO_ACID", 60, 70], ["residue", "AMINO_ACID", 71, 78], ["PeB variants", "DNA", 29, 41], ["specificity three PeB variants", "PROBLEM", 11, 41], ["single amino acid residue exchanges", "TREATMENT", 53, 88], ["three PeB", "OBSERVATION_MODIFIER", 23, 32], ["acid residue", "OBSERVATION", 66, 78]]], ["No binding was observed with the three variants, suggesting that the binding of virus is indeed specific to the CDR sequence (Fig 4A).", [["CDR sequence", "DNA", 112, 124], ["binding", "PROBLEM", 3, 10], ["the binding of virus", "PROBLEM", 65, 85], ["binding", "OBSERVATION", 3, 10]]], ["The results also exclude the possibility that binding is mediated by the oligolysine terminus.", [["oligolysine", "CHEMICAL", 73, 84], ["oligolysine terminus", "PROTEIN", 73, 93], ["the oligolysine terminus", "TREATMENT", 69, 93]]], ["Furthermore, several well-known proteins were tested for unspecific binding to the peptide modified chip surface (Fig 4B).", [["unspecific binding", "PROBLEM", 57, 75]]], ["All proteins were injected at the same mass concentration.", [["All proteins", "TREATMENT", 0, 12], ["mass", "OBSERVATION", 39, 43]]], ["Only for core-streptavidin and lysozyme minor binding to PeB was found showing that surface inertness is not impaired.Binding of peptides to hemagglutinin ::: ResultsVery likely, viruses bind to the peptide-covered surfaces in a multivalent manner (see Discussion).", [["surface", "ANATOMY", 84, 91], ["streptavidin", "GENE_OR_GENE_PRODUCT", 14, 26], ["lysozyme", "GENE_OR_GENE_PRODUCT", 31, 39], ["PeB", "GENE_OR_GENE_PRODUCT", 57, 60], ["surface", "CELLULAR_COMPONENT", 84, 91], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 141, 154], ["lysozyme", "PROTEIN", 31, 39], ["PeB", "PROTEIN", 57, 60], ["hemagglutinin", "PROTEIN", 141, 154], ["core-streptavidin", "TREATMENT", 9, 26], ["lysozyme minor binding", "TREATMENT", 31, 53], ["viruses bind", "PROBLEM", 179, 191], ["surface inertness", "OBSERVATION", 84, 101], ["not", "UNCERTAINTY", 105, 108], ["impaired", "OBSERVATION", 109, 117], ["viruses", "OBSERVATION", 179, 186]]], ["As it is not possible to calculate reliable binding constants from the multivalent binding, the inverse experiment using surface immobilized HA from Aichi H3N2 was performed.", [["surface", "ANATOMY", 121, 128], ["Aichi H3N2", "ORGANISM", 149, 159], ["Aichi H3N2", "SPECIES", 149, 159], ["reliable binding constants", "PROBLEM", 35, 61], ["the multivalent binding", "PROBLEM", 67, 90], ["Aichi H3N2", "TREATMENT", 149, 159], ["not possible", "UNCERTAINTY", 9, 21]]], ["From steady-state affinity calculation for PeB a binding constant KD of 56.8 \u03bcM (Rmax = 35.6 RU; chi2 = 0.088), was obtained (Fig 5A and 5B).", [["PeB", "SIMPLE_CHEMICAL", 43, 46], ["PeB", "PROTEIN", 43, 46], ["PeB a binding constant KD", "TEST", 43, 68], ["Rmax", "TEST", 81, 85], ["chi2", "TEST", 97, 101]]], ["To assess whether PeB binds to and thus blocks the sialic binding pocket of Aichi H3N2 neuraminidase, an enzyme activity assay with the substrate MUNANA was performed (for details see Material and Methods).", [["PeB", "CHEMICAL", 18, 21], ["PeB", "SIMPLE_CHEMICAL", 18, 21], ["Aichi H3N2 neuraminidase", "ORGANISM", 76, 100], ["PeB", "PROTEIN", 18, 21], ["sialic binding pocket", "PROTEIN", 51, 72], ["Aichi H3N2 neuraminidase", "PROTEIN", 76, 100], ["Aichi H3N2", "SPECIES", 76, 86], ["PeB binds", "PROBLEM", 18, 27], ["Aichi H3N2 neuraminidase", "TREATMENT", 76, 100], ["an enzyme activity assay", "TEST", 102, 126], ["the substrate MUNANA", "TEST", 132, 152]]], ["While the neuraminidase inhibitor DANA (N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid), serving as a positive control, was able to inhibit neuraminidase activity (IC50 2.2 \u00b1 0.3 \u03bcM), PeB did not reduce the catalytic activity of the enzyme up to 360 \u03bcM peptide concentrations (S2 Fig).", [["DANA", "CHEMICAL", 34, 38], ["N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid", "CHEMICAL", 40, 83], ["PeB", "CHEMICAL", 181, 184], ["DANA", "CHEMICAL", 34, 38], ["N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid", "CHEMICAL", 40, 83], ["PeB", "CHEMICAL", 181, 184], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 10, 23], ["DANA", "SIMPLE_CHEMICAL", 34, 38], ["N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid", "SIMPLE_CHEMICAL", 40, 83], ["PeB", "SIMPLE_CHEMICAL", 181, 184], ["neuraminidase", "PROTEIN", 137, 150], ["enzyme", "PROTEIN", 230, 236], ["the neuraminidase inhibitor DANA", "TREATMENT", 6, 38], ["N-Acetyl", "TREATMENT", 40, 48], ["dehydro", "TREATMENT", 53, 60], ["deoxyneuraminic acid", "TREATMENT", 63, 83], ["a positive control", "TREATMENT", 97, 115], ["neuraminidase activity", "TREATMENT", 137, 159], ["IC50", "TEST", 161, 165], ["PeB", "TREATMENT", 181, 184], ["the enzyme", "TEST", 226, 236]]], ["Thus, PeB is not compromising the accessibility to the catalytic cleft of NA.Binding of peptides to hemagglutinin ::: ResultsTo further support specificity of binding, inhibition of binding of Aichi H3N2 to surface immobilized fetuin by PeB was studied.", [["surface", "ANATOMY", 207, 214], ["PeB", "CHEMICAL", 6, 9], ["NA", "CHEMICAL", 74, 76], ["PeB", "SIMPLE_CHEMICAL", 6, 9], ["NA", "SIMPLE_CHEMICAL", 74, 76], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 100, 113], ["Aichi H3N2", "ORGANISM", 193, 203], ["surface", "CELLULAR_COMPONENT", 207, 214], ["fetuin", "GENE_OR_GENE_PRODUCT", 227, 233], ["PeB", "GENE_OR_GENE_PRODUCT", 237, 240], ["PeB", "PROTEIN", 6, 9], ["hemagglutinin", "PROTEIN", 100, 113], ["PeB", "PROTEIN", 237, 240], ["Aichi H3N2", "SPECIES", 193, 203], ["PeB", "TREATMENT", 6, 9], ["Aichi H3N2 to surface immobilized fetuin", "TREATMENT", 193, 233], ["cleft", "OBSERVATION", 65, 70]]], ["Fetuin contains \u03b1-linked 2,3\u2019- and 2,6\u2019-sialic acids, which are the HA binding constituents on the surface of epithelial cells.", [["surface", "ANATOMY", 99, 106], ["epithelial cells", "ANATOMY", 110, 126], ["Fetuin", "CHEMICAL", 0, 6], ["\u03b1-linked 2,3\u2019- and 2,6\u2019-sialic acids", "CHEMICAL", 16, 52], ["\u03b1-linked 2,3\u2019- and 2,6\u2019-sialic acids", "CHEMICAL", 16, 52], ["Fetuin", "SIMPLE_CHEMICAL", 0, 6], ["\u03b1-linked 2,3\u2019-", "SIMPLE_CHEMICAL", 16, 30], ["2,6\u2019-sialic acids", "SIMPLE_CHEMICAL", 35, 52], ["surface", "CELLULAR_COMPONENT", 99, 106], ["epithelial cells", "CELL", 110, 126], ["Fetuin", "PROTEIN", 0, 6], ["epithelial cells", "CELL_TYPE", 110, 126], ["Fetuin", "TEST", 0, 6], ["sialic acids", "TEST", 40, 52], ["the HA binding constituents", "PROBLEM", 64, 91], ["epithelial cells", "OBSERVATION", 110, 126]]], ["As shown in Fig 6A, Aichi H3N2 binding to fetuin was inhibited by PeB.", [["Aichi H3N2", "ORGANISM", 20, 30], ["fetuin", "GENE_OR_GENE_PRODUCT", 42, 48], ["fetuin", "PROTEIN", 42, 48], ["Aichi H3N2", "SPECIES", 20, 30], ["Aichi H3N2 binding", "PROBLEM", 20, 38]]], ["From the sigmoidal fit an IC50 value of 75 \u00b1 13\u03bcM for PeB was calculated.", [["an IC50 value", "TEST", 23, 36], ["PeB", "TREATMENT", 54, 57], ["sigmoidal", "ANATOMY_MODIFIER", 9, 18]]], ["Furthermore, PeB also prevented binding of Aichi H3N2 to 2,6\u2019-sialyllactose immobilized on a SPR chip at lower concentrations than soluble 2,6\u2018-sialyllactose, with IC50 values of 120\u00b17 \u03bcM and 1790\u00b190 \u03bcM, respectively (S6 Fig).", [["PeB", "CHEMICAL", 13, 16], ["2,6\u2019-sialyllactose", "CHEMICAL", 57, 75], ["2,6\u2018-sialyllactose", "CHEMICAL", 139, 157], ["PeB", "CHEMICAL", 13, 16], ["2,6\u2019-sialyllactose", "CHEMICAL", 57, 75], ["2,6\u2018-sialyllactose", "CHEMICAL", 139, 157], ["PeB", "SIMPLE_CHEMICAL", 13, 16], ["Aichi H3N2", "ORGANISM", 43, 53], ["2,6\u2019-sialyllactose", "SIMPLE_CHEMICAL", 57, 75], ["2,6\u2018-sialyllactose", "SIMPLE_CHEMICAL", 139, 157], ["PeB", "PROTEIN", 13, 16], ["Aichi H3N2", "SPECIES", 43, 53], ["Aichi H3N2", "PROBLEM", 43, 53], ["a SPR chip", "TREATMENT", 91, 101], ["IC50 values", "TEST", 164, 175], ["Aichi H3N2", "OBSERVATION", 43, 53]]], ["These results provide evidence that PeB competes successfully for the SA binding site and, thus, may serve as a virus binding inhibitor.Improvement of peptides by site-directed substitution ::: ResultsOur MD simulations have shown that the main contributions of PeB binding to HA originate from residues 4 to 12 of the peptide.", [["PeB", "CHEMICAL", 36, 39], ["PeB", "CHEMICAL", 262, 265], ["PeB", "SIMPLE_CHEMICAL", 36, 39], ["PeB", "GENE_OR_GENE_PRODUCT", 262, 265], ["PeB", "PROTEIN", 36, 39], ["SA binding site", "DNA", 70, 85], ["PeB", "PROTEIN", 262, 265], ["PeB competes", "TREATMENT", 36, 48], ["the SA binding site", "PROBLEM", 66, 85], ["a virus binding inhibitor", "TREATMENT", 110, 135], ["PeB binding", "PROBLEM", 262, 273], ["HA", "PROBLEM", 277, 279]]], ["In search for peptides with higher binding affinity, a full substitutional analysis using microarrays was performed.", [["peptides", "PROBLEM", 14, 22], ["higher binding affinity", "PROBLEM", 28, 51], ["a full substitutional analysis", "TEST", 53, 83], ["microarrays", "TEST", 90, 101]]], ["Thus, 152 PeB mutant variants were generated.", [["PeB", "GENE_OR_GENE_PRODUCT", 10, 13], ["152 PeB mutant variants", "DNA", 6, 29]]], ["In each of them, the full-length sequence was preserved except for only one amino acid from the eight loop-forming amino acids of the original PeB peptide (ARDFYDYDVFYYAMD) which was substituted with the 19 remaining natural amino acids (Fig 6B).", [["amino acid", "CHEMICAL", 76, 86], ["amino acids", "CHEMICAL", 115, 126], ["ARDFYDYDVFYYAMD", "CHEMICAL", 156, 171], ["amino acids", "CHEMICAL", 225, 236], ["amino acid", "CHEMICAL", 76, 86], ["amino acids", "CHEMICAL", 115, 126], ["amino acids", "CHEMICAL", 225, 236], ["amino acid", "AMINO_ACID", 76, 86], ["amino acids", "AMINO_ACID", 115, 126], ["amino acids", "AMINO_ACID", 225, 236], ["full-length sequence", "DNA", 21, 41], ["loop-forming amino acids", "PROTEIN", 102, 126], ["the full-length sequence", "TEST", 17, 41], ["one amino acid", "PROBLEM", 72, 86], ["amino acids", "TREATMENT", 115, 126], ["the 19 remaining natural amino acids", "TREATMENT", 200, 236]]], ["To assess binding, Aichi H3N2 was labeled with a protein reacting fluorophore.Improvement of peptides by site-directed substitution ::: ResultsMost notably, substitution of D6 generally leads to an increased binding signal.", [["Aichi H3N2", "ORGANISM", 19, 29], ["Aichi H3N2", "SPECIES", 19, 29], ["Aichi H3N2", "PROBLEM", 19, 29], ["a protein reacting fluorophore", "TREATMENT", 47, 77], ["substitution of D6", "TREATMENT", 157, 175], ["an increased binding signal", "PROBLEM", 195, 222], ["increased", "OBSERVATION_MODIFIER", 198, 207], ["binding signal", "OBSERVATION", 208, 222]]], ["This is in agreement with our MD simulations, predicting that this residue causes repulsive forces (+3.7 kcal mol-1) by interacting with HA.", [["this residue", "PROBLEM", 62, 74], ["repulsive forces", "PROBLEM", 82, 98], ["repulsive forces", "OBSERVATION", 82, 98]]], ["Although the results are essentially consistent with the theoretical predictions, we noticed a deviation: following the microarray results, aspartic acid D8 seems to be essential for binding while the MD simulation assigned it to be repulsive.", [["aspartic acid", "CHEMICAL", 140, 153], ["aspartic acid D8", "CHEMICAL", 140, 156], ["aspartic acid D8", "SIMPLE_CHEMICAL", 140, 156], ["the microarray results", "TEST", 116, 138], ["aspartic acid D8", "PROBLEM", 140, 156], ["consistent with", "UNCERTAINTY", 37, 52]]], ["Notably, for some substitutions of Y11 we observed also an enhanced binding of virus.Improvement of peptides by site-directed substitution ::: ResultsThe microarray approach was applied to other influenza virus strains which are of higher medical relevance (S7 Fig): New York H3N2, Victoria H3N2 and California H1N1.", [["influenza virus", "ORGANISM", 195, 210], ["New York H3N2", "ORGANISM", 267, 280], ["Victoria H3N2", "ORGANISM", 282, 295], ["California H1N1", "ORGANISM", 300, 315], ["influenza virus", "SPECIES", 195, 210], ["Victoria H3N2", "SPECIES", 282, 295], ["California H1N1", "SPECIES", 300, 315], ["influenza virus", "SPECIES", 195, 210], ["Victoria H3N2", "SPECIES", 282, 295], ["some substitutions of Y11", "PROBLEM", 13, 38], ["an enhanced binding of virus", "PROBLEM", 56, 84], ["The microarray approach", "TREATMENT", 150, 173], ["other influenza virus strains", "PROBLEM", 189, 218], ["virus", "OBSERVATION", 79, 84]]], ["Similar as for Aichi H3N2, most substitutions of D6 increased binding of California H1N1 and\u2013although rather marginal\u2014of New York H3N2.", [["Aichi H3N2", "ORGANISM", 15, 25], ["California H1N1", "ORGANISM", 73, 88], ["Aichi H3N2", "SPECIES", 15, 25], ["Aichi H3N2", "PROBLEM", 15, 25]]], ["However, for the latter as well as for Victoria H3N2 substitutions of other residues caused significantly enhanced binding.", [["Victoria H3N2", "ORGANISM", 39, 52], ["Victoria H3N2 substitutions", "TREATMENT", 39, 66], ["other residues", "PROBLEM", 70, 84], ["significantly enhanced binding", "PROBLEM", 92, 122]]], ["For both strains all substitutions of Y11 lead to enhanced affinity.Improvement of peptides by site-directed substitution ::: ResultsVirus binding of selected peptide variants was evaluated by SPR to identify variants with improved binding.", [["Y11", "CHEMICAL", 38, 41], ["Y11", "SIMPLE_CHEMICAL", 38, 41], ["selected peptide variants", "PROBLEM", 150, 175]]], ["Particularly, we were interested in variants showing binding to various influenza virus strains.", [["influenza virus", "ORGANISM", 72, 87], ["various influenza virus strains", "PROBLEM", 64, 95]]], ["To this end, several doubly substituted variants were probed.", [["several doubly substituted variants", "PROBLEM", 13, 48], ["substituted variants", "OBSERVATION", 28, 48]]], ["Based on the results for monosubstituted variants (see above), we have chosen D6 and Y11 for substitution.", [["D6", "PROTEIN", 78, 80], ["monosubstituted variants", "PROBLEM", 25, 49], ["substitution", "TREATMENT", 93, 105]]], ["Fig 6C shows the results for the binding of three virus strains to PeB-Lys and 10 mono- and double-substituted variants.Improvement of peptides by site-directed substitution ::: ResultsThe best variant was PeBGF with the sequence ARDFYGYDVFFYAMD.", [["PeB-Lys", "CHEMICAL", 67, 74], ["Lys", "CHEMICAL", 71, 74], ["PeB-Lys", "SIMPLE_CHEMICAL", 67, 74], ["PeBGF", "GENE_OR_GENE_PRODUCT", 206, 211], ["PeBGF", "PROTEIN", 206, 211], ["Fig 6C", "TEST", 0, 6], ["three virus strains", "PROBLEM", 44, 63], ["PeB-Lys", "TEST", 67, 74], ["mono", "TEST", 82, 86], ["double-substituted variants", "TREATMENT", 92, 119], ["the sequence ARDFYGYDVFFYAMD", "PROBLEM", 217, 245]]], ["The repulsive amino acid D6 (+0.8 kcal mol-1) and the only slightly attractive residue Y11 (-0.1 kcal mol-1) (see MD simulation above) were replaced by G and F, respectively.", [["amino acid", "CHEMICAL", 14, 24], ["amino acid", "CHEMICAL", 14, 24], ["amino acid", "AMINO_ACID", 14, 24], ["The repulsive amino acid D6", "TREATMENT", 0, 27]]], ["Contribution to the total binding free energy change of every amino acid of PeBGF binding to HA of Aichi H3N2 obtained by MD-simulations is shown in Fig 2B.", [["amino acid", "CHEMICAL", 62, 72], ["PeBGF", "CHEMICAL", 76, 81], ["amino acid", "CHEMICAL", 62, 72], ["amino acid", "AMINO_ACID", 62, 72], ["PeBGF", "SIMPLE_CHEMICAL", 76, 81], ["Aichi H3N2", "ORGANISM", 99, 109], ["PeBGF", "PROTEIN", 76, 81], ["Aichi H3N2", "SPECIES", 99, 109], ["the total binding free energy change", "TREATMENT", 16, 52], ["every amino acid", "TREATMENT", 56, 72], ["PeBGF binding", "PROBLEM", 76, 89], ["Aichi H3N2", "PROBLEM", 99, 109]]], ["D6G and Y11F mutations decreased the contribution of free energy changes of these residues (S4 Fig and Discussion).", [["D6G", "GENE_OR_GENE_PRODUCT", 0, 3], ["Y11F", "GENE_OR_GENE_PRODUCT", 8, 12], ["D6G", "TREATMENT", 0, 3], ["Y11F mutations", "TREATMENT", 8, 22], ["free energy", "OBSERVATION", 53, 64]]], ["Y11F alters only moderately its interaction with HA, but it induces a favorable contribution change in the interaction of its neighbor residue phenylalanine 10 with HA.", [["Y11F", "CHEMICAL", 0, 4], ["phenylalanine", "CHEMICAL", 143, 156], ["phenylalanine", "CHEMICAL", 143, 156], ["Y11F", "SIMPLE_CHEMICAL", 0, 4], ["phenylalanine 10", "AMINO_ACID", 143, 159], ["Y11F", "PROTEIN", 0, 4], ["HA", "PROBLEM", 49, 51], ["HA", "PROBLEM", 165, 167], ["moderately", "OBSERVATION_MODIFIER", 17, 27]]], ["The side chain of residue 11 is oriented towards the solvent in PeB, due to its polar property.", [["PeB", "CHEMICAL", 64, 67], ["PeB", "CHEMICAL", 64, 67], ["PeB", "SIMPLE_CHEMICAL", 64, 67], ["the solvent in PeB", "TREATMENT", 49, 67], ["side chain", "OBSERVATION_MODIFIER", 4, 14]]], ["On the other hand, the absence of a -OH group in the residue side chain in PeBGF induces a slight change in the orientation of the loop, tilting now the phenylalanine side chain towards a hydrophobic region of the HA \u03b1-helix, located between residues 160\u2013163.Improvement of peptides by site-directed substitution ::: ResultsThe amount of hemagglutinin bound to PeBGF compared to PeB was 2-, 4- and 20-fold for Aichi H3N2, New York H3N2 and California H1N1, respectively.", [["PeBGF", "CHEMICAL", 75, 80], ["phenylalanine", "CHEMICAL", 153, 166], ["residues 160\u2013163", "CHEMICAL", 242, 258], ["OH", "CHEMICAL", 37, 39], ["phenylalanine", "CHEMICAL", 153, 166], ["PeBGF", "SIMPLE_CHEMICAL", 75, 80], ["\u2013163", "AMINO_ACID", 254, 258], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 338, 351], ["PeBGF", "GENE_OR_GENE_PRODUCT", 361, 366], ["PeB", "GENE_OR_GENE_PRODUCT", 379, 382], ["Aichi H3N2", "ORGANISM", 410, 420], ["New York H3N2", "ORGANISM", 422, 435], ["California H1N1", "ORGANISM", 440, 455], ["PeBGF", "PROTEIN", 75, 80], ["phenylalanine side chain", "PROTEIN", 153, 177], ["hydrophobic region", "PROTEIN", 188, 206], ["HA \u03b1-helix", "PROTEIN", 214, 224], ["hemagglutinin", "PROTEIN", 338, 351], ["PeBGF", "PROTEIN", 361, 366], ["California H1N1", "SPECIES", 440, 455], ["Aichi H3N2", "SPECIES", 410, 420], ["New York H3N2", "SPECIES", 422, 435], ["California H1N1", "SPECIES", 440, 455], ["a -OH group in the residue side chain", "PROBLEM", 34, 71], ["a slight change", "PROBLEM", 89, 104], ["the phenylalanine side chain", "TREATMENT", 149, 177], ["the HA \u03b1-helix", "TREATMENT", 210, 224], ["hemagglutinin bound", "PROBLEM", 338, 357], ["PeBGF", "TEST", 361, 366], ["PeB", "TEST", 379, 382], ["Aichi H3N2", "PROBLEM", 410, 420], ["slight", "OBSERVATION_MODIFIER", 91, 97], ["change", "OBSERVATION_MODIFIER", 98, 104], ["amount", "OBSERVATION_MODIFIER", 328, 334]]], ["Specific binding of PeBGF to the receptor binding site of HA was evidenced by SPR (Fig 6A, Table 2).", [["PeBGF", "GENE_OR_GENE_PRODUCT", 20, 25], ["HA", "GENE_OR_GENE_PRODUCT", 58, 60], ["PeBGF", "PROTEIN", 20, 25], ["receptor binding site", "DNA", 33, 54], ["HA", "PROTEIN", 58, 60], ["HA", "PROBLEM", 58, 60]]], ["Compared to PeB, PeBGF showed a 6-fold lower IC50 (13 \u03bcM vs 75 \u03bcM) for inhibition of Aichi H3N2 binding to a fetuin-immobilized SPR surface.", [["surface", "ANATOMY", 132, 139], ["PeBGF", "CHEMICAL", 17, 22], ["PeBGF", "SIMPLE_CHEMICAL", 17, 22], ["Aichi H3N2", "ORGANISM", 85, 95], ["fetuin", "GENE_OR_GENE_PRODUCT", 109, 115], ["PeB", "PROTEIN", 12, 15], ["fetuin", "PROTEIN", 109, 115], ["Aichi H3N2", "SPECIES", 85, 95], ["PeB", "TEST", 12, 15], ["PeBGF", "TEST", 17, 22], ["\u03bcM", "TEST", 54, 56], ["Aichi H3N2 binding", "PROBLEM", 85, 103], ["a fetuin-immobilized SPR surface", "TREATMENT", 107, 139], ["Aichi H3N2", "OBSERVATION", 85, 95]]], ["For PeB we observed a minor tendency to bind to immobilized fetuin, which becomes obvious from calculated inhibition values higher than 100%.Peptide mediated inhibition of virus infection ::: ResultsTo characterize the potential of antibody derived peptides to prevent virus replication, we studied virus binding and infection of host cells in the presence of PeB, PeBGF and PeBP.", [["cells", "ANATOMY", 335, 340], ["infection", "DISEASE", 178, 187], ["infection", "DISEASE", 317, 326], ["PeB", "CHEMICAL", 360, 363], ["PeBGF", "CHEMICAL", 365, 370], ["PeBP", "CHEMICAL", 375, 379], ["PeB", "SIMPLE_CHEMICAL", 4, 7], ["fetuin", "GENE_OR_GENE_PRODUCT", 60, 66], ["host cells", "CELL", 330, 340], ["PeB", "SIMPLE_CHEMICAL", 360, 363], ["PeBGF", "SIMPLE_CHEMICAL", 365, 370], ["PeBP", "SIMPLE_CHEMICAL", 375, 379], ["PeB", "PROTEIN", 4, 7], ["host cells", "CELL_TYPE", 330, 340], ["PeB", "PROTEIN", 360, 363], ["PeBGF", "PROTEIN", 365, 370], ["PeBP", "PROTEIN", 375, 379], ["PeB", "TREATMENT", 4, 7], ["a minor tendency", "PROBLEM", 20, 36], ["immobilized fetuin", "PROBLEM", 48, 66], ["calculated inhibition values", "TEST", 95, 123], ["Peptide mediated inhibition of virus infection", "PROBLEM", 141, 187], ["antibody derived peptides", "TREATMENT", 232, 257], ["virus replication", "PROBLEM", 269, 286], ["virus binding", "PROBLEM", 299, 312], ["infection of host cells", "PROBLEM", 317, 340], ["PeB", "TREATMENT", 360, 363], ["PeBGF", "TREATMENT", 365, 370], ["PeBP", "TREATMENT", 375, 379], ["virus infection", "OBSERVATION", 172, 187], ["host cells", "OBSERVATION", 330, 340]]], ["The latter is assumed to be a structurally distinct variant due to the presence of a proline residue, used as a negative control.", [["proline", "CHEMICAL", 85, 92], ["proline", "CHEMICAL", 85, 92], ["a structurally distinct variant", "PROBLEM", 28, 59], ["a proline residue", "PROBLEM", 83, 100], ["assumed to be", "UNCERTAINTY", 14, 27], ["proline residue", "OBSERVATION", 85, 100]]], ["Both PeB and PeBGF efficiently prevented Aichi H3N2 mediated aggregation of red blood cells (RBC) as assessed by HAI (Fig 7A).", [["red blood cells", "ANATOMY", 76, 91], ["RBC", "ANATOMY", 93, 96], ["PeB", "CHEMICAL", 5, 8], ["PeBGF", "CHEMICAL", 13, 18], ["PeBGF", "CHEMICAL", 13, 18], ["PeB", "GENE_OR_GENE_PRODUCT", 5, 8], ["PeBGF", "SIMPLE_CHEMICAL", 13, 18], ["Aichi H3N2", "ORGANISM", 41, 51], ["red blood cells", "CELL", 76, 91], ["RBC", "CELL", 93, 96], ["PeB", "PROTEIN", 5, 8], ["PeBGF", "PROTEIN", 13, 18], ["red blood cells", "CELL_TYPE", 76, 91], ["RBC", "CELL_TYPE", 93, 96], ["Aichi H3N2", "SPECIES", 41, 51], ["Aichi H3N2", "TREATMENT", 41, 51], ["red blood cells", "TEST", 76, 91], ["RBC", "TEST", 93, 96]]], ["However, PeBGF was much more efficient in comparison to PeB.", [["PeBGF", "CHEMICAL", 9, 14], ["PeB.", "CHEMICAL", 56, 60], ["PeBGF", "GENE_OR_GENE_PRODUCT", 9, 14], ["PeBGF", "PROTEIN", 9, 14], ["PeB.", "SPECIES", 56, 60], ["PeBGF", "TEST", 9, 14]]], ["The inhibitory constant Ki(HAI) was 235 \u03bcM and 31.9 \u03bcM for PeB and PeBGF, respectively.", [["PeBGF", "CHEMICAL", 67, 72], ["PeB", "SIMPLE_CHEMICAL", 59, 62], ["PeB", "PROTEIN", 59, 62], ["PeBGF", "PROTEIN", 67, 72], ["PeB and PeBGF", "TREATMENT", 59, 72]]], ["Furthermore, we could show binding inhibition of Rostock H7N1 virus to turkey erythrocytes at Ki(HAI) values of 47 \u03bcM for PeB and 23 \u03bcM for PeBGF (Table 2).", [["erythrocytes", "ANATOMY", 78, 90], ["Rostock H7N1 virus", "ORGANISM", 49, 67], ["turkey", "ORGANISM", 71, 77], ["erythrocytes", "CELL", 78, 90], ["turkey erythrocytes", "CELL_TYPE", 71, 90], ["turkey", "SPECIES", 71, 77], ["Rostock H7N1 virus", "SPECIES", 49, 67], ["turkey", "SPECIES", 71, 77], ["Rostock H7N1 virus", "TREATMENT", 49, 67], ["PeB", "TREATMENT", 122, 125]]], ["Hemagglutination by both viral strains was not inhibited by PeBP.Peptide mediated inhibition of virus infection ::: ResultsBoth peptides also protected efficiently MDCK II cell from infection (MOI 0.05) by Aichi H3N2 (Fig 7B) and Rostock H7N1 (Fig 7C).", [["MDCK II cell", "ANATOMY", 164, 176], ["Hemagglutination", "DISEASE", 0, 16], ["PeBP", "CHEMICAL", 60, 64], ["infection", "DISEASE", 102, 111], ["MDCK II", "CHEMICAL", 164, 171], ["infection", "DISEASE", 182, 191], ["PeBP", "CHEMICAL", 60, 64], ["PeBP", "SIMPLE_CHEMICAL", 60, 64], ["MDCK II cell", "CELL", 164, 176], ["Aichi H3N2", "ORGANISM", 206, 216], ["PeBP", "PROTEIN", 60, 64], ["MDCK II cell", "CELL_LINE", 164, 176], ["Aichi H3N2", "SPECIES", 206, 216], ["Rostock H7N1 (Fig 7C", "SPECIES", 230, 250], ["Hemagglutination", "TEST", 0, 16], ["both viral strains", "PROBLEM", 20, 38], ["Peptide mediated inhibition of virus infection", "PROBLEM", 65, 111], ["ResultsBoth peptides", "TEST", 116, 136], ["infection", "PROBLEM", 182, 191], ["viral strains", "OBSERVATION", 25, 38], ["virus infection", "OBSERVATION", 96, 111], ["II cell", "OBSERVATION_MODIFIER", 169, 176], ["infection", "OBSERVATION", 182, 191]]], ["PeBP did not compromise the infection at all.", [["PeBP", "CHEMICAL", 0, 4], ["infection", "DISEASE", 28, 37], ["PeBP", "CHEMICAL", 0, 4], ["PeBP", "SIMPLE_CHEMICAL", 0, 4], ["the infection", "PROBLEM", 24, 37], ["infection", "OBSERVATION", 28, 37]]], ["Importantly, all three peptides did not impair cell viability within 24 h treatment with peptides up to the maximum concentration (400 \u03bcM) studied (S8 Fig).Peptide mediated inhibition of virus infection ::: ResultsSimilar results were obtained from a microneutralization assay, in which the peptide inhibitors are present in solution throughout the whole 24 h incubation (Fig 7D and 7E and Table 2).", [["cell", "ANATOMY", 47, 51], ["infection", "DISEASE", 193, 202], ["cell", "CELL", 47, 51], ["impair cell viability", "PROBLEM", 40, 61], ["peptides", "TREATMENT", 89, 97], ["the maximum concentration", "TEST", 104, 129], ["Peptide mediated inhibition of virus infection", "PROBLEM", 156, 202], ["a microneutralization assay", "TEST", 249, 276], ["the peptide inhibitors", "TREATMENT", 287, 309], ["cell viability", "OBSERVATION", 47, 61], ["virus infection", "OBSERVATION", 187, 202]]], ["Here, viral nucleoprotein expression was detected by immunostaining of infected cells, and the results were compared to untreated, infected cells.", [["cells", "ANATOMY", 80, 85], ["cells", "ANATOMY", 140, 145], ["cells", "CELL", 80, 85], ["cells", "CELL", 140, 145], ["infected cells", "CELL_TYPE", 71, 85], ["infected cells", "CELL_TYPE", 131, 145], ["viral nucleoprotein expression", "PROBLEM", 6, 36], ["infected cells", "PROBLEM", 71, 85], ["infected cells", "PROBLEM", 131, 145], ["viral", "OBSERVATION", 6, 11], ["nucleoprotein expression", "OBSERVATION", 12, 36], ["infected cells", "OBSERVATION", 71, 85], ["infected cells", "OBSERVATION", 131, 145]]], ["The IC50 values of Rostock H7N1 were similar to that obtained by the MTS based infection inhibition assay.", [["MTS", "CHEMICAL", 69, 72], ["infection", "DISEASE", 79, 88], ["MTS", "CHEMICAL", 69, 72], ["Rostock H7N1", "SPECIES", 19, 31], ["The IC50 values", "TEST", 0, 15], ["Rostock H7N1", "TEST", 19, 31], ["the MTS based infection inhibition assay", "PROBLEM", 65, 105], ["infection", "OBSERVATION", 79, 88]]], ["However, the IC50 values for Aichi H3N2 were somewhat lower (3\u20135 fold) with respect to the MTS assay.Peptide mediated inhibition of virus infection ::: ResultsAlthough micromolar IC50 values seem to be rather high concentrations from the point of view of medical applications, the results are very promising for developing multivalent inhibitors (see Discussion).Peptide mediated inhibition of virus infection ::: ResultsTo evaluate the inhibitory potential of the antibody derived peptides in relation to that of already published HA binding peptides, we compared these peptides in the HAI assay (Fig 8) [16\u201318, 20, 45].", [["infection", "DISEASE", 138, 147], ["infection", "DISEASE", 400, 409], ["MTS", "CHEMICAL", 91, 94], ["Aichi H3N2", "ORGANISM", 29, 39], ["Aichi H3N2", "SPECIES", 29, 39], ["the IC50 values", "TEST", 9, 24], ["Aichi H3N2", "PROBLEM", 29, 39], ["the MTS assay", "TEST", 87, 100], ["Peptide mediated inhibition of virus infection", "PROBLEM", 101, 147], ["micromolar IC50 values", "TEST", 168, 190], ["multivalent inhibitors", "TREATMENT", 323, 345], ["Peptide mediated inhibition of virus infection", "PROBLEM", 363, 409], ["the antibody derived peptides", "PROBLEM", 461, 490], ["already published HA binding peptides", "PROBLEM", 514, 551], ["these peptides", "TEST", 565, 579], ["the HAI assay", "TEST", 583, 596], ["lower", "OBSERVATION_MODIFIER", 54, 59], ["virus infection", "OBSERVATION", 132, 147], ["virus infection", "OBSERVATION", 394, 409]]], ["We normalized Ki(HAI) values to that of 2,6-sialyllactose as the natural receptor for H3.", [["2,6-sialyllactose", "CHEMICAL", 40, 57], ["2,6-sialyllactose", "CHEMICAL", 40, 57], ["2,6-sialyllactose", "SIMPLE_CHEMICAL", 40, 57], ["H3", "GENE_OR_GENE_PRODUCT", 86, 88], ["H3", "PROTEIN", 86, 88], ["sialyllactose", "TREATMENT", 44, 57], ["H3", "PROBLEM", 86, 88]]], ["With reduction of Ki(HAI) by 200 and 1600 fold, PeB respectively PeBGF showed superior potential compared to other published peptides, with the exception of the \u201centry blocker\u201d EB.", [["PeBGF", "CHEMICAL", 65, 70], ["PeBGF", "CHEMICAL", 65, 70], ["PeBGF", "SIMPLE_CHEMICAL", 65, 70], ["PeB", "PROTEIN", 48, 51], ["PeBGF", "PROTEIN", 65, 70], ["PeB respectively PeBGF", "TEST", 48, 70], ["reduction", "OBSERVATION_MODIFIER", 5, 14]]], ["As in previous experiments, peptide PeBGF showed an higher inhibitory potency than PeB as observed by its 8-fold lower Ki(HAI).", [["PeBGF", "CHEMICAL", 36, 41], ["PeB", "CHEMICAL", 83, 86], ["PeBGF", "SIMPLE_CHEMICAL", 36, 41], ["PeB", "SIMPLE_CHEMICAL", 83, 86], ["peptide PeBGF", "TEST", 28, 41]]], ["Additionally both peptides showed lower Ki(HAI)-values than peptides obtained by phage display against H3N2 (s2(1\u20135)), H5N1 and H9N2.", [["H5N1 and H9N2", "DISEASE", 119, 132], ["H3N2", "ORGANISM", 103, 107], ["s2(1\u20135)", "ORGANISM", 109, 116], ["H5N1", "ORGANISM", 119, 123], ["H9N2", "ORGANISM", 128, 132], ["H9N2", "SPECIES", 128, 132], ["both peptides", "TEST", 13, 26], ["lower Ki(HAI)", "PROBLEM", 34, 47], ["H3N2", "PROBLEM", 103, 107], ["H5N1", "PROBLEM", 119, 123], ["H9N2", "TREATMENT", 128, 132], ["lower Ki", "OBSERVATION_MODIFIER", 34, 42]]], ["Only the entry blocker EB showed superior hemagglutination inhibition, revealed by its 20-fold lower Ki(HAI) as compared to PeBGF.", [["EB", "CHEMICAL", 23, 25], ["PeBGF", "CHEMICAL", 124, 129], ["EB", "SIMPLE_CHEMICAL", 23, 25], ["PeBGF", "GENE_OR_GENE_PRODUCT", 124, 129], ["PeBGF", "PROTEIN", 124, 129], ["the entry blocker EB", "TEST", 5, 25], ["superior hemagglutination inhibition", "PROBLEM", 33, 69], ["PeBGF", "TEST", 124, 129], ["superior", "OBSERVATION_MODIFIER", 33, 41], ["hemagglutination inhibition", "OBSERVATION", 42, 69]]], ["However, due to its amphiphilic character, EB forms micelles and thus may act in a multivalent manner [45].", [["EB", "CHEMICAL", 43, 45], ["EB", "SIMPLE_CHEMICAL", 43, 45], ["its amphiphilic character", "PROBLEM", 16, 41]]], ["Therefore, it inhibits Aichi H3N2 hemagglutination more efficiently than other monovalent peptides.Peptide mediated inhibition of virus infection ::: ResultsFor the sake of completeness we mention that Mucroporin M-1 showed strong hemolytic effects and strong interference with gold surfaces, which made it impossible to obtain reliable data [20].Selection of antibody-derived peptides ::: DiscussionOur aim was to obtain peptide inhibitors that recognize the conserved region of the sialic acid binding pocket of HA with a broader specificity to cover several influenza virus strains.", [["infection", "DISEASE", 136, 145], ["Mucroporin M-1", "CHEMICAL", 202, 216], ["hemolytic", "DISEASE", 231, 240], ["sialic acid", "CHEMICAL", 484, 495], ["sialic acid", "CHEMICAL", 484, 495], ["Aichi H3N2", "ORGANISM", 23, 33], ["sialic acid", "AMINO_ACID", 484, 495], ["influenza virus", "ORGANISM", 561, 576], ["sialic acid binding pocket", "PROTEIN", 484, 510], ["Aichi H3N2", "SPECIES", 23, 33], ["Aichi H3N2 hemagglutination", "PROBLEM", 23, 50], ["monovalent peptides", "TREATMENT", 79, 98], ["Peptide mediated inhibition of virus infection", "PROBLEM", 99, 145], ["Mucroporin M", "TEST", 202, 214], ["strong hemolytic effects", "PROBLEM", 224, 248], ["Selection of antibody", "TEST", 347, 368], ["peptide inhibitors", "TREATMENT", 422, 440], ["the sialic acid binding pocket", "PROBLEM", 480, 510], ["HA", "PROBLEM", 514, 516], ["several influenza virus strains", "PROBLEM", 553, 584], ["Aichi H3N2", "OBSERVATION", 23, 33], ["virus infection", "OBSERVATION", 130, 145], ["hemolytic", "OBSERVATION", 231, 240], ["sialic acid", "OBSERVATION", 484, 495], ["binding pocket", "OBSERVATION", 496, 510], ["influenza virus strains", "OBSERVATION", 561, 584]]], ["The three CDRs of the VH-chain of antibody HC19 against hemagglutinin of influenza virus Aichi H3N2 were used as templates to design peptides being a potential inhibitor of virus binding to host cells.", [["cells", "ANATOMY", 195, 200], ["HC19", "CHEMICAL", 43, 47], ["hemagglutinin of", "ORGANISM", 56, 72], ["influenza virus Aichi H3N2", "ORGANISM", 73, 99], ["host cells", "CELL", 190, 200], ["VH-chain", "PROTEIN", 22, 30], ["antibody HC19", "PROTEIN", 34, 47], ["hemagglutinin", "PROTEIN", 56, 69], ["host cells", "CELL_TYPE", 190, 200], ["influenza virus Aichi H3N2", "SPECIES", 73, 99], ["influenza virus Aichi H3N2", "SPECIES", 73, 99], ["antibody HC19", "TREATMENT", 34, 47], ["hemagglutinin", "PROBLEM", 56, 69], ["influenza virus Aichi H3N2", "PROBLEM", 73, 99], ["design peptides", "PROBLEM", 126, 141], ["virus binding", "PROBLEM", 173, 186]]], ["We used complementary experimental approaches as SPR and peptide microarrays, and MD to select appropriate peptides and to enhance their affinity to HA by site directed substitutions of amino acids.", [["amino acids", "CHEMICAL", 186, 197], ["amino acids", "CHEMICAL", 186, 197], ["HA", "GENE_OR_GENE_PRODUCT", 149, 151], ["amino acids", "AMINO_ACID", 186, 197], ["complementary experimental approaches", "TREATMENT", 8, 45], ["SPR and peptide microarrays", "TREATMENT", 49, 76], ["amino acids", "TREATMENT", 186, 197]]], ["This was validated by assessing their potential to prevent virus binding to cell surfaces and, eventually, infection of host cells.Selection of antibody-derived peptides ::: DiscussionThree peptides\u2013PeA, PeB and PeC\u2013have been derived from the three CDR sequences of the HC19 antibody\u2019s heavy chain.", [["cell surfaces", "ANATOMY", 76, 89], ["cells", "ANATOMY", 125, 130], ["infection", "DISEASE", 107, 116], ["PeB", "CHEMICAL", 204, 207], ["PeC\u2013have", "CHEMICAL", 212, 220], ["cell", "CELL", 76, 80], ["host cells", "CELL", 120, 130], ["peptides\u2013PeA", "SIMPLE_CHEMICAL", 190, 202], ["PeB", "SIMPLE_CHEMICAL", 204, 207], ["host cells", "CELL_TYPE", 120, 130], ["PeA", "PROTEIN", 199, 202], ["PeB", "PROTEIN", 204, 207], ["PeC\u2013have", "PROTEIN", 212, 220], ["CDR sequences", "DNA", 249, 262], ["HC19 antibody\u2019s heavy chain", "PROTEIN", 270, 297], ["virus binding", "PROBLEM", 59, 72], ["infection of host cells", "PROBLEM", 107, 130], ["Selection of antibody", "TEST", 131, 152], ["the three CDR sequences", "TEST", 239, 262], ["infection", "OBSERVATION", 107, 116], ["host cells", "OBSERVATION", 120, 130]]], ["In agreement with predictions from our MD calculations of peptide-HA complexes, we found by SPR experiments that binding of surface immobilized peptide PeB to HA from Aichi H3N2 was superior to PeC (Fig 3).", [["surface", "ANATOMY", 124, 131], ["PeB", "CHEMICAL", 152, 155], ["surface", "CELLULAR_COMPONENT", 124, 131], ["Aichi H3N2", "ORGANISM", 167, 177], ["HA complexes", "PROTEIN", 66, 78], ["Aichi H3N2", "SPECIES", 167, 177], ["HA complexes", "PROBLEM", 66, 78], ["surface immobilized peptide", "TREATMENT", 124, 151], ["HA", "PROBLEM", 159, 161], ["Aichi H3N2", "TREATMENT", 167, 177]]], ["Therefore, and as PeB matches the conserved sialic acid binding site better than PeC (PDB 2vir) [46], subsequent studies were performed with PeB and its derivatives.", [["sialic acid", "CHEMICAL", 44, 55], ["PeB", "CHEMICAL", 141, 144], ["sialic acid", "CHEMICAL", 44, 55], ["PeB", "CHEMICAL", 141, 144], ["PeB", "GENE_OR_GENE_PRODUCT", 18, 21], ["sialic acid", "AMINO_ACID", 44, 55], ["PeC", "SIMPLE_CHEMICAL", 81, 84], ["PeB", "SIMPLE_CHEMICAL", 141, 144], ["PeB", "PROTEIN", 18, 21], ["sialic acid binding site", "PROTEIN", 44, 68], ["PeC", "PROTEIN", 81, 84], ["the conserved sialic acid binding site", "PROBLEM", 30, 68], ["subsequent studies", "TEST", 102, 120], ["PeB", "TREATMENT", 141, 144], ["its derivatives", "TREATMENT", 149, 164], ["sialic acid", "OBSERVATION", 44, 55]]], ["Inhibition of virus binding to surface immobilized fetuin and 2,6\u2019-sialyllactose by PeB confirmed the specific binding of the peptides to the sialic acid binding pocket of HA.", [["surface", "ANATOMY", 31, 38], ["2,6\u2019-sialyllactose", "CHEMICAL", 62, 80], ["PeB", "CHEMICAL", 84, 87], ["sialic acid", "CHEMICAL", 142, 153], ["2,6\u2019-sialyllactose", "CHEMICAL", 62, 80], ["PeB", "CHEMICAL", 84, 87], ["sialic acid", "CHEMICAL", 142, 153], ["fetuin", "GENE_OR_GENE_PRODUCT", 51, 57], ["2,6\u2019-sialyllactose", "SIMPLE_CHEMICAL", 62, 80], ["PeB", "SIMPLE_CHEMICAL", 84, 87], ["sialic acid", "SIMPLE_CHEMICAL", 142, 153], ["PeB", "PROTEIN", 84, 87], ["sialic acid binding pocket", "PROTEIN", 142, 168], ["virus binding", "PROBLEM", 14, 27], ["fetuin", "TEST", 51, 57], ["the sialic acid binding pocket of HA", "PROBLEM", 138, 174], ["virus", "OBSERVATION", 14, 19]]], ["The IC50 values are in the range of 75\u2013120 \u03bcM, depending on the assay, which is about one order of magnitude lower than the IC50 of \u03b1-2,6-sialyllactose.Selection of antibody-derived peptides ::: DiscussionAn important observation which may be also of interest for upcoming studies is that we found specific binding of viruses to surface immobilized peptides consisting only of amino acids representing the PeB core sequence, and a four lysine long linker (Fig 3).", [["surface", "ANATOMY", 329, 336], ["\u03b1-2,6-sialyllactose", "CHEMICAL", 132, 151], ["amino acids", "CHEMICAL", 377, 388], ["\u03b1-2,6-sialyllactose", "CHEMICAL", 132, 151], ["amino acids", "CHEMICAL", 377, 388], ["lysine", "CHEMICAL", 436, 442], ["\u03b1-2,6-sialyllactose", "SIMPLE_CHEMICAL", 132, 151], ["amino acids", "AMINO_ACID", 377, 388], ["PeB core sequence", "PROTEIN", 406, 423], ["lysine long linker", "PROTEIN", 436, 454], ["The IC50 values", "TEST", 0, 15], ["the assay", "TEST", 60, 69], ["the IC50", "TEST", 120, 128], ["Selection of antibody", "TEST", 152, 173], ["upcoming studies", "TEST", 264, 280], ["surface immobilized peptides", "TREATMENT", 329, 357], ["amino acids", "TREATMENT", 377, 388], ["the PeB core sequence", "TREATMENT", 402, 423], ["a four lysine long linker (Fig", "TREATMENT", 429, 459], ["IC50 values", "OBSERVATION_MODIFIER", 4, 15], ["viruses", "OBSERVATION", 318, 325]]], ["Nevertheless, PeB and its derivatives harboring only those amino acids which are essential for the recognition of SA are presumably not efficient binders in their monomeric form.", [["PeB", "CHEMICAL", 14, 17], ["amino acids", "CHEMICAL", 59, 70], ["SA", "CHEMICAL", 114, 116], ["PeB", "CHEMICAL", 14, 17], ["amino acids", "CHEMICAL", 59, 70], ["PeB", "SIMPLE_CHEMICAL", 14, 17], ["amino acids", "AMINO_ACID", 59, 70], ["SA", "GENE_OR_GENE_PRODUCT", 114, 116], ["PeB", "TREATMENT", 14, 17], ["those amino acids", "TREATMENT", 53, 70], ["SA", "PROBLEM", 114, 116]]], ["The affinities of the peptides are in the micromolar range, whereas the reported KD value of antibody HC19 binding to hemagglutinin from Aichi H3N2 is 28 \u00b1 8 nM [47].", [["HC19", "GENE_OR_GENE_PRODUCT", 102, 106], ["Aichi H3N2", "ORGANISM", 137, 147], ["antibody HC19", "PROTEIN", 93, 106], ["hemagglutinin", "PROTEIN", 118, 131], ["Aichi H3N2", "SPECIES", 137, 147], ["KD value", "TEST", 81, 89], ["antibody HC19 binding", "PROBLEM", 93, 114], ["hemagglutinin", "TEST", 118, 131], ["Aichi H3N2", "TEST", 137, 147]]], ["However, weak binding interactions for such shorter monomeric peptides could be enhanced by a multivalent interaction as it occurs very likely in the SPR based experiments, where binding of even 6.5\u2219108 viruses ml-1 to immobilized PeB could be detected (Fig 3).", [["PeB", "GENE_OR_GENE_PRODUCT", 231, 234], ["PeB", "PROTEIN", 231, 234], ["weak binding interactions", "PROBLEM", 9, 34], ["such shorter monomeric peptides", "PROBLEM", 39, 70], ["immobilized PeB", "TREATMENT", 219, 234]]], ["Extensions of the C- and N-termini of the CDR sequences could be important for (i) the formation of a stable peptide structure, which exposes the CDR loop region in its native arrangement or (ii) direct involvement in binding and foster interaction with HA.Substitutional analysis and improvement of binding affinity of PeB ::: DiscussionAccording to the MD simulations PeB adopts a strand-loop-strand conformation with the loop consisting of residues D6 to Y11.", [["PeB", "CHEMICAL", 370, 373], ["C", "CHEMICAL", 18, 19], ["N", "CHEMICAL", 25, 26], ["PeB", "SIMPLE_CHEMICAL", 320, 323], ["C- and N-termini", "PROTEIN", 18, 34], ["CDR sequences", "DNA", 42, 55], ["CDR loop region", "PROTEIN", 146, 161], ["HA", "PROTEIN", 254, 256], ["PeB", "PROTEIN", 320, 323], ["Y11", "PROTEIN", 458, 461], ["the CDR sequences", "TEST", 38, 55], ["a stable peptide structure", "PROBLEM", 100, 126], ["HA", "PROBLEM", 254, 256], ["Substitutional analysis", "TEST", 257, 280], ["a strand-loop-strand conformation", "TREATMENT", 381, 414], ["stable", "OBSERVATION_MODIFIER", 102, 108], ["peptide structure", "OBSERVATION", 109, 126], ["CDR loop", "OBSERVATION", 146, 154], ["native", "OBSERVATION_MODIFIER", 169, 175], ["arrangement", "OBSERVATION_MODIFIER", 176, 187]]], ["As shown in Fig 2B, residues within and adjacent to the loop (Y5 to Y12) include the residues yielding the largest contributions to the binding free energy.", [["Y5 to Y12", "PROTEIN", 62, 71], ["the residues", "PROBLEM", 81, 93], ["Fig 2B", "OBSERVATION", 12, 18], ["loop", "ANATOMY_MODIFIER", 56, 60], ["largest", "OBSERVATION_MODIFIER", 107, 114], ["free energy", "OBSERVATION", 144, 155]]], ["Most of these contributions are attractive (negative free energies changes) but some are also repulsive (positive free energies changes).", [["positive free energies changes", "PROBLEM", 105, 135], ["repulsive", "OBSERVATION_MODIFIER", 94, 103], ["free energies", "OBSERVATION", 114, 127]]], ["The contributions of each amino acid to the free energy calculated by MM-PBSA were largely consistent with the results of microarray-based substitutional analysis, despite the described discrepancy for D8.", [["amino acid", "CHEMICAL", 26, 36], ["amino acid", "CHEMICAL", 26, 36], ["amino acid", "AMINO_ACID", 26, 36], ["D8", "PROTEIN", 202, 204], ["each amino acid", "TEST", 21, 36], ["microarray-based substitutional analysis", "TEST", 122, 162], ["consistent with", "UNCERTAINTY", 91, 106]]], ["Possibly, substitution of D8 changes the secondary structure leading to a lower affinity.Substitutional analysis and improvement of binding affinity of PeB ::: DiscussionIn the light of improving the affinity of PeB and to enable a broader specificity we also probed the binding of the peptide to HA of other virus strains by microarray-based substitutional analysis.", [["PeB", "CHEMICAL", 212, 215], ["PeB", "SIMPLE_CHEMICAL", 152, 155], ["PeB", "SIMPLE_CHEMICAL", 212, 215], ["PeB", "PROTEIN", 152, 155], ["PeB", "PROTEIN", 212, 215], ["a lower affinity", "PROBLEM", 72, 88], ["Substitutional analysis", "TEST", 89, 112], ["PeB", "TREATMENT", 212, 215], ["other virus strains", "PROBLEM", 303, 322], ["microarray-based substitutional analysis", "TEST", 326, 366], ["secondary structure", "OBSERVATION", 41, 60], ["lower affinity", "OBSERVATION", 74, 88]]], ["We identified that Y11 is also an important residue for improving binding.", [["Y11", "GENE_OR_GENE_PRODUCT", 19, 22]]], ["Based on that, we investigated the affinity of selected variants of PeB having two substitutions.", [["PeB", "GENE_OR_GENE_PRODUCT", 68, 71], ["PeB", "PROTEIN", 68, 71]]], ["In this screen, we identified PeBGF as the best binder.", [["PeBGF", "GENE_OR_GENE_PRODUCT", 30, 35], ["PeBGF", "PROTEIN", 30, 35]]], ["The two substitutions, D6G and Y11F, altered the ligand moiety and its binding contacts, resulting in favorable changes to the contribution to the free energy change of residues 6, 8 and 10 (Fig 2B).", [["residues 6, 8 and 10", "PROTEIN", 169, 189], ["D6G", "TREATMENT", 23, 26], ["Y11F", "TREATMENT", 31, 35], ["altered the ligand moiety", "PROBLEM", 37, 62], ["substitutions", "OBSERVATION_MODIFIER", 8, 21], ["ligand moiety", "OBSERVATION", 49, 62]]], ["The mutation of residue 6 (D6G), replacing a charged amino acid by a neutral one, resulted in two major changes.", [["amino acid", "CHEMICAL", 53, 63], ["amino acid", "CHEMICAL", 53, 63], ["amino acid", "AMINO_ACID", 53, 63], ["The mutation of residue", "PROBLEM", 0, 23], ["a charged amino acid", "TREATMENT", 43, 63], ["major", "OBSERVATION_MODIFIER", 98, 103], ["changes", "OBSERVATION", 104, 111]]], ["Firstly, it induces a decrease of its own electrostatic contribution to the binding free energy, but such a change is largely overcome by an increase in the contribution to the polar solvation free energy change (S3 Fig).", [["the binding free energy", "PROBLEM", 72, 95], ["decrease", "OBSERVATION_MODIFIER", 22, 30], ["increase", "OBSERVATION_MODIFIER", 141, 149]]], ["On the other hand, one should notice that residues 6 and 8 are located in close contact to each other in the loop region.", [["loop region", "PROTEIN", 109, 120], ["loop", "OBSERVATION", 109, 113]]], ["As a consequence for PeB, this involves repulsive interaction between two negatively charged residues (D6 and D8).", [["PeB", "SIMPLE_CHEMICAL", 21, 24], ["PeB", "PROTEIN", 21, 24], ["D8", "PROTEIN", 110, 112], ["PeB", "TREATMENT", 21, 24], ["repulsive", "OBSERVATION", 40, 49]]], ["The replacement of D6 by an uncharged residue in PeBGF probably induces a slight reorganization in the loop structure, favoring van der Waals and polar solvation interaction contributions between this residue and the HA moieties (S3 Fig).Inhibition of virus binding and infection by peptides ::: DiscussionDue to its orientation towards the SA binding region of HA, CDR3 sequences of antibody HC19 [26, 27] against HA of Aichi H3N2 are promising candidates for getting variants with broad influenza strain specificities.", [["PeBGF", "CHEMICAL", 49, 54], ["infection", "DISEASE", 270, 279], ["PeBGF", "CHEMICAL", 49, 54], ["PeBGF", "SIMPLE_CHEMICAL", 49, 54], ["Aichi H3N2", "ORGANISM", 421, 431], ["D6", "PROTEIN", 19, 21], ["PeBGF", "PROTEIN", 49, 54], ["SA binding region", "DNA", 341, 358], ["CDR3 sequences", "DNA", 366, 380], ["Aichi H3N2", "SPECIES", 421, 431], ["Aichi H3N2", "SPECIES", 421, 431], ["The replacement of D6", "TREATMENT", 0, 21], ["an uncharged residue in PeBGF", "PROBLEM", 25, 54], ["a slight reorganization in the loop structure", "PROBLEM", 72, 117], ["van der Waals and polar solvation interaction", "TREATMENT", 128, 173], ["this residue", "PROBLEM", 196, 208], ["the HA moieties", "PROBLEM", 213, 228], ["virus binding", "PROBLEM", 252, 265], ["infection", "PROBLEM", 270, 279], ["HA", "PROBLEM", 362, 364], ["CDR3 sequences", "TEST", 366, 380], ["antibody HC19", "TEST", 384, 397], ["HA", "PROBLEM", 415, 417], ["Aichi H3N2", "PROBLEM", 421, 431], ["broad influenza strain specificities", "PROBLEM", 483, 519], ["replacement", "OBSERVATION", 4, 15], ["uncharged residue", "OBSERVATION", 28, 45], ["slight", "OBSERVATION_MODIFIER", 74, 80], ["reorganization", "OBSERVATION", 81, 95], ["loop structure", "OBSERVATION", 103, 117], ["polar solvation", "OBSERVATION", 146, 161], ["virus binding", "OBSERVATION", 252, 265], ["infection", "OBSERVATION", 270, 279]]], ["Indeed, both peptides PeB and PeBGF were found to bind to HA of other strains (Rostock H7N1, New York H3N2, and California H1N1).", [["PeB", "CHEMICAL", 22, 25], ["PeBGF", "CHEMICAL", 30, 35], ["PeB", "GENE_OR_GENE_PRODUCT", 22, 25], ["PeBGF", "GENE_OR_GENE_PRODUCT", 30, 35], ["Rostock H7N1", "ORGANISM", 79, 91], ["New York H3N2", "ORGANISM", 93, 106], ["California H1N1", "ORGANISM", 112, 127], ["PeBGF", "PROTEIN", 30, 35], ["California H1N1", "SPECIES", 112, 127], ["Rostock H7N1", "SPECIES", 79, 91], ["New York H3N2", "SPECIES", 93, 106], ["other strains", "PROBLEM", 64, 77]]], ["It is worth to note that all HAs of different influenza subtypes, which could be bound and inhibited by peptides PeB or PeBGF reveal strong structural similarities, especially for those amino acids involved in peptide binding (S2 Table).", [["influenza", "DISEASE", 46, 55], ["PeB", "CHEMICAL", 113, 116], ["PeBGF", "CHEMICAL", 120, 125], ["amino acids", "CHEMICAL", 186, 197], ["amino acids", "CHEMICAL", 186, 197], ["PeB", "GENE_OR_GENE_PRODUCT", 113, 116], ["PeBGF", "GENE_OR_GENE_PRODUCT", 120, 125], ["amino acids", "AMINO_ACID", 186, 197], ["different influenza subtypes", "PROBLEM", 36, 64], ["peptides PeB or PeBGF", "TEST", 104, 125], ["those amino acids", "TEST", 180, 197], ["influenza", "OBSERVATION", 46, 55]]], ["This close relation supports the wide binding ability and inhibitory potency of PeB for a variety of influenza A strains.Inhibition of virus binding and infection by peptides ::: DiscussionSuch broader specificity is also supported by the similarity between the VH-CDR3 of the mouse antibodies against Aichi H3N2 hemagglutinin in PDB 1ken (antibody HC63, amino acids 97\u2013109: AAFYYDYDFFFDY) and PDB 2vir, antibody HC19, amino acids 97\u2013109: RDFYDYDVFYYAM), and also a human antibody against H3: (EGDYDILTGYYYYFDY), respectively [26, 48, 49].", [["PeB", "CHEMICAL", 80, 83], ["infection", "DISEASE", 153, 162], ["amino acids 97\u2013109", "CHEMICAL", 355, 373], ["amino acids 97\u2013109", "CHEMICAL", 419, 437], ["amino acids", "CHEMICAL", 355, 366], ["amino acids", "CHEMICAL", 419, 430], ["PeB", "SIMPLE_CHEMICAL", 80, 83], ["influenza A strains", "ORGANISM", 101, 120], ["mouse", "ORGANISM", 277, 282], ["Aichi H3N2 hemagglutinin", "ORGANISM", 302, 326], ["PDB 1ken", "ORGANISM", 330, 338], ["amino acids", "AMINO_ACID", 355, 366], ["PDB 2vir", "GENE_OR_GENE_PRODUCT", 394, 402], ["amino acids", "AMINO_ACID", 419, 430], ["human", "ORGANISM", 466, 471], ["PeB", "PROTEIN", 80, 83], ["VH", "DNA", 262, 264], ["CDR3", "DNA", 265, 269], ["mouse antibodies", "PROTEIN", 277, 293], ["Aichi H3N2 hemagglutinin", "PROTEIN", 302, 326], ["PDB 1ken", "PROTEIN", 330, 338], ["antibody HC63", "PROTEIN", 340, 353], ["amino acids 97\u2013109", "PROTEIN", 355, 373], ["AAFYYDYDFFFDY", "PROTEIN", 375, 388], ["PDB 2vir", "PROTEIN", 394, 402], ["antibody HC19", "PROTEIN", 404, 417], ["human antibody", "PROTEIN", 466, 480], ["H3", "PROTEIN", 489, 491], ["mouse", "SPECIES", 277, 282], ["Aichi H3N2 hemagglutinin", "SPECIES", 302, 326], ["human", "SPECIES", 466, 471], ["mouse", "SPECIES", 277, 282], ["Aichi H3N2 hemagglutinin", "SPECIES", 302, 326], ["human", "SPECIES", 466, 471], ["the wide binding ability", "PROBLEM", 29, 53], ["PeB", "TREATMENT", 80, 83], ["influenza A strains", "PROBLEM", 101, 120], ["virus binding", "PROBLEM", 135, 148], ["infection", "PROBLEM", 153, 162], ["the mouse antibodies", "TEST", 273, 293], ["Aichi H3N2 hemagglutinin", "TEST", 302, 326], ["PDB", "TEST", 330, 333], ["antibody HC63", "TEST", 340, 353], ["amino acids", "TEST", 355, 366], ["AAFYYDYDFFFDY", "TEST", 375, 388], ["PDB 2vir", "TEST", 394, 402], ["antibody", "TEST", 404, 412], ["amino acids", "TEST", 419, 430], ["RDFYDYDVFYYAM", "TEST", 439, 452], ["virus binding", "OBSERVATION", 135, 148], ["infection", "OBSERVATION", 153, 162]]], ["Notably, there is enrichment of aromatic amino acids Tyr and Phe, and of Asp.", [["amino acids", "CHEMICAL", 41, 52], ["Phe", "CHEMICAL", 61, 64], ["Asp", "CHEMICAL", 73, 76], ["amino acids", "CHEMICAL", 41, 52], ["Tyr", "CHEMICAL", 53, 56], ["Phe", "CHEMICAL", 61, 64], ["Asp", "CHEMICAL", 73, 76], ["amino acids", "AMINO_ACID", 41, 52], ["Tyr", "AMINO_ACID", 53, 56], ["Phe", "AMINO_ACID", 61, 64], ["Asp", "AMINO_ACID", 73, 76], ["aromatic amino acids", "TEST", 32, 52], ["Asp", "PROBLEM", 73, 76], ["enrichment", "OBSERVATION_MODIFIER", 18, 28], ["aromatic amino acids", "OBSERVATION", 32, 52]]], ["In line with these findings, a recently published human antibody against H1 shows a higher proportion of aromatic amino acids in the HCDR3 domain, too [50].", [["amino acids", "CHEMICAL", 114, 125], ["aromatic amino acids", "CHEMICAL", 105, 125], ["human", "ORGANISM", 50, 55], ["antibody against H1", "GENE_OR_GENE_PRODUCT", 56, 75], ["amino acids", "AMINO_ACID", 114, 125], ["human antibody", "PROTEIN", 50, 64], ["H1", "PROTEIN", 73, 75], ["HCDR3 domain", "PROTEIN", 133, 145], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["a recently published human antibody", "TEST", 29, 64], ["H1", "PROBLEM", 73, 75], ["aromatic amino acids", "TREATMENT", 105, 125], ["aromatic amino acids", "OBSERVATION", 105, 125]]], ["The crucial role of an Asp residue and hydrophobic amino acids in the HA binding of many receptor mimicking antibodies is highlighted by Lee et al [13].Inhibition of virus binding and infection by peptides ::: DiscussionAs shown exemplarily for Aichi H3N2 and Rostock H7N1 inhibition of virus binding by peptides leads to a strong protection from virus infection of host cells.", [["cells", "ANATOMY", 371, 376], ["amino acids", "CHEMICAL", 51, 62], ["infection", "DISEASE", 184, 193], ["infection", "DISEASE", 353, 362], ["Asp", "CHEMICAL", 23, 26], ["amino acids", "CHEMICAL", 51, 62], ["Asp residue", "AMINO_ACID", 23, 34], ["hydrophobic", "AMINO_ACID", 39, 50], ["amino acids", "AMINO_ACID", 51, 62], ["Aichi H3N2", "ORGANISM", 245, 255], ["Rostock H7N1", "ORGANISM", 260, 272], ["host cells", "CELL", 366, 376], ["antibodies", "PROTEIN", 108, 118], ["host cells", "CELL_TYPE", 366, 376], ["Aichi H3N2", "SPECIES", 245, 255], ["an Asp residue", "PROBLEM", 20, 34], ["hydrophobic amino acids", "TREATMENT", 39, 62], ["the HA binding", "PROBLEM", 66, 80], ["many receptor mimicking antibodies", "TREATMENT", 84, 118], ["virus binding", "PROBLEM", 166, 179], ["infection", "PROBLEM", 184, 193], ["Aichi H3N2", "PROBLEM", 245, 255], ["Rostock H7N1 inhibition", "TREATMENT", 260, 283], ["virus binding", "PROBLEM", 287, 300], ["a strong protection", "TREATMENT", 322, 341], ["virus infection of host cells", "PROBLEM", 347, 376], ["Asp residue", "OBSERVATION", 23, 34], ["virus binding", "OBSERVATION", 166, 179], ["infection", "OBSERVATION", 184, 193], ["host cells", "OBSERVATION", 366, 376]]], ["In the MTS based infection inhibition assay PeBGF was found to be superior with respect to PeB, too.", [["infection", "DISEASE", 17, 26], ["PeBGF", "CHEMICAL", 44, 49], ["PeBGF", "SIMPLE_CHEMICAL", 44, 49], ["PeB", "SIMPLE_CHEMICAL", 91, 94], ["PeBGF", "PROTEIN", 44, 49], ["infection inhibition assay PeBGF", "TEST", 17, 49], ["PeB", "TREATMENT", 91, 94], ["infection", "OBSERVATION", 17, 26]]], ["A similar observation was made for Rostock H7N1 when using the microneutralization assay, which provides a direct measure for viral replication.", [["Rostock H7N1", "SPECIES", 35, 47], ["the microneutralization assay", "TEST", 59, 88], ["viral replication", "TREATMENT", 126, 143]]], ["However, for Aichi H3N2 we did not find a preference for PeBGF indicating strain dependent differences of the antiviral potential of the peptides.Inhibition of virus binding and infection by peptides ::: DiscussionThe inhibitory potential of our antibody derived peptides demonstrated a remarkable performance compared to other published peptides binding to HA (Fig 8).", [["PeBGF", "CHEMICAL", 57, 62], ["infection", "DISEASE", 178, 187], ["Aichi H3N2", "ORGANISM", 13, 23], ["PeBGF", "GENE_OR_GENE_PRODUCT", 57, 62], ["Aichi H3N2", "SPECIES", 13, 23], ["Aichi H3N2", "PROBLEM", 13, 23], ["PeBGF", "PROBLEM", 57, 62], ["strain dependent differences", "PROBLEM", 74, 102], ["virus binding", "PROBLEM", 160, 173], ["infection", "PROBLEM", 178, 187], ["our antibody derived peptides", "TEST", 242, 271], ["virus binding", "OBSERVATION", 160, 173], ["infection", "OBSERVATION", 178, 187]]], ["As summarized in Table 2, PeB and PeBGF provides better inhibition against Aichi H3N2 compared to Rostock H7N1, with the exception of the results from the HAI assay.", [["PeB", "CHEMICAL", 26, 29], ["PeBGF", "CHEMICAL", 34, 39], ["Aichi H3N2", "DISEASE", 75, 85], ["PeB", "GENE_OR_GENE_PRODUCT", 26, 29], ["PeBGF", "SIMPLE_CHEMICAL", 34, 39], ["Aichi H3N2", "ORGANISM", 75, 85], ["Rostock H7N1", "ORGANISM", 98, 110], ["PeBGF", "PROTEIN", 34, 39], ["Aichi H3N2", "SPECIES", 75, 85], ["Rostock H7N1", "SPECIES", 98, 110], ["PeB and PeBGF", "TREATMENT", 26, 39], ["Aichi H3N2", "PROBLEM", 75, 85], ["the HAI assay", "TEST", 151, 164]]], ["However, we should take into consideration that the performance of a peptide as inhibitor depends on many factors.", [["a peptide as inhibitor", "TREATMENT", 67, 89]]], ["As a consequence, the hemagglutination inhibition efficiency may not necessarily be stronger against Aichi H3N2, even though the peptide was derived from an antibody binding to this influenza strain.", [["Aichi H3N2", "ORGANISM", 101, 111], ["Aichi H3N2", "SPECIES", 101, 111], ["the hemagglutination inhibition efficiency", "PROBLEM", 18, 60], ["Aichi H3N2", "PROBLEM", 101, 111], ["the peptide", "PROBLEM", 125, 136], ["an antibody binding", "PROBLEM", 154, 173], ["this influenza strain", "PROBLEM", 177, 198]]], ["One can speculate that Rostock H7N1 is more prone to neutralization by blocking this binding site, while for Aichi H3N2 PeB and PeBGF can be displaced more easily in a binding competition experiment with erythrocytes.", [["erythrocytes", "ANATOMY", 204, 216], ["PeBGF", "CHEMICAL", 128, 133], ["Aichi H3N2 PeB", "ORGANISM", 109, 123], ["PeBGF", "GENE_OR_GENE_PRODUCT", 128, 133], ["erythrocytes", "CELL", 204, 216], ["erythrocytes", "CELL_TYPE", 204, 216], ["Aichi H3N2 PeB", "SPECIES", 109, 123], ["Aichi H3N2 PeB", "TREATMENT", 109, 123], ["PeBGF", "TREATMENT", 128, 133]]], ["This trend could also be explained by the use of erythrocytes derived from different species (see Material and Methods).", [["erythrocytes", "ANATOMY", 49, 61], ["erythrocytes", "CELL", 49, 61], ["erythrocytes", "CELL_TYPE", 49, 61], ["erythrocytes derived", "PROBLEM", 49, 69], ["different species", "PROBLEM", 75, 92], ["could also be explained", "UNCERTAINTY", 11, 34]]], ["Similar strain-dependent efficiencies have been obtained by L\u00f3pez-Martinez et al. [22].", [["Similar strain-dependent efficiencies", "PROBLEM", 0, 37], ["dependent efficiencies", "OBSERVATION", 15, 37]]], ["Although a peptide was designed against broadly conserved epitopes, the antiviral efficiency was not the same against all tested serotypes (three different H1N1 strains and H5N2).Inhibition of virus binding and infection by peptides ::: DiscussionShort oligomeric biomolecules with sufficient affinity are of high interest for diagnostics and drug design, as development, synthesis and further chemical modifications are easy to implement.Inhibition of virus binding and infection by peptides ::: DiscussionLinear short CDR derived peptides as used here can be expected to differ from the loop structure they adopt within the antibody, leading to lower affinity.", [["infection", "DISEASE", 211, 220], ["infection", "DISEASE", 471, 480], ["H5N2", "ORGANISM", 173, 177], ["broadly conserved epitopes", "PROBLEM", 40, 66], ["the antiviral efficiency", "PROBLEM", 68, 92], ["all tested serotypes", "PROBLEM", 118, 138], ["different H1N1 strains", "TREATMENT", 146, 168], ["H5N2", "TREATMENT", 173, 177], ["virus binding", "PROBLEM", 193, 206], ["infection", "PROBLEM", 211, 220], ["synthesis", "TREATMENT", 372, 381], ["further chemical modifications", "TREATMENT", 386, 416], ["virus binding", "PROBLEM", 453, 466], ["infection", "PROBLEM", 471, 480], ["DiscussionLinear short CDR derived peptides", "PROBLEM", 497, 540], ["lower affinity", "PROBLEM", 647, 661], ["antiviral efficiency", "OBSERVATION", 72, 92], ["virus binding", "OBSERVATION", 193, 206], ["infection", "OBSERVATION", 211, 220], ["virus binding", "OBSERVATION", 453, 466], ["infection", "OBSERVATION", 471, 480]]], ["Cyclisation of CDR peptides using a D-Pro-L-Pro template has been shown to force them into canonical conformations [51].", [["D-Pro-L-Pro", "CHEMICAL", 36, 47], ["D-Pro-L-Pro", "CHEMICAL", 36, 47], ["CDR peptides", "GENE_OR_GENE_PRODUCT", 15, 27], ["D-Pro-L-Pro template", "DNA", 36, 56], ["Cyclisation of CDR peptides", "TREATMENT", 0, 27], ["a D-Pro-L-Pro template", "TREATMENT", 34, 56]]], ["In this report, the L3 loop of the HC19 antibody adopted a hairpin structure and an aromatic T-stacking as in the antibody crystal structure.", [["HC19 antibody", "GENE_OR_GENE_PRODUCT", 35, 48], ["L3 loop", "PROTEIN", 20, 27], ["HC19 antibody", "PROTEIN", 35, 48], ["antibody crystal structure", "PROTEIN", 114, 140], ["a hairpin structure", "PROBLEM", 57, 76], ["an aromatic T-stacking as in the antibody crystal structure", "PROBLEM", 81, 140], ["L3", "ANATOMY", 20, 22], ["loop", "ANATOMY_MODIFIER", 23, 27], ["hairpin structure", "OBSERVATION", 59, 76], ["aromatic", "OBSERVATION_MODIFIER", 84, 92], ["antibody crystal", "OBSERVATION", 114, 130]]], ["This and other strategies to generate peptidomimetics by stabilizing or mimicking turns, \u00df-sheets and helices, have been recently reviewed [52].Inhibition of virus binding and infection by peptides ::: DiscussionWhereas the gain in affinity by cyclization of a peptide is limited by the affinity of the native structure, larger improvements can be achieved by multivalency, especially when a virus with a high target protein density on its surface has to be bound [53\u201356].", [["surface", "ANATOMY", 440, 447], ["infection", "DISEASE", 176, 185], ["surface", "CELLULAR_COMPONENT", 440, 447], ["peptidomimetics", "TREATMENT", 38, 53], ["virus binding", "PROBLEM", 158, 171], ["infection", "PROBLEM", 176, 185], ["a virus", "PROBLEM", 390, 397], ["a high target protein density", "PROBLEM", 403, 432], ["virus binding", "OBSERVATION", 158, 171], ["infection", "OBSERVATION", 176, 185], ["larger", "OBSERVATION_MODIFIER", 321, 327], ["density", "OBSERVATION", 425, 432]]], ["For example, sialyl-containing oligosaccharides constituting the natural receptors of hemagglutinin on mammalian epithelial cells, exhibit a millimolar 1:1 affinity, but due to multivalent virus-cell attachment the binding is strong enough to enable infection.", [["epithelial cells", "ANATOMY", 113, 129], ["cell", "ANATOMY", 195, 199], ["infection", "DISEASE", 250, 259], ["sialyl", "CHEMICAL", 13, 19], ["sialyl-containing oligosaccharides", "SIMPLE_CHEMICAL", 13, 47], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 86, 99], ["mammalian epithelial cells", "CELL", 103, 129], ["cell", "CELL", 195, 199], ["natural receptors", "PROTEIN", 65, 82], ["hemagglutinin", "PROTEIN", 86, 99], ["mammalian epithelial cells", "CELL_TYPE", 103, 129], ["sialyl-containing oligosaccharides", "TREATMENT", 13, 47], ["mammalian epithelial cells", "TREATMENT", 103, 129], ["a millimolar 1:1 affinity", "PROBLEM", 139, 164], ["multivalent virus", "PROBLEM", 177, 194], ["enable infection", "PROBLEM", 243, 259], ["mammalian epithelial cells", "OBSERVATION", 103, 129], ["virus", "OBSERVATION", 189, 194], ["infection", "OBSERVATION", 250, 259]]], ["Effective inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles and other glycoarchitectures has been described [57, 58].", [["influenza virus infection", "DISEASE", 24, 49], ["sialic-acid", "CHEMICAL", 65, 76], ["sialic-acid", "CHEMICAL", 65, 76], ["influenza virus", "ORGANISM", 24, 39], ["sialic-acid", "SIMPLE_CHEMICAL", 65, 76], ["gold nanoparticles", "SIMPLE_CHEMICAL", 92, 110], ["influenza virus", "SPECIES", 24, 39], ["influenza virus", "SPECIES", 24, 39], ["influenza virus infection", "PROBLEM", 24, 49], ["acid-functionalized gold nanoparticles", "TREATMENT", 72, 110], ["influenza virus", "OBSERVATION", 24, 39]]], ["More recently, a trivalent glycopeptide mimetic containing three sialyl residues matching the three sialyl binding sites in a HA trimer, was reported to bind to H5 hemagglutinin 4000 fold better than the monomer [59].", [["sialyl", "CHEMICAL", 65, 71], ["sialyl", "CHEMICAL", 100, 106], ["sialyl binding sites", "PROTEIN", 100, 120], ["HA trimer", "PROTEIN", 126, 135], ["H5 hemagglutinin", "PROTEIN", 161, 177], ["a trivalent glycopeptide mimetic", "TREATMENT", 15, 47], ["three sialyl residues", "TREATMENT", 59, 80], ["the three sialyl binding sites", "PROBLEM", 90, 120], ["a HA trimer", "PROBLEM", 124, 135]]], ["Recently, we demonstrated that the antiviral effectivity of acylated PeBGF can be increased, upon presentation in a multivalent fashion by 10-fold against Rostock H7N1 and by 20-fold against Aichi H3N2 [60].", [["PeBGF", "CHEMICAL", 69, 74], ["acylated PeBGF", "CHEMICAL", 60, 74], ["PeBGF", "SIMPLE_CHEMICAL", 69, 74], ["Rostock H7N1", "ORGANISM", 155, 167], ["Aichi H3N2", "ORGANISM", 191, 201], ["PeBGF", "PROTEIN", 69, 74], ["Aichi H3N2", "SPECIES", 191, 201], ["Rostock H7N1", "SPECIES", 155, 167], ["Aichi H3N2", "SPECIES", 191, 201], ["acylated PeBGF", "TREATMENT", 60, 74]]], ["Further, multivalent presentation of the short s2 peptide (ARLPR) with a dendrimer resulted in sub-micromolar inhibitory activities [61].ConclusionsThe antibody derived peptide PeB and its mutant variant PeBGF are promising hemagglutinin binding peptides, which both could have potential for application in viral diagnostics and therapeutics.", [["dendrimer", "CHEMICAL", 73, 82], ["PeB", "GENE_OR_GENE_PRODUCT", 177, 180], ["PeBGF", "GENE_OR_GENE_PRODUCT", 204, 209], ["hemagglutinin binding peptides", "GENE_OR_GENE_PRODUCT", 224, 254], ["PeB", "PROTEIN", 177, 180], ["mutant variant PeBGF", "PROTEIN", 189, 209], ["the short s2 peptide", "PROBLEM", 37, 57], ["The antibody derived peptide PeB", "TREATMENT", 148, 180], ["its mutant variant PeBGF", "PROBLEM", 185, 209], ["hemagglutinin binding peptides", "PROBLEM", 224, 254], ["viral diagnostics", "TEST", 307, 324], ["therapeutics", "TREATMENT", 329, 341]]], ["Infection inhibition could be achieved at micromolar concentrations.", [["Infection inhibition", "PROBLEM", 0, 20]]], ["Strategies to improve the peptide structure and to apply the peptides for developing multivalent binders with high affinities are discussed.ConclusionsFinally, the workflow presented involving complementary experimental and theoretical approaches could be a template for the development of antiviral agents, which could be also applied for influenza detecting biochips.", [["the peptide structure", "PROBLEM", 22, 43], ["the peptides", "TREATMENT", 57, 69], ["developing multivalent binders", "TREATMENT", 74, 104], ["high affinities", "PROBLEM", 110, 125], ["a template", "TREATMENT", 256, 266], ["antiviral agents", "TREATMENT", 290, 306], ["influenza", "PROBLEM", 340, 349], ["binders", "OBSERVATION", 97, 104], ["antiviral agents", "OBSERVATION", 290, 306]]], ["In a coevolutionary approach the peptide\u2019s primary sequence may also be adapted to seasonal upcoming mutations of the influenza virus with minor additional efforts, costs and in short time without the additional development of novel monoclonal antibodies.", [["influenza", "DISEASE", 118, 127], ["influenza virus", "ORGANISM", 118, 133], ["novel monoclonal antibodies", "PROTEIN", 227, 254], ["influenza virus", "SPECIES", 118, 133], ["seasonal upcoming mutations", "PROBLEM", 83, 110], ["the influenza virus", "PROBLEM", 114, 133], ["novel monoclonal antibodies", "PROBLEM", 227, 254], ["influenza virus", "OBSERVATION", 118, 133], ["monoclonal antibodies", "OBSERVATION", 233, 254]]]]}